Salt Name,Category,Schedule,Indications,Availability,Dose,Contraindications,Precautions,Adverse Effects,Storage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Acetylsalicylic Acid,Pregnancy Category-D,,"Management of mild to moderate pain suchas headache, acute migraine attacks,transientmusculoskeletal pain, dysmenorrhoeal painand for reducing fever; pain and inflammationof rheumatoid arthritis; antiplatelet agent forprophylaxis of myocardial infarction, stableangina pectoris; stroke prophylaxis.","TABLETS 50, 60, 75, 80, 150, 300 and 325 mg.","OralAdult- Analgesic and antipyretic including migraine attacks: 0.3 to 0.9g, 3 to 4 times a day (max. 4g daily). Acute Rheumatic fever: 4 to 6g or 75 to 100 mg/kg daily in divided doses. Antiplatelet: 75-325 mg/day .Child- Under 16 years: not recommended (can cause Reye’s syndrome).",Hypersensitivity (including asthma, angioede-ma, urticaria or rhinitis) to acetylsalicylic acidor any other NSAID, children and adolescentsunder 16 years (may cause Reye’s syndrome),gastrointestinal ulceration, haemophilia andother bleeding disorders, not for treatmentof gout, severe renal or hepatic impairment,lactation. It is known to cause haemolyticanaemia in people who have the geneticdisease- G-6-PD-deficiency.,"Asthma, allergic disease; impaired renal orhepatic function (Appendices 7d and 7a);lactation (Appendix 7b); pregnancy (Appendix7c); elderly; G-6-PD-deficiency; dehydration;interactions (Appendix 6a, 6c, 6d).","Generally mild and infrequent for lowerdoses, but common with anti-inflammatorydoses; gastrointestinal discomfort or nausea,ulceration with occult bleeding (occasion-ally major haemorrhage); also other haem-orrhage (including subconjunctival); hearingdisturbances such as tinnitus (rarely, deaf-ness); vertigo; confusion; hypersensitivityreactions (angioedema; bronchospasm andrash); increased bleeding time, blood disor-ders (particularly thrombocytopenia); rarely,oedema; myocarditis; Reye’s syndrome",Store protected from moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Diclofenac,Pregnancy Category-B,Schedule H,Acute musculo-skeletal pain, arthritis, gout,spondylitis, migraine, post-operative pain,"TABLETS 25 and 50 mg Plain; 75 and 100 mgSR; CAPSULES 100 mg, 100 mg CR; INJECTION3 ml ampoule (25 mg/ml); EyE/EAR DROPS0.1% w/v; SUPPOSITORIES 25, 50 and 100mg; GEL 1%w/w.","Oral100 to 150 mg daily in 2 to 3 divided doses,(max 150 mg/day) maintenance by 50 to 100mg in divided doses.Intramuscular injection 75 mg, 2 to 3 times daily. TopicallyAdult- Apply 1% w/w gel on to affected area 3 to 4 times daily.Instill to eyePost-operative ocular inflammation:Adult- as sodium (1% w/v), 4 times daily starting 24 h after surgery for up to 28 days.RectalPost-operative pain.Adult- 75 to 150 mg daily in divided doses (max. 150 mg/day, inclusive of diclofenac administered through other routes). Child- 6 to 12 year: 1 to 2 mg/kg/day in divided doses for max. of 4 days.","Porphyria; avoid injections containing benzylalcohol in neonates; history of gastric ulcers,bleeding or perforation. Additional contraindications include concomitant NSAID or anticoagulant use (including low-dose heparin); history of haemorrhagic diathesis; history of confirmed or suspected cerebrovascular bleeding; operations with high risk of haemorrhage; history of asthma; moderate or severe renal impairment; hypovolaemia; dehydration.","NSAIDs should be used with caution inthe elderly (risk of serious side-effects andfatalities); interactions (Appendix 6a, 6c,6d); pregnancy (Appendix 7c); patients withcoagulation disorders; hepatic, renal andcardiac impairment; history of gastrointestinallesions.","Injection site reactions; transient epigastricpain, risk of thrombotic events; toxicepidermal necrolysis; Abnormality in kidneyfunction.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ibuprofen,Pregnancy Category-C,Schedule H,"Pain and inflammation in rheumatic diseaseand other musculoskeletal disorders includingjuvenile arthritis; mild to moderate painincluding dysmenorrhoeal pain, headache;pain in children; acute migraine attack.","TABLETS 200, 400 and 600 mg; CAPSULES400 mg Plain, 300 mg SR; SUSPENSION 100mg/5 ml.","OralAdult- and Child over 12 years- initially 300 to 400 mg 3 to 4 times daily, increase if necessary (max. 2.4g daily), maintenance dose of 0.6 to 1.2g daily may be adequate.Infant or Child over 3 months- 5-10 mg/kg 3 to 4 times/day, Maximum daily dose: 40 mg/kg/day.Intravenous injection and infusionNeonate- initially by intravenous injection (over atleast 5 min) 25-100 µg/kg then by continuous intravenous infusion 5-40 µg/ kg/h. adjusted according to response. Child- 1-6 months: initially by intravenous injection (over atleast 5 min) 100-200µg/kg then by continous infusion 10-30 µg/h. adjusted according to response.6 months-12 years: initially by intravenous injection (over atleast 5 min) 100-200µg/kg, adjusted according to response. Juvenile rheumatoid arthritis: 20 to 40 mg/ kg/day in 3 to 4 divided doses.",Hypersensitivity (including asthma, angioede-ma, urticaria or rhinitis) to acetylsalicylic acidor any other NSAID, active peptic ulceration,for treatment of pre-operative pain in thesetting of coronary artery bypass graft sur-gery, neonates with congenital heart disease.,"Renal and hepatic impairment (Appendix 7a);preferably avoid if history of peptic ulceration;cardiac disease; elderly; pregnancy (Appendix7c); lactation (Appendix 7b); coagulationdefects; allergic disorders; interactions(Appendix 6a, 6c, 6d).","Gastrointestinal disturbances includingnausea, diarrhoea, dyspepsia, gastrointestinalhaemorrhage; hypersensitivity reactionsincluding rash, angioedema; bronchospasm;headache; dizziness; nervousness; depression;drowsiness; insomnia; vertigo; tinnitus;photosensitivity; haematuria; renal failure;fluid retention (rarely, precipitating congestiveheart failure in elderly), raised bloodpressure; rarely, hepatic damage; alveolitis,pulmonary eosinophilia; pancreatitis; visualdisturbances; erythema multiforme (Stevens-Johnson syndrome); toxic dermal necrolysis(Lyell's syndrome); colitis; aseptic meningitis.Skin reactions like dermatitis.",Store protected from light and moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Mefenamic Acid,Pregnancy Category-C,,"Treatment of rheumatoid arthritis,osteoarthritis, dysmenorrhea, mild tomoderate pain, inflammation, fever dentalpain.","TABLETS 100 mg, 250 mg, 500 mg. CAPSULES250 mg. SUSPENSION 50 mg/5 ml","Adult Pain: 500 mg orally, followed by 250 mg every 6 hours as needed, not to exceed 7 days. Dysmenorrhea: 500 mg orally, followed by 250 mg every 6 hours starting with the onset of menses.ChildrenPain: 14 to 18 years: 500 mg orally followed by250 mg every 6 hours as needed, not to exceed7 days.","Known hypersensitivity to mefenamic acid;patients who have experienced asthma,urticaria, or allergic-type reactions aftertaking aspirin or other NSAIDs; peri-operativepain in the setting of coronary artery bypassgraft (CABG) surgery, active ulceration orchronic inflammation of the gastrointestinaltract, pre-existing renal disease, pregnancy(Appendix 7c), interactions (Appendix 6c).","Hepatic effects: Borderline elevations of oneor more liver function tests may occur. Theselaboratory abnormalities may progress, mayremain unchanged, or may be transient withcontinuing therapy. A patient with symptomsand/or signs suggesting liver dysfunction,or in whom an abnormal liver test hasoccurred, should be evaluated for evidenceof the development of a more severe hepaticreaction while on therapy. If clinical signsand symptoms consistent with liver diseasedevelop, or if systemic manifestations occur(e.g., eosinophilia, rash, etc.), the drug shouldbe discontinued.Anaemia: Patients on long-term treatmentshould have their hemoglobin or hematocritchecked if they exhibit any signs or symptomsof anaemia.Asthma: Mefenamic acid should not beadministered to patients with aspirin sensitiveasthma and should be used with caution inpatients with preexisting asthma.","Gastrointestinal experiences including-abdominal pain, constipation, diarrhoea,dyspepsia, flatulence, gross bleeding/perforation, heartburn, nausea,gastrointestinal ulcers, vomiting, abnormalrenal function, bronchospasm, anaemia,dizziness, edema, elevated liver enzymes,headaches, increased bleeding time, pruritus,rashes, tinnitus.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Paracetamol,Pregnancy Category-B,,"Mild to moderate pain including dysmenor-rhoeal pain, headache; pain relief in osteoar-thritis and soft tissue lesions; pyrexia includingpost-immunisation pyrexia; acute migraineattack",TABLETS 500 and 650 mg Plain, 750 mg DT,SyRUPS/SUSPENSION 125 and 250 mg/5 ml,INJECTION 2 ml ampoule 125 mg/ml., Intra-venous infusion 500 mg and 1g.,"OralAdult- 0.5 to 1g every 4 to 6 h (max. 4g, max 2g in alcoholics per day).Child- for post-immunisation pyrexia, up to 2 months: 60 mg. 3 month to 1 year: 60 to 120mg every 4 to 6 h. 1 to 5 years: 120 to 250 mgevery 4 to 6 h. 6 to 12 years: 250 to 500 mgevery 4 to 6 h.Intramuscular injectionAdult- 250 mg every 4 to 6 h or as required.Intravenous infusionAdult- 1g every 6 hours, maximum daily dose 4 g.Child- 15 mg/kg upto 4 times a day, maximum daily dose 60 mg/kg.",,Hepatic impairment (Appendix 7a), renalimpairment, alcohol dependence, lactation(Appendix 7b), pregnancy (Appendix 7c),overdosage: chapter 7.2, interactions(Appendix 6a), G-6-PD deficiency.,Rare but rashes and blood disorders reported,important: liver damage (and less frequentlyrenal damage) following overdosage,dyspepsia.,Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Paracetamol,Pregnancy Category-C,Schedule H,Mild to moderate pain, diarrhoea, coughsuppressant, irritable bowel syndrome.,TABLET 10 mg, SyRUP 15 mg/5 ml.,OralAdult- 30 to 60 mg every 4 h. (max. 240 mg/ day).Child- 1 year to 12 year: 3 mg/kg daily in divided doses.,Respiratory depression, obstructive airwaysdisease, acute asthma attack, where risk ofparalytic ileus, hypersensitivity, head injury,increased intracranial pressure.,Hepatic impairment (Appendix 7a) and renalimpairment, opioids dependence, lactation,overdosage: chapter 7.2, pregnancy(Appendix 7c), interactions (Appendix 6c),hypothyroidism, shock.,"Constipation particularly troublesome inlong-term use, dizziness, nausea, vomiting;difficulty with micturition; ureteric or biliaryspasm; dry mouth; headaches; sweating;facial flushing; in therapeutic doses, codeineis much less liable than morphine to producetolerance, dependence, euphoria, sedation orother adverse effects; orthostatic hypotension;respiratory depression; rhabdomyolysis;convulsions (especially in children).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Morphine (Controlled Medicine Under the Narcotic Drugs and PsychotropicSubstances Act, 1985)",Pregnancy Category-C,"Schedule H, X","In severe pain (acute and chronic); myocardialinfarction, acute pulmonary oedema; adjunctduring major surgery and postoperativeanalgesia; prolonged relief of severe andintractable pain.","INJECTION 10 ml ampoule (1 mg/ml, 10 mg/ml, 15 mg/ml); TABLETS 10, 20, 30 and 60mg.","Subcutaneous or intramuscular injectionAdult- Acute pain: 10 mg every 4 h.Elderly or frail- Acute pain: 5 mg, adjust according to response (not suitable for patients having oedema).Child- Acute pain: can be given to children in dose range of 0.2 to 0.8 mg/kg every 12 h. After 1 to 6 months: initially 100 to 200 µg/kg every 6 h, 2 to 12 years: initially 200 µg/kg every 4 h, 12 to 18 years: initially 2.5 to 10mg every 4 h.Slow intravenous injectionAdult- Acute pain: 2.5 mg every 4 h. Myocardial infarction: 10 mg (2 mg/min), followed by another 5 to 10 mg if necessary.Elderly or frail- Acute pain: reduced dose.Child- 0.1-0.15 mg/kgSubcutaneous or intramuscular injectionPremedication: up to 10 mg, 1 to 1.5 h before operation.Oral or subcutaneous or intramuscular injectionChronic acute pain: 5 to 20 mg every 4 h or as per recovery (not suitable for patient having oedema).","Acute respiratory depression, obstructiveairway disease; acute alcoholism; where riskof paralytic ileus; raised intracranial pressureor head injury (interferes with respiration,also affects pupillary responses vital forneurological assessment); avoid injection inpheochromocytoma.","Renal and hepatic impairment (Appendix7a); reduce dose or avoid in elderly anddebilitated; dependence (severe withdrawalsymptoms if withdrawn abruptly);hypothyroidism; convulsive disorders, seizuredisorder; decreased respiratory reserveand acute asthma; hypotension; prostatichypertrophy; pregnancy (Appendix 7c) andlactation (Appendix 7b); overdosage: chapter7.2; interactions (Appendix 6a, 6c, 6d); drivingand operating machinery.","Nausea, vomiting (particularly in initialstages) constipation, drowsiness, also drymouth, anorexia; spasm of urinary andbiliary tract; bradycardia/tachycardia;palpitations; decreased libido; rash, urticaria,pruritus; sweating; headache; facial flushing;vertigo; postural hypotension; hypothermia;hallucinations, euphoria, confusion,dependence; miosis; larger doses producerespiratory depression and hypotension;somnolence; sepsis, peripheral oedema.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pentazocine,Pregnancy Category-C,,Moderate to severe pain, pre-anaestheticmedication, colic, trauma, surgicalprocedures, burns.,"TABLETS 25 mg Plain, Combination:Paracetamol 500 mg + Pentazocine 15 mg;INJECTION 1 ml ampoule (30 mg/ml).","OralAdult- Pentazocine 50 mg every 3 to 4 h preferably after food (range 25 to 100 mg, max. 600 mg daily).Child- 6 to 12 years: 25 mg.Subcutaneous, intramuscular or intravenous injectionAdult- Moderate pain: 30 mg. Severe pain: 45 to 60 mg every 3 h to 4 h when necessary. Child (Over 1 year)- by subcutaneous or intramuscular injection: 1 mg/kg; by intravenous injection: 500 µg/kg.",Patients dependent on opioids, arterialor pulmonary hypertension, heart failure,narcotic dependence, hypersensitivity,ischaemia, myocardial infarction.,Avoid in porphyria, interactions (Appendix6a), impaired respiratory function,pregnancy (Appendix 7c), renal or hepaticfunction, thyroid dysfunction, biliary tractimpairment.,"Nausea, vomiting; euphoria, sedation,occasional hallucinations",Store protected from light and moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tramadol,Pregnancy Category-C,Schedule H,"Moderate or severe pain, post operative pain,in patients contraindicated to NSAIDs",TABLETS 50 mg and 100 mg SR, CAPSULE50 and 100 mg SR, INJECTION 1 and 2 mlampoule (50 mg/ml).,"Adult- Moderate to severe pain: 50 to 100 mg, 4 to 6 hourly (max 400 mg/day).Post operative pain: 100 mg i.v. initially followed by 50 mg every 10 to 20 min upto max. of 250 mg in the 1st h. Maintenance dose 50 to 100 mg, 4 to 6 hourly (max 600 mg/day).",Patients with suicidal tendency, raisedintracranial pressure, severe renalimpairment, acute alcoholism, lactation.,Renal or hepatic impairment, history ofepilepsy, inflammatory or obstructive boweldisease, myasthenia gravis, hypothyroidism,adreno-cortical insufficiency, respiratorydepression, prostatic hyperplasia, pregnancy(Appendix 7c).,"Same as other opioids, however it has less addictive potential.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Aluminium Hydroxide,Pregnancy Category-C,,Ulcer and non-ulcer dyspepsia, GERD, hyperphosp hataemia,TABLETS 300 and 840 mg, GEL 610 mg/10 ml, In combination as Tablet/Suspension/Gel/Syrup.,"Oral, Adult- Dyspepsia, GERD: 1 to 2 tablets chewed 4 times daily and at bedtime or 5 to 10 ml suspension 4 times daily between meals and at bedtime. Hyperphosphataemia: 2 to 10g daily in divided doses with meals. Child- 6 to 12 years: 5 ml up to three times daily.",Hypophosphataemia, undiagnosed gastroin- testinal or rectal bleeding, appendicitis, por- phyria, hypersensitivity to aluminium salts.,"Impaired renal function and renal dialysis; hepatic impairment (Appendix 7a); constipation; dehydration; fluid restriction; gastrointestinal disorders associated with decreased bowel motility or obstruction; pregnancy (Appendix 7c); interactions (Appendix 6c); oedema, cirrhosis and low sodium diets.","Constipation, intestinal obstruction (largedoses); hypophosphataemia with increasedbone resorption, hypercalciuria and risk ofosteomalacia (patients on low phosphate dietor prolonged therapy); hyperalbuminaemia-resulting in osteomalacia, encephalopathy,dementia, microcytic anaemia (in chronicrenal failure treated with aluminiumhydroxide as phosphate-binding agent); lossof appetite",protected from moisture at a temperature not exceeding 30⁰C. Do not freeze Gel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Famotidine,Pregnancy Category-B,Schedule H,"Duodenal or benign gastric ulcers, GERD.Zollinger-Ellison syndrome.","TABLETS 10, 20, 40 & 100 mg; CAPSULES 20 & 40 mg; INJECTION 2 ml (10 mg/ml)","Oral,Benign gastric and duodenal ulceration Adult: 40 mg daily at bedtime for 4-8 weeks or 20 mg twice daily. To prevent recurrence of duodenal ulceration: 20 mg at bedtime may be taken.Gastro-oesophageal reflux diseaseAdult: 20 mg twice daily for 6-12 week or upto 40 mg twice daily if there is oesophagealulceration. Maintenance dose: 20 mg twicedaily may be given to prevent recurrence.Child: 1-16 yr: 1-2 mg/kg/day divided twicedaily up to 40 mg twice daily.Zollinger-Ellison syndromeAdult: Initially, 20 mg every 6 hr, up to 640mg daily if necessary.Child: 1-16 yr: 0.5-1 mg/kg/day up to 40 mg/day, given once at bedtime or taken twicedaily.Non-ulcer dyspepsia Adult: 10 mg twice daily.Heartburn-Adult: 10 mg twice daily. Intravenous -Benign gastric and duodenal ulcerationAdult: 20 mg every 12 hr, as an injection overat least 2 minutes or as an infusion over 15-30 minutes.",Hypersensitivity,"Possibility of gastric malignancy shouldbe excluded, Impaired renal function, liver cirrhosis, pregnancy (Appendix 7c),lactation, children and elderly, interactions (Appendix 6c).","Headache, dizziness, onstipation, diarrhoea,nausea, vomiting, anorexia, ash, fatigue,gynaecomastia and impotence.","Store protected from light, Tablets to be stored at room temperature, 15 -30⁰C (59- 86⁰F). Injection to be stored between 2-8⁰C (36-46⁰F).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Magnesium Hydroxide,Pregnancy Category-B,,Ulcer and non-ulcer dyspepsia, GERD,TABLET 310 mg, SUSPENSION 110 ml and 340 ml (8%).,"Oral Adult- Dyspepsia, GERD: 5 to 10 ml repeated according to patient’s needs.",Severe renal impairment.,Renal impairment, hepatic impairment(Appendix 7a), interactions (Appendix 6c),abdominal pain,"Diarrhoea; in renal impairment-hypermagnesaemia resulting in loss of deep tendon reflexes and espiratory depression with other symptoms including nausea, vomiting, flushing of in, thirst, hypotension, drowsiness, onfusion, muscle weakness, bradycardia, coma nd cardiac arrest; allergic reaction.",Store protected from light. Do not store Gel in refrigerator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Omeprazole,Pregnancy Category-C,Schedule H,"Benign gastric and duodenal ulcers; Zollinger Ellison syndrome; gastric acid reduction during gastric surgery; GERD, NSAID- induced ulcer, prophylaxis during NSAIDs treatment in patients with high risk for peptic ulceration, eradication of H.pylori, as preoperative medication, systemic mastocytosis and in patients not responsive to H2 blockers.","TABLETS 20 and 40 mg; INJECTION 10 ml vial (40 mg/10 ml); CAPSULES 10, 20 and 40 mg.","OralBenign gastric and duodenal ulcers: 20 mg once a day for 4 weeks in duodenal ulcers, for 8 weeks in gastric ulcers, Increase to 40 mg in severe case. Maintenance for recurrent duodenal ulcers: 20 mg once daily. Prevention of relapse: 10 mg daily. NSAIDs associated gastric or duodenal ulcers or gastro-duodenal erosions: 20 mg daily for 4 weeks. Prophylaxis in case of history associated with gastric/duodenal ulcers or dyspepsia: 20 mg daily. Zollinger-Ellison syndrome: 60 mg to 120 mg/day or more, into divided doses.Gastric acid reduction during gastric surgery: 40 mg on preceding evening then 40 mg 2 to 6 h before surgery.",Hypersensitivity,"Interactions (Appendix 6c, 6d); pregnancy (Appendix 7c); oncomitant gastric malignancy.","Nausea, abdominal pain, constipation, flatulence, diarrhoea, headache, skin rashes, subacute, myopathy, arthralgias, increased risk of hip fractures, decreased B12 absorption, hypergastrenemia, respiratory and Clostridium difficile infections, hepatic dysfunction.",Store protected from light and moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pantoprazole,Pregnancy Category-B,Schedule H,"Duodenal ulcer, gastric ulcer, GERD, erosive esophagitis.","TABLETS 20 and 40 mg, INJECTIONS 20 and 40 mg/vial, CAPSULES 20 and 40 mg.",Oral Adult- 40 mg once daily up to 8 weeks.Intravenous Adult- 40 mg twice daily.,Hypersensitivity,Hepatic impairment, monitor liver function,pregnancy (Appendix 7c), cyanocobalamindeficiency, tumorogenicity.,Diarrhoea, pruritus, dizziness, pyrexia, blurred vision, vertigo.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ranitidine,Pregnancy Category-B,Schedule H,"Benigngastricandduodenalulceration,GERD,Zollinger-Ellison syndrome, other conditionswhere gastric acid reduction is beneficial.Prophylaxis during NSAIDs treatment inpatients with high risk for peptic ulceration,eradication of H.pylori, as preoperativemedication, systemic mastocytosis","TABLETS 150 and 300 mg. INJECTION 2 mlampoule (25 mg/ml), SyRUP 375 mg/5 ml","Oral Adult- Benign gastric and duodenal ulceration: 150 mg twice daily or 300 mg at night for 4 to 8 weeks, up to 6 weeks in chronic episodic dyspepsia and up to 8 weeks in NSAID-associated ulceration (in duodenal ulcer 300 mg can be given twice daily for 4 weeks to achieve a higher healing rate); maintenance, 150 mg at night. Prophylaxis of NSAID-induced duodenal ulcer: 150 mg twice daily. Reflux oesophagitis: 150 mg twice daily or 300 mg at night for up to 8 weeks, or if necessary 12 weeks (moderate to severe, 150 mg 4 times daily for up to 12 weeks). Long-term treatment of healed oesophagitis: 150 mg twice daily.Zollinger- Ellison syndrome: 150 mg 3 times daily (up to 6g daily in divided doses has been used). Gastric acid reduction (prophylaxis of acid aspiration) in obstetrics: 150 mg at onset of labour, then every 6 h. Surgical procedures: 150 mg 2 h before induction of anaesthesia and also, when possible on the preceding evening.Child- Peptic ulcer: 2 to 4 mg/kg twice daily (max. 300 mg daily).Intramuscular injectionAdult- Benign gastric and duodenal ulceration, reflux oesophagitis, Zollinger- Ellison syndrome: 50 mg every 6 to 8 h.Surgical procedures: 50 mg 45 to 60 min before induction of anaesthesia.Slow intravenous injectionBenign gastric and duodenal ulceration, reflux oesophagitis, Zollinger-Ellison syndrome: 50 mg diluted to 20 ml and given over at least 2 min, may be repeated every 6 to 8h. Surgical procedures: 50 mg 45 to 60 min before induction of anaesthesia (intravenous injection diluted to 20 ml and given over at least 2 min).Intravenous infusionBenign gastric and duodenal ulceration, reflux oesophagitis, Zollinger-Ellison syndrome: 25 mg/h for 2 h, may be repeated every 6 to 8 h.Prophylaxis of stress ulceration: initial slow intravenous injection of 50 mg diluted to 20 ml and given over at least 2 min then by continuous intravenous infusion, 125- 250 µg/kg per h (may be followed by 150 mg twice daily by mouth when oral feeding commences).",Porphyria,Hepatic impairment (Appendix 7a), renalimpairment, lactation (Appendix 7b), middle-aged or older patients and those whosesymptoms change-may mask gastric cancer,interactions (Appendix 6a), pregnancy(Appendix 7c),"Diarrhoea and other gastrointestinaldisturbances; headache; dizziness; rash;tiredness; acute pancreatitis; bradycardia,tachycardia; AV block, confusion; depression;rarely, hallucinations (particularly in theelderly or the very ill); hypersensitivityreactions (including fever, arthralgia, myalgia,anaphylaxis); blood disorders (includingagranulocytosis, leukopenia, pancytopenia,thrombocytopenia); hepatitis; agitation;visual disturbances; erythema multiforme;alopecia; gynaecomastia and impotence;malaise; somnolence.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Adrenaline (Epinephrine),Pregnancy Category-C,Schedule H,Severe anaphylactic reaction, severeangioedema, cardiac arrest, hemostaticagent.,INJECTION 1 ml ampoule (1 mg/ml).,Intramuscular injectionAnaphylaxis: preferable site is the midpoint in anterior thigh [1:1000 solution]. This route should be used by specialists only with extreme care.Slow intravenous injectionWhen there is doubt regarding adequacy of circulation and absorption from the intramuscular site, slow intravenous injection of 1:10000 (10 mg/ml) solution be injected in severely ill patients only.,"Narrow angle glaucoma, organic brain dam-age, cardiac dilation, coronary insufficiency.","Hyperthyroidism, hypertension, diabetesmellitus, heart disease, arrhythmias,cerebrovascular disease; second stage oflabour; elderly; interactions (Appendix6c); pregnancy (Appendix 7c); lactation(Appendix 7b).","“Epinephrine fastness”, tachycardia andarrhythmias, hypertension, tremor, anxiety,sweating, nausea, vomiting, weakness,hyperglycaemia, dizziness, pulmonaryoedema have all been reported; headachecommon",Store protected from light preferably in containers filled with nitrogen.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Chlorpheniramine,Pregnancy Category-C,"Schedule H,G","Symptomatic relief of allergy, allergic rhinitis(hay fever); conjunctivitis; urticaria; insectstings and pruritus of allergic origin; adjunctin the emergency treatment of anaphylacticshock and severe angioedema.","TABLETS 2, 4 and 6 mg; INJECTIONS 10mg/10 ml, CAPSULE 8 mg; SyRUP 10 mg/50ml, 100 mg/100 ml.","OralAdult- Allergic reactions: 4 mg every 4 to 6 h (max. 24 mg daily). Child- 1 to 2 years: 1 mg twice daily.2 to 5 years: 1 mg every 4 to 6 h (max. 12mg daily). 6 to 12 years: 2 mg every 4 to 6 h(max. 12 mg daily)Intramuscular or intravenous injectionAdult- Allergic reactions: 10 to 20 mg, repeated if required (max. 40 mg in 24 h).Subcutaneous injectionChild- Allergic reactions: 87.5 µg/kg, repeated if necessary up to 4 times daily.Intravenous injection (over 1 min).Adult- Anaphylaxis (adjunct): 10 to 20 mg.Child- Anaphylaxis (adjunct)- under 1 year: 250 µg/kg. 1 to 5 years: 2.5 to 5 mg. 6 to 12years: 5 to 10 mg.","Prostatic enlargement, urinary retention;ileus or pyloroduodenal obstruction; asthma;child under 1 year; hypersensitivity, narrowangle glaucoma, pregnancy (Appendix 7c),lactation (Appendix 7b).","Performing works requiring utmost alertnesssuch as vehicle driving, operating machinesetc within 24 h of taking the drug should beavoided.Lactation (Appendix 7b); renal andhepatic impairment (Appendix 7a); epilepsy;interactions (Appendix 6a); atropic gastritis,elderly.","Drowsiness (rarely, paradoxical stimulationwith high doses, or in children or elderly),hypotension, headache, palpitations,psychomotor impairment, urinary retention,dry mouth, blurred vision, gastrointestinaldisturbances; liver dysfunction; blooddisorders; also rash and photosensitivityreactions, hypersensitivity reactions(including bronchospasm, angioedema,anaphylaxis); sweating and tremor, injectionsmay be irritant; flatulence, diarrhoea.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cinnarizine,Pregnancy Category-C,Schedule H,"Motion sickness, nausea, vomiting, vertigoand tinnitus associated with Meniere diseaseand other middle ear disorders, as a nootropicdrug, adjunct therapy for symptoms ofperipheral arterial disease.",TABLETS 25 & 75 mg Plain and 75 mg SR.,OralMotion sicknessAdult: 30 mg 2 hr before travel and 15 mg every8 hr during travel if needed.VertigoAdult: 30 mg thrice daily.Child: 5-12 year: half of adult dose.Peripheral circulatory disorders Adult: 75 mg tablets three times daily.,"Hypersensitivity, Parkinson's disease, children below 5 years.","Hypotension, patients should not drive oroperate machinery, pregnancy (Appendix7c), lactation, elderly, children and neonates,interactions (Appendix 6c).","Drowsiness, rarely skin and hypersensitivityreactions, dry mouth, extrapyramidalsymptoms sometimes associated withsevere depression, muscular weakness,headache, euphoria, GI upsets, blurredvision, urinary difficulty or retention,constipation and increased gastric reflux,fatigue, hypolipidaemic effect.","Store below 25⁰C, protected from light",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Dexamethasone,Pregnancy Category-C,Schedule H,"Adjunct in the emergency treatmentof anaphylaxis; short-term suppressionof inflammation in allergic disorders;adrenocortical insufficiency, ocularinflammation, autoimmune disorders,rheumatic disorder, cerebral oedema,unresponsive shock, bacterial meningitisalong with antibiotics.",TABLETS 0.5 mg, INJECTION 2 ml vial (4 mg/ml), CREAM 5 and 15 g (0.1% w/w).,"OralAdult- 0.5 to 10 mg daily in divided doses, repeat if necessary.Child- 0.02 to 0.3 mg/kg in three or four divided doses daily. Intravenous injection4 to 10 mg every 6 h.","Untreated systemic infection (unlesscondition life-threatening); administrationof live virus vaccines; renal failure, diabetesmellitus, psychosis, osteoporosis, pregnancy(Appendix 7c), CHF, tuberculosis, fungalinfections of the eye.","Increased susceptibility to and severityof infection; activation or exacerbation oftuberculosis,amoebiasis,strongyloidiasis;riskof severe chickenpox in non-immune patient(varicella-zoster immunoglobulin required ifexposed to chickenpox); avoid exposure tomeasles (normal immunoglobulin possiblyrequired if exposed); diabetes mellitus;peptic ulcer; hypertension; precautionsrelating to long-term use of corticosteroids;glaucoma, epilepsy; drug should not beabruptly withdrawn; interactions (Appendix6c), lactation (Appendix 7b).","Nausea, dyspepsia, malaise, hiccups;hypersensitivity reactions includinganaphylaxis; perineal irritation afterintravenous administration; adverse effectsassociated with long-term corticosteroidtreatment; hyperglycaemia, abdominaldistension, angioedema, bradycardia,acne, erythema, Cushing’s syndrome,oropharangeal candidiasis, hypothalamicpituitary adrenal axis suppression.",Store protected from light at a temperature not exceeding 30⁰C. ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Fexofenadine,Pregnancy Category-C,Schedule H,"Allergic rhinitis, urticaria.","TABLETS 30, 60, 120 and 180 mg;SyRUP 30 mg/5 ml.","Allergic rhinitis: Adult- 120 mg once daily.Child (6-11year)- 30 mg twice daily.Urticaria and skin allergy: Adult-180 mg once daily.Child- (6 month to 2 years): 15 mg twice daily, more than 2 years: 30 mg twice daily.",Hypersensitivity,"Bradycardia, hypokalemia, preexisting longQT interval, renal impairment, pregnancy(Appendix 7c), lactation, interactions(Appendix 6a, 6c).","Dizziness, stomach discomfort, pain inextremity, back pain, vomiting, diarrhoea,upper respiratory tract infection, headache,dysmenorrhoea.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hydrocortisone,Pregnancy Category-C,Schedule H,"Adjunct in the emergency treatment ofanaphylaxis; inflammatory skin conditions;inflammatory bowel disease; adrenocorticalinsufficiency; As acetate: rheumatology,neurology, episcleritis, sinusitis; Addison’sdisease, Simmond’s disease, terculousmeningitis; perineal trauma, jointinflammation, subaortic dermatitis.","TABLETS 5, 10 and 20 mg, CREAM 10g (1%w/w), OINTMENT 1%, 2.5% w/w INJECTION100, 200 and 400 mg/vial, (25 mg/5 ml).","Intramuscular injection or slow intravenous injection or intravenous infusionAdult-100 mg to 500 mg, 3 to 4 times in 24 h or as required.Slow intravenous injectionChild- Up to 1year: 25 mg. 1 to 5 years: 50 mg.",Not relevant to emergency use but forcontra-indications relating to long-term use,ulcers.,"Not relevant to emergency use but forprecautions relating to long-term use,interactions (Appendix 6d), lactation(Appendix 7b), pregnancy (Appendix 7c).",Adverse effects associated with long-termcorticosteroid treatment, opportunisticinfections,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Levocetirizine,Pregnancy Category-B,Schedule H,"Allergic rhinitis, chronic urticaria",TABLETS 5 mg, SyRUP 2.5 mg/5 ml.,"OralRhinitis, chronic urticaria: Adult & children (>12 years) - 5 mg once daily in the evening. Children (6-12 yrs) - 2.5 mg once daily. Children (6 months - 5 yrs) – 1.25 mg once daily.","Hypersensitivity, end-stage renal diseasewith creatinine clearance < 10 ml/min. Notrecommended for lactating mothers orchildren below 6 months.","May impair the ability to drive or operatemachinery, concurrent use of alcohol orCNS depressant drugs should be avoided,pregnancy (Appendix 7c), elderly, interactions(Appendix 6c).","Somnolence, fatigue, dry mouth,nasopharyngitis have been reported in adults.Fever, cough, epistaxis and diarrhoea mayoccur in children <12 years.","Store protected from heat, light and moisture at a temperature not exceeding 30⁰C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Noradrenaline,Pregnancy Category-C,,"Acute hypotension, adjunct in cardiac arrest,upper gastrointestinal haemorrhage.","INJECTIONS Vials (4 mg/ml, 4 mg/2 ml and2 mg/2 ml)","ParenteralIntravenousAcute hypotensionAdult: 8-12 µg/minute, up to 8-30 µg/minutein refractory shock. Infused using a solutionof 4 µg/ml in glucose 5%, or sodium chloride0.9% and glucose 5% at a rate of 2-3 ml/minute. Adjust according to blood pressureresponse. Average maintenance dose: 0.5-1ml/minute (2-4 µg/minute). Infuse via acentral venous catheter or into a large vein.Child: Administer at a rate of 2 µg/minute.Alternatively, 2 µg/m2/minute. Adjust rateaccording to BP response and perfusion.Elderly: Initial dose should be at low end ofdose range. Upper gastrointestinal haemorrhageAdult: 8 mg in 250 ml of 0.9% sodiumchloride injection via intraperitoneal routeAlternatively, instill 8 mg in 100 ml of 0.9%sodiumchloridesolutionthroughanasogastrictube every hr for 6–8 hrs, then every 2 hrs for4–6 hrs. Withdraw drug gradually.ReconstitutionDilute with 5% glucose injection, with orwithout sodium chloride; dilution withsodium chloride injection alone is notrecommended.","Hypertension, pregnancy (Appendix 7c),patients with peripheral or mesentericvascular thrombosis unless necessary as alife-saving procedure.During cyclopropane and halothaneanaesthesia, noradrenaline is consideredcontraindicated because of the risk ofproducing ventricular tachycardia orfibrillation",,,"Store protected from light, in single dose containers.Store at room temperature (25⁰C) and protect from light. Store in tight, light- resistant containers as it is readily oxidised. Do not use if discoloured (e.g. pink, dark yellow, brown) or if there is a precipitate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pheniramine,Pregnancy Category-C,Schedule H,Symptomatic relief of allergy, allergic rhinitis,urticaria.,TABLETS 25 and 50 mg, INJECTION 2 mlampoule (22.75 mg/ml), SyRUP 15 mg/ml.,"OralAdult- 25 mg, 2 to 3 times a day or 50 mg twice daily.Intramuscular injectionAdult- 1 to 2 ml twice a day. Child- 6 months to 3 years: 0.4 to 1 ml once or twice daily. Over 4 years: 0.8 to 2 ml once or twice daily.",Epilepsy, pregnancy (Appendix 7c), acuteasthma, acute porphyria, symptomaticprostatic hypertrophy, neonates andpremature infants.,"Glaucoma; driving or operating machinery;asthma or severe cardiovascular disease,pregnancy (Appendix 7c), lactation.",Drug abuse, CNS depression, dry mouth,blurred vision, dizziness, excitation inchildren.,Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Prednisolone,Pregnancy Category-C,Schedule H,"Short-term as well as long term suppressionof inflammation in allergic disorders;malignant disease; Autoimmune disease,bronchial asthma.","TABLETS 5, 10, 20, 30 and 40 mg; SyRUP 1mg/ml and 3 mg/ml; EyE DROPS 1% w/v;INJECTION 2 ml vial (40 mg/ml).","OralAdult and Child- Initially up to 10 to 20 mg daily in divided doses (severe diseases up to 60 mg), preferably after breakfast.Intramuscular injectionAdult and Child- 25 mg to 100 mg once or twice weekly.",Untreated systemic infection, administrationof live virus vaccines, hypersensitivity.,"Increased susceptibility to and severityof infection; activation or exacerbation oftuberculosis,amoebiasis,strongyloidiasis;riskof severe chickenpox in non-immune patient(varicella-zoster immunoglobulin required ifexposed to chickenpox); avoid exposure tomeasles (normal immunoglobulin possiblyrequired if exposed); diabetes mellitus; pepticulcer; hypertension; further precautionsrelating to long-term use of corticosteroids;myasthenia gravis, congestive heart failure,renal insufficiency, pregnancy (Appendix 7c),osteoporosis, glaucoma, psychologicaldisorders, diverticulitis, interactions(Appendix 6c, 6d), lactation (Appendix 7b),hepatic impairment (Appendix 7a).","Nausea, dyspepsia, malaise, hiccups; hyper-sensitivity reactions including anaphylaxis;supraclavicular lump, fragile skin.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Donepezil,Pregnancy Category-C,Schedule H,For the treatment of mild to moderate Alzheimer’s disease.,TABLETS 5 and 10 mg Plain.,OralAdult- Initially 5 mg daily in the evening. If necessary increase upto 10 mg once daily after 4-6 weeks.Extended release tablet- once daily (23 mg/ day).Maximum dose- 10 mg daily.,"Hypersensitivity, severe hepatic and renalimpairment, pregnancy (Appendix 7c),lactation, not recommended for children.","Mechanicalintestinalobstructionorperitonitis,Recent intestinal or bladder surgery, bronchialasthma or COPD, arrhythmias, bradycardia,recent MI and hypotension, vagotonia,epilepsy, hyperthyroidism, parkinsonism,moderate renal or hepatic impairment orpeptic ulcer, sick sinus syndrome.","Nausea, vomiting, diarrhoea, fatigue,insomnia, muscle cramps, bradycardia,convulsions, gastrointestinal, haemorrhage,hepatitis, urinary incontinence, influenza,pruritus, increased liver transaminases.","Store protected from moisture, at a temperature not exceeding 25⁰C.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Galantamine,Pregnancy Category-B,Schedule H,"To treat the symptoms of mild to moderateAlzheimer’s disease, Dementia syndrome.","TABLETS 4 mg, 8 mg and 12 mg; CAPSULES ER8, 16 and 24 mg; ORAL SOLUTION 4 mg/ml.","Oral with mealsFor Alzheimer’s disease: 4 mg twice daily. For Dementia Syndrome: 8 to 12 mg twicedaily.Extended Release Capsule: 16 to 24 mg once daily. Oral Solution: Initially 4 mg twice daily, Maximum 12 mg twice daily (24 mg/day) and in hepatic/renal impairment (max. dose:16 mg/day).","Hypersensitivity to galantamine, severekidney and liver problems, pregnancy(Appendix 7c), lactating mothers, children.","Patients with asthma or lung disease,epilepsy, stomach ulcer, take plenty of fluidsduring treatment.","Diarrhoea, nausea, anorexia and weight loss,chest pain or shortness of breath.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Memantine,Pregnancy Category-B,,Treatment of moderate to severe dementia of Alzheimer’s disease.,TABLETS 5 and 10 mg, CAPSULES 10 mg,ORAL SOLUTION 2 mg/ml.,5 mg once daily, (max. dose upto 20 mg/day).,Hypersensitivity to memantine,"Seizure, rise in urine pH results in increasedplasma levels, pregnancy (Appendix 7c),lactation, children.","Fatigue, pain, hypertension, dizziness,headache, constipation, vomiting, backpain, confusion, somnolence, hallucination,coughing, dyspnea, insomnia, urinary tractinfections, anxiety, peripheral oedema,arthralgia.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Rivastigmine,Pregnancy Category-B,Schedule H,Moderate to severe dementia.,"TABLETS 3 and 4.5 mg; CAPSULES 1.5, 3, 4.5and 6.0 mg.Transdermal patches containing 9 mg in 5cm2 and 18 mg in 10cm2.",Adult - Initially 1.5 mg twice daily, (max. dose 6 mg twice daily).,"Hypersensitivity to carbamate derivativesand severe hepatic impairment, children,lactation.","Renal or hepatic impairment, acid pepticdisease, pregnancy (Appendix 7c), asthma,sick-sinus syndrome.","Mild peripheral cholinergic effect, nausea,vomiting, anorexia, dyspepsia, asthenia,abdominal pain, depression, gastrointesti-nal haemorrhage, weight loss, urinary tractinfections, insomnia, hallucinations, hyper-tension, elevated LFTs.Smaller patch associated with fewer adverse effects.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tacrine,Pregnancy Category-C,Schedule H,Mild to moderate Alzheimer’s typedementia.,"CAPSULES 10, 20, 30 and 40 mg.","10 mg, 4 times par day; (max. dose 40 mg 4 times par day).","Hepatic impairment, hyperbilirubinaemia,bradycardia, bronchial asthma, seizures andgastro intestinal obstruction","Haematological disorders, pregnancy (Appendix 7c), lactation.","Hepatotoxicity, cholinergic side effects.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Biperiden,Pregnancy Category-C,Schedule H,Medicine-induced extrapyramidal symptoms(but not tardive dyskinesias) and adjunctivetreatment of parkinsonism.,TABLET 2 mg, INJECTION 1 ml ampoule(5 mg/ml).,"OralAdult- Medicine-induced extra-pyramidal symptoms, parkinsonism: initially 1 mg twice daily, increased gradually to 2 mg thrice daily; usual maintenance dose 3 to 12 mg daily in divided doses.Intramuscular injection or Slow intravenous injectionAdult- Medicine-induced extra-pyramidal symptoms, parkinsonism: 2.5 to 5 mg repeated as necessary to max. 20 mg in 24 h.",Angle-closure glaucoma, bowel obstruction,megacolon, untreated urinary retention,prostatic hypertrophy, myasthenia gravis,gastrointestinal obstruction.,,,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Bromocriptine,Pregnancy Category-B,Schedule H,Parkinsonism,"TABLETS 1.25, 2.5 and 5 mg.","OralAdult- First week 1 to 1.25 mg at night, second week 2 to 2.5 mg at night, third week2.5 mg twice daily, fourth week 2.5 mg 3 times daily, then increasing by 2.5 mg every 3 to 14 days according to response to a usual range of 10 to 40 mg daily. Take with food.Child- Under 15 years; not recommended.","Hypersensitivity to bromocriptine or otherergot alkaloids; ischaemic heart disease;toxaemia of pregnancy and hypertension inpostpartum women or in puerperium.Should not be used postpartum or in puerperium in women with high blood pressure, coronary artery disease or symptoms (or history) of serious mental disorder; monitor blood pressure carefully (especially during first few days) in postpartum women. Very rarely, hypertension, myocardial infarction, seizures or stroke (both sometimes preceded by severe headache or visual disturbances) and mental disorders have been reported in postpartum women given bromocriptine for lactation suppression-caution with antihypertensive therapy and avoid other ergot alkaloids. Discontinue immediately if hypertension, unremitting headache or signs of CNS toxicity develop.","Specialist evaluation-monitor for pituitaryenlargement, particularly during pregnancy,annual gynaecological assessment (post-menopausal, every 6 months), monitor forpeptic ulceration in acromegalic patients;contraceptive advice if appropriate (oralcontraceptives may increase prolactin con-centration); avoid lactation for about 5 daysif lactation prevention fails; history of seriousmental disorders (especially psychotic disor-ders) or cardiovascular disease or Raynaud'ssyndrome; monitor for retroperitoneal fibro-sis; porphyria; hepatic impairment; interac-tions (Appendix 6a, 6c, 6d). Hypotensive reactions may be disturbing in some patients during the first few days of treatment and particular care should be exercised when driving or operating machinery; tolerance may be reduced by alcohol.","Nausea, constipation, headache, drowsiness,nasal congestion; less commonly vomiting,postural hypotension, fatigue, dizziness,dyskinesia, dry mouth, leg cramps; also,particularly with high doses, confusion,psychomotor excitation, hallucinations;rarely, constrictive pericarditis, pericardialeffusion, pleural effusion (may necessitatediscontinuation), retroperitoneal fibrosisreported (monitoring required), hair lossand allergic skin reactions; very rarely,gastro-intestinal bleeding, gastric ulcer,vasospasm of fingers and toes particularlyin patients with Raynaud's syndrome andeffects like neuroleptic malignant syndromeon withdrawal, increased libido andhypersexuality also reported; conjunctivalinfection.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Levodopa + Carbidopa,Pregnancy Category-C,Schedule H,All forms of parkinsonism other thanmedicine-induced.,TABLETS Levodopa 100 mg + Carbidopa 10mg, Levodopa 100 mg + Carbidopa 25 mg,Levodopa 200 mg + Carbidopa 50 mg,Levodopa 250 mg + Carbidopa 25 mg.,"OralAdult- Parkinsonism: expressed in terms of levodopa, initially 100 mg (with carbidopa10 mg) twice daily, increased by 100 mg (with carbidopa 10 mg) every few days as necessary, to a max. of 1.5g.Optimum daily dose must be determined for each patient by careful monitoring and be taken after meals.",Concurrent use of monoamine oxidaseinhibitors, undiagnosed chin lesion, lactation,psychosis, decompensated endocrine, angle-closure glaucoma, confirmed or suspectedmalignant melanoma.,"Pulmonary disease, peptic ulceration,cardiovascular disease (including previousmyocardial infarction); diabetes mellitus,osteomalacia, open-angle glaucoma, historyof melanoma (risk of activation), psychiatricillness (avoid if severe); close monitoringof hepatic, haematological, psychiatric,cardiovascular and renal function requiredin long-term therapy; elderly: avoid rapiddose increases; warn patients to resumenormal activities gradually; avoid abruptwithdrawal; pregnancy (toxicity in animals)(Appendix 7c), lactation; interactions(Appendix 6c).","Nausea, anorexia and vomiting, particularlyat the start of treatment; posturalhypotension at the start of treatment,particularly in elderly and those receivingantihypertensives; excessive drowsinessand sudden onset of sleep (warn patientof these effects); confusion, vivid dreams,dizziness, tachycardia, arrhythmias; reddishdiscolouration of body fluids; insomnia,headache, flushing, gastrointestinal bleeding,peripheral neuropathy; taste disturbances,pruritus, rash, liver enzyme changes;psychiatric symptoms including psychosis,depression, hallucinations, delusionsand neurological disturbances includingdyskinesias may be dose-limiting; painfuldystonic spasms (‘end-of-dose’ effects) and(‘on-off’ effects) after prolonged treatment(see notes above); neuroleptic malignantsyndrome, on sudden withdrawal; rarely,hypersensitivity, dyspnoea; upper respiratoryinfection.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Trihexyphenidyl (Benzhexol),Pregnancy Category-C,Schedule H,"All forms of parkinsonism other thanmedicine-induced, control of extrapyramidaldisorders caused by CNS drugs.",TABLETS 2 and 5 mg, INJECTION vial 2 mg/ml,"1 mg daily, increased gradually; usual maintenance dose 5 to 15 mg daily in 3 to 4 divided doses (max. 20 mg daily); elderly preferably lower end of range.",Avoided in gastro-intestinal obstruction andmyasthenia gravis, closed angle glaucoma,chronic pulmonary disease, sick sinussyndrome, thyrotoxicosis, tachycardia.,"Use with caution in cardiovascular disease,hypertension, psychotic disorders,prostatic hypertrophy, pyrexia, in thosesusceptible to angle-closure glaucoma andin the elderly. It should not be withdrawnabruptly in patients receiving long-termtreatment. Antimuscarinics are liable toabuse. Elderly males with possible prostatehypertrophy; tardive dyskinesia; neurolepticmalignant syndrome. Use with caution inrenal impairment and hepatic impairment,lactation and interactions (Appendix 6a).","Constipation, dry mouth, nausea, vomiting,tachycardia, dizziness, confusion, euphoria,hallucinations, impaired memory, anxiety,restlessness, urinary retention, blurred visionand rash. Angle-closure glaucoma may occurvery rarely, paralytic ileus; dilation of colon.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Carbamazepine,Pregnancy Category-D,Schedule H,Partial seizures with or without secondarygeneralisation, trigeminal neuralgia, bipolardisorder,"TABLETS 100, 200 and 400 mg Plain; 100 mg DT;200, 300 and 400 mg CR and SR; SyRUP 100 ml(100 mg/5 ml).",OralAdult- Initially 100 and 200 mg 1 to 2 times daily increased slowly to usual dose of 400 mg to 1.2g daily in divided doses. In some cases 1.6 to 2g may be needed. Administer lower initial dose to elderly.Child- Start with 5 - 10 mg/kg/day in two to three divided doses then gradually increase at weekly intervals to a max. dose of 30-35 mg/ kg/day,Atrioventricular conduction abnormalities,history of bone-marrow depression, porphyria.,"Hepatic impairment (Appendix 7a); renalimpairment; cardiac disease (see alsoContraindications); skin reactions (seeAdverse effects); history of blood disorders(blood counts before and during treatment);glaucoma; lactation (Appendix 7b); avoidsudden withdrawal; interactions (Appendix 6b,6c, 6d); pregnancy (Appendix 7c).Patients or their caretakers should be told how to recognize signs of blood, liver or skin disorders and advised to seek immediate medical attention if symptoms such as fever, sore throat, rash, mouth ulcers, bruising or bleeding develop. Leukopenia which is severe, progressive and associated with clinical symptoms requires withdrawal (if necessary under cover of suitable alternative).May impair ability to perform skilled tasks, for example operating machinery, driving; see also notes above","Dizziness, drowsiness, headache, ataxia,blurred vision, diplopia (may be associatedwith high plasma levels); gastrointestinalintolerance including nausea and vomiting,anorexia, abdominal pain, dry mouth, diarrhoeaor constipation; commonly, mild transientgeneralized erythematous rash (withdraw ifworsens or is accompanied by other symptoms);leukopenia and other blood disorders (includingthrombocytopenia, agranulocytosis and aplasticanaemia); cholestatic jaundice, hepatitis, acuterenal failure, Stevens-Johnson syndrome(erythema multiforme), toxic epidermalnecrolysis, alopecia, thromboembolism,arthralgia, fever, proteinuria, lymph nodeenlargement, arrhythmias, heart blockand heart failure, dyskinesia, paraesthesia,depression, impotence, male infertility,gynaecomastia, galactorrhoea, aggression,activation of psychosis, photosensitivity,pulmonary hypersensitivity, hyponatraemia,oedema, disturbances of bone metabolismwith osteomalacia also reported; confusionand agitation in elderly.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Clobazam,Pregnancy Category-D,Schedule H,"Add-on for refractory partial, complex andgeneralized seizures, add-on in West syndrome,LGS, myoclonic epilepsy, absence seizures,to cover short period of increased seizuresusceptibility addition of new AED examinationsovernight travel catamenial epilepsy,intermittent prophylaxis in febrile seizures.","TABLETS 5, 10 and 20 mg.","Oral0.3-2.9 mg/kg/day, (average 1 mg/kg/day) single at bed time or twice daily dose.",,"Pregnancy (Appendix 7c), interactions(Appendix 6c).","Sedation, dizziness, hyperactivity, behaviouralproblem, irritability, drooling, weight gain,sleep disturbance, blurring, diplopia.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Clonazepam,Pregnancy Category-D,Schedule H,"Absence seizures, myoclonic seizures, akineticseizures, panic disorder, subcortical myoclonus,adjuvant treatment of refractory epilepsy.","TABLETS 0.25, 0.5, 1 and 2 mg","Adult- 0.5 - 5 mg thrice daily, initial dose should not exceed 1.5 mg/day, slow titration is recommended Maintenance dose 4-8 mg daily, Maximum dose 20 mg daily.Infants and child: Initial dose 0.01-0.03 mg/ kg/day (not to exceed 0.05 mg/kg/day) given in 2-3 divided doses. Maintenance dose 0.1-0.2 mg/kg/day in 3 divided doses.Panic disorder: Adult- Initial dose 0.25 mg twice daily, usual maintenance dose 1 mg/day, maximum dose 4 mg/day.","Hypersensitivity to benzodiazepines, acutepulmonary insufficiency, acute narrow angleglaucoma.","Neonates, chronic pulmonary insufficiency,hepatic and renal dysfunction, porphyria,elderly, pregnancy (Appendix 7c), lactation(Appendix 7b), interactions (Appendix 6a, 6c);avoid sudden withdrawal.","Sedation, dullness, CNS depression, ataxia,bronchial hypersecretion, abnormal eyemovement, blood dyscrasias.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Diazepam,Pregnancy Category-D,Schedule H,Status epilepticus, emergency managementof recurrent seizures, febrile convulsions,seizures associated with poisoning andmedicine withdrawal, adjunct in acute alcoholwithdrawal, premedication, anxiety disorders,psychosomatic behaviour disorder, spasticity.,"TABLETS 2, 5 and 10 mg; CAPSULE 10 mg;SUSPENSION 2 mg/ml; INJECTION 2 mlampoule (5 mg/ml)","Intravenous injection Adult-Treatment of status epilepticus and convulsions due to poisoning: 10 mg at the rate of 1 ml/min (5 mg) repeated if necessary after 10 min.Child-Under 12 years: 300 to 400 µg/kg, repeated after 10 min if necessary.","Respiratory depression; acute pulmonaryinsufficiency; sleep apnoea; severe hepaticimpairment; myasthenia gravis; avoid injectionscontaining benzyl alcohol in neonates,narrow angle glaucoma; hypersensitivity tobenzodiazepine.","Respiratory disease, muscle weakness, historyof alcohol or drug abuse, marked personalitydisorder; pregnancy (Appendix 7c); lactation(Appendix 7b); reduce dose in elderly ordebilitated patients and in hepatic impairment(avoid if severe, Appendix 7a), renalimpairment; avoid prolonged use and abruptwithdrawal; when given intravenously, facilitiesfor reversing respiratory depression withmechanical ventilation must be at hand (seebelow); porphyria; interactions (Appendix 6a,6c); blood count test on prolonged treatment.Intravenous infusion of diazepam is potentially hazardous (especially if prolonged) calling for close and constant observation and best carried out in a speciality centre with intensive care facilities. Prolonged intravenous infusion may lead to accumulation and delay recovery.May impair ability to perform skilled tasks, for example operating machinery, driving; see also notes above.","Drowsiness and lightheadedness the nextday; confusion and ataxia (especially in theelderly); amnesia; dependence; paradoxicalincrease in aggression; muscle weakness;occasionally headache, vertigo, salivationchanges, gastrointestinal disturbances, skinreactions, visual disturbances, dysarthria,tremors, incontinence, urinary retention;blood disorders and jaundice; hypotensionand apnoea, pain and thrombophlebitis (withinjection); increased appetite; weight gain.",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Fosphenytoin,Pregnancy Category-D,Schedule H,Generalized tonic-clonic status epilepticus.,INJECTION 2 ml vial (75 mg/ml).,Adult- 15 mg/kg i.v. infusion at the rate of 100- 150 mg/min.,Porphyria,"Uremia, hypoalbuminemia, interactions(Appendix 6b, 6c); pregnancy (Appendix 7c)","Cardiovascular collapse and/or central nervoussystem depression, nystagmus, dizziness,pruritus, paresthesia, headache, somnolence,ataxia, hypotension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Gabapentin,Pregnancy Category-C,Schedule H,"Add-on drug in resistant partial seizures withor without secondary generalization, rolandicepilepsy- preferred for safety reason, first linein epilepsy patients with hepatic disease.",TABLETS/CAPSULES 100 and 300 mg.,"OralInitially 10 mg/kg/day, increase 10 mg/kg/day to maintenance dose 30-100 mg/kg/day, in three divided doses.",Pregnancy (Appendix 7c),"Somnolence, dizziness, fatigue, nystagmus,behavioral changes (<10%)-aggression,hyperexcitability, tantrum, euphoria, weightgain.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Lamotrigine,Pregnancy Category-C,Schedule H,Partial seizures and secondary generalisedtonic-clonic seizures.,"TABLETS 25, 50 and 100 mg Plain; 5, 150 and200 mg DT","OralAdult and Child over 12 years- 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 weeks, increase by 50 to 100 mg every 1 to 2 weeks to maintenance dose of 100 to 200 mg daily.Child- Monotherapy- Inital dose 2 mg/kg/day for 2 weeks then 5 mg/kg/day for 2 weeks. max. dose 5 - 15 mg/kg/day once or twice daily. With valproic acid- Initial dose - 0.5 mg/kg/ day to max. dose of 1 - 5 mg/kg/day in single dose.With enzyme inducer- 2 mg/kg/day for 2 weeks than 5 mg/kg/day for 2 weeks. Max. 5 - 15 mg/ kg/day once or twice daily, when valproic acid added to already regimen with lamotrigine, reduce dose of lamotrigine by 25 - 50%.",Child less than 12 years, hypersensitivity,severe hepatic and renal impairment.,Monitoring of liver and renal function, abruptwithdrawal to be avoided, pregnancy (Appendix7c) and lactation, avoid in patients who needto undertake task requiring mental alertness,patients taking sodium valproate.,Skin eruptions, nausea, vomiting, headache,toxic epidermal necrosis, hepatotoxicity,leucopenia, thrombocytopenia, confusion,hallucination.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Levetiracetam,Pregnancy Category-C,Schedule H,"Good effect difficult-to-treat idiopathic focalepilepsies of childhood, including variationssuch as continuous spike and wave duringsleep or Landau-Kleffner syndrome (LKS),photosensitivity and myoclonus- Generalisedepilepsy with photosensitivity, idiopathicepilepsy– control of GTCS and Myoclonic,treatment of postanoxic and post-encephaliticmyoclonic epilepsy, epileptic encephalopathies-LGS, West Syndrome, severe myoclonic epilepsy,absence seizure, rolandic epilepsy.","TABLETS 250, 500 and 750 mg, SyRUP 100 mg/ml, INJECTION 5 ml ampoule (100 mg/ml).","Oral Initial dose- 10-20 mg/kg/day, increase by 10 mg/kg/day every 1-2 week upto 40-60 mg/kg/ day in two divided doses.Intravenous injection20-30 mg/kg at the rate of 5 mg/kg/min.",Hypersensitivity,Renal disease, pregnancy (Appendix 7c).,"Most frequent somnolence, asthenia (dosedependent); headache, hair loss, vertigo,nausea, infection; behavioral changes such ashostility aggression, apathy, anxiety, depression,psychosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Magnesium Sulphate,Pregnancy Category-A,,Prevention of recurrent seizures in eclampsia,prevention of seizures in pre-eclampsia, acutenephritis in children.,INJECTION 500 mg/ml.,"Intravenous injection (concentration of magnesium sulphate should not exceed 20%)Prevention of seizure occurrence in eclampsia: initially 4g over 5 to 15 min, followed by infusion 1g/hr for at least 24 h after last seizure. If seizures recur, additional dose of 2g (or 4g if body weight is over 70 kg).",Not to be injected parenterally in patients withheart block or myocardial damage.,"Hepatic impairment (Appendix 7a); pregnancy(Appendix 7c); renal impairment; in severehypomagnesaemia administer initially viacontrolled infusion device (preferably syringepump); monitor blood pressure, respiratoryrate, urinary output and for signs of overdosage(loss of patellar reflexes, weakness, nausea,sensation of warmth, flushing, drowsiness,double vision and slurred speech).","Generally associated with hypermagnesaemia,nausea, vomiting, thirst, flushing of skin,hypotension, arrhythmias, coma, respiratorydepression, drowsiness and confusion, lossof tendon reflexes, muscle weakness; colicand diarrhoea following oral administration;hypothermia; stupor.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Oxcarbamazepine,Pregnancy Category-C,Schedule H,"Monotherapy or adjunctive therapy in thetreatment of partial seizures, secondarygeneralzed seizure, substitution forcarbamazepine can be made abruptly withan oxcarbamazepine-to-carbamazepine ratioof 300:200.","TABLETS 150, 300, 450, 500 and 600 mg;SUSPENSIONS 300 mg/5 ml.","Initial dose: 8-10 mg/kg/day, increasing by 8-10 mg/kg/day as tolerated at 3-7 day interval. Given in two divided doses. Maximum- 30 mg/ kg.",,Pregnancy (Appendix 7c), interactions (Appendix6c).,"Lessfrequentlythantheydowithcarbamazepine(2.8% vs 6.5%), hyponatremia is more commonbut not clinically significant, rash, weight gain,alopecia, nausea, headache, somnolence.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Phenobarbitone,Pregnancy Category-D,Schedule H,"Generalized tonic-clonic seizures; partialseizures; neonatal seizures; febrile convulsions;status epilepticus; sedative, hypnotic, pre-anaesthetic.",TABLETS 30 and 60 mg, INJECTION 1 mlampoule (200 mg/ml), SyRUP 20 mg/ml.,"Slow intravenous injectionStatus epilepticus: (dilute injection 1 in 10 with water for injections), Adult- 10 mg/kg at a rate of not more than 100 mg/min (up to max. total dose of 1 g); Child- 10-20 mg/kg at a rate of not more than 30 mg/min.OralAdult- 60-180 mg daily at night. Child- 1 month-12 years: 1-1.5 mg/kg twice daily, maintenance dose 2.5-4 mg/kg once/ twice daily. 12-18 years: Initially 60-180 mg twice daily, maintenance dose 60-180 mg once daily.",Absence seizures, latent porphyria.,"Elderly, debilitated, children (may causebehavioural changes); impaired renal functionor hepatic function (Appendix 7a), respiratorydepression (avoid if severe); pregnancy (seenotes above; Appendix 7c); lactation (Appendix7b); avoid sudden withdrawal; interactions(Appendix 6a, 6b, 6c); habbit forming.","Sedation, mental depression, agitation,hallucination, syncope; ataxia, nystagmus;allergic skin reactions including rarely, exfoliativedermatitis, toxic epidermal necrolysis, Steven’s-Johnson syndrome (erythema multiforme);paradoxical excitement, restlessness andconfusion in the elderly; irritability andhyperactivity in children; megaloblasticanaemia (may be treated with folic acid);osteomalacia; status epilepticus (on treatmentwithdrawal); hypotension, bradycardia, shock;laryngospasm and apnoea (with intravenousinjection); cognitive impairment; aplasticanaemia; hepatic failure; connective tissuedisorder; hyperkinesias.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Phenytoin,Pregnancy Category-D,Schedule H,Generalized tonic-clonic seizures, partial seizures, status epilepticus.,"TABLETS 100, 150 and 200 mg Plain; 300 mgSR; CAPSULES 25 mg, 100 mg; INJECTION 2 mlampoule (50 mg/ml); SUSPENSION 25 mg/ml","Oral or slow intravenous injection or infusionAdult- Status epilepticus: (with regular BP and ECG monitoring) 18 mg/kg at rate not exceeding 50 mg/min as loading dose, maintenance dose of about 100 mg should be given thereafter at an interval of 6 to 8 h (dose can be reduced according to weight).Child- Status epilepticus: 20 mg/kg at a rate not exceeding 1 mg/kg/min, maintenance dose 4-7 mg/kg/day in 2 divided doses, max dose 300 mg/day.","Porphyria; avoid parenteral use in sinusbradycardia, sino-atrial block, second- andthird-degree heart block, Stokes-Adamssyndrome; pregnancy (Appendix 7c).",,,Store protected from moisture at temperaturenot exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sodium Valproate,Pregnancy Category-D,Schedule H,Generalized tonic-clonic seizures, partialseizures, atonic seizures, absence seizures,myoclonic seizures, acute mania, migraine.,"TABLETS 125, 200, 250, 300 and 500 mg Plain;200, 300 and 500 mg CR; SyRUP 200 mg/5 ml;INJECTION 100 mg/vial, 5 ml ampoule (100mg/5 ml) CR.","OralAdult- 600 mg daily in two divided doses (preferably after food) thereafter increase by 200 mg at 3 days interval clinical response till desired.Child- Initial dose 20 mg/kg/day, max. dose 60 mg/kg/day.","Active liver disease, family history of severehepatic dysfunction; pancreatitis; porphyria;hypersensitivity.","Monitor liver function before and during first6 months of therapy (Appendix 7a), especiallyin patients at most risk (children under 3years of age, those with metabolic disorders,degenerative disorders, organic brain disease orsevere seizure disorders associated with mentalretardation, or multiple antiepileptic therapy);ensure no undue potential for bleedingbefore starting and before major surgery oranticoagulant therapy; renal impairment;pregnancy {important see notes above, (neuraltube screening)} (Appendix 7c); lactation (seenotes above; Appendix 7b); systemic lupuserythematosus; false-positive urine tests forketones; avoid sudden withdrawal; interactions(Appendix 6a, 6c, 6d); hyperammonemia.","Gastrointestinal irritation, nausea, increasedappetite and weight gain, hyperammonaemia;ataxia, tremor; transient hair loss (regrowthmay be curly); oedema, thrombocytopenia,inhibition of platelet aggregation; impairedhepatic function and rarely, fatal hepaticfailure (see Precautions-withdraw treatmentimmediately if malaise, weakness, lethargy,oedema, abdominal pain, vomiting, anorexia,jaundice, drowsiness or loss of seizure control);sedation reported and also increased alertness;behavioural disturbances; rarely, pancreatitis(measure plasma amylase if acute abdominalpain), extrapyramidal symptoms, leukopenia,pancytopenia, red cell hypoplasia, fibrinogenreduction; irregular periods, amenorrhoea,gynaecomastia, hearing loss, Fanconi syndrome,dementia, toxic epidermal necrolysis, Steven’s-Johnson syndrome (erythema multiforme),vasculitis, hirsutism and acne reported;hallucinations; abnormal gut; pneumonia;headache; taste perversion; polycystic ovary.",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Topiramate,Pregnancy Category-C,Schedule H,"Resistant partial seizures, LGS- I.S, GeneralizedTonic-Clonic Seizures (GTCS), severe myoclonicepilepsy of infancy.","TABLETS 25, 50, 100 and 200 mg.","OralInitial dose: 0.5 - 1 mg/kg/day (two divided doses) increase by 0.5 - 1 mg/kg/day at 1 to 2 week intervals, maintenance dose usually 5 - 9 mg/kg/day, max.-24 mg/kg/day.For prophylaxis of migraine headache: 100 mg/ day.",,"Pregnancy (Appendix 7c); interactions(Appendix 6a, 6c).","Anorexia, weight loss, cognitive slowing andbehavior changes, difficulty with memory,somnolence, dizziness, ataxia, fatigue, kidneystones (1.5%) 2-4 times higher than generalpopulation, paresthesias, liver functions- in 1%transient and mild enzymes, metabolic acidosis,Ac. myopia and sec, angle glaucoma- mostlyat start, oligohydrosis, hyperthermia and secrash, hyperammonemia and encephalopathywith concomitant valproic acid use, behavioralreactions (26%), Most frequent such asaggressiveness, hyperactivity, excitement,anxiety, obsessive behaviour, cognitive delayof various degree more in children than adultsbecause of preexisting behavioral problems inchildren with drug resistant epilepsy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Vigabatrin,Pregnancy Category-C,,"Infantile spasms, refractory partial seizureswith or without secondary generalization.",CAPSULES 500 mg.,"Initial dose- 40 mg/kg/day in two divided doses, increase to 80-100 mg/kg/day.In infantile spasms- Initial dose 40-50 mg/ kg/day increase by 50 mg/kg/day till spasm control or to 150-200 mg/kg/day",,Pregnancy (Appendix 7c).,"Psychosis (5%), behavioral problems,hyperactivity (most common cause fordiscontinuation), confusion, fatigue, insomnia,ataxia, drowsiness, weight gain, facialoedema, GIT upset (dose related), no effecton cognition. Chronic toxicity-most serious:persistent ncentric visual field defects in 1/3rdcases (rarely, reversible with early withdrawal),many patients are asymptomatic.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Zonisamide,Pregnancy Category-C,Schedule H,"Add-on in partial seizures, primary generalizedtonic clonic seizures, myoclonic epilepsy, absenceseizures, LGS, infantile spasms","CAPSULES 25, 50 and 100 mg; TABLET 100mg.","Oral Child- Initial dose - 2-4 mg/kg/day divided twice daily, with increments at 2- week intervals to 6-8 mg/kg/day and a possible maximum of 12 mg/kg/day.",,Pregnancy (Appendix 7c).,"Drowsiness, anorexia, ataxia, fatigue (doserelated), photosensitivity; cognitive effects-reversible psychotic effects, behavioralabnormalities, abnormal thinking, irritability(Do slow titration); weight loss, renal stones(mostly small); idiosyncratic-in 1.4% skin rash(including SJS, TEN), blood dyscrasias, hepaticfailure; oligohidrosis and hyperthermia (morein children).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Furazolidone,Pregnancy Category-C,Schedule H,Giardiasis, cholera, gastrointestinalinfections, protozoal or bacterial diarrhoeaand enteritis, food poisoning,TABLETS 100 mg, CAPSULE 100 mg,SUSPENSION 25 mg/5 ml.,OralAdult- 100 mg 3 to 4 times a day. Child- 5 mg/kg body weight daily in 4 divided doses.,Hypersensitivity, alcoholics, primaquinesensitivity.,"Urine colour changes to yellow afteradministration; orthostatic hypotension;hypoglycaemia; pregnancy (Appendix 7c);interactions (Appendix 6a, 6c).","Nausea, vomitting, headache; hypotension;urticaria; dyspnea; dizziness.",Store protected from light at temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Loperamide,Pregnancy Category-C,Schedule H,For the control and symptomatic relief ofacute nonspecific diarrhoea and chronicdiarrhoea associated with inflammatorybowel disease or gastroenteritis, for reducingthe volume of discharge from ileostomies.,TABLET/CAPSULE 2 mg, LIQUID 1 mg/5 ml.,OralAdult- 4 mg initially thereafter 2 mg after every motion.Child- 2 mg followed by 2 mg after every motion.,"Conditions where inhibition of peristalsisshould be avoided, where abdominaldistension develops, or in conditions suchas active ulcerative colitis or antibiotic-associated colitis.",Liver disease, pregnancy: (Appendix 7c),interactions (Appendix 6c), glaucoma, Crohn’sdisease, urinary bladder obstruction.,"Abdominal cramps, dizziness, drowsiness andskin reactions including urticaria; paralyticileus and abdominal bloating also reported;constipation; headache; meteorism; nausea;dry mouth; urinary retention.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Bisacodyl,Pregnancy Category-B,,Constipation,TABLETS 5 mg, SUPPOSITORIES 5 and 10mg.,Oral/RectalAdult and child over 10 years- 5 to 10 mg daily at night. Before radiological procedure and surgery: 16 to 20 mg at night before procedure.,"Intestinal obstruction (causes abdominalcramps), acute surgical abdominal conditions,acute inflammatory bowel disease, severedehydration; faecal impaction, chronic use.","Excessive use of stimulant laxatives cancause diarrhoea and related effects suchas hypokalaemia; however, prolonged usemay be justifiable in some circumstances;don’t give antacid within 1 hour, pregnancy(Appendix 7c), inflammatory bowel disease,pre-existing heart disease or bowel disease,allergies, interactions (Appendix 6d).","Tablets- griping; suppositories-localirritation; fainting, dizziness, soreness inanal region due to suppository leakage;abdominal discomfort, electrolyte imbalance,hypokalaemia.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ispaghula,,,Constipation, irritable colon syndrome.,GRANULES (flavoured and sweetened) 37.5and 100g.,OralAdult- 6 teaspoonful of water or milk at night before bed time.Child- 1-3 teaspoonful in water or milk before bed time.,Intestinal obstruction, colonic atony, difficulty in swallowing.,Salt restriction, interactions (Appendix 6c).,"Abdominal discomfort, flatulence,gastrointestinal obstruction.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Lactulose,,,"Constipation, hepatic encephalopathy.",SOLUTION/SyRUP 3.35g/5 ml.,"10 to 20g (15 to 20 ml/day, max 45 ml/day).","Galactosemia, intestinal obstruction, patients on low galactose diet.","Lactose intolerance, diabetes mellitus.","Diarrhoea (dose related), nausea, vomiting,hypokalaemia; dehydration; hypernatremia;bloating and abdominal cramps.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Senna,Pregnancy Category-C,,Constipation,TABLETS (containing Sennoside B-11.5 mg).,"OralAdult- 2 to 4 tablets, usually at night; initial dose should be low, then gradually increased.Child- over 6 years, half the adult dose in the morning (on doctor’s advice).",Intestinal obstruction, undiagnosed abdominal symptoms.,"Avoid prolonged use unless indicated forprevention of faecal impaction; pregnancy(Appendix 7c), lactation (Appendix 7b);hypersensitivity, undiagnosed abdominalpain, intestinal blockage.","Abdominal discomfort; atonic non-functioning colon and hypokalaemia (withprolonged use or overdosage); red or yellowbrown urine, diarrhoea, nausea, vomiting,bloating.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Oral Rehydration Salts,,,Dehydration from acute diarrhoea.,"GLUCOSE SALT SOLUTION 5 and 37.5g.Sodium chloride 2.6 g/litre of water Sodium citrate 2.9 g/litre of water Potassium chloride 1.5 g/litre of water Glucose (anhydrous) 13.5 g/litre of waterWhen glucose and sodium citrate are not available, they may be replaced bySucrose (common sugar) 27 g/litre of water Sodium bicarbonate 2.5 g/litre of waterIn cases of cholera, oral rehydration salts containing a higher concentration of sodium may be required to prevent hyponatraemia",Oral5g (single use): dissolve in water and drink, 37.5g: to reconstitute it with 1 litre of clean water.Adult- Fluid and electrolyte loss in acute diarrhoea, 200 to 400 ml solution after every loose motion.,,Renal impairment.,Vomiting- may indicate too rapidadministration, hypernatraemia andhyperkalaemia may result from overdose inrenal impairment or administration of tooconcentrated a solution. ,Store protected from moisture in a sachet preferably made of aluminium foil containing sufficient powder for single dose or for a day treatment or for use in hospital.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Activated Charcoal,,,Treatment of acute poisoning.,"POWDER (for oral suspension), TABLETS 500mg.","OralAdult and child over 12years- 50g, 0.5g/kg may be repeated every 4-6 h for upto 12-24 h.Child- Below 12years; 1g/kg (max 50g). May be repeated every 4 h.",Poisoning by hydrocarbons with highpotential for harm if aspirated, poisoningby corrosive substances-may preventvisualization of lesions caused by poison.,"Drowsy or unconscious patients-risk ofaspiration (intubate before administrationvia nasogastric or gastric tube); not effectivefor poisoning with alcohols, clofenotane(dicophane, DDT), cyanides, malathion andmetal salts including iron and lithium.","Black stools; vomiting, constipation ordiarrhoea; pneumonitis-due to aspiration.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Calcium Disodium Edetate,Pregnancy Category-B,,Lead poisoning (acute and chronic) and leadencephalopathy.,AMPOULE 5 ml (200 mg/ml).,"Intravenous injectionLead poisoning without encephalopathy: 1000 mg/m2/day as continous infusion for 5 days.Lead encephalopathy: 1500 mg/m2/day by continous intravenous infusion in 5% dextrose or 0.9% NaCl (Final Concentration of edentate < 500 mg/100 ml), starting 4 h after first dose of BAL and after an adequate urine flow is established. Infusion is continued for 5 days.Intramuscular injection to be used if fluidoverload is a concern.1000 mg/m2/day divided into equal doses spaced 8 to 12 h apart.Lignocaine or procaine should be added to the injection to minimize pain at the injection site.",Anuria, patients with active renal disease orhepatitis, pregnancy (Appendix 7c).,"Ensure adequate urine output, pre-existingmild renal disease; patients with leadencephalopathy and cerebral edema mayexperience a lethal increase in intracranialpressure following intravenous infusion, theintramuscular route is preferred for thesepatients.","Renal tubular toxicity which may lead toacute renal failure, fever, chills, lacrimation,increased prothrombin time, pain atintramuscular injection site; hypotension;cardiac rhythm irregularities; thirst;headache; fatigue; malaise; urinaryfrequency; glycosuria; proteinuria;microscopic hematuria; histamine-likereactions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Atropine,Pregnancy Category-C,Schedule H,Organophosphate and carbamate poisoning,premedication, antispasmodic, as mydriatic,cycloplegic refraction procedures,INJECTION 1 ml ampoules and 50 ml vial (0.6mg/ml).,"Intramuscular and intravenous injectionAdult- 1.8 - 3.0 mg intravenous bolus followed by doubling dose every 3 to 5 minutes depending upon response. End-point for atropinization include clear chest with no wheeze, systolic BP >80mm Hg, pulse >80 beats/min., pupils no longer pinpoint and dry axillae. Following that infusion of atropine at 10-20 % of total initial dose required/hour; may require boluses during infusion.Child-20-30 µg/kg initially with same schedule as above.","In myasthenia gravis (but may be usedto decrease muscarinic side-effects ofanticholinesterases), paralytic ileus, pyloricstenosis and prostatic enlargement; refluxoesophagitis; unstable cardiac rhythm.","Elderly, Down syndrome; angle-closureglaucoma; myasthenia gravis; prostaticenlargement; pyrexia; lactation (Appendix7b); interactions (Appendix 6a); pregnancy(Appendix 7c).","Constipation, transient bradycardia (followedby tachycardia, palpitation and arrhythmias),reduced bronchial secretions, urinary urgencyand retention, dilatation of the pupils withloss of accommodation, photophobia, drymouth, flushing and dryness of the skin.Occasionally, confusion (particularly in theelderly), nausea, vomiting and giddiness;very rarely, angle-closure glaucoma mayoccur.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Desferrioxamine Mesylate,Pregnancy Category-C,,Acute iron poisoning, chronic ironoverload, aluminium overload, primaryhemochromatosis.,INJECTION 5 ml and 10 ml vial (500 mg/vial).,"Continuous intravenous infusion Adult and Child- Begin with 5 mg/kg/h, increasing over 15 minutes if tolerated to 15 mg/kg/h, to minimize the risk of hypotension. After 1 to 2 h reduce to 3-4 mg/kg/h for the next 22-23 hrs (max dose is 100 mg/kg over 24 hrs).Patients with cardiovascular collapse: 5 mg/ kg/h (up to max. of 80 mg/kg in 24 h.)Chronic iron overload: Intramuscular 500 to 1000 mg daily, in addition 2g by intravenous infusion with each unit of blood transfused.",Severe renal disease, pregnancy(Appendix 7c).,Renal impairment, eye and ear examinationsbefore and at 3-month intervals duringtreatment, aluminium encephalopathy(may exacerbate neurological dysfunction),children under 3 years (may retard growth),lactation, interactions (Appendix 6c).,"Anaphylaxis; flushing, urticaria, hypotension,shock (especially if given by too rapidintravenous infusion); gastrointestinaldisturbances; fever, headache, arthralgia,myalgia; arrhythmias; renal impairment;blood disorders; neurological disturbancesincluding neuropathy, paraesthesiaand dizziness; convulsions; Yersinia andmucormycosis infections; visual disturbances(including lens opacity and retinopathy) andhearing loss; rash; rarely, growth retardation(in young children); rarely, acute respiratorydistress syndrome; pain on intramuscular orsubcutaneous injection; local irritation onprolonged subcutaneous infusion; reddish-brown discolouration of urine.",Store protected from light in refrigerator (2-8⁰C). Do not freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Dimercaprol (BAL),Pregnancy Category-C,,"Acute poisoning by antimony, arsenic,bismuth, copper gold, mercury and possiblythallium; adjunct (with sodium calciumedetate) in lead poisoning.",OILy INJECTION 2 ml ampoule (50 mg/ml).,Intramuscular injection To be administerd by deep intramuscular injection onlyLead poisoning: Adults-4 mg/kg every 4 h for5 days. Child- 75 mg/m2 every 5 h for 5 days.Arsenic poisoning: 3 mg/kg every 4 h for48 h and then twice a day for 7-10 days.Mercury poisoning: 5 mg/kg followed by 2.5mg/kg every 12-24 h for upto 10 days,"Not indicated for iron, selenium or cadmiumpoisoning; severe hepatic impairment (unlessdue to arsenic poisoning); hypertension;tellurium poisoning, peanut allergy, G-6-PDdeficiency.","Hypertension; renal impairment (discontinueor use with extreme caution if renal failureoccurs during treatment); any abnormalreaction such as hyperpyrexia should beassessed; elderly; pregnancy (Appendix 7c);lactation, alkalinize urine to pH of 7.5-8.0using sodium bicarbonate.","Hypertension, tachycardia; malaise, nausea,vomiting, abdominal pain, salivation,lacrimation, sweating, burning sensationin the mouth, throat and eyes; feeling ofconstriction in throat and chest; headache,muscle spasms, tingling of the extremities;fever in children; local pain and abscess atinjection site, iron toxicity potentiation.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
D-Penicillamine,Pregnancy Category-D,Schedule H,"Poisoning by heavy metals, particularlylead and copper; Wilson’s disease; severerheumatoid arthritis.",CAPSULE/TABLET 250 mg.,"Oral (given before food)Adult- 1 to 2g daily in three divided doses starting with 250 mg OD and gradually increasing to full dose over 2-3 weeks.Child- 20 mg/kg/day administered in 3-4 divided doses, initiating treatment at 25% of this dose and gradually increasing to full dose over 2-3 weeks to minimize adverse reactions. Continue till blood lead levels <45 µg/dl.","Hypersensitivity; lupus erythematosus;gold or antimalarial drug; penicillamine-induced agranulocytosis; aplastic anaemia;thrombocytopenia, pregnancy, lactation (forrheumatoid arthritis).","Monitor throughout treatment includingblood counts and urine tests; renalimpairment; immunosuppressive treatment;avoid oral iron within 2 h of a dose; hepaticimpairment; pregnancy (Appendix 7c).In Wilson’s disease, consider withdrawal if platelet count falls below 120 000/mm3 or white blood cells below 2500/mm3 or if 3 successive falls within reference range (can restart at reduced dose when counts return to reference range but permanent withdrawal necessary if neutropenia or thrombocytopenia recur).In Wilson’s disease warn patient to tell doctor immediately if sore throat, fever, infection, non-specific illness, unexplained bleeding and bruising, purpura, mouth ulcers or rashes develop.","Initially nausea (less of a problem if takenwith food and on retiring), anorexia,fever; taste loss (mineral supplementsnot recommended); blood disordersincluding thrombocytopenia, neutropenia,agranulocytosis and aplastic anaemia;proteinuria, rarely, haematuria (withdrawimmediately); haemolytic anaemia,nephrotic syndrome, lupus erythematosus-like syndrome, myasthenia gravis-likesyndrome, polymyositis (rarely, with cardiacinvolvement), dermatomyositis, mouthulcers, stomatitis, alopecia, bronchiolitisand pneumonitis, pemphigus, Goodpasturesyndrome and Stevens-Johnson syndromealso reported; male and female breastenlargement reported; rash early intreatment (usually allergic-may needtemporary withdrawal), late rashes (reducedose or withdraw treatment).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Flumazenil,Pregnancy Category-C,,"Antidote for benzodiazepine overdose,reversal of sedative effects produced bybenzodiazepenes administered duringgeneral anaesthesia or diagnostic ortherapeutic procedures.",INJECTION 0.1 mg/ml.,"Adult- 0.2 mg (2 ml) administered over 30 seconds, i.v, repeat 0.3 mg and 0.5 mg at 1-2 minute intervals. Not more than 3 mg over one hour.Child- 10 µg/kg, i.v, for 2 doses.","Epilepsy, neuromuscular blockade,hypersensitivity to benzodiazepines, patientsof suspected tricyclic antidepressantoverdose, raised intracranial pressure.","History of seizures, panic attack, alcoholdrug dependence, bleeding disorder, liverdisease, head injury, respiratory depression,pregnancy (Appendix 7c).","Convulsions, fatigue, injection site pains,increased sweating, facial erythema, raisedintracranial pressure, agitation, dizziness,abnormal vision, may cause complete heartblock, flushing, transient increase in bloodpressure and heart-rate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Methylene Blue (Methylthioninium Chloride),Pregnancy Category-C,,Acute methaemoglobinaemia.,INJECTION 10 mg/ml.,"Intravenous injectionMethaemoglobinaemia caused by high dosage of prilocaine infusion: 1-2 mg/kg intravenously over 5 minutes, followed immediately by a fluid flush of 15-30 ml to minimize local pain. May be repeated in 30- 60 minutes. Maximum dose: 7 mg/kg.",Severe renal impairment, methaemoglo-binaemia due to chlorate or induced bysodium nitrite in treatment of cyanidepoisoning, affects ability to drive machinery.,G-6-PD deficiency-may cause haemolyticanaemia, monitor blood methaemoglobinthroughout treatment, pregnancy (Appendix7c), lactation.,"Nausea, vomiting, abdominal pain, chestpain, headache, dizziness, confusion, profusesweating; hypertension or hypotensionreported; haemolytic anaemia-in G-6-PDdeficiency; methaemoglobinaemia-withhigh dosage; bluish skin discolouration; bluesaliva, urine and faeces. ",Store protected from light in an airtight container,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Naloxone,Pregnancy Category-B,Schedule H,Opioid overdosage, postoperative respiratorydepression.,INJECTION 0.4 mg/ml.,"Intravenous injectionSubcutaneous or intramuscular route (if i.v. route is not feasible but the dose is same, can be given oral as well).Adult- Opioid poisoning: Start with 0.4 to 2 mg (at all ages) as intravenous bolus, Repeat every 2 minutes if no response to a total of 10 mg. Once response occurs start infusion of naloxone at 2/3rd the total loading dose given every hour with continous monitoring for reccurence of respiratory depression. May require additional bolus during infusion.Child- Opioid poisoning: 10 µg/kg, followed by 100 µg/kg if there is no response.",Hypersensitivity.,Physical dependence on opioids orother situations where acute withdrawalsyndrome may be precipitated (see above),lactation, cardiovascular disease, pregnancy(Appendix 7c).,"Nausea, vomiting, sweating-may also be due to opioid withdrawal",Store protected from light in an airtight container,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pralidoxime (2-PAM),Pregnancy Category-C,Schedule H,"Adjunct to atropine in the treatmentof organophosphate poisoning andanticholinesterase overdosage used inthe treatment of myasthenia gravis (mg),respiratory depression or severe muscleweakness due to carbamate poisoning.","INJECTION i.v infusion 500 mg/20 ml, 1g/20ml (as chloride and iodide salt).","For Chloride salt, 30 mg/kg i.v. over 15-20 minutes followed by infusion at 8-10 mg/ kg/h. To be continued 12-24 hours after atropine is no longer required.For Iodide salt, dose is about 30% higher than chloride salt.Child- 25 to 50 mg/kg, diluted to 5% concentration in NS and infused over 5-30 minutes. May be repeated after one h, then every 6 to 12 h.Severe poisoning:Adult- 500 mg/h via continuous infusion.max.- 12g/24 h.Child- 9 to 19 mg/kg/h.For anticholinesterase overdose in MG: Adult- 1-2g i.v. initially, then 250 mg every 5 minutes.Child (0-18 years)- 15-25 mg/kg by slow i.v (up to 1 g).Maintainance dose- (< 12 years) 15-50 mg/ kg i.v every 5 minutes (up to 250 mg).",Carbamate poisoning and organophosphateswithout anticholinesterase activity,hypersensitivity to the drug.,"Impaired renal function; large doses cancause neuromuscular blockade, myastheniagravis; atropinization occur faster onconcurrent use with atropine; paediatrics;allergies; pregnancy (Appendix 7c).","Headache,nausea;blurredvision,drowsiness,dizziness, impaired accommodation,tachycardia, hyperventilation, muscularweakness; transient elevation in SGOT and/or SGPT levels; laryngospasm and rigidity.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sodium Nitrite,Pregnancy Category-C,,Cyanide poisoning (together with Sodiumthiosulphate).,INJECTION 30 mg/ml (10 ml).,Intravenous injection (over 5 to 20 min)Adult-300 mg at 2.5-5.0 mg/minute.Child- 4 to 10 mg/kg (max 300 mg) at 5 mg/ minute.,Methaemoglobinaemia, hemolytic anaemia,G-6-PD deficiency.,Monitor plasma methaemoglobin levels,severe cardiovascular or cerebrovascular dis-ease, hypotension, pregnancy (Appendix 7c).,"Nausea, vomiting and abdominal pain,vasodilatation resulting in syncope,hypotension, tachycardia, flushing,headache; methaemoglobinaemia; cyanosis,dyspnoea, tachypnoea.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sodium Thiosulphate,Pregnancy Category-C,,"Prophylactically with prolonged use of nitroprusside to prevent cyanide toxicity, cyanidepoisoning (together with Sodium nitrite);pityriasis versicolor; skin disease.",INJECTION 250 mg/ml, 500 mg/ml (50 ml).,Intravenous injection (over 10 min).Adult- 12.5g intravenously over 10-30 minutes may be repeated at half the initial dose at 1-2 hours.Child- 500 mg/kg intravenously over 10-30 minutes may be repeated at half the initial dose at 1-2 hours (12.5g maximum),Hypersensitivity, pregnancy (Appendix 7c).,,Irritation, urticaria, hypotension, burning, stinging on application.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Domperidone,,Schedule H,"Nausea and vomiting from any cause inadult, epigastric senses of fullness; upperabdominal distress; non ulcer dyspepsia;migraine.",,OralAdult- 10 to 20 mg 3 to 4 times a dayChild- 0.3 to 0.6 mg/kg TDS.,"Hypersensitivity; prolactinoma, hepaticimpairment; where increased gastro-intestinal motility harmful; pregnancy;gastro intestinal haemorrhage; intestinalobstruction.","Children; renal impairment, interactions(Appendix 6c); history of breast cancer;allergies; pheochromocytoma; i.v. adminis-tration can lead to hypokalaemia and cardiacarrhythmias.","Rarely, gastro-intestinal disturbances(including cramps) and hyperprolactinaemia;very rarely, extrapyramidal effects andrashes; headache; dizziness; dry mouth;nervousness; flushing.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Metoclopramide,Pregnancy Category-B,Schedule H,Nausea and vomiting in gastrointestinaldisorders and treatment with cytotoxics orradiotherapy, gastro-oesophageal refluxdisease, gastroparesis, premedication andpostoperatively, aid to gastrointestinalintubation, nausea and vomiting in migraine,diabetic gastric stasis. ,TABLETS 10 and 15 mg, INJECTION 2 mlampoule (5 mg/ml), SyRUP 30 ml (1 mg/ml).,"Oral or intramuscular injection or Slow intravenous injectionAdult- Nausea and vomiting, gastro- esophageal reflux, gastroparesis: (over 1 to 2 min for slow intravenous injection), 10 mg 3 times daily. 15 to 19 years (under 60 kg) 5 mg 3 times daily. Aid to gastrointestinal intubation: 20 mg as a single dose 5 to 10 min before examination; Adolescent (15 to 19 years), 10 mg.Child- Up to 1 year (up to 10 kg) 1 mg twice daily; 1 to 3years (10 to 14 kg) 1 mg 2 to 3times daily; 3 to 5 years (15 to 19 kg) 2 mg2 to3 times daily; 5 to 9 years (20 to 29 kg)2.5 mg 3 times daily; 9 to 14 years (30 kg andover) 5 mg 3 times daily (usual max. 500 µg/kg daily, particularly for children and youngadult).Slow intravenous injection onlyAdult- Premedication: 10 mg as a single dose.","Gastrointestinal obstruction, haemorrhageor perforation, 3-4 days after gastrointestinalsurgery; convulsive disorders; pheochromo-cytoma; hypersensitivity.","Elderly, children and young adults; hepaticimpairment (Appendix 7a); renal impairment(Appendix 7d); pregnancy (Appendix 7c);may mask underlying disorders such ascerebral irritation; avoid for 3-4 days aftergastrointestinal surgery; lactation (Appendix7b); interactions (Appendix 6a); Parkinson’sdisease; epilepsy; depression; porphyria;driving or operating machines; hypertension;cirrhosis; congestive heart failure.","Extrapyramidal symptoms (especiallyin children and young adults; see notesabove); tardive dyskinesias on prolongeduse; hyperprolactinaemia; drowsiness,restlessness, dizziness, headache,diarrhoea, depression, hypotension andhypertension reported; rarely, neurolepticmalignant syndrome; rashes, pruritus,oedema; cardiac conduction abnormalitiesfollowing intravenous administration; rarely,methaemoglobinaemia (more severe in G-6-PD deficiency); galactorrhoea; amenorrhoea;bradykinesia; gynaecomastia; insomnia.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ondansetron,Pregnancy Category-B,Schedule H,"Postoperative nausea and vomiting,chemotherapy and/or radiotherapy inducednausea and vomiting.",TABLETS 4 and 8 mg, INJECTION 2 and 4ml ampoule (2 mg/ml), DROPS 2 mg/5 ml,SyRUP 2 mg/5 ml, SUSPENSION 1 mg/5 ml.,"OralPrevention of post-operative nausea and vomiting: Adult 16 mg, 1 h before induction of anaesthesia.Nausea and vomiting associated with cancer chemotherapy:Adult- 24 mg as a single dose taken 30 min before start of single day chemotherapy.Child (4-11 yrs)- 4 mg tablets 3 times a day; continue for 1-2 days after completion of chemotherapy.ParenteralPost-operative nausea and vomiting:Adult- 4 mg by i.m or slow i.v as a singledose.Prevention of chemotherapy-induced nausea and vomiting:Adult- single 32 mg i.v dose infused over15 min begining 30 min before start ofemetogenic chemotherapy.",Hypersensitivity.,"Moderate to severe liver impairment;pregnancy (Appendix 7c), lactation;hypersensitivity to other selective 5-HT3 - receptor antagonists, subacute intestinal obstruction; cardiac disease, electrolyte abnormalities, QT interval prolongation (avoid concomitant administration of drugs that prolong QT interval), interactions (Appendix 6c).","Headache, constipation or diarrhoea,dizziness; flushing, hypersensitivity reaction,anaphylaxis/anaphylactoid reactions,angioedema; bronchospasm, hypotension,laryngeal edema, urticaria, hiccups,oculagyric crisis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Prochlorperazine,Pregnancy Category-C,Schedule H,Nausea and vomiting,TABLETS 3 and 5 mg, INJECTION 1 mlampoule (2.5 mg/ml).,"Oral and intravenous injectionAdult- Nausea, vomiting acute attack: initially 20 mg then 20 mg every 2 h. Prevention; 5 to10 mg 2 to 3 times daily.Child- (over 10 kg only).Oral: 0.4 mg/kg/day in 3-4 divided doses.Intravenous injection: 0.13 mg/kg/day in 3-4 divided doses.Adult- Labyrinthine disorder: 5 mg 3 times daily increased to 30 mg daily in divided doses that decrease after meal to 5 to 10 mg daily.Child- Labyrinthine disorder Not recommended.Intravenous injection: 0.13 mg/kg/day in 3-4 divided doses.","Comatose states, CNS depression andpheochromocytoma. Most antipsychoticsare best avoided during pregnancy;hypersensitivity; prolactin dependant tumors.","Patients with hepatic impairment, renalimpairment, cardiovascular disease,Parkinson’s disease (may be exacerbatedby antipsychotics), epilepsy (and conditionspredisposing to epilepsy), depression,myasthenia gravis, prostatic hypertrophy, ora susceptibility to angle-closure glaucoma.Caution is also required in severe respiratorydisease and in patients with a history ofjaundice or who have blood dyscrasias(perform blood counts if unexplainedinfection or fever develops). Caution shouldbe taken in elderly, who are particularlysusceptible to postural hypotension andto hyper- or hypothermia in very hot orcold weather. Serious consideration shouldbe given before prescribing these drugsfor elderly patients. As photosensitisationmay occur with higher dosages, patientsshould avoid direct sunlight; extrapyramidalsyndrome; pregnancy (Appendix 7c);interactions (Appendix 6a).","Less sedating; extrapyramidal symptoms,particularly dystonias, more frequent;respiratory depression may occur in suscep-tible patients; amenorrhoea; blurred vision;cholestatic jaundice; neuroleptic malignantsyndrome; leucopenia; agranulocytosis.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Promethazine,Pregnancy Category-C,Schedule G,"Nausea, vomiting, labyrinthine disorders,motion sickness; premedication; allergicrhinitis; vasomotor rhinitis.",TABLETS 10 and 25 mg, SyRUP 60 ml (5 mg/5ml), INJECTION 2 ml ampoule (25 mg/ml).,"OralNausea and vomiting (including postoperative): 12.5 to 25 mg, repeated at intervals of not less than 4 h (usual max., 100 mg in 24 h). Motion sickness, prevention: 20 to 25 mg at bedtime on night before travel, repeated on day of travel if necessary.Child- Motion sickness, prevention; 2 to 5 years: 5 mg at night and on day of travel, if necessary. 5 to 10 years: 10 mg at night and on day of travel, if necessary. Intramuscular injection or Slow intravenous injectionNausea and vomiting (including postoperative); (diluted to 2.5 mg/ml in water for injection); 12.5 to 25 mg, repeated at intervals of not less than 4 h (usual max., 100 mg in 24 h).",Porphyria, hypersensitivity, coma,hypokalaemia.,,,Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Diloxanide Furoate,,Schedule H,Amoebiasis (asymptomatic carriers in non-endemic areas, eradication of residualluminal amoebae after treatment of invasivedisease with other drugs).,TABLET 500 mg,OralAdult- 500 mg every 8 h for 10 days.Child- 20 mg/kg body weight daily in three divided doses for 10 days.,Lactation (Appendix 7b), systemic amoebiasis.,Pregnancy (defer treatment until after firsttrimester).,"Flatulence; occasionally vomiting, pruritusand urticaria; furred tongue.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Metronidazole,Pregnancy Category-B,Schedule H,Invasive amoebiasis and giardiasis,trichomoniasis, tissue nematode infections,bacterial infections, Helicobacter pylorieradication, ulcerative gingivitis.,TABLETS 200 and 400 mg, SUSPENSION200 mg/5 ml, INJECTION 500 mg in 100 mlinfusion.,OralAdult- Amoebiasis: 400 to 800 mg three times a day for 5 to7 days. Giardiasis: 200 mg threetimes a day for 7 to 10 days.Child- 35 to 50 mg/kg body weight in amoebiasis and 10 to 15 mg/kg body weight in giardiasis.Intravenous injectionAdult- 500 mg every eight h up to 7 days.Child- (Below 12 years) 7.5 mg/kg body weight.,"Chronic alcohol dependence; neurologicaldisease, blood dyscrasias, first trimester ofpregnancy.","Disulfiram-like reaction with alcohol; hepaticimpairment and hepatic encephalopathy(Appendix 7a); pregnancy (Appendix 7c); seealso notes above); lactation (Appendix 7b);clinical and laboratory monitoring in courseslasting longer than 10 days; interactions(Appendix 6a, 6c, 6d); prolonged use mayresult in fungal or bacterial superinfection,phenobarbitones, history of seizure disorder.","Nausea, vomiting, unpleasant metallic taste,furred tongue and gastrointestinal distur-bances; rarely, headache, drowsiness, dizzi-ness, ataxia, darkening of urine, erythemamultiforme, pruritus, urticaria, angioedemaand anaphylaxis; abnormal liver functiontests, hepatitis, jaundice; thrombocytope-nia, aplastic anaemia; myalgia, arthralgia;peripheral neuropathy, epileptiform seizures;leukopenia on prolonged or high dosage reg-imens; anorexia, glossitis, dryness of mouth.",Store protected from light and moisture.Store injection in a single dose container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tinidazole,Pregnancy Category-C,Schedule H,"Amoebiasis, trichomoniasis and giardiasis,anaerobic infections, necrotising ulcerativegingivitis, bacterial vaginosis, H. pyloriassociated peptic ulcers, abdominal surgeryprophylaxis.","TABLETS 300 and 500 mg, 1g; INJECTION400 ml infusion (2 mg/ml); SUSPENSION 75mg/5 ml, 150 mg/5 ml.","OralAnaerobic infections:Adult- 2g on first day, followed by 1g daily or0.5g twice daily for 5-6 days.Amoebiasis:Adult- 1.5 - 2g daily as a single dose for 3 - 6days.Child- 30-50 mg/kg daily as a single dose for 3 days.Trichomoniasis and giardiasis: Adult- 2g as a single dose.Child- 50 to 75 mg/kg as a single dose.ParenteralBacterial vaginosis and ulcerative gingivitis:Adult- 2g as a single dose parenterally.Anaerobic infections:Adult- Initially 800 mg/400 ml infused i.v. ata rate of 10 ml/minute followed by 800 mgdaily.Abdominal surgical prophylaxis:Adult- 2.0g as single i.v. infusion 12 h priorto surgery.","Hypersensitivitytonitroimidazolederivatives,first trimester of pregnancy (Appendix7c), lactation, blood dyscrasias, porphyria;interactions (Appendix 6a).","Seizures, peripheral neuropathy, CNS disease,disulfiram-like reaction with alcohol.",Similar to metronidazole.,Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Amoxycillin,Pregnancy Category-B,Schedule H,"Urinary-tract infections, upper respiratory-tract infections, bronchitis; pneumonia; otitismedia; dental abscess; osteomyelitis; Lymedisease in children; endocarditis prophylaxis;post-splenectomy prophylaxis; gynaecologicalinfections; gonorrhoea; Helicobacter pylorieradication.","TABLETS 250 mg, 500 mg; KID TABLETS 125,250 mg; CAPSULES 250, 500 mg; DRy SyRUP125 and 250 mg per 5 ml; INJECTION 1 mlampoule (100 mg/ml), 250 mg/vial; DROP10 ml (100 mg/ml)","OralAdult- 250 mg every 8 h, double in severe infection. Otitis media: 1g every 8 h.Enteric fever: 2 to 4g daily in divided doses for 14 to 21 days.Intramuscular injection500 mg every 8 h.Intravenous injection or infusion500 mg every 8 h, increase to 1g every 6 h in case of severe infection.Child up to 10 years- 125 mg every 8 h, double in severe infections.Otitis media: 40 mg/kg body weight daily in three divided doses.Enteric fever: 50 to 100 mg/kg body weight in three divided doses for 14 to 21 days.Intramuscular injection50 to 100 mg/kg body weight in divided doses.Intravenous injection or infusion50 to 100 mg/kg body weight in divided doses.",Hypersensitivity to penicillins (see notesabove).,"History of allergy; renal impairment;erythematous rashes common in glandularfever, chronic lymphatic leukaemia and pos-sibly HIV infection; lactation (Appendix 7b);interactions (Appendix 6b, 6c, 6d); possibil-ity of super infection with mycotic patho-gens, mononucleosis, hepatic impairment(Appendix 7a); pregnancy (Appendix 7c).","Nausea and vomiting, diarrhoea; rashes(hypersensitivity or toxic response, may beserious reaction-discontinue treatment);hypersensitivity reactions including Steven’sJohnson syndrome, urticaria, angioedema,anaphylaxis, serum sickness-likereactions, haemolytic anaemia, interstitialnephritis; rarely, antibiotic-associatedcolitis; neutropenia, thrombocytopenia,coagulation disorders; rarely, central nervoussystem disorders including convulsionsassociated with high doses or impairedrenal function; mucocutaneous candidiasis,with discolouration; agitation.","Tablet, Capsule and Oral suspension: Store protected from moisture at a temperature not exceeding 30⁰C. Injection: Store protected from moisture in a sterile, tamper evident container sealed so as to exclude micro-organisms at temperature not exceeding 30⁰C.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Amoxycillin + Clavulanic acid,Pregnancy Category-B,Schedule H,"Treatment of infections caused by susceptibleorganisms, sinusitis, otitis media, dentalabcesses, severe respiratory tract infections,urinary tract infections, skin and soft tissueinfections, surgical prophylaxis.",TABLETSAmoxycillin + Clavulanic acid500 mg + 125 mg250 mg + 125 mg875 mg + 125 mg200 mg + 28.5 mg (DT)CAPSULSAmoxycillin + Clavulanic acid500 mg + 125 mg250 mg + 125 mgSUSPENSIONAmoxycillin + Clavulanic acid200 mg + 28.5 mg/5 ml125 mg + 31.25 mg/5 ml250 mg + 62.5 mg/5 mlINJECTIONAmoxycillin + Clavulanic acid250 mg + 50 mg1g + 200 mg125 mg + 25 mg500 mg + 100 mg,"OralUpperandlowerrespiratorytractinfections, sinusitis, otitis media, skin and soft tissue infections, susceptible infections:Adult- 250-500 mg every 8 hours or 500-750 mg every 12 hours.Child- 125-250 mg every 8 hours;Children weighing <40 kg: 20-40 mg/kg/dayin divided doses every 8 hours;Infants <3 months: up to 30 mg/kg/day individed doses every 12 hours.Dental abcesses: Adult- 3 g as a single dose, followed by a second dose 8 hours later. Severe or recurrent respiratory tractinfections: Adult-3 g twice daily.Child (2-6 years)- 5 ml twice daily;(7-12 years)- 10 ml twice daily before meals,upto 14 days (dose should be specified interms of strength).ParenteralSusceptible infections and surgical prophylaxis: Adult- 500 mg every 8 hr. In severe infections, dose may be increased to 1 g every 6 hours, upto 14 days. Can be given via i.m or slow i.v over 3-4 minutes ori.v infusion over 30-60 minutes.Child: <10 years: 50-100 mg/kg/day individed doses.","Hypersensitivity to penicillins, infectiousmononucleosis, jaundice.","Renal impairment, hepatic dysfunction,patients on anticoagulant therapy,pregnancy (Appendix 7c), lactation,interactions (Appendix 6c).","GI upset, mycosis, rash, nausea, vomiting,anaphylaxis, cholestatic jaundice, blooddyscracias, toxic epidermal necrolysis,convulsions, exfoliative dermatitis, StevensJohnson syndrome, angioedema, hepatitis,tooth discolouration.",Store protected from moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ampicillin,Pregnancy Category-B,Schedule H,Mastoiditis, gynaecological infections,septicaemia, peritonitis, endocarditis,meningitis, cholecystitis, osteomyelitis,respiratory tract infection,"TABLETS 125 and 250 mg; CAPSULES 250,500 mg and 1g; DRy SyRUP 125 and 250mg/5 ml; INJECTION 100, 250 and 500 mg/vial.",OralAdult- 250 mg to 1g every 6 h at least 30 min before food.Urinary tract infection Adult- 500 mg every 8 h. Children under 10 years- Half of adult dose.Intramuscular and intravenous injection or infusion500 mg every 4 to 6 h.Listeria meningitis (in combination with antibiotics), by intravenous infusion 2g every 4h for 10 to 14 days.Child- Half of the adult dose.Listeria meningitis (in combination with antibiotics), infants 1 to 3 months, 50 to 100 mg/kg body weight every 6 h. 3 months to 12 years, 100 mg/kg body weight every 76 h (max 12g daily).,Hypersensitivity to penicillins (see notesabove).,"History of allergy (see notes above); renalimpairment (Appendix 7d); erythematousrashes common in glandular fever, acuteor chronic lymphocytic leukaemia andcytomegalovirus infection; lactation(Appendix 7b); interactions (Appendix 6b,6c, 6d); pregnancy (Appendix 7c).","Nausea and vomiting, diarrhoea; rashes, highfever (hypersensitivity or toxic response-maybe serious reaction, discontinue treatment);hypersensitivity reactions including urticaria,angioedema, anaphylaxis, serum sickness-like reaction, haemolytic anaemia, interstitialnephritis (see also notes above); rarely,antibiotic-associated colitis; neutropenia,thrombocytopenia, coagulation disorders;sore tongue; asthma.","Tablets, Capsule, Oral suspension: Store protected from moisture and light at a temperature not exceeding 30⁰C. Injection: Store protected from light in a sterile tamper evident container sealed so as to exclude micro-organisms at a temperature not exceeding 30⁰C.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Azithromycin,Pregnancy Category-B,Schedule H,Uncomplicated genital chlamydial infectionsand trachoma.,"TABLETS 100, 250 and 500 mg; CAPSULES250 and 500 mg; INJECTION 500 mg/vialDRy SyRUP 100, 200 mg/5 ml.",OralAdult- 500 mg once daily for 3 days or 500 mg on first day then 250 mg once daily for 4 days.Child- over 6 months: 10 mg/kg body weight once daily for three days.Body weight 15 to 20 kg: 200 mg once daily for 3 days, body weight 26 to 35 kg: 300 mg daily for 3 days.Uncomplicated genital chlamydia infection and non-gonococcal infection: 500 mg once daily for 7 days.,Hepatic impairment (Appendix 7a),hypersensitivity to erythromycin.,"Pregnancy (Appendix 7c) and lactation(Appendix 7b); renal impairment,prolongation of QT interval (ventriculartachycardia reported); interactions(Appendix 6c, 6d); exacerbation ofsymptoms of myasthenia gravis; impairedhepatic function.","Fewer gastrointestinal effects as comparedto erythromycin, also anorexia, dyspepsia,constipation; dizziness, headache,drowsiness; photosensitivity; hepatitis,interstitial nephritis, acute renal failure,asthenia, paraesthesia, convulsions andmild neutropenia reported; rarely, tinnitus,hepatic necrosis, hepatic failure and tastedisturbances; flatulence, somnolence,angioedema; eczema, pharyngitis; arthalgia,conjunctivitis.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Benzyl Penicillin,Pregnancy Category-B,Schedule H,"Mild to moderate infections of upperrespiratory tract due to susceptiblestreptococci, syphilis, prophylaxis ofrheumatic fever.","INjECTABLE SUSPENSION- 6, 12, 24 Lacunits; INjECTABLE SUSPENSION- 1200,000units/2 ml",,"Hypersensitivity, neurosyphilis.",,"Hypersensitivity reactions such asexfoliative dermatitis, pain at injectionsite; thrombophlebitis of injected vein,diarrhoea, nausea, joint pain, angioedema,serum sickness like reactions, haemolyticanaemia, interstitial nephritis.",Store protected from moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cefazolin,Pregnancy Category-B,Schedule H,Respiratory tract infection, urinary tractinfection, skin and soft tissue infection,biliary tract infection, bone and jointinfection, endocarditis, septicaemia,preoperative prophylaxis.,"INJECTION 125, 250, 500 mg and 1g/vial.",Intramuscular and intravenous injection Adult- 1 to 4g daily in 2 to 3 divided doses. Child- 50 to 100 mg/kg body weight every6 h.,Hypersensitivity and cephalosporin, colitis,lactation, pregnancy (Appendix 7c).,Renal function impairment (Appendix 7d),over growth of non-susceptible organism,interactions (Appendix 6c).,"Eosinophilia; diarrhoea; fever; convulsions;neutropenia, anaphylaxis, phlebitis, oralcandidiasis, leucopenia; transient rise inSGOT and SGPT and alkaline phosphatase.",Store protected from light and moisture at a temperature not exceeding 30⁰C. The constituted solution should be stored protected from light and used within 24 hours when stored at a temperature not exceeding 30⁰C or within 4 days when stored between 2 to 8⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cefixime,Pregnancy Category-B,Schedule H,"Otitis media, respiratory tract infections,uncomplicated UTIs, effective againstinfections caused by Enterobacteriaceae, H.influenza species.","TABLETS 50, 100, 200 and 400 mg; CAPSULES100 and 200 mg; SyRUP/SUSPENSION 50mg/5 ml, 100 mg/5 ml.",Adult- 200-400 mg/day as a single dose or in two divided doses.Child- (more than 6 months) 8 mg/kg/day as a single dose or two divided doses.Uncomplicated gonorrhea: Adult- 400 mg as a single dose.,Hypersensitivity to cephalosporins.,"History of allergy to penicillins, renalfailure (Appendix 7d) or patients under-going continuous ambulatory peritonealdialysis (CAPD) and hemodialysis (HD), gas-trointestinal disease, pregnancy (Appendix7c), lactation, interactions (Appendix 6c).","Diarrhoea, pseudomembranous colitis, looseor frequent stools, abdominal pain, nausea,dyspepsia; hypersensitivity reactions.",Store protected from light and moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cefoperazone,Pregnancy Category-B,Schedule H,"Urinary, biliary, respiratory, skin softtissue infections, meningitis, septicemias,Pseudomonas, Salmonella typhi, B. fragilisinfections.","INJECTIONS 0.25, 1.0, 2.0 g/vial.",25-100 mg/kg/day in 2-3 divided doses.,"Hypersensitivity, interactions (Appendix 6a).",,"Anaphylaxis, fever, skin rashes; nephritis;granulocytopenia, and hemolytic anaemia,hypoprothrombinaemia and bleedingdisorders. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cefotaxime,Pregnancy Category-B,Schedule H,"Infections due to sensitive Gram positiveand Gram negative bacteria such as bacter-aemia, cellulites, intra-abdominal infections,gonorrhoea, bone or joint infections, skinand skin structure infections, urinary tractinfections, septicaemias, surgical prophy-laxis, endometritis, life threatening resist-ant/hospital acquired infections, infectionsin immuno-compromised patients, Haemo-philus epiglottitis and meningitis.","INJECTION 125, 250, 500 mg, and 1g/vial","Susceptible infections: 1–2g by i.v or i.m injection, 8 – 12 hourly. Max.-12 g/day.Child- 50-100 mg/kg/day.Surgical prophylaxis: 1g by i.v or i.m injection, 30-90 minutes before procedure.Gonorrhoea: 0.5–1g by i.m injection, as a single dose.Septicaemia, meningitis:Adult- 2g i.v, 6-8 hourly for 14-28 days.Neonates- 50 mg/kg daily in 2–4 divided doses may be increased to 150–200 mg/kg daily in severe infections.Child- 100–150 mg/kg daily in 2–4 divided doses increased up to 200 mg/kg daily in very severe infections.",Renaldisease(Appendix7d),hypersensitivity to cephalosporins.,"Impaired kidney or liver disease, colitis;history of penicillin allergy; pregnancy(Appendix 7c), lactation; diabetes.","Local inflammation or pain at injection site;thrombocytopenia,eosinophilia,leukopenia;pseudomembranous colitis, moniliasis,diarrhoea, candidiasis, decreased urination;seizures, headache, nausea and vomiting;jaundice; Steven’s Johnson syndrome.",Store protected from light at a temperature not exceeding 30⁰C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ceftazidime,Pregnancy Category-B,Schedule H,"Infections due to sensitive bacteria,especially those due to Pseudomonasspp. and including those resistant toaminoglycosides.","INJECTION 250, 500 mg, 1g and 2g vial",Deep intramuscular and intravenous injection and infusionAdult- 1g every 8 h or 2g every 12 h.Severe infections: 2g every 12 h or 3g every12 h (1g single dose by intravenous route).Immunocompromised or meningitispatients: 150 mg/kg body weight daily in3 divided doses (max 6g daily) given by i.vroute only.Elderly- Usual max dose of 3g daily.Child- Up to 2 months, 25 to 60g/kg body weight in two divided doses. Over 2 months: 30 to 100 mg/kg body weight in 2 to 3 divided doses,Cephalosporin hypersensitivity, porphyria.,"Penicillin sensitivity; renal impairment;lactation (Appendix 7b); false positiveurinary glucose (if tested for reducingsubstances) and false positive Coombs’ test;interactions (Appendix 6b, 6c); pregnancy(Appendix 7c); fall in prothrombin activity,colitis.","Diarrhoea, nausea, vomiting, abdominaldiscomfort, headache; rarely, antibiotic-associated colitis (particularly with higherdoses); allergic reactions including rashes,pruritus, urticaria, serum sickness-likereaction,feverandarthralgiaandanaphylaxis;erythema multiforme, toxic epidermalnecrolysis reported; transient hepatitis,cholestatic jaundice; eosinophilia and blooddisorders (including thrombocytopenia,leukopenia, agranulocytosis, aplasticanaemia and haemolytic anaemia);reversible interstitial nephritis; nervousness,sleep disturbances, confusion, hypertoniaand dizziness; phlebitis, angioedema,myoclonia, candidiasis, transient elevationof blood urea and serum creatinine.",Store in sterile containers sealed so as to exclude micro-organisms protected from moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ceftriaxone,Pregnancy Category-B,Schedule H,"Serious infections due to sensitive bacteria,including septicaemia, pneumonia andmeningitis; surgical prophylaxis; prophylaxisof meningococcal meningitis; gonorrhea;bone and joint infection.","INJECTION 125, 250, 500 mg, 1g and 2gvial.","Intramuscular and intravenous injection or infusionAdult- Urinary tract infection, pneumonia, pelvic inflammatory disease, prophylaxis of surgical infections and meningitis: 4g initially once daily for 10 days or up to 72 h after fever disappears.Typhoid: 4g daily for two days followed by 2g daily for next two days. 1 to 2g daily is used for any other type of condition.Child- Meningitis: 75 to 100 mg/kg body weight for 7 to 9 days.Typhoid: 5 mg/kg body weight for 7 days. 50 to 75 mg/kg body weight is used in case of any other condition (max 2g/day).","Cephalosporin hypersensitivity; porphyria;neonates with jaundice, hypoalbuminaemia,acidosis or impaired bilirubin binding.","Penicillin sensitivity; severe renalimpairment; hepatic impairment ifaccompanied by renal impairment(Appendix 7a); premature neonates; maydisplace bilirubin from serum albumin;treatment longer than 14 days, renal failure,dehydration or concomitant total parenteralnutrition-risk of ceftriaxone precipitation ingallbladder; lactation (but appropriate touse, see Appendix 7b); pregnancy (Appendix7c); false positive urinary glucose (if testedfor reducing substances) and false positiveCoombs’ test; interactions (Appendix 6b,6c); phrophylactic indication, patients withimpaired vit K synthesis, monitoring ofprothrombin time is recommended.","Diarrhoea, nausea and vomiting, abdominaldiscomfort, headache; antibiotic-associatedcolitis (particularly with higher doses);allergic reactions including rashes, pruritus,urticaria, serum sickness-like reactions,fever and arthralgia and anaphylaxis;erythema multiforme, toxic epidermalnecrolysis reported; transient hepatitisand cholestatic jaundice; elevation of SGOTand SGPT; eosinophilia and blood disorders(including thrombocytopenia, leukopenia,agranulocytosis, aplastic anaemia andhaemolytic anaemia); reversible interstitialnephritis, hyperactivity, nervousness, sleepdisturbances, confusion, hypertonia anddizziness; calcium ceftriaxone precipitatesin urine (particularly in very young,dehydrated, or those who are immobilized)or in gall bladder-consider discontinuationif symptomatic; rarely, prolongation ofprothrombin time, pancreatitis; localreaction, hypersensitivity.",Store protected from light at a temperature not exceeding 30⁰C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cephalexin,Pregnancy Category-B,Schedule H,Respiratory tract infections, otitis media, skinand skin structure infections, genitourinarytract infection, bone infection,"CAPSULES/TABLETS 125, 250 and 500 mg;125 mg Kid tablets; 250 mg DT; DRy SyRUP125 and 250 mg/5 ml","To be given preferably on empty stomach.Adult- 250 mg every 6 h or 500 mg every 8to 12 h, increased to 1 to 1.5g every 6 to 8 hfor severe infections.Prophylaxis of severe urinary tractinfection: 125 mg at night.Child- 25 mg/kg body weight daily in divided doses doubled for severe infections (max. 100 mg/kg body weight daily); Under 1year: 125 mg every 12 h; 1 to 5 years: 125 mgevery 8 h; 5 to 12 years: 250 mg every 8 h.",Cephalosporin hypersensitivity.,"Sensitivity to beta-lactam antibacterials(avoid if history of immediatehypersensitivity reaction, renal impairment;lactation; false positive urinary glucose (iftested for reducing substances) and falsepositive Coombs' test; poor nutritionalstate; pregnancy (Appendix 7c).","Diarrhoea and rarely, antibiotic-associatedcolitis (more likely with higher doses),nausea and vomiting, abdominaldiscomfort, headache; allergic reactionsincluding rashes, pruritus, urticaria, serumsickness-like reactions with rashes, feverand arthralgia and anaphylaxis; Stevens-Johnson syndrome, toxic epidermalnecrolysis reported; disturbances in liverenzymes, transient hepatitis and cholestaticjaundice; other side-effects reportedinclude eosinophilia and blood disorders(including thrombocytopenia, leucopenia,agranulocytosis, aplastic anaemia andhaemolytic anaemia); reversible interstitialnephritis, hyperactivity, nervousness, sleepdisturbances, hallucinations, confusion,hypertonia and dizziness; dyspnoea, colitis,increased blood urea, creatinine, alkalinephosphatase, bilirubin, LDH.",Store protected from light and moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Chloramphenicol,Pregnancy Category-C,Schedule H,"Severe life-threatening infections, particularlythose caused by Haemophilus influenzae andtyphoid fever; cerebral abscess; mastoiditis;relapsing fever; gangrene; granulomainguinale; listeriosis; severe melioidosis;plague; psittacosis; tularaemia; Whipple’sdisease; septicaemia; empirical treatment ofmeningitis; ocular infection.",CAPSULES 250 and 500 mg, SyRUP 125mg/5 ml, INJECTION 250 and 500 mg/vial.,"Oral, intramuscular or intravenous injection or infusionAdult- 50 mg/kg body weight in four divided doses (can be doubled in very severe infections, septicaemia, meningitis, reduce as soon as clinically indicated).Child- Haemophilus epiglotitis and pyrogenic meningitis: 50 to 100 mg/kg body weight daily in divided doses (can be doubled in severe infections, reduce as soon as clinically indicated).",,Avoid repeated courses and prolongeduse, reduce dose in hepatic impairment(Appendix 7a) and severe renal impairment,blood counts required before and duringtreatment, monitor plasma concentrationsin neonates (see below), lactation (Appendix7b), interactions (Appendix 6c), regularblood count, over growth of non-susceptibleorganism may occur, seizure disorders.,"Bone marrow depression-reversible andirreversible aplastic anaemia (with reportsof leukaemia), anaemia, leukopenia andthrombocytopenia; nocturnal haemoglob-inuria; peripheral neuritis and optic neuri-tis; nausea, vomiting, diarrhoea, dry mouth,stomatitis, glossitis; headache, depression;hypersensitivity reactions including, rashes,fever, angioedema and rarely, anaphylaxis;grey baby syndrome (vomiting, greenishdiarrhoea, abdominal distension, hypother-mia, pallid cyanosis, irregular respiration,circulatory collapse) may follow excessivedoses in neonates with immature hepaticmetabolism; also reported in infants bornto mothers treated in late pregnancy; ocularirritation, angioneuretic edema.",Capsule: Store protected from moisture.Syrup and Injection: Store protected fromlight and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ciprofloxacin,Pregnancy Category-C,Schedule H,"Gastroenteritis-includingcholera,shigellosis,travellers’ diarrhoea, campylobacter andsalmonella enteritis; typhoid; gonorrhoea;chancroid; legionnaires’ disease; meningitis(including meningococcal meningitisprophylaxis); respiratory-tract infections-including pseudomonal infections in cysticfibrosis, but not pneumococcal pneumonia;urinary-tract infections; bone and jointinfections; septicaemia; anthrax; skininfections; prophylaxis in surgery.","TABLETS 100, 250, 500 and 750 mg;INFUSION 50, 100 and 200 ml (2 mg/ml).","Oral Adult- Urinary tract infection, respiratory tract infection: 250 to 500 mg, twice daily. Severe respiratory tract infections: up to 750 mg twice daily (however in acute uncomplicated cystitis in women 100 mg twice daily for three days).Chronic prostatitis: 500 mg twice daily for 28 days.Gonorrhoea: 500 mg as a single dose.Child- Not recommended.Intravenous infusion (30 to 60 min)Adult- Urinary tract infection, ENT infection, skin, soft tissue and bone infection, joint infection, gastrointestinal tract infection, severe systemic infection, gonorrhea, surgical prophylaxis and septicaemia; 100 to 200 mg twice daily by slow intravenous injection or infusion.","History of tendon disorders related toquinolone use; exposure to strong sunlight,hypersensitivity to quinolones derivatives;tizanidine therapy.","History of epilepsy or conditionsthat predispose to seizures, G-6-PDdeficiency, myasthenia gravis (risk ofexacerbation), pregnancy (Appendix7c), lactation (Appendix 7b), children oradolescents (see below); avoid exposureto excessive sunlight (discontinue ifphotosensitivity occurs); rarely, tendondamage-discontinue at first sign ofpain or inflammation and rest affectedlimb; hepatic impairment; renal failure(Appendix 7d); avoid excessive alkalinityof urine and ensure adequate fluid intakeas there is risk of crystalluria; interactions(Appendix 6c); cerebral arteriosclerosis,anxiety, paranoia, erythema, blistering.Use In Children. Ciprofloxacin causes arthropathy in the weight-bearing joints of immature animals and is therefore generally not recommended in children and growing adolescents. However, the significance of this effect in humans is uncertain and in some specific circumstances short-term use of ciprofloxacin in children may be justified. Ciprofloxacin is used for pseudomonal infections in cystic fibrosis (for children over 5 years) and for treatment and prophylaxis of anthrax.May impair ability to perform skilled tasks, for example operating machinery, driving. ","Nausea, vomiting, dyspepsia, abdominalpain, flatulence, diarrhoea (rarely,antibiotic-associated colitis), dysphagia,tremor, hyperglycaemia, headache,dizziness, sleep disorders, rash (rarely,erythema multiforme (Stevens-Johnsonsyndrome) and toxic epidermal necrolysis)and pruritus; vasculitis, erythema nodosum,petechiae, haemorrhagic bullae; lessfrequently anorexia, increase in blood ureaand creatinine; drowsiness, restlessness,asthenia, depression, confusion,hallucinations, convulsions, paraesthesia;photosensitivity, hypersensitivity reactionsincluding fever, urticaria, angioedema,arthralgia, myalgia and anaphylaxis; blooddisorders(includingeosinophilia,leukopenia,thrombocytopenia), altered prothrombintime; disturbances in vision, taste,hearing and smell, tinnitus; tenosynovitis;tachycardia, oedema, syncope, hot flushesand sweating; if psychiatric, neurological orhypersensitivity reactions (including severerash) occur discontinue; arthralgia.",Eye drops and Tablet: Store protected from light. Injection: Store protected from light at a temperature not exceeding 30⁰C. The container should not be allowed to freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Clarithromycin,Pregnancy Category-C,Schedule H,"For the treatment of bacterial infections(pharyngitis/tonsillitis, sinusitis, bronchitis,pneumonia, uncomplicated skin andskin structure infections) caused by H.influenzae, M. catarrhalis, M. pneumoniae,S. pneumoniae, C. pneumoniae, S. aureus,S. pyogenes, Mycobacterium avium andMycobacterium intracellulare.",TABLETS 250 and 500 mg , 125 mg DT.SUSPENSION 125 mg/5 ml,OralAdult- 250 mg to 500 mg twice a day for 7 to 14 days increase in severe infections to 500 mg every 12 h up to 14 days.Child- Body weight under 8 kg: 7.5 mg/kg body weight twice daily, 8 to 11 kg: 62.5 mg twice daily, 30 to 40 kg: 250 mg twice daily.,Hypersensitivity to clarithromycin,cephalosporin.,"Neonate under 2 weeks (risk of hypertrophicpyloric stenosis); predisposition to QTinterval prolongation (including electrolytedisturbances, concomitant use of drugs thatprolong QT interval); avoid in porphyria;hepatic impairment; renal impairment;pregnancy (not known to be harmful)(Appendix 7c); lactation (only smallamounts in milk); interactions (Appendix6c); myasthenia gravis.","Nausea, vomiting, abdominal discomfort,diarrhoea (antibiotic-associated colitisreported); less frequently urticaria, rashesand other allergic reactions; reversiblehearing loss reported after large doses;cholestatic jaundice, pancreatitis,cardiac effects (including chest pain andarrhythmias), myasthenia-like syndrome,Stevens-Johnson syndrome, toxic epidermalnecrolysis also reported, dyspepsia, toothand tongue discolouration, smell andtaste disturbances, stomatitis, glossitisand headache; less commonly hepatitis,arthralgia and myalgia; rarely, tinnitus;very rarely, pancreatitis, dizziness,insomnia, nightmares, anxiety, confusion,psychosis, paraesthesia, convulsions,hypoglycaemia, renal failure, leucopeniaand thrombocytopenia; on intravenousinfusion, local tenderness, phlebitis.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Clindamycin,Pregnancy Category-B,Schedule H,"Respiratory tract infections, penicillinresistant staphylococcal infections andmany anaerobes such as bacteroides, skin,soft tissue and dental infections.",TABLETS/CAPSULES 150 & 300 mg, SyRUP4 ml (150 mg/ml), INJECTION 2 ml (150 mg/ml), CREAM/GEL/OINTMENT 10g (1%w/w),LOTION 25 ml (1%w/v).,"OralSerious anaerobic infectionsAdult: 150-300 mg 6 every hr; for moresevere infection: 300 to 450 mg every 6 hr.Child: 2-4 mg/kg every 6 hr; for more severeinfection: 3-6 mg/kg every 6 hr; 10 kg: 37.5mg every 8hr.Prophylaxis of endocarditis 600 mg 1 hrbefore dental procedure. Intravenous/IntramuscularSerious anaerobic infectionsAdult: 0.6-2.7 g/day in 3-4 divided doses, upto 4.8 g/day for severe infections.Child: 20-40 mg/kg daily in 3-4 divideddose.Neonate: 15-20 mg/kg daily in 3-4 divideddoseToxic shock syndromeAdult: 900 mg every 8 hr along withpenicillin G or ceftriaxone.Pelvic inflammatory diseaseAdult: 900 mg every 8 hr along withgentamicin.VaginalBacterial vaginosisAs pessary or 2% cream: 100 mg oncenightly for 3-7 days.TopicalAcneAs 1% preparation: Apply twice daily.","Hypersensitivity, meningitis as it has lesspenetration into CNS, pseudomembranouscolitis","Hepatic and renal impairment, pregnancyand lactation, GI disease, elderly, atopicpatients, regular monitoring of bloodcounts, in conjuction with antibiotic therapy,pregnancy (Appendix 7c), interactions(Appendix 6c).","Urticaria, rashes, contact dermatitis,exfoliative and vesiculous dermatitis, localirritation abdominal pain, oesophagitis,nausea, vomiting, diarrhoea, jaundice andliver abnormalities, eosinophilia, erythemamultiforme, thrombophloebitis, gaspingsyndrome (premature infants and neonates)due to preservative benzoyl alcohol inparenteralformulation,pseudomembranouscolitis, azotemia, oliguria, proteinuria.",Store protected from moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cloxacillin,Pregnancy Category-B,Schedule H,Multibacillary (MB) leprosy, type 2 leprareactions, gram positive infection includingresistant staphylococci.,Multibacillary (MB) leprosy, type 2 leprareactions, gram positive infection includingresistant staphylococci.,Oral Adult- 250-500 mg every 6 h at least 30 min. before food. Osteomyelitis, upto 8g daily in 2 to 3 divided doses. Surgical prophylaxis, 1 to 2g at induction thereafter up to 4 further doses each of 500 mg may be given every 6 h.Slow intravenous injection or infusionAdult- Surgical prophylaxis, 1 to 2g at induction thereafter up to 4 further doses each of 500 mg may be given every 6 h.Child- High risk procedures, Under 2 years, quarter adult dose. 2 to 10 years, half adult dose.,Hypersensitivity to penicillins (see notesabove).,History of allergy (see notes above), renaland hepatic impairment (Appendix 7a),heart failure, lactation (Appendix 7b),pregnancy (Appendix 7c).,"Nausea and vomiting, diarrhoea; hypersen-sitivity reactions including urticaria, fever,joint pain, rashes, angioedema, anaphy-laxis, serum sickness-like reactions, haemo-lytic anaemia, interstitial nephritis (see alsonotes above); neutropenia, thrombocyto-penia, coagulation disorders; antibiotic-associated colitis; hepatitis and cholestaticjaundice-may be delayed in onset; electro-lyte disturbances; pain, inflammation, phle-bitis or thrombophlebitis at injection sites.",Store protected from moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cotrimoxazole,Pregnancy Category-C,Schedule H,"Urinary-tract infections; respiratory-tractinfections including bronchitis, pneumonia,infections in cystic fibrosis; melioidosis;listeriosis; brucellosis; granuloma inguinale;otitis media; skin infections; Pneumocystiscarinii pneumonia.",TABLETS (TMP + SMZ) 80 mg + 400 mg and160 mg + 800 mg, SUSPENSION 40 mg TMP+ 200 mg SMZ/5 ml.,Adult- 1 to 2 tablets twice daily for 7-14 days (160 + 800 mg).Child- Suspension 5 ml twice daily (40 + 200 mg). infant 2.5 ml.,"Hypersensitivity to sulfonamides ortrimethoprim; porphyria; marked liverparenchymal damage, blood dyscrasias,severe renal insufficiency.","Renal impairment; hepatic impairment(avoid if severe; Appendix 7a); maintainadequate fluid intake (to avoid crystalluria);avoid in blood disorders (unless underspecialist supervision); monitor bloodcounts and discontinue immediately ifblood disorder develops; rash-discontinueimmediately; predisposition to folatedeficiency, elderly; asthma; G-6-PDdeficiency; lactation (Appendix 7b); avoid ininfants under 6 weeks; elderly.; pregnancy(Appendix 7c); interactions (Appendix 6c).","Nausea, vomiting, diarrhoea, headache;hypersensitivity reactions including rashes,pruritus, photosensitivity reactions,exfoliativedermatitisanderythemanodosum;rarely, erythema multiforme (Stevens-Johnson syndrome) and toxic epidermalnecrolysis; systemic lupus erythematosus,myocarditis, serum sickness; crystalluria-resulting in haematuria, oliguria, anuria;blood disorders including granulocytopenia,agranulocytosis, aplastic anaemia, purpura-discontinue immediately; also reported, liverdamage, pancreatitis, antibiotic-associatedcolitis, eosinophilia, cough and shortnessof breath, pulmonary infiltrates, asepticmeningitis, depression, convulsions, ataxia,tinnitus, vertigo, dizziness, hallucinationsand electrolyte disturbances; megaloblasticanaemia due to trimethoprim; elevation oftransaminase and bilirubin; skin rashes.",Store protected from light and moisture.Suspension should not be allowed to freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Doxycycline,Pregnancy Category-D,Schedule H,"Respiratory-tract infections, including pneu-monia and chronic bronchitis; urinary-tractinfections; syphilis; chlamydia, mycoplasmaand rickettsia; prostatitis; lymphogranulo-ma venereum; pelvic inflammatory disease(with metronidazole); Lyme disease; brucel-losis (with rifampicin); leptospirosis, scrubtyphus and travellers’ diarrhoea; psittaco-sis; cholera; melioidosis; plague; anthrax; Qfever; Treatment of acute malaria caused byP. malariae and susceptible P. falciparum; P.vivax and P. ovale (followed by primaquineto eliminate intrahepatic forms); prophy-laxis of malaria for pregnant women andnon-immune individuals at risk.",TABLETS/CAPSULES 100 and 200 mg,SyRUP 25 mg/5 ml.,"OralSevere infections including refractory urinary tract infection: 200 mg daily.Early syphilis: 100 mg twice daily for 14 days. Latent syphilis: 200 mg twce daily for 28 days.Uncomplicated genital Chlamydia, non-gonococcal urethritis: 100 mg twice dailyfor 7 days.Child- Only if alternate antibacterial cannot be given 5 mg/kg body weight in two divided doses.",Pregnancy (Appendix 7c), children (seenotes above), porphyria, systemic lupuserythematosus, hypersensitivity totetracycline.,"Avoid exposure to sunlight or sunlamps-photosensitivity reported; renal impairment;hepatic impairment (Appendix 7a); lactation(Appendix 7b); interactions (Appendix 6a,6b, 6c 6d); predisposition to candidiasis.","Gastrointestinal disturbances; anorexia,erythema (discontinue treatment);photosensitivity; hypersensitivity reactions;headache and visual disturbances;hepatotoxicity, blood disorders, pancreatitisand antibiotic-associated colitis reported;staining of growing teeth and occasionaldental hypoplasia; erythematous rashes,nasophryngitis, sinusitis, increased bloodglucose levels, haemolytic anaemia,neutropenia.",Store protected from light and moisture at a temperature not exceeding 30⁰C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Erythromycin,Pregnancy Category-B,Schedule H,"Alternative to penicillin in hypersensi-tive patients; pneumonia; legionnaires’disease; syphilis; chancroid; chlamydia; non-gonococcal urethritis; prostatitis; lym-phogranuloma venereum; campylobacterenteritis; relapsing fever; diphtheria andwhooping cough prophylaxis upper respira-tory tract infection, acne vulgaris, sycosis,vulgaris.","TABLETS 125, 250 and 500 mg plain; 125 DT;SyRUP 125 mg/5 ml; OINTMENT 2 and 3%w/w; CREAM 3% w/w.",OralAdult and child over 8 years- 250 to 500 mg every 6 h or 0.5 to 1g every 12 h upto 4g daily in severe infections.Child- 1 month to 2 years, 12.5 mg/kg bodyweight every 6 h, 2 to 8 years 250 mg every6 h (doses doubled for severe infections).Early syphilis: 500 mg three times daily for 14 days,Hypersensitivity to erythromycin or othermacrolides, porphyria, myasthenia gravis.,Hepatic impairment (Appendix 7a) and renalimpairment (Appendix 7d), prolongationof the QT interval (ventricular tachycardiareported), pregnancy (Appendix 7c), (notknown to be harmful), lactation (Appendix7b), interactions (Appendix 6c).,"Nausea, vomiting, abdominal discomfort,diarrhoea and (antibiotic-associatedcolitis); urticaria, rashes and other allergicreactions (rarely, anaphylaxis); reversiblehearing loss after large doses; cholestaticjaundice, cardiac effects (including chestpain and arrhythmias), myasthenia-like syndrome, erythema multiforme(Stevens-Johnson syndrome) and toxicepidermal necrolysis; burning sensation,itching, anorexia.",Store protected from light at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Framycetin,,Schedule H,"Bacterial skin infections, burns, ENTinfections, surgical infections, traumaticinjury, conjunctivitis, blepharitis.","CREAM 1% - 5, 15 and 40g; DROPS 5 ml(0.5%); DRESSING 1%; POWDER 15g.","TopicalSkin infections: Adult- as 1% dressing. OphthalmicBlepharitis along with conjunctivitis:Adult- as 0.5 % ointment, apply 2-3 timesdaily.Otitis externaAdult- 0.5% drops.","Tuberculosis,glaucoma,perforatedtympanicmembrane, fungal, viral or resistant bacterialinfections of eye, hypersensitivity","Pregnancy, ototoxicity due to systemicabsorption may occur if applied on largeareas in children, elderly and patientswith renal failure, avoid prolonged use,interactions (Appendix 6c).","Ototoxicity, gastrointestinal symptoms,inflammation, transient irritation, contactdermatitis, burning sensation, pruritus.","Store protected from light and moisture at a temperature not exceeding 30⁰C. If the material is sterile, the container should be tamper-evident and sealed so as to exclude micro-organisms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Gentamicin,Pregnancy Category-C,Schedule H,Pneumonia, cholecystitis, peritonitis,septicaemia, acute pyelonephritis,prostatitis, skin infections, pelvicinflammatory disease, endocarditis,meningitis, listeriosis, tularaemia,brucellosis, plague, surgical prophylaxis,ocular bacterial infection.,"EyE DROPS 0.3% w/v, CREAM 15g (0.1%w/w); INJECTION 2 ml ampoule (40 mg/ml),2 and 10 ml vials (40 mg/ml).","Intravenous infusionOnce daily dose regime; 5 to 7 mg/kg body weight, then adjust as per serum gentamicin concentration.Intramuscular or slow intravenous injectionover at least 3 min.Multiple daily dose regimen: 3 mg/kg body weight divided into 8 hly doses. Child- 2 weeks to 12 years; 2 mg/kg bodyweight 8 hly.",Myasthenia gravis.,"Renal impairment (Appendix 7d), infantsand elderly (dosage adjustment and monitorrenal, auditory and vestibular function andserum-gentamicin concentrations); avoidprolonged use; conditions characterized bymuscularweakness;significantobesity(mon-itor serum-gentamicin concentration closelyand possibly reduce dose); see notes above;interactions (Appendix 6c); purulentdischarge, discontinue if pain/inflam-mation becomes aggravated; pregnancy(Appendix 7c).","Vestibular and auditory damage,nephrotoxicity; rarely, hypomagnesaemiaon prolonged therapy; antibiotic-associatedcolitis, also nausea, vomiting, rash; bacterial/fungal corneal ulcers, ocular burning orirritation, thrombocytopenia, joint pain",Store protected from moisture if it is intended for use in the manufacture of parenteral preparations.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Imipenem + Cilastatin,Pregnancy Category-C,Schedule H,"Severe aerobic and anaerobic Gram-positiveand Gram-negative infections in hospital-acquired infections (not indicated for CNSinfections), including infections caused byresistant Pseudomonas and Acinetobacterspecies.",INJECTION Imipenem + Cilastatin125 mg + 125 mg vial250 mg + 250 mg vial500 mg + 500 mg vial1g + 1g vial2g + 2g vial,"Intravenous infusion in terms of imipenemAdult- 2g daily in 2 to 3 divided doses. Less susceptible organism may be given up to 3 to 4 divided doses (max 4g daily).Surgical prophylaxis: 1g for induction, repeated every three h, supplemented in high risk surgery by doses of 500 mg for 8 to 16 h.Child- 3 months and older: 60 mg/kg body weight in four divided doses. Over 40 kg: adult dose.",Hypersensitivity to beta-lactam antibiotics,local anaesthetics of the amide type and inpatients with severe shock or heart block.,"Renal impairment; CNS disorders, suchas epilepsy; lactation (Appendix 7b);interactions (Appendix 6c); pregnancy(Appendix 7c).","Nausea, vomiting, diarrhoea; antibiotic-associated colitis; taste disturbances; toothor tongue discolouration, hearing loss;blood disorders, (decreased haematocrit,increased prothrombin time) positiveCoombs’ test; allergic reactions includingrash, pruritus, urticaria, erythemamultiforme (Steven’s-Johnson syndrome),fever, anaphylactic reactions, rarely, toxicepidermal necrolysis, exfoliative dermatitis;myoclonic activity, convulsions, confusionand mental disturbances; slight increase inliver enzymes and bilirubin, rarely, hepatitis;increase in serum creatinine and blood urea;red coloration of urine in children; erythema,pain and induration and thrombophlebitisat injection sites; bone marrow depression.",Store protected from moisture in a single dose or multi dose container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Meropenem,Pregnancy Category-B,Schedule H,"Nosocomial infection like septicemia, febrileneutropenia, intraabdominal and pelvicinfection etc caused by cephalosporinsresistant bacteria, meningitis, cystic fibrosis.","INJECTIONS 0.125, 0.250, 0.5, 1 g/vial.",Adult- 0.5-2 g or 10-40 mg/kg by slow i.v injection 8 hourly.Neonate (less than 7 days)- 20 mg/kg 12 hourly.7-28 days- 20 mg/kg 8 hourly.1-3 months- 10 mg/kg 8 hourly.> 3 months- 10- 20 mg/kg 8 hourly.Meningitis: Adult- 2g 8 hourly.Child- (> 3 months)- 40 mg/kg 8 hourly.,Hypersensitivity.,"Renal insufficiency, neurological disorders,prolonged use of meropenem may result inovergrowth of nonsusceptible organisms,pregnancy (Appendix 7c), lactation, historyof hypersensitivity to other β-lactamantibiotics; interactions (Appendix 6c).","Inflammation at the injection site;nausea, vomiting, headache, rash;diarrhoea, thrombophlebitis, anaphylaxis,pseudomembranous colitis, disturbancesin LFTs.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Nalidixic Acid,Pregnancy Category-C,Schedule H,Urinary-tract infections, shigellosis.,"TABLETS 250, 500 mg and 1g; SUSPENSION300 mg/5 ml.","OralAdult- 1g every 6 h for 7 days. Reduced in chronic infection to 600 mg every 6 h.Child- Over 3 months: max 50 mg/kg body weight in divided doses, in prolonged therapy, reduced to 30 mg/kg body weight daily.","Hypersensitivity; children <3 years age,porphyria; convulsive disorder.","History of epilepsy or conditions thatpredispose to seizures; G-6-PD deficiency;myasthenia gravis (risk of exacerbation);pregnancy (Appendix 7c); lactation(Appendix 7b); avoid exposure to excessivesunlight (discontinue if photosensitivityoccurs); rarely, tendon damage-discontinueat first sign of pain or inflammation andrest affected limb; porphyria; hepaticimpairment; renal impairment; false positiveurinary glucose (if tested for reducingsubstances); monitor blood counts, renaland liver function if treatment exceeds 2weeks; interactions (Appendix 6c); cerebro-arterial sclerosis. ","Nausea, vomiting, dyspepsia, abdominalpain, diarrhoea (rarely, antibiotic-associat-ed colitis), headache, dizziness, weakness,sleep disorders; rash (rarely, erythema mul-tiforme (Stevens-Johnson syndrome) andtoxic epidermal necrolysis) and pruritus;less frequently anorexia, increase in bloodurea and creatinine; metabolic acidosis;drowsiness, restlessness, asthenia, depres-sion, confusion, hallucinations, convulsions,paraesthesia, raised intracranial pres-sure, cranial nerve palsy; photosensitivity,hypersensitivity reactions including fever,urticaria, angioedema, arthralgia, myalgiaand anaphylaxis; blood disorders (includingeosinophilia, leukopenia, thrombocytope-nia); disturbances in vision, taste, hearingand smell; also isolated reports of tendoninflammation and damage (especially in theelderly and in those taking corticosteroids);haemolytic anaemia, renal failure, intersti-tial nephritis and hepatic dysfunction (in-cluding hepatitis and cholestatic jaundice);if psychiatric, neurological or hypersensitiv-ity reactions (including severe rash) occur,discontinue.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Nitrofurantoin,Pregnancy Category-B,Schedule H,Urinary-tract infections, cystitis,"TABLETS 50, 100 and 200 mg","Adult- 50 mg every 6 h with food for 3-7 days.Child- Over 3 months: 3 mg/kg body weight daily in four divided doses. Severe chronic recurrent infections: 100 mg every 6 h with food for 7 days, discontinue or reduce dosage in case of nausea.","Impaired renal function; infants less than3 months; G-6-PD-deficiency includinglactation of affected infants (Appendix7b); pregnancy, at term (Appendix 7c);porphyria; anuria, oliguria, labour anddelivery, neonates; interactions (Appendix6a, 6d)",Pulmonary disorders or hepatic impairment(Appendix 7a), monitor lung and liverfunction on long-term therapy (discontinueif lung function deteriorates), neurologicalor allergic disorders, anaemia, diabetesmellitus, elderly and debilitated, vitamin Band folate deficiency, false positive urinaryglucose (if testing for reducing substances),urine may be coloured yellow or brown.,"Dose-related gastrointestinal disorders,nausea; hypersensitivity reactionsincluding urticaria, rash, sialadenitis,pruritus, angioedema; anaphylaxisreported; rarely, cholestatic jaundice,hepatitis, exfoliative dermatitis; erythemamultiforme, pancreatitis, arthralgia;blood disorders; pulmonary reactions(pulmonary fibrosis; possible associationwith lupus erythematosus-like syndrome);peripheral neuropathy; benign intracranialhypertension; transient alopecia; dyspepsia,dizziness, nystagmus.",Store protected from light and moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Norfloxacin,Pregnancy Category-C,Schedule H,Uncomplicated gonorrhea, chronic bacterialprostatitis, complicated UTI, gastroenteritis,conjunctivitis.,"TABLETS 200, 400, 800 mg; 100 mg DT;SUSPENSION 100 mg/5 ml.","OralUrinary tract infection and upper respiratory tract infections: 200 to 400 mg daily preferably in the morning. Increase if necessary in upper urinary tract infection to 400 mg twice daily. Uncomplicated gonorrhea: 400 mg as a single dose.Uncomplicated genital chlamydia infections, non-gonococcal urethritis: 400 mg daily in single dose for 7 days or divided doses for 7 days.","History of hypersensitivity, tendinitis.","Should be used with caution in patientswith a history of epilepsy or conditions thatpredispose to seizures, in G-6-PD deficiency,myasthenia gravis (risk of exacerbation),in renal impairment; during lactation.Exposure to excessive sunlight should beavoided (discontinue if photosensitivityoccurs). Quinolones may induce convulsionsin patients with or without a history ofconvulsions; taking NSAIDs at the sametime, organ system assessment, haemolyticreaction, pregnancy (Appendix 7c).","Nausea, vomiting, dyspepsia, abdominalpain, diarrhoea (rarely, antibiotic-associat-ed colitis), headache, dizziness, sleep dis-orders; rash (rarely, Stevens-Johnson syn-drome and toxic epidermal necrolysis) andpruritus. Less frequent side-effects includeanorexia, increase in blood urea and cre-atinine; drowsiness, restlessness, asthenia,depression, confusion, hallucinations,convulsions, tremor, paraesthesia, hypo-aesthesia; photosensitivity, hypersensitivityreactions including fever, urticaria,angioedema, arthralgia, myalgia and ana-phylaxis; blood disorders (including eosi-nophilia, leucopenia, thrombocytopenia);disturbances in vision, taste, hearing andsmell. The drug should be discontinued ifpsychiatric, neurological or hypersensitiv-ity reactions (including severe rash) occur;rash, heart burn, abdominal cramps, irrita-bility",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ofloxacin,Pregnancy Category-C,Schedule H,"Acute uncomplicated cystitis, communityacquired pneumonia, acute exacerbation ofchronic bronchitis","TABLETS 100, 200 and 400 mg; SyRUP 30 ml(50 mg/5 ml, 100 mg/5 ml); INJECTION 100ml (2 mg/ml);EyE DROPS 0.3% w/v.","OralCommunity acquired pneumonia: Adult- 400 mg twice daily for 10 days.Pelvic inflammatory disease:Adult- 400 mg twice daily for 14 days.Complicated UTI:Adult- 200 mg twice daily for 10 days. ParenteralComplicated UTI:Adult- 200 mg daily by i.v infusion overatleast 30 minutes, max. 400 mg twiceinfused over at least 1 h.Septicaemia, lower respiratory tract infection:Adult- 200 mg twice daily by i.v infusion over at least 30 minutes, max. 400 mg twice daily infused over at least 1 h.Bacterial corneal ulcer:Adult- 0.3%, 1-2 drops every 30 minutes.OphthalmicBacterial conjunctivitis:Adult- 0.3%, 1-2 drops every 2-4 h.Child- >1year, 1-2drops every 2-4 h.",Hypersensitivity.,"Patients with epilepsy, kidney disease,tendon problem, nervous system problem,liver disease (Appendix 7a), limit alcoholintake, pregnancy (Appendix 7c); lactation(Appendix 7b).","Sinus tachycardia, hallucination, Steven’sJohnson syndrome, seizure; dizziness,headache, nausea, vomiting, diarrhoea;insomnia, pruritus, photosensitivity.",Tablets: Store protected from light and moisture. Eye Drops: Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Phenoxymethyl Penicillin (Penicillin V),Pregnancy Category-B,Schedule H,Streptococcal pharyngitis, otitis media,erysipelas, mouth infections, secondaryprophylaxis of rheumatic fever, post-splenectomy prophylaxis.,TABLETS 125 and 250 mg.,Adult- 500 mg every 6 hour increased to 750 mg every 6 h in severe cases.Child- up to 1 year: 62.5 mg every 6 h. 1 to 5 years: 125 mg every 6 h.6 to 12 years: 250 mg every 6 h.,Hypersensitivity to penicillins (see notesabove), serious infections (see notesabove).,History of allergy (see notes above), lactation(Appendix 7b), pregnancy (Appendix 7c),interactions (Appendix 6c), cross sensitivitywith cephalosporins may occur.,"Hypersensitivityreactionsincludingurticaria,serum sickness reaction; joint pain, rash,angioedema, anaphylaxis (see notes above);nausea and diarrhoea; epigastric distress,skin eruptions; haemolytic anaemia.",Store protected from moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Piperacillin + Tazobactam,Pregnancy Category-B,Schedule H,"Nosocomial pneumonia, infections followingburns, urinary tract infections","INJECTIONS Piperacillin 4g +Tazobactam0.5g Piperacillin 2g + Tazobactam 0.25g,Piperacillin 1g +Tazobactam 0.0125g.",4.5g (Piperacillin 4g + Tazobactam 0.5g) every 6 h for 7-14 days.,Hypersensitivity to penicillins.,"Pregnancy (Appendix 7c), lactation;prolonged treatment may increase superinfections, interactions (Appendix 6c)","Hypersensitivity reactions like rash, fever,bronchospasm, vasculitis, serum sickness,exfoliative dermatitis, Steven’s-Johnsonsyndrome, and anaphylaxis.",Store below 25⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Procaine Benzyl Penicillin(Procaine Penicillin G),Pregnancy Category-B,Schedule H,Syphilis, anthrax, childhood pneumonia,diphtheria carrier state, cellulitis, mouthinfections, bites.,VIALS 5 and 10 lac units.,Intramuscular and intravenous injection or infusionAdult- Streptococcal infection and pyroderma: single dose 12 lac units. Syphilis: 24 lac units every week for three weeks. Rheumatic fever: 12 lac units every 3 to 4 weeks.,Hypersensitivity to penicillins (see notesabove), intravascular injection.,History of allergy (see notes above), renalfailure, pregnancy (Appendix 7c).,"Hypersensitivity reactions including urticaria,fever, joint pains, rashes, angioedema,anaphylaxis, serum sickness-like reaction,haemolytic anaemia, interstitial nephritis(see also notes above); neutropenia,thrombocytopenia, coagulation disordersand central nervous system toxicity(associated with high doses and severe renalfailure); Jarisch-Herxheimer reaction (duringtreatment for syphilis and other spirochaeteinfections, probably due to release ofendotoxins); rarely, non-allergic (embolic-toxic) reactions; pain and inflammation atinjection site.",The constituted solution should be used immidiately after preparation but in any case within the period recommended by the manufacturer.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Roxithromycin,Pregnancy Category-B,Schedule H,"Susceptible infections; pneumonia, acutebronchitis, sinusitis, pharyngitis, tonsillitis,genital infection.",TABLETS 150 and 300 mg, SUSPENSION 50mg/ml, DROPS 10 ml (25 mg/ml).,Adult- 150 mg twice a day at least 15 min before meals.Child- 5 to 8 mg/kg body weight in two divded doses for not more than 10 days.,Concomitant use with ergot alkaloid typecompounds.,Hepatic dysfunction, paediatrics (reducedose), interactions (Appendix 6d),pregnancy (Appendix 7c).,Diarrhoea, vomiting, nausea, transient risein liver transaminase, skin rash, gastralgia.,Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sulphadiazine,Pregnancy Category-C,Schedule H,Prevention of recurrences of rheumaticfever, toxoplasmosis, prophylaxis ofmeningococcal infections.,TABLET 500 mg.,OralAdult- 500 mg twice a day.Child- Up to 8 years: 125 mg twice daily. 8 to 12 years: 250 mg twice daily,"Hypersensitivity to sulfonamides; porphyria;severe renal hepatic impairment, blooddyscrasias, elderly.",Hepatic impairment (avoid if severe,Appendix 7a), renal impairment, maintainadequate fluid intake (to avoid crystalluria),avoid in blood disorders (unless underspecialist supervision), monitor bloodcounts and discontinue immediatelyif blood disorder develops, rashes-discontinue immediately, predisposition tofolate deficiency, elderly, asthma, G-6-PDdeficiency, lactation (Appendix 7b), avoidin infants under 6 weeks, interactions(Appendix 6d), pregnancy (Appendix 7c).,"Nausea, vomiting, diarrhoea, headache;hypersensitivity reactions including rashes,pruritus,photosensitivityreactions,exfoliativedermatitis and erythema nodosum; rarely,erythema multiforme (Stevens-Johnsonsyndrome) and toxic epidermal necrolysis;systemic lupus erythematosus, myocarditis,serum sickness; crystalluria-resulting inhaematuria, oliguria/anuria; blood disordersincluding granulocytopenia, agranulocytosis,aplastic anaemia, purpura-discontinueimmediately; also reported, liver damage,pancreatitis, antibiotic-associated colitis,eosinophilia, cough and shortness of breath,pulmonary infiltrates; aseptic meningitis,depression, ataxia, tinnitus, vertigo, dizziness,hallucinations, and electrolyte disturbances;convulsions, hypoprothrombinemia,methaemoglobinemia, anorexia,pancreatitis.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tetracycline,Pregnancy Category-D,Schedule H,Rocky Mountain spotted fever, typhus, Qfever, rickettsial pox, tick fever caused byRickettsiae, respiratory tract infectionscaused by Mycoplasma pneumonia,chlamydia infection, nongonococcalurethritis, chancroid, plague, tularemia,cholera, brucellosis, bartonellosis,granuloma inguinale, haemophilus andkleibsella infections, psittacosis.,CAPSULES/TABLETS 250 and 500 mg.,"Adult- 250 mg every 6 h, increase to 500 mg every 6 to 8 h in severe infections.Non-gonococcal urethritis: 500 mg every 6 h for 7 to 14 days (21 days if failure or relapse after course is seen).To be taken with plenty of fluid while sitting or standing.Child- 25 to 50 mg/kg body weight, daily in three divided doses. Avoid in children below 8 years.","Deposition of tetracyclines in growing boneand teeth (by binding to calcium) causesstaining and occasionally dental hypoplasiaand they should not be given to childrenunder 12 years, or to pregnant (Appendix 7c)or lactating women (Appendix 7b). However,doxycycline may be used in children fortreatment and post-exposure prophylaxisof anthrax when an alternative antibacterialcannot be given (unlicensed indication). Withthe exception of doxycycline and minocycline,the tetracyclines may exacerbate renal failureand should not be given to patients withkidney disease; hypersensitivity; interactions(Appendix 6c, 6d)","Used with caution in patients with hepaticimpairment or those receiving potentiallyhepatotoxic drugs. Tetracyclines mayincrease muscle weakness in patientswith myasthenia gravis and exacerbatesystemic lupus erythematosus; antacidsand aluminium, calcium, iron, magnesiumand zinc salts decrease the absorptionof tetracyclines; milk also reduces theabsorption of tetracyclines, demeclocyclinesand oxytetracycline; cerebrovascularsensitisation, maculopapular rashes,increased blood urea nitrogen, anaemia. ","Nausea, vomiting, diarrhoea (antibiotic-associated colitis reported occasionally),dysphagia and oesophageal irritation. Otherrare side-effects include hepatotoxicity,pancreatitis, blood disorders, photosensitiv-ity (particularly with demeclocycline) andhypersensitivity reactions (including rash,exfoliative dermatitis, Stevens-Johnson syn-drome, urticaria, angioedema, anaphylaxis,pericarditis). Headache and visual distur-bances may indicate benign intracranialhypertension (discontinue treatment); bulg-ing fontanelles have been reported in in-fants; anaemia.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Trimethoprim,Pregnancy Category-C,Schedule H,Urinary-tract infections, bronchitis.,Refer cotrimoxazole above.,OralAdult- 200 mg every 12 h.Child- 1 month to 12 years: 4 mg/kg bodyweight (max. 200 mg) every 12 h. 6 weeksto 6 months: 25 mg every 12 h.,Blood disorders, porphyria, hypersensitivity.,Renal impairment, lactation (Appendix7b), predisposition to folate deficiency,elderly, blood counts on long-term therapy(but practical value not proven), neonates(specialist supervision required), pregnancy(Appendix 7c).,"Rashes, pruritus; depression ofhaematopoiesis; gastrointestinaldisturbances including nausea andvomiting; rarely, exfoliative dermatitis andtoxic epidermal necrolysis, photosensitivityand other allergic reactions includingangioedema and anaphylaxis; asepticmeningitis; erythema, multiforme, elevationof transaminase and bilirubin.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Vancomycin,Pregnancy Category Oral Capsules- BParenteral Formulation- C,Schedule H,Methicillin-resistant staphylococcalpneumonia, staphylococcal meningitis,endocarditis prophylaxis (with gentamicin).,"TABLETS 500 mg; INJECTION 250 mg, 500mg and 1g/vial; CAPSULE 125 and 250 mg.",Adult- 1 to 1.5g every 12 h.Elderly over 65 years, 500 mg every 12 h or 1g once daily.Child- Over 1 month, 15 mg/kg body weight every 8 h (max. 2g daily).,"Allergy to corn/corn products,hypersensitivity.","Avoid rapid infusion (risk of anaphylactoidreactions, see Adverse effects); rotateinfusion sites; renal impairment (Appendix7d); elderly; history of deafness-avoid;plasma-vancomycin concentrationmeasured after 3 or 4 doses (earlier if renalimpairment), blood counts, urinalysis andrenal function tests-use only in hospitalsetting; monitor auditory function andplasma-vancomycinconcentrationsinelderlyor in renal impairment; lactation (Appendix7b); pregnancy (Appendix 7c); interactions(Appendix 6c); Pseudomembranous colitis.","Nephrotoxicity including renal failure andinterstitial nephritis; ototoxicity (discontinueif tinnitus occurs); blood disorders; nausea,chills, fever, eosinophilia, anaphylaxis,rashes, including exfoliative dermatitis,erythema multiforme (Stevens-Johnsonsyndrome), toxic epidermal necrolysisand vasculitis; phlebitis; on rapid infusion,severe hypotension (with shock, cardiacarrest), wheezing, dyspnoea, urticaria,pruritus, flushing of the upper body (‘redman’ syndrome), pain and muscle spasmof back and chest; hypotension, pruritus,haematopoitic flebitis.",Store in an air tight container protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Diethylcarbamazine,,,Treatment of loiasis, prophylaxis of loiasis intemporary residents in endemic areas, tissuenematode infections, lymphatic filariasis,toxocariasis.,TABLETS 50 and 100 mg, SyRUP 5 mg/ml and120 mg/5 ml.,OralAdult and child- 11 mg/kg body weight daily in three divided doses on the first day. Thereafter increase gradually to 6 mg/kg body weight given after food daily for two to three days. Hookworm infection: treat for 21 days. Filariasis: 2 mg/kg body weight is given three times a day for 3 to 4 weeks. 1 mg/kg body weight for an adult of 50 kg. Treatment may be repeated once after 6 months.,"Pregnancy (delay treatment until afterdelivery); infants, elderly, debilitated (usuallyexcluded from mass treatment programmes;see also Precautions); cardiac disease,hypersensitivity, impaired renal function.",Renal impairment, cardiac disorders,other severe acute diseases-delaydiethylcarbamazine treatment until afterrecovery, risk of meningoencephalitis insevere infection (see notes above).,"Headache, dizziness, drowsiness, nausea andvomiting; immunological reactions, withina few hour of the first dose, subsiding byfifth day of treatment and including fever,headache, joint pain, dizziness, anorexia,malaise, nausea and vomiting, urticaria andasthma in asthmatics (similar to Mazzottireaction), induced by disintegratingmicrofilariae; microencephalitis (with heavymicrofilaraemia, see notes above); reversibleproteinuria; enlargement of lymph nodes.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ivermectin,Pregnancy Category-C,,"Nematodal infections such as ascariasis,trichuriasis, strongyloidiasis, enterbiasis,lymphatic filariasis, scabies and pediculosis.","TABLETS 3, 6, 9 and 12 mg; INJECTION 10 ml(0.1% w/v). ",OralStrongyloidiosis: 200 µg/kg of body weight once daily for 1-2 days.Lymphatic filariasis: 400 µg/kg of body weight simple annual dose for 4-6 years. Scabies and pediculosis: 150-200 µg/kg of body weight single oral dose highly effective. Second dose may be required 7-10 days later.,"Hypersensitivity, CNS disorders, pregnancy,meningitis, trypanosomiasis, seizures,contraindicated to children below the age of< 5 years old or under 15 kg body weight.","Concurrent Loa Loa infection, impairedblood-brain barrier function, pregnancy(Appendix 7c), lactation, hepatic,cardiovascular, renal or pulmonary disease,anaemia, coagulation disorder, severeasthma, interactions (Appendix 6c).","Nausea, vomiting, constipation, abdominalpain and fatigue, rash, arthralgia, fever,myalgia, asthenia, hypotension, tachycardia,edema, lymphadenopathy, sore throat,cough, headache, somnolence, transienteosinophilia, dizziness, diarrhoea, pruritus,orthostatic hypotension, lymph-nodetenderness, rare but serious adverseeffects such as marked disability andencephalopathies in patients coinfected withheavy burdens of Loa microfilaria.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Amphotericin B,Pregnancy Category-B,Schedule H,"Life-threatening fungal infections includ-ing histoplasmosis, coccidioidomycosis,paracoccidioidomycosis, blastomycosis,aspergillosis, cryptaococcosis, mucormycosis,sporotrichosis and candidiasis; visceral andmucocutaneous leishmaniasis unresponsiveto pentavalent antimony compounds; severemeningitis, perioral candidiasis.","VIALS 10, 25, 50 and 100 mg plain, 50 mg/vial (liposomal).","Intravenous infusion (plain) Adult- Systemic fungal infection: 250 µg/kg body weight daily, increase gradually 1 mg/ kg body weight if tolerated (max 1.5 mg/kg body weight daily) or alternate days.Child- Same as for Adult based on body weight.Intravenous (liposomal)For fever in neutropenic patients: 3 mg/kg/ day, max. dose 5 mg/kg/day i.v.For cryptococcal meningitis: 3-4 mg/kg, max. 6 mg/kg, i.v. once daily.Visceral leismaniasis: Immunocompetent patients: 3 mg/kg.Immunocompromized patients: 4 mg/kg.","Toxic effects must be weighed againstbenefits. Regular kidney, liver functiontests and blood counts must be conducted;lactation; antineoplastic therapy.","Close medical supervision throughouttreatment and initial test dose required (seenote, below); renal impairment (Appendix7d); pregnancy (Appendix 7c); hepatic andrenal function tests; blood counts and plasmaelectrolyte monitoring; corticosteroids(avoid, except to control reactions); lactation;avoid rapid infusion (risk of arrhythmias);interactions (Appendix 6c); geriatric use.Anaphylaxis occurs rarely, with intravenous amphotericin B and a test dose is advisable before the first infusion. The patient should be observed for about 30 min after the test dose.","Fever,headache,anorexia,weightloss,nauseaand vomiting, malaise, diarrhoea, muscleand joint pain, dyspepsia and epigastricpain; renal function disturbances includinghypokalaemia, hypomagnesaemia and renaltoxicity; blood disorders; cardiovasculartoxicity (including arrhythmias); neurologicaldisorders (including peripheral neuropathy);abnormal liver function (discontinuetreatment); rash; anaphylactoid reactions(see above); pain and thrombophlebitis atinjection site; respiratory failure.","Store in a tightly closed container between 2 to 8⁰C, protected from light.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Clotrimazole,Pregnancy Category-B,Schedule H,"Vulvo-vaginal candidiasis, trichomoniasis,vaginitis, non-specific vaginitis, mixed vaginalinfection, Gram-positive and Gram-negativebacterial infection, infective leucorrhoeas;prevention of athletes foot and ringwormdisease of skin folds.",PESSARIES/VAGINAL TABLETS 100 and 200mg, CREAM 1% w/w, POWDER 75g, LOTION50 ml.,"Adult- Pessaries/vaginal tablets: 100 mg pessary/vaginal tablet to be inserted into vagina at night before going to bed as deep as possible for consecutive 6 to 7 days or 200 mg for 3 consecutive night before going to bed or 500 mg single dose.Child- Pessaries/vaginal tablets: not recommended. Cream: Rub on affected area 2 to 3 times by applying in thin layer and rubbing, continue for 14 days after healing.",Ophthalmic use, hypersensitivity.,"Avoid contact with eyes, pregnancy(Appendix 7c) and lactation.","Local irritation, burning sensation anditching, abnormal liver function, unpleasantmouth sensation.",Store protected from light and moisture. Do not crush pessaries.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Fluconazole,Pregnancy Category-C,Schedule H,"Systemic mycosis including histoplasmosis,non-meningeal coccidioidomycosis, para-coccidioidomycosis and blastomycosis treat-ment and, in AIDS and other immunosup-pressed patients, prophylaxis of cryptococcalmeningitis; oesophageal and oropharyngealcandidiasis, vaginal candidiasis and systemiccandidiasis. ","TABLETS/CAPSULES 50, 100, 150 and 200mg; EyE DROPS 5 ml (0.3% w/v).",Adult- Mucosal: 50 to 100 mg daily for 14 to 30 days. Vaginal: 150 mg as a single dose. Oral: systemic loading dose of 400 mg on first day and thereafter 200 to 400 mg once daily for at least 28 days.Prophylaxis of fungal infection: 50 to 100 mg once daily.,"Sensitivity to primaquine; infants below 1year of age; alcohol; coadministration ofcisapride, terfenadine.","Renal impairment (Appendix 7d); lactation(Appendix 7b); monitor liver function-discontinue if signs or symptoms of hepaticdisease (risk of hepatic necrosis; Appendix 7a);interactions: (Appendix 6b, 6c); pregnancy(Appendix 7c); immunocompromisedpatients.","Nausea, vomiting, abdominal pain; flatulence,diarrhoea; headache, taste disturbance,hepatic disorders, dizziness, seizures,alopecia, pruritus; rash (withdraw treatment);angioedema, anaphylaxis, bullous lesions,toxic epidermal necrolysis and erythemamultiforme (Stevens-Johnson syndrome)reported (skin reactions more commonin AIDS); hyperlipidaemia, leukopenia,thrombocytopenia, hypokalaemia.",Stor in an airtight container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Flucytosine,Pregnancy Category-C,Schedule H,"Adjunct to amphotericin B (or fluconazole)in cryptococcal meningitis; adjunct toamphotericin B in systemic candidiasis;septicemia, pulmonary infection.",CAPSULE 250 mg, INFUSION 2.5g in 250 ml.,OralAdult- 250 mg four times a day for not more than 7 days.Intravenous infusion- over 20 to 40 min, Adult and Child- 200 mg/kg body weight daily in four divided doses.,"Renal impairment; elderly; blood disorders,pregnancy (Appendix 7c); hypersensitivity.",Elderly, renal impairment, also the use withamphotericin B (both nephrotoxic), liver-and kidney function tests and blood countsrequired (weekly in renal impairment orin blood disorders), lactation (Appendix7b), interactions (Appendix 6c), pregnancy(Appendix 7c).,"Rash, nausea, vomiting and diarrhoea; alter-ations in liver function tests; less frequently,confusion, hallucinations, convulsions, head-ache, sedation, vertigo; blood disorders in-cluding leukopenia, potentially fatal throm-bocytopenia and aplastic anaemia; cardiacarrest, myocardial toxicity, dyspnoea, azo-temia, ataxia, hypoglycemia.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Griseofulvin,Pregnancy Category-C,,"Fungal infections of the skin, scalp, hair andnails where topical treatment has failed or isinappropriate; athlete’s foot.","TABLETS 125, 250, 375 and 500 mg;CAPSULES 125 mg.","OralAdult- 500 mg once a day or in divided doses, in severe infections dose may be doubled. Reduce when response occurs. Administer with meals.Child- Under 50 kg: 10 mg/kg body weight once daily or divided doses with meals.",Severe liver disease (Appendix 7a), pregnancy(Appendix 7c) (avoid pregnancy during andfor 1 month after treatment, men should notfather children within 6 months of treatment,porphyria, systemic lupus erythematosusand related disorders,"Pre-existing hepatic insufficiency (closelymonitor hepatic function throughouttreatment); blood disorders (monitorblood count weekly during first month oftreatment); lactation; interactions (Appendix6a, 6b, 6c, 6d); avoid exposure to sunlight/artificial light.May impair ability to perform skilled tasks, for example operating machinery, driving.","Headache, nausea, vomiting, diarrhoea,rashes, dizziness, fatigue reported; drymouth and angular stomatitis; leukopenia,agranulocytosis; proteinuria reported;photosensitivity; lupus erythematosus, toxicepidermal necrolysis, erythema multiforme;serum sickness, angioedema; peripheralneuropathy; confusion and impairedcoordination.",Store in a well closed container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ketoconazole,Pregnancy Category-C,Schedule H,"Malassezia fulliculitis dermatophytosis andchronic conditions which cannot be treatedtopically; infections resistant to fluconazole;blastomycosis, candidiasis, chromomycosis.",TABLETS 200 mg, CREAM 2% and 5% w/w,SOLUTION 2%w/v, LOTION 2%w/v.,"Adult- 200 to 400 mg daily once preferably after food.Child- (Over 2 years) 3.3 to 6.6 mg/kg body weight once daily after food.Local application- 3 to 4 times daily, apply thoroughly.",Hepatic impairment, lactation, concomitantuse with cisapride.,"Predisposition to adrenocortical insufficien-cy; avoid in porphyria; pregnancy (Appendix7c); interactions (Appendix 6a, 6c), hepato-toxicity Potentially life-threatening hepatotoxicity reported very rarely,; risk of hepatotoxicity greater if given for longer than 14 days. Monitor liver function before treatment, then on weeks 2 and 4 of treatment, then every month. Avoid or use with caution if abnormal liver function tests (avoid in active liver disease) or if history of hepatotoxicity with other drugs.","Nausea, vomiting, abdominal pain; pruritus;less commonly diarrhoea, headache, dizzi-ness, drowsiness and rash; very rarely, fatalliver damage (see Hepatotoxicity above), dys-pepsia, raised intracranial pressure, adreno-cortical insufficiency, erectile dysfunction,menstrual disorders, azoospermia (with highdoses), gynaecomastia, thrombocytopenia,photophobia and alopecia.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Nystatin,Pregnancy Category-C,Schedule H,"Oral, oesophageal, intestinal, vaginal andcutaneous candidiasis.","TABLETS 5,00,000 units; OINTMENT 3g(100000 IU).","OralAdult- Intestinal candidiasis: 5,00,000 units every six h, doubled in severe infections.Child- 1 month to 12 years: 1,00,000 units 4 times daily, immunocompromised children may require higher doses up to 5,00,000 units.Topical applicationDissolve one tablet in glycerine and apply locally 3 to 4 times.IntravaginalInsert one tablet deep into vagina before bed time once at night.",Hypersensitivity.,"Lactation; discontinue if sensitivity develops,teratogenic effect, should not be used for thetreatment of systemic, oral, intravaginal orophthalmic infections; preganacy (Appendix7c).","Nausea, vomiting, diarrhoea at high doses;oral irritation and sensitization; rash andrarely, erythema multiforme (Steven’s-Johnson syndrome); eczema, burning.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tolnaftate,Pregnancy Category-C,,"Ringworm infections, athlete’s foot.",CREAM 10% w/w., OINTMENT- 10 % w/w.SOLUTION- 10% w/v.,Rub sufficient quantity gently into affected area 2-3 times daily.,"Hypersensitivity, deep infections","Avoid contact with eyes and mucous mem-branes; mixed infections. Discontinue ifirritation occurs on application, pregnancy(Appendix 7c).","Stinging, irritation, sensitization.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Albendazole,Pregnancy Category-C,Schedule H,"Echinococcus multilocularis and E. granulosusinfections prior to or not amenable to surgery;neurocysticercosis; nematode infections;filariasis; ascariasis, hookworm infections,strongyloidiasis, enterobiasis, trichuriasis,trichostrongyliasis and capillariasis; cestodeinfections; tissue nematode infections.","CHEWABLE/PLAIN TABLET 150, 200, 400 mg& 1.5g; CAPSULE 400 mg; ORAL SUSPENSION200 mg/5 ml; SyRUP 200 mg/5 ml;DROPS 10 ml (200 mg/ml)","OralAdult and child above 2 years- 400 mg daily as a single dose.Strongyloidiasis, taeniasis and H. nana infection: 400 mg once daily is given for 3 consecutive days. Hydatid disease: 400 mg twice daily with meals for 28 days (therapy may be repeated after 14 days in three cycles).Child- 1 to 2 years: 200 mg as a single dose.","Pregnancy, adequate measures must be takenfor non-hormonal contraceptive during andone month after therapy; hypersensitivity.","Pregnancy (see notes above and Appendix7c); liver impairment, increased intracranialpressure; seizures; monitor blood count andliver function.","Gastrointestinal discomfort; headache;adverse effects associated with use incestode infections; reversible alopecia;leucopenia, neurocystecercosis; Steven’sJohnson syndrome.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Mebendazole,Pregnancy Category-C,Schedule H,Echinococcus granulosus and E. multilocularisinfections before surgery or not amenable tosurgery, nematode infections.,TABLET 100 mg, ORAL SUSPENSION 100mg/5 ml.,"OralAdult and child over 2 years- Threadworm infection: 100 mg single dose. If re-infection occurs second dose may be needed after2 weeks. Whip worm, roundworm and hookworm infection: 100 mg twice daily for 3 days.",Pregnancy, lactation, hypersensitivity,patients with CNS disorders.,"Pregnancy (Appendix 7c; see also notesabove); lactation; interactions (Appendix 6c,6d); expulsion of ascaris from mouth or nose;monitor blood count or hepatic function.","Gastrointestinal disturbances; headache anddizziness; adverse effects associated withuse in cestode infections; abdominal pain,diarrhoea; rashes, urticaria, angioedema.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Niclosamide,Pregnancy Category-B,Schedule H,"Taenia saginata, T. solium, Hymenolepis nanaand Diphyllobothrium latum infections.",TABLETS 500 mg and 1g,OralAdult- 1g (2 tablets) chewed and swallowed with water on empty stomach. Followed by another dose of 1g one h later. Brisk purgative after 2 h of last dose is recommended.H. nana infection: 2g daily after food on first day thereafter 1g for next 6 days.,Hypersensitivity, purgative must be givenafter two h to clear bowel since ova in deadsegments are not cleared without purgative.Infection may recur if purgative is not given.,Chronic constipation (restore regular bowelmovement before treatment), give antiemeticbefore treatment, not effective against larvalworms, pregnancy (Appendix 7c).,"Nausea; retching; abdominal pain;lightheadedness; pruritus; anorexia, emesis,perianal itching.",Store protected from light and moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pyrantel Pamoate,Pregnancy Category-C,Schedule H,Ascariasis, hookworm infections,enterobiasis, trichostrongyliasis, tissuenematode infection.,TABLET 250 mg,ORAL SUSPENSION 250 mg/ml,Oral11 mg/kg (max 1g) in a single dose (given for 2 consecutive days in case of heavy hookworm infestation).,Hepatic diseases.,"Pregnancy (Appendix 7c; lactation; liverdisease (reduce dose); severe malnutrition,anaemia, concurrent administration withpiperazine.",Mild gastrointestinal disturbances, headache,dizziness, drowsiness, insomnia, rash andelevated liver enzymes.,Store protected from light at temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Miltefosine,Pregnancy Category-X,Schedule H,As directly observed therapy (DOT) ofvisceral Leishmaniasis caused by Leishmaniadonovani.,"CAPSULES10 mg, 50 mg","OralAdult- (>12 years): Weighing >25 kg: 100 mg/day, twice a day, after meals for 28 days.<25 kg: 50 mg/day, after meals for 28 days Child (2-11 years): 2.5 mg/kg daily after meals for 28 days, i.e., 50 mg once daily.","Children below 2 years, patients with HIV,newborns, pregnancy (Appendix 7C) andlactation","Avoid contact with eyes, kidney or liver im-pairment, may impair ability to drive or oper-ate machinery.","Nausea and vomiting, GI irritation, diarrhoea,constipation, ocular, hepatic, renal toxicity,skin rash, leukocytosis, thrombocytosis","Store in a cool place, protected from light and moisture.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pentamidine,Pregnancy Category-C,Schedule H,Leishmaniasis, African trypanosomiasis,Pneumocystis carinii pneumonia.,INJECTION 200 and 300 mg Vials.,Deep intramuscular injection.3 to 4 mg/kg body weight on alternate days to a max. of 10 injection. Course may be repeated if necessary.,Severe renal impairment.,"Risk of severe hypotension following admin-istration (establish baseline blood pressureand administer with patient lying down);monitor blood pressure during administra-tion and treatment period; hypertension;hypoglycaemia or hyperglycaemia; hepaticimpairment; leukopenia, thrombocytopenia,anaemia; immunodeficiency-if acute dete-rioration in bone marrow, renal or pancreaticfunction, interrupt or discontinue treatment;renal impairment; pregnancy-in potentiallyfatal visceral leishmaniasis, pregnancy (Ap-pendix 7c); lactation (Appendix 7b); historyof asthma.","Nephrotoxicity; acute hypotension-withdizziness, headache, breathlessness;tachycardia and syncope following rapidintravenous injection; hypoglycaemia-may be followed by hyperglycaemia andtype I diabetes mellitus; pancreatitis; alsohypocalcaemia,gastrointestinaldisturbances;confusion, hallucinations; arrhythmias;thrombocytopenia, leukopenia, abnormalliver function tests; hyperkalaemia; rash,Stevens-Johnson syndrome, reported; pain,local induration, sterile abscess and musclenecrosis at injection site; night sweat,diarrhoea, nausea, anaemia, wheezing,bad taste, anxiety, insomnia, miscarriage,erythema.",Store protected from moisture in a single dose container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sodium Stibogluconate,,,Leishmaniasis/Kala-azar.,INJECTION vial 30 ml (0.33g equivalent tototal antimony 100 mg/ml).,4 to 6g for full course.Slow intravenous infusion20 mg/kg/day.,Severe kidney disorders, lactation.,"Provide protein-rich diet throughouttreatment and, if possible, correct iron andother nutritional deficiencies; renal andhepatic impairment; monitor cardiac, renalandhepaticfunction-reducedoseorwithdrawtreatment if abnormalities occur; pregnancy-in potentially fatal visceral leishmaniasis,treat without delay; intravenous injectionsmust be given slowly over 5 min (to reducerisk of local thrombosis) and stopped ifcoughing or substernal pain; mucocutaneousdisease (see below); treat intercurrentinfection (for example pneumonia); lactation;ECG monitoring.Successful treatment of mucocutaneous leishmaniasis may induce severe inflammation around lesions (may be life-threatening if pharyngeal or tracheal involvement)-may require corticosteroids.","Anorexia, nausea, vomiting, abdominalpain, ECG changes (possibly requiringdose reduction or withdrawal), headache,lethargy, myalgia; raised liver enzymes;renal function impairment; coughing andsubsternal pain (see Precautions); rarely,anaphylaxis, fever, sweating, flushing,vertigo, bleeding from nose or gum, jaundice,rash; pain and thrombosis on intravenousadministration; pain on intramuscularinjection; phlebotoxicity, metallic taste inmouth, dizziness.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Chloroquine,Pregnancy Category-D,,Treatment of acute malaria caused by P.malariae and susceptible P. falciparum, P.vivax and P. ovale (followed by primaquineto eliminate intrahepatic forms), prophylaxisof malaria for pregnant women and non-immune individuals at risk, rheumaticdisorders.,TABLETS 250 and 500 mg, INJECTION 10 and30 ml (40 mg/ml), SUSPENSION 50 mg/ml.,"OralAdult- Immediately 600 mg, after 6 h 300 mg followed by 300 mg daily for 2 days.Child- 10 mg/kg body weight followed by 5 mg/kg body weight after 6 h, thereafter once a day for 2 days.Intramuscular injectionAdult- 10 ml followed by 5 ml after 6 h. Thereafter 5 ml daily for two days.Child- 5 mg/kg body weight administered every 12 h followed by oral therapy.",Severe haematologic distress orgastrointestinal distress, eye dysfunction,liver disease.,"If patient continues to deteriorate afterchloroquine-suspect resistance andadminister quinine intravenously asemergency measure; hepatic impairment;renal impairment (Appendix 7d); pregnancy(but in malaria, benefit considered tooutweigh risk; Appendix 7c); lactation(Appendix 7b); may exacerbate psoriasis;neurological disorders (avoid for prophylaxisif history of epilepsy); may aggravatemyasthenia gravis; severe gastrointestinaldisorders; G-6-PD deficiency; avoidconcurrent therapy with hepatotoxic drugs;interactions (Appendix 6c, 6d).","Headache, gastrointestinal disturbances;also convulsions; visual disturbances(retinopathy associated with long-term,high dose therapy or inappropriate self-medication); depigmentation or loss of hair;rashes; pruritus-may become intolerable;bone-marrow suppression; hypersensitivityreactions such as urticaria and angioedema;atrioventricular block (may be result ofinappropriate self-medication); porphyriaand psoriasis in susceptible individuals.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Primaquine,,,"RadicalcureofP.vivaxandP.ovalemalaria(afterchloroquine therapy to eradicate erythrocyticforms), elimination of gametocytes ofP. Falciparum, malaria prophylaxis.","TABLETS 2.5, 7.5 and 15 mg.","Radical treatmentAdult- 15 mg daily for 14 days, may be increased to higher dose.Child- 250 µg/kg daily for 14 days.Malaria prophylaxisAdult- 30 mg once daily; Child- 0.5 mg/kg once daily (to be started 1-2 days before travel and continue for 7 days after departure from malaria endemic area).Gametocidal treatment of P. falciparum malaria (after standard blood schizontocide therapy).Adult and Child- 500–50 µg/kg as a single dose.","Hypersensitivity, granulocytopenia,pregnancy, lactation, children below 1 year.","Patients with history of granulocytosis/methaemoglobinaemia, G-6-PD deficiency,monitor Hb levels, blood counts routinelyand withdraw if signs of haemolysis ormethaemoglobinaemia occur; lactation(Appendix7b).","Nausea, vomiting, abdominal cramps,haemolytic anaemia in G-6-PD deficientpatients; rarely, leukopenia, agranulocytosis,leukocytosis, methaemoglobinaemia andcardiac arrythmias.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Proguanil,Pregnancy Category-B,Schedule H,"With chloroquine, prophylaxis of malaria in areas of low resistance.",TABLET 100 mg.,"OralProphylaxisAdult- Preferably 200 mg once daily, start 1 to 2 days before entering endemic area and continue for 4 weeks after leaving.Child- (11-20 kg) - 25 mg once daily; (21-30 kg)- 50 mg once daily;(31-40 kg)- 75 mg once daily;more than 40 kg- 100 mg once daily.TreatmentAdult and child- over 40 kg; 100 mg once daily.Child- Up to 1 year: 25 mg; 1 to 4 years; 50mg; 5 to 8 years: 100 mg; 9 to 14 years: 150mg; above 14 years: 200 mg.",Use in areas of known resistance to eitherproguanil or pyrimethamine.,"Renal impairment; pregnancy (folatesupplements required, Appendix 7c);lactation","Mild gastric intolerance, diarrhoea;occasional mouth ulcers and stomatitis;skin reactions and hair loss reported; rarely,hypersensitivity reactions such as urticariaand angioedema.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Amodiaquine,,Schedule H,Treatment of uncomplicated malaria causedby P. falciparum.,TABLET 200 mg, SUSPENSION 50 mg/5 ml.,"OralAdult- Prophylaxis: 300 mg once weekly, start one week before entering endemic area and continue for 4 weeks after leaving.Infant- up to 12 weeks, body weight under 6 kg: 37.5 mg once weekly,1 year body weight 6 to 10 kg: 75 mg once weekly.Child- 1 to 4 years, body weight 10 to 16 kg:11 to 12.5 mg once weekly.4 to 8 years: body weight16 to 25 kg: 150 mg once a week.8 to 13 years, body weight over 45 kg: adultdose is used.","Hepatic impairment (Appendix 7a); blood disorders, retinopathy.","Pregnancy and lactation; G-6-PD deficiency;avoid concurrent therapy with hepatotoxicdrugs.Patients and their caretakers should be told how to recognize the signs of blood disorders and advised to seek medical attention as soon as possible if symptoms such as fever, sore throat, rash, mouth ulcers, purpura, bruising or bleeding develop. They should also be told how to recognize signs of hepatitis and advised to seek medical attention if symptoms such as anorexia, abnormal weight loss, asthenia, abdominal pains, fever, nausea or vomiting develop.","Blood disorders including leukopenia andagranulocytosis; hepatitis; gastrointestinaldisturbances, visual disturbances(retinopathy associated with long-term,high-dose therapy); rarely, rash, pruritus,skin pigmentation, neuromyopathy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Arteether,Pregnancy Category-C,Schedule H,Complicated falciparum malaria, chloroquineresistant malaria, cerebral malaria,INJECTION 2 ml ampoule (150 mg/2 ml). (Arteether is an ethyl derivative of dihydro- artimisinin. It is a mixture of α and β arteether in a 30:70 ratio),"Adult- 150 mg daily i.m. injection, once daily for 3 consecutive days.",Hypersensitivity to artemisinin derivatives,preganacy (Appendix 7c).,,It is clinically very well tolerated withoutany significant side effects, neurological orbiochemical.,Store protected from light in tamper evident container so as to avoid contamination by micro-organisms.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Artemether,Pregnancy Category-C,Schedule H,Treatment of severe P. falciparum malaria inareas where evidence is there that quinine isineffective, multi drug resistant malaria.,"CAPSULE 40 mg; INJECTION 1 ml ampoule(80 mg/ml, 160 mg/2 ml).","OralAdult- 160 mg in two divided doses on first day followed by 80 mg once a day for next four days.Intramuscular injectionAdult- 80 mg twice a day for 3 days.Child- 1.6 mg/kg body weight twice a day followed by 1.6 mg/kg body weight once a day for 4 days, alternatively 1.6 mg/kg body weight twice a day for 3 days.",First trimester of pregnancy (Appendix 7c),hypersensitivity.,"Electrolyte disturbances, concomitant usewith other drugs known to cause QT-intervalprolongation; hepatic impairment; renalimpairment; monitor patients unable totake food (greater risk of recrudescence);interactions (Appendix 6c); lactation(Appendix 7b).Dizziness may impair ability to perform skilled tasks, for example operating machinery, driving.","Headache, nausea, vomiting, abdominalpain, diarrhoea; dizziness, tinnitus,neutropenia, elevated liver enzymevalues; cardiotoxicity (after high doses);neurotoxicity-in animal studies; decrease inreticulicyte count.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Artesunate,Pregnancy Category-C,Schedule H,Treatment of uncomplicated P. falciparummalaria in areas of multiple drug resistance.,"TABLET 25, 50 & 60 mg; INJECTION 50, 60,1000 & 2000 mg/vial.",OralAdult- total oral dose 600 mg can be divided into two 50 mg tablets twice a day on first day thereafter 50 mg twice a day for next 4 days.Child- half adult dose. Intramuscular injection 60 mg twice daily.,First trimester of pregnancy (Appendix 7c),hypersensitivity.,"Risk of recurrence if used alone in non-immune patients; hepatic/renal insufficiency,pregnancy (Appendix 7c), lactation,paediatrics.Dizziness may impair ability to perform skilled tasks, for example operating machinery, driving.","Headache, nausea, vomiting, abdominalpain, diarrhoea, dizziness, tinnitus,neutropenia, elevated liver enzyme values;ECG abnormalities, including prolongationof QT interval; temporary suppression ofreticulocyte response and induction ofblackwater fever reported; neurotoxicity-inanimal studies.",Store protected from light and moisture. ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Quinine,Pregnancy Category-X,,Multiple drug resistant P. falciparum malaria.,"TABLETS 100, 150, 300 and 600 mg;SUSPENSION 150 mg/5 ml; INJECTION 1 and2 ml ampoule (300 mg/ml).","OralAdult- 300 to 600 mg every 8 h in divided doses for 5 to 7 days.Child- 25 mg/kg body weight every 8 h in divided doses for 5 to 7days.Intravenous infusion for patients unable to swallow tabletsLoading dose 900 mg to 1.4g infused over 4 h, then 300 to 600 mg every 8 h infused over 4 h.","Haemoglobinuria; optic neuritis; tinnitus;quinine resistant falciparum, pregnancy(Appendix 7c), lactation, prolonged QTinterval.","Atrial fibrillation, conduction defects, heartblock; monitor for signs of cardiac toxicityand blood glucose levels (with intravenoususe); renal impairment (Appendix 7d); G-6-PD deficiency; may aggravate myastheniagravis; interactions (Appendix 6d).","Cinchonism (tinnitus, headache, blurredvision, temporary blindness, altered auditoryacuity, nausea, diarrhoea, hot and flushedskin, rashes, confusion); hypersensitivityreactions including angioedema; rarely,haemorrhage and asthma; hypoglycaemia(especially after parenteral administration);renal damage (culminating in acute renalfailure and anuria); blood disorders;cardiovascular, gastrointestinal and CNSeffects; very toxic in overdosage-immediatemedical attention required; acute haemolyticanaemia.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sulfadoxine + Pyrimethamine,Pregnancy Category-C,,Schedule H,TABLETSSulfadoxine500mg+Pyrimethamine25 mg, SUSPENSION 5 ml (500 mgsulfadoxine+25 mg pyrimethamine).,OralAdult- Prophylaxis: one tablet once a week. Treatment: 2 tablets in single dose.Child- Under 4 years: half a tablet. 4 to 8 years: one tablet.9 to 14 years: two tablets single dose.Prophylaxis: Under 4 years 1/4th tablet. 4 to 8 years: half tablet.9 to 14 years: 3/4th tablet once a week.,"Hypersensitivity to sulfonamides orpyrimethamine; severe hepatic or renalimpairment (except where no alternativetreatment available); blood dyscrasias,neonates, megaloblastic anaemia and folatedeficiency.","Avoid in blood disorders-unless specialistsupervision; discontinue immediately ifblood disorder occurs; rash, sore throat,mouth ulcers, or shortness of breath-withdraw treatment; G-6-PD deficiency;predisposition to folate deficiency; hepaticimpairment (Appendix 7a); pregnancy(Appendix 7c); lactation (Appendix 7b);interactions (Appendix 6c).","Rashes, pruritus, slight hair loss; rarely,erythema multiforme (Stevens-Johnsonsyndrome) and toxic epidermal necrolysis;gastrointestinal disturbances includingnausea, vomiting, stomatitis; rarely,hepatitis, leukopenia, thrombocytopenia,megaloblastic anaemia and purpura-withdraw treatment; fatigue, headache,fever, polyneuritis, also reported; pulmonaryinfiltrates such as eosinophilic or allergicalveolitis-if symptoms of cough or shortnessof breath-withdraw treatment.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Clofazimine,Pregnancy Category-C,Schedule H,MB leprosy, type 2 lepra reactions.,"TABLETS 25, 50, 100 mg; CAPSULES 50 and100 mg.",OralAdult- 300 mg spread over a week. Sulfone resistant cases: 600 mg weekly preferably after meal.Lepra reaction: 200 mg daily for 3 weeks or as required.Child- 1 to 2 mg/kg body weight daily or 4 to 6 mg/kg body weight once a month.,"Pregnancy (Appendix 7c), lactation, renal and hepatic impairment.","Pre-existing gastrointestinal symptoms(reduce dose, increase dose interval ordiscontinue if symptoms develop duringtreatment); liver and renal impairment;may discolour soft contact lenses;paediatrics, elderly, interactions (Appendix6d).","Reversible discolouration of skin, hair, cornea,conjunctiva, tears, sweat, sputum, faecesand urine; dose-related gastrointestinalsymptoms including pain, nausea,vomiting and diarrhoea; severe mucosaland submucosal oedema, with prolongedtreatment with high doses-may be severeenough to cause subacute small-bowelobstruction (see also Precautions); pruritus,ichthyosis, elevated blood sugar, diminishedvision, dizziness, eosinophillic enteropathy.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Dapsone,Pregnancy Category-C,Schedule H,"PB and MB leprosy; acne vulgaris, dermatitis,pneumocystic pneumonia.","TABLETS 25, 50 and 100 mg; GEL 5% w/w.","Oral Adult- Leprosy: 50 to 100 mg daily depending upon body weight. Dermatitis herpetiformis: start with 50 mg daily and increase up to 400 mg till full response is obtained; dose reduced to minimum maintenance level as soon as possible.Child- 1 to 2 mg/kg body weight as minimum dose to start with, increased weekly so that at the end of 7th week patient is receiving max. dose.",Hypersensitivity to sulfones, severe anaemia,porphyria.,"Anaemia(treatsevereanaemiabeforetherapyand monitor blood counts during treatment);susceptibility to haemolysis includingG-6-PD deficiency (including lactationaffected infants); lactation (Appendix 7b);porphyria; interactions (Appendix 6c);hyperbilirubinemia, methaemoglobinemia;renal impairment (Appendix 7d); pregnancy(Appendix 7c).On long-term treatment patients and their caretakers should be told how to recognize blood disorders and advised to seek immediate medical attention if symptoms such as fever, sore throat, rash, mouth ulcers, purpura, bruising or bleeding develop.","Haemolysis and methaemoglobinaemia;allergic dermatitis (rarely, including toxicepidermal necrolysis and the Stevens-John-son syndrome); rarely, hepatitis and agranu-locytosis; ‘dapsone syndrome’ resemblingmononucleosis-rare hypersensitivity reac-tion with symptoms including rash, fever,jaundice and eosinophilia; gastrointestinalirritation; tachycardia, headache, nervous-ness, insomnia, blurred vision, paraesthe-sia, reversible peripheral neuropathy andpsychoses reported; increase in reticulo-cytes, vertigo; pancreatitis; renal papillarynecrosis; anorexia.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Rifampicin,Pregnancy Category-C,Schedule H,PB leprosy, MB leprosy, tuberculosis.,"CAPSULES 150, 300, 450 and 600 mg;TABLETS 150, 300, 350, 450, 500, 600 and750 mg; SyRUP 100 mg/5 ml.",OralAdult- 450 to 600 mg single dose before breakfast.Child- 10 to 20 mg/kg body weight daily.,Hypersensitivity, jaundice, patients withearlier drug induced liver disease.,"Reduce dose in hepatic impairment(Appendix 7a); liver function tests and bloodcounts required in liver disorders, alcoholdependency, elderly and on prolongedtherapy; renal impairment (if dose above 600mg daily); lactation; porphyria; discolourssoft contact lenses; advise patients on oralcontraceptives to use additional means;interactions (Appendix 6b, 6c, 6d); pregnancy(Appendix 7c).Patients or their caretakers should be told how to recognize signs of liver disorders and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.","Severe gastrointestinal disturbancesincluding anorexia, nausea, vomitingand diarrhoea (antibiotic-associatedcolitis reported); headache, drowsiness;rashes, fever, influenza-like syndrome andrespiratory symptoms, collapse, shock,haemolytic anaemia, acute renal failure andthrombocytopenic purpura-m ore frequentwith intermittent therapy; alterations ofliver function-jaundice and potentially fatalhepatitis (dose-related, do not exceed max.daily dose of 600 mg); oedema, muscularweakness and myopathy, exfoliativedermatitis, toxic epidermal necrolysis,pemphigoid reactions, leukopenia,eosinophilia and menstrual disturbances;urine, tears, saliva and sputum colouredorange-red; cerebral haemorrhage, visualdisturbances.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Amikacin,Pregnancy Category-D,Schedule H,"Short-term treatment of serious infectionsdue to susceptible strains of Gram-negativebacteria, including Pseudomonas species,Escherichia coli, species of indole-positive andindole-negative Proteus, Providencia species,Klebsiella, Enterobacter, Serratia species andAcinetobacter (Mima-Herellea) species.","INJECTION 10 ml vial (100 mg/2 ml), 2 ml vial(250 mg/2 ml), (500 mg/2 ml).","Intramuscular or intravenous injection or infusionAdult- 15 mg/kg body weight daily in two divided doses, increased to 22.5 mg/kg body weight daily in three divided doses in severe infections. (max 1.5g daily for 10 days, max. cumulative dose is 15g).Child- 15 mg/kg body weight daily in two divided doses.Neonates- loading dose is 10 mg/kg body weight followed by 15 mg/kg body weight in two divided doses.",Myasthenia gravis, hypersensitivity.,"Pregnancy (Appendix 7c), renal impairment(Appendix 7d); neonates, infants and elderly;cross allergenicity.","Vestibular and auditory damage,nephrotoxicity; rarely, hypomagnesaemiaon prolonged therapy, antibiotic-associatedcolitis, stomatitis; also reported, nausea,vomiting, rash, blood disorders; acutemuscular paralysis; albuminuria; azotemia.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Capreomycin,Pregnancy Category-C,Schedule H,"Tuberculosis, in combination with other firstline drugs for tuberculosis.","INJECTION 0.5, 0.75 and 1g/vial.","Deep intramuscular injectionAdult- 1g daily for 2 to 4 months (not more than 20 mg/kg body weight). Then 1 to 2g 2 to 3 times each week, in case of renal impairment reduce the dose in accordance with creatinine clearance.",Not for paediatric use, hypersensitivity tocapreomycin.,"Renal impairment; hepatic impairment;auditory impairment; monitor renal,hepatic, auditory and vestibular functionand electrolytes; pregnancy (teratogenicin animals; Appendix 7c) and lactation;interactions (Appendix 6c).","Hypersensitivity reactions including urticariaand rashes; eosinophilia; leucocytosis orleucopenia, rarely, thrombocytopenia;changes in liver function tests; nephrotoxicity,electrolyte disturbances; hearing loss withtinnitus and vertigo; neuromuscular blockafter large doses, pain and induration atinjection site.",Store protected from moisture at a temperature not exceeding 25⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cycloserine,Pregnancy Category-C,Schedule H,Tuberculosis resistant to first-line drugs.,CAPSULE/TABLET 250 mg.,"OralAdult- Initially 250 mg every 12 h for 2 weeks, increase according to blood concentration and response to 500 mg every 2 h.Child- Initially 10 mg/kg body weight daily adjusted to blood concentration and response.","Severe renal impairment; epilepsy;depression, severe anxiety, psychoticstates, alcohol dependence; porphyria;hypersensitivity.","Reduce dose in renal impairment (avoid ifsevere); monitor haematological, renal andhepatic function; lactation; discontinue orreduce dose if allergic skin reactions or CNStoxicity occur, pregnancy (Appendix 7c).","Mainly neurological, including headache,dizziness, vertigo, drowsiness, tremor,convulsions, confusion, psychosis, depression(discontinue or reduce dose if symptomsof CNS toxicity); rashes, allergic dermatitis(discontinue or reduce dose); megaloblasticanaemia; changes in liver function tests;heart failure at high doses reported.",Store at a temperature not exceeding 30⁰C (tablets). Store protected from moisture (capsules).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ethambutol,Pregnancy Category-C,Schedule H,"Tuberculosis, in combination with other drugs.","TABLETS 200, 400, 600, 800 mg and 1g.","OralAdult- 15 mg/kg body weight as a single dose, retreatment with 25 mg/kg body weight as a single dose for two months, thereafter reduce to 15 mg/kg body weight. Given as combination therapy with other anti-tubercular drugs.Child- Same as for Adult. Do not use under 3 years.",Optic neuritis, children under 5 years-unableto report symptomatic visual disturbances,severe renal impairment, hypersensitivity.,Visual disturbances-ocular examinationrecommended before and during treatment(see note below), reduce dose in renalimpairment (Appendix 7d) and monitorplasma concentration, elderly, pregnancy(Appendix 7c) (not known to be harmful),lactation.,"Optic neuritis-reduced visual acuity and red/green colour blindness (early changes usuallyreversible, prompt withdrawal may preventblindness); peripheral neuritis-especially inlegs; gout; rarely, rash, pruritus, urticaria,thrombocytopenia; pulmonary infiltratesgastrointestinal upset.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Isoniazid,Pregnancy Category-C,Schedule H,"Tuberculosis, in combination with otherdrugs; tuberculosis prophylaxis also.",TABLETS 100 and 300 mg.,"Oral Adult- 3 to 5 mg/kg body weight up to 300 mg as single dose daily.Child- 10 to 15 mg/kg body weight as a single dose, not to exceed 300 mg/day.",Drug-induced Hepatic Disease.,"Hepatic impairment (monitor hepaticfunction; Appendix 7a); malnutrition, chronicalcohol dependence, chronic renal failure(Appendix 7d); diabetes mellitus and HIVinfection-prophylactic pyridoxine 10 mg dailyrequired because risk of peripheral neuritis;epilepsy; slow acetylator status (increasedrisk of adverse effects); history of psychosis;pregnancy (Appendix 7c) (not known to beharmful); lactation (Appendix 7b); porphyria;interactions (Appendix 6a, 6c, 6d).Patients or their caretakers should be told how to recognize signs of liver disorder and advised to discontinue treatment and seek immediate medical attention if symptoms such as nausea, vomiting, malaise or jaundice develop.","Gastrointestinal disorders including nauseaand vomiting, diarrhoea and pain, alsoconstipation, dry mouth; hypersensitivityreactions including fever, rashes, jointpain, erythema multiforme, purpurausually during first weeks of treatment;peripheral neuropathy; blood disordersincluding agranulocytosis, haemolyticanaemia, aplastic anaemia; optic neuritis,toxic psychoses and convulsions; hepatitis(especially over age of 35 years and regularusers of alcohol)-withdraw treatment; alsoreported systemic lupus erythematosus-like syndrome, pellagra, hyperreflexia,difficulty with micturition, hyperglycaemiaand gynaecomastia; memory impairement,elevated serum transaminase, rheumaticsyndrome, pyridoxine syndrome.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Kanamycin,Pregnancy Category-D,Schedule H,"Tuberculosis; hepatic coma; penicillinresistant gonorrhoea, chronic bacterialinfections.","INJECTION Vial 500, 750 mg and 1g.","Intramuscular and intravenous injectionAdult- 1g daily as a single dose. Child- 6 to 15 mg/kg body weight daily in divided doses, 8 to 12 h (slow injection), usual duration of therapy 7 to 10 days.",Lactation, pregnancy (Appendix 7c),hypersensitivity, renal impairment.,Myasthenia gravis, renal impairment, elderlypatients with neuromuscular disorder.,Nephrotoxicity, ototoxicity, skin rash,urticaria, neuromuscular blockade,malabsorption syndrome.,Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pyrazinamide,Pregnancy Category-C,Schedule H,"Tuberculosis, in combination with otherdrugs.","TABLETS 300, 500 and 750 mg; 1 and 1.5g;SUSPENSION 100 ml (5%).",OralAdult and Child- 20 to 35 mg/kg body weight as a single dose (max. 3g daily).,Severe hepatic impairment, porphyria.,"Hepatic impairment (monitor hepaticfunction; (Appendix 7a); renal impairment(Appendix 7d); diabetes mellitus (monitorblood glucose-may change suddenly); gout;pregnancy (Appendix 7c) and lactation;hypouricemia.Patients or their caretakers should be told how to recognize signs of liver disorder and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.","Hepatotoxicity including fever, anorexia,hepatomegaly, splenomegaly, jaundice, liverfailure; nausea, vomiting; arthralgia; gout;sideroblastic anaemia; rash, photosensitivity;porphyria, dysuria, thrombocytopenia,hyperplasia, myalgia.",Store in single dose containers protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Rifampicin + Isoniazid,Pregnancy Category-C,Schedule H,Tuberculosis.,TABLETS/CAPSULES Rifampicin + Isoniazid 60 mg + 30 mg100 mg + 100 mg100 mg + 300 mg100 mg + 50 mg150 mg + 100 mg150 mg + 75 mg300 mg + 150 mg450 mg + 300 mg600 mg + 300 mg,Adult- One tablet daily before breakfast.,,Combined preparation usually not suitablefor use in children, see under Rifampicin andIsoniazid, pregnancy (Appendix 7c).,,Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Rifampicin + Isoniazid + Ethambutol,Pregnancy Category-C,Schedule H,Tuberculosis.,TABLETS Schedule H Rifampicin + Isoniazid + Ethambutol 150 mg + 275 mg + 275 mg150 mg + 75 mg + 275 mg450 mg + 300 mg + 800 mg450 mg + 225 mg + 825 mg100 mg + 50 mg + 800 mg300 mg + 150 mg + 550 mgCAPSULESRifampicin + Isoniazid + Ethambutol225 mg + 150 mg + 400 mg,One tablet daily before breakfast in accordance with dose of individual drugs.,,Pregnancy (Appendix 7c).,,Store protected from moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Rifampicin + Isoniazid + Pyrazinamide,Pregnancy Category-C,Schedule H,"Tuberculosis, in combination with otherdrugs.",TABLETS/CAPSULESRifampicin + Isoniazid + Pyrazinamide60 mg + 30 mg + 150 mg100 mg + 50 mg + 300 mg150 mg + 100 mg + 500 mg450 mg + 300 mg + 1000 mg120 mg + 80 mg + 250 mg225 mg + 150 mg + 750 mg150 mg + 100 mg + 375 mg450 mg + 300 mg + 1500 mg,OralAdult- One tablet daily before breakfast.,"Combined preparation not suitable for usein children; see Rifampicin, Isoniazid andPyrazinamide; pregnancy (Appendix 7c).",,,Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Rifampicin + Isoniazid + Pyrazinamide + Ethambutol,Pregnancy Category-C,Schedule H,Tuberculosis.,TABLETS Schedule H Rifampicin+Isoniazid+Pyrazinamide+ Ethambutol 150 mg + 100 mg + 500 mg + 800 mg225 mg + 150 mg + 750 mg + 400 mg150 mg + 75 mg + 400 mg + 275 mg150 mg + 100 mg + 500 mg + 267 mg450 mg + 300 mg + 1500 mg + 800 mg600 mg + 300 mg + 800 mg + 1100 mg1450 mg + 225 mg + 1200 mg + 825 mg,OralAdult- One tablet daily before breakfast.,,Pregnancy (Appendix 7c).,,Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Streptomycin,Pregnancy Category-D,Schedule H,"Tuberculosis, in combination with otherdrugs",INJECTION vial 750 mg and 1g.,Deep intramuscular injection.Adult- 0.75g to 1g daily. Elderly- 0.5g daily.Child- 20 to 40 mg/kg body weight daily.,Hearing disorders, myasthenia gravis,pregnancy (Appendix 7c).,"Children-painful injection, avoid use ifpossible; renal impairment (Appendix 7d),infants and elderly (dosage adjustmentand monitor renal, auditory and vestibularfunction and plasma streptomycinconcentrations); interactions (Appendix 6c).","Vestibular and auditory damage,nephrotoxicity; hypersensitivity reactions-withdraw treatment; paraesthesia of mouth;rarely, hypomagnesaemia on prolongedtherapy; antibiotic-associated colitis; also,nausea, vomiting, rash; rarely, haemolyticanaemia, aplastic anaemia, agranulocytosis,thrombocytopenia; pain and abscess atinjection site.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Thiacetazone + Isoniazid,Pregnancy Category-C,Schedule H,"Tuberculosis, in combination with otherdrugs.",TABLETSThiacetazone + Isoniazid150 mg + 300 mg37.5 mg + 750 mg,OralAdult- One tablet daily before breakfast.,"See Isoniazid; hepatic impairment; renalimpairment; HIV infection-thioacetazoneassociated with high incidence of serious,sometimes fatal cutaneous hypersensitivityreactions, including exfoliative dermatitis.",See Isoniazid, determine efficacy and toxic-ity of thiacetazone-geographical differences,hypersensitivity reactions-withdraw treat-ment, Pregnancy (Appendix 7c).,"SeeIsoniazid;thiacetazonecausesthefollowing-nausea, vomiting, diarrhoea; hypersensitivityreactions including conjunctivitis, vertigo,rashes; fatal exfoliative dermatitis, acutehepatic failure reported; also, agranulocytosis,thrombocytopenia and aplastic anaemia.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Abacavir,Pregnancy Category-C,Schedule H,HIV infection in combination with atleast twoother antiretroviral drugs.,TABLET 300 mg.,OralAdult- 300 mg twice daily or 600 mg once daily. Child- 3 months to 12 years: 8 mg/kg body weight every 12 h (max. 600 mg daily).,Pregnancy (Appendix 7c), lactation (Appendix7b), hepatic dysfunction (Appendix 7a), renaldisease.,Hepatic impairment (see below and Appendix7a), renal impairment, pregnancy (see notesabove and Appendix 7c), lactation (Appendix7b) (see notes above), hypersensitivityreaction, interactions (Appendix 6a).,"Life-threatening hypersensitivity reactionsreported-characterized by fever or rashand possibly nausea, vomiting, diarrhoea,abdominal pain, lethargy, malaise,headache, myalgia and renal failure; lessfrequently mouth ulceration, oedema,hypotension, dyspnoea, sore throat, cough,paraesthesia, arthralgia, conjunctivitis,lymphadenopathy, lymphocytopenia andanaphylaxis (hypersensitivity reactionspresenting as sore throat, influenza-likeillness, cough and breathlessness identified);rarely, myolysis; laboratory abnormalitiesmay include raised liver enzymes andcreatine kinase; symptoms usually appearin the first 6 weeks, but may occur at anytime; monitor for symptoms every 2 weeksfor 2 months; discontinue immediately ifany symptom of hypersensitivity developsand do not rechallenge (risk of more severehypersensitivity reaction); discontinue ifhypersensitivity cannot be ruled out, evenwhen other diagnosis possible-if rechallengenecessary it must be carried out in hospitalsetting; if abacavir is stopped for anyreason other than hypersensitivity, excludehypersensitivity reaction as the cause andrechallenge only if medical assistanceis readily available; care needed withconcomitant use of drugs which cause skintoxicity.Patients should be told the importance of regular dosing (intermittent therapy may increase sensitization), how to recognize signs of hypersensitivity and advised to seek immediate medical attention if symptoms develop or before re-starting treatment.Potentially life-threatening lactic acidosis and severe hepatomegaly with steatosis reported-caution in liver disease, liver enzyme abnormalities, or risk factors for liver disease (particularly in obese women); suspend or discontinue if deterioration in liver function tests, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis.",Store at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Didanosine,Pregnancy Category-B,Schedule H,HIV infection in combination with atleast twoother antiretroviral drugs.,"TABLETS 100, 250 mg and 400 mg; CAPSULES250 and 400 mg.","OralAdult- Under 60 kg: 250 mg daily in 1 to 2 divided doses. 60 kg and over: 400 mg daily in 1 to 2 divided doses, 30 min before meals or 2 h after meals.Child- 2week - 8 months: 100 mg/m2 twice daily.>8 months: 120 mg/m2 twice daily.",Hypersensitivity, pancreatitis, co-administration of allopurinol and ribavirin.,"History of pancreatitis (preferably avoid,otherwise extreme caution, see also below);peripheral neuropathy or hyperuricaemia (seeunder Adverse effects); history of liver disease(see below); renal and hepatic impairment(see Appendices 7d and 7a); pregnancy(Appendix 7c) and lactation (Appendix7b) (see notes above); dilated retinalexaminations recommended (especially inchildren) every 6 months, or if visual changesoccur; interactions (Appendix 6c, 6d); immunereconstitution syndrome, fat redistribution,retinal changes and optic neuritis.If symptoms of pancreatitis develop or if serum amylase or lipase is raised (even if asymptomatic) suspend treatment until diagnosis of pancreatitis excluded; on return to normal values re-initiate treatment only if essential (using low dose increased gradually if appropriate). Whenever possible avoid concomitant treatment with other drugs known to cause pancreatic toxicity (for example intravenous pentamidine isothionate); monitor closely if concomitant therapy unavoidable. Since significant elevations of triglycerides cause pancreatitis monitor closely if elevated.Potentially life-threatening lactic acidosis and severe hepatomegaly with steatosis reported therefore caution in liver disease, excessive alcohol intake, liver enzyme abnormalities, or risk factors for liver disease (particularly in obese women); suspend or discontinue if deterioration in liver function tests, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis","Pancreatitis (see also under Precautions);peripheral neuropathy especially in advancedHIV infection-suspend (reduced dose maybe tolerated when symptoms resolve);hyperuricaemia (suspend treatment ifsignificant elevation); diarrhoea (occasionallyserious); also reported, nausea, vomiting, drymouth, asthenia, headache, hypersensitivityreactions; retinal and optic nerve changes(especially in children); diabetes mellitus,raised liver enzymes (see also underPrecautions); liver failure.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Emtricitabine,Pregnancy Category-B,Schedule H,HIV infection.,CAPSULE 200 mg.,Oral Schedule H Adult and child over 33 kg- 200 mg once a day.Child- Under 33 kg: 6 mg/kg body weight once a day.,Lactation, hypersensitivity.,"Monitor patients with hepatitis B (riskof exacerbation of hepatitis); obesity,lactic acidosis, severe hepatomegaly, co-infection with hepatitis B virus; pregnancy(Appendix 7c).","Gastro-intestinal disturbances (such asnausea, vomiting, abdominal pain, flatulenceand diarrhoea); anorexia; pancreatitis;liver damage (see also Lactic Acidosis,above); dyspnoea; cough, headache;insomnia; dizziness; fatigue; blood disorders(including anaemia, neutropenia andthrombocytopenia); myalgia, arthralgia, rash,urticaria and fever. Lipodystrophy, abnormaldreams, pruritus and hyperpigmentation.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Lamivudine,Pregnancy Category-C,Schedule H,HIV infection in combination with at leasttwo other antiretroviral drugs.,"TABLETS 100, 150 and 300 mg; ORALSOLUTION 50 mg/ml.",OralAdult- 150 mg twice daily administered with zidovudine.Child- 3 months to 12 years: 4 mg/kg body weight twice a day (max. 150 mg twice daily).,Pregnancy (Appendix 7c), lactation (Appendix7b), hepatic dysfunction (Appendix 7a), renaldisease (Appendix 7d).,"Renal impairment (Appendix 7d); hepaticdisease (see below); pregnancy (Appendix7c) and lactation (Appendix 7b) (see notesabove); interactions (Appendix 6c).Potentially life-threatening lactic acidosis and severe hepatomegaly with steatosis reported therefore caution (particularly in obese women) in liver disease, liver enzyme abnormalities, or risk factors for liver disease; suspend or discontinue if deterioration in liver function tests, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis. Recurrent hepatitis in patients with chronic hepatitis B may occur on discontinuation of lamivudine.","Nausea, vomiting, diarrhoea, abdominal pain;cough; headache, fatigue, insomnia; malaise,fever, rash, alopecia, muscle disorders; nasalsymptoms; peripheral neuropathy reported;rarely, pancreatitis (discontinue); neutropenia,anaemia, thrombocytopenia and red-cellaplasia; lactic acidosis; raised liver enzymesand serum amylase.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Stavudine,Pregnancy Category-C,Schedule H,HIV infection in combination with atleast twoother antiretroviral drugs.,TABLETS/CAPSULES 30 and 40 mg.,OralAdult- Under 60 kg: 30 mg every 12 h preferably at least 1 h before food.60 kg and over: 40 mg every 12 h.Neonate under 2 weeks- 500 µg/kg body weight. Child- over 2 weeks and body weight under 30 kg: 1 mg/kg body weight every 12 h.30 kg and over: 30 mg every 12 h.,Hypersensitivity.,"History of peripheral neuropathy (see below);history of pancreatitis or concomitant usewith other drugs associated with pancreatitis;hepatic disease (see below); renalimpairment; pregnancy (Appendix 7c) andlactation (Appendix 7b) (see notes above);fat redistribution, immune reconstitutionsyndrome.Suspend if peripheral neuropathy develops- characterized by persistent numbness, tingling or pain in feet or hands; if symptoms resolve satisfactorily on withdrawal and if stavudine needs to be continued, resume treatment at half previous dose.Potentially life-threatening lactic acidosis and severe hepatomegaly with steatosis reported therefore caution in liver disease, liver enzyme abnormalities, or risk factors for liver disease (particularly in obese women); suspend or discontinue if deterioration in liver function tests, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis.","Peripheral neuropathy (dose-related, seeabove); pancreatitis; nausea, vomiting,diarrhoea, constipation, anorexia, abdominaldiscomfort; chest pain; dyspnoea; headache,dizziness, insomnia, mood changes;asthenia, musculoskeletal pain; influenza-like symptoms, rash and other allergicreactions; lymphadenopathy; neoplasms;elevated liver enzymes (see hepatic disease,above) and serum amylase; neutropenia,thrombocytopenia.",Store protected from moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tenofovir,Pregnancy Category-B,Schedule H,HIV infection,TABLET 300 mg.,OralAdult- 300 mg once daily.,Lactation, hypersensitivity,"Should be used with caution in patients withchronic hepatitis B or C (greater risk of hepaticside-effects), in hepatic impairment, in renalimpairment and in pregnancy (Appendix 7c).Test renal function and serum phosphatebefore treatment, then every 4 weeks(more frequently if at increased risk of renalimpairment) for 1 year and then every 3months, interrupt treatment if renal functiondeteriorates or serum phosphate decreases;concomitant or recent use of nephrotoxicdrugs; on discontinuation, monitor patientswith hepatitis B (risk of exacerbation ofhepatitis).","Gastro-intestinal disturbances (such asnausea, vomiting, abdominal pain, flatu-lence and diarrhoea); anorexia; pancreatitis;liver damage; dyspnoea; cough; headache,insomnia, dizziness, fatigue; blood disorders(including anaemia, neutropenia and throm-bocytopenia); myalgia, arthralgia, rash, urti-caria and fever. See notes above for metabol-ic effects and lipodystrophy; hypophospha-taemia; reduced bone density; nephrogenicdiabetes insipidus and renal failure; lacticacidosis, decrease in bone mineral density,acute exacerbation of hepatitis.",Store protected from moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Zidovudine (AZT),Pregnancy Category-C,Schedule H,HIV infection in combination with at leasttwo other antiretroviral drugs, monotherapyfor prevention of maternal-fetal HIVtransmission.,"TABLETS 30, 40, 100 and 300 mg; CAPSULES100 and 300 mg; SyRUP 50 mg/5 ml.","OralHIV infectionAdult- 600 mg daily in divided doses in combination with other antiretroviral drugs.Child- 6 weeks to 12 years: 160 mg/m2 every 8 hour, max. dose 200 mg every 8 hour.Prevention of maternal-foetal HIV transmission. Adult- 100 mg five times daily or 200 mg thrice daily or 300 mg twice daily, start treatment after 14th week of gestation until the start of labour.Prevention of HIV transmission in neonates.Child- neonates- 2 mg/kg every 6 hour for first 6 weeks of life, starting with12 hour after birth.",Abnormally low neutrophil counts orhaemoglobin, neonates either with hyperbi-lirubinaemia requiring treatment other thanphototherapy or with raised transaminase,life threatening allergic reactions.,"Haematological toxicity; vitamin B12deficiency (increased risk of neutropenia);reduce dose or interrupt treatment if anaemiaor myelosuppression; renal impairment(Appendix 7d); hepatic impairment (Appendix7a); risk of lactic acidosis; elderly; lactation(Appendix 7b); interactions (Appendix 6c,6d); pregnancy (Appendix 7c); myopathy, usewith interferon and ribavirin based regimensin HIV/HCV coinfected patients, immunereconstitution syndrome.","Anaemia (may require transfusion),neutropenia and leukopenia (all morefrequent with high dose and advanceddisease); also nausea and vomiting,abdominal pain, dyspepsia, diarrhoea,flatulence, taste disturbance, pancreatitis,liver disorders including fatty change andraised bilirubin and liver enzymes (see hepaticdisease, above); chest pain, dyspnoea, cough;influenza-like symptoms; headache; fever;paraesthesia, neuropathy; convulsions;dizziness; somnolence, insomnia; anxiety;depression; malaise; anorexia; asthenia;myopathy; myalgia; pancytopenia,thrombocytopenia; gynaecomastia; urinaryfrequency; rash, pruritus, pigmentation ofnail, skin and oral mucosa.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Efavirenz,Pregnancy Category-D,Schedule H,HIV infection in combination with at leasttwo other antiretroviral drugs.,"TABLETS/CAPSULES 200, 400 and 600 mg.",OralAdult- 600 mg once a day.Child- Over 3 years13 to 14 kg body weight: 200 mg once a day.15 to 19 kg body weight: 250 mg once a day,25 to 32.5 kg body weight: 400 mg once a day,over 40 kg body weight: adult dose.,Pregnancy (see notes above and (Appendix7c), substitute nevirapine for efavirenzin pregnant women or women for whomeffective contraception cannot be assured),hypersensitivity.,"Hepatic impairment (avoid if severe;Appendix 7a); severe renal impairment;lactation (Appendix 7b) (see notes above);elderly; history of mental illness or substanceabuse; interactions (Appendix 6b, 6c);psychiatric symptoms.Rash, usually in the first 2 weeks, is the most common adverse effect; discontinue if severe rash with blistering, desquamation, mucosal involvement or fever; if rash mild or moderate, may continue without interruption-rash usually resolves within 1 month.","Rash including Stevens-Johnson syndrome(see also above); dizziness, headache, insom-nia, somnolence, abnormal dreams, fatigue,impaired concentration (administration atbedtime especially in the first 2-4 weeksreduces CNS effects); nausea; less frequentlyvomiting, diarrhoea, hepatitis, depression,anxiety, psychosis, amnesia, ataxia, stupor,vertigo; also reported raised serum choles-terol, elevated liver enzymes (especially if se-ropositive for hepatitis B or C), pancreatitis.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Nevirapine,Pregnancy Category-C,Schedule H,"HIV infection, in combination with at leasttwo other antiretroviral drugs; prevention ofmother-to-child transmission in HIV-infectedpatients.",TABLET/CAPSULE 200 mg,ORAL SUSPENSION 100 mg/5 ml.,"Oral Adult- 200 mg once a day for 14 days, if tolerated and no rash is observed then increase to 200 mg two times a day.Child- 2 months to 8 years: 4 mg/kg body weight once a day for 14 days, if tolerated and no rash is observed increase to 4 mg/kg body weight two times a day.",Acute porphyria, severe hepatic impairment,post-exposure prophylaxis, breast feeding.,"Hepatic impairment (see below and Appen-dix 7a); history of chronic hepatitis (greaterrisk of hepatic adverse effects), pregnancy(Appendix 7c) and lactation (Appendix 7b);interactions (Appendix 6b, 6c).Potentially life-threatening hepatotoxicity including fatal fulminant hepatitis reported usually occurring in first 8 weeks; monitor liver function before long-term treatment then every 2 weeks for 2 months then after 1 month and then every 3-6 months; discontin- ue permanently if abnormalities in liver func- tion tests accompanied by hypersensitivity reaction (rash, fever, arthralgia, myalgia, lym- phadenopathy, hepatitis, renal impairment, eosinophilia, granulocytopenia); suspend if severe abnormalities in liver function tests but no hypersensitivity reaction-discontinue permanently if significant liver function ab- normalities recur; monitor patient closely if mild to moderate abnormalities in liver func- tion tests with no hypersensitivity reaction.Rash, usually in first 8 weeks, is most common adverse effect; incidence reduced if introduced at low dose and dose increased gradually; discontinue permanently if severe rash or if rash accompanied by blistering, oral lesions, conjunctivitis, swelling, general malaise or hypersensitivity reactions; if rash mild or moderate may continue without interruption but dose should not be increased until rash resolves.Patients should be told how to recognize hypersensitivity reactions and advised to seek immediate medical attention if symptoms develop","Rash including Stevens-Johnson syndromeand rarely, toxic epidermal necrolysis(see also Precautions above); hepatitis orjaundice reported (see also Precautionsabove); nausea, vomiting, abdominal pain,diarrhoea, headache, drowsiness, fatigue,fever; hypersensitivity reactions (may involvehepatic reactions and rash, see Precautionsabove); anaphylaxis, angioedema, urticariaalso reported; granulocytopenia.",Store protected from light and moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Lamivudine + Nevirapine + Stavudine,Pregnancy Category-C,Schedule H,HIV infection.,TABLET Lamivudine + Nevirapine + Stavudine 40 mg + 10 mg + 70 mg150 mg + 40 mg + 200 mg150 mg + 30 mg + 200 mg100 mg + 30 mg + 200 mg,"Adult- One tablet twice daily. Patients with body weight less than 50 kg, 2 mg/kg body weight two times a day.Child- 3 months to 12 years; half adult dose is given two times a day.",,Pregnancy (Appendix 7c).,,Store protected from moisture at a temperature not exceeding 25⁰C for DT.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Lamivudine + Zidovudine,Pregnancy Category-C,Schedule H,HIV infection.,TABLET lamivudine + zidovudine 150 mg + 300 mg.,Adult- 2 tablets three times a day or as prescribed.Child- Half the adult dose.,,Pregnancy (Appendix 7c).,,Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Zidovudine + Lamivudine + Nevirapine,,Schedule H,HIV infection.,TABLETS Zidovudine 300 mg + Lamivudine150 mg + Nevirapine 200 mg.,Adult- 2 tablets three times a day.Child- Half adult dose.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Indinavir,Pregnancy Category-C,Schedule H,HIV infection in combination with twonucleoside reverse transcriptase inhibitorsand usually with low-dose ritonavir booster.,TABLET/CAPSULE 400 mg.,"OralAdult- 800 mg every 8 h with water, 1 h before or 2 h after meals.Child- 4 to 17 years: 500 mg every 8 h. Safety and efficacy is not established in patients less than 4 years.",Pregnancy, concurrent use of cisapride, alprazolam, midazolam.,"Hepatic impairment (Appendix 7a); ensureadequate hydration to reduce risk of nephro-lithiasis; diabetes mellitus; haemophilia; preg-nancy (see notes above and Appendix 7c);lactation (Appendix 7b) (see notes above);metabolism of many drugs inhibited if admin-istered concomitantly; interactions (Appendix6c, 6d); hyperbilirubinemia, tubulo-interstitialnephritis.","Nausea, vomiting, diarrhoea, abdominaldiscomfort, dyspepsia, flatulence, pancrea-titis, dry mouth, taste disturbances; head-ache, dizziness, insomnia; myalgia, myositis,rhabdomyolysis, asthenia, hypoaesthesia,paraesthesia; hyperglycaemia; anaphylactoidreactions, rash (including Stevens-Johnsonsyndrome), pruritus, dry skin, hyperpig-mentation, alopecia, paronychia; interstitialnephritis, nephrolithiasis (may require inter-ruption or discontinuation; more frequentin children), dysuria, haematuria, crystallu-ria, proteinuria, pyuria (in children); hepa-titis, transient hyperbilirubinaemia; blooddisorders including neutropenia, haemo-lytic anaemia; lipodystrophy and metaboliceffects, see notes above; hydronephrosis.",Store protected from light and moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Lopinavir + Ritonavir,Pregnancy Category-C,Schedule H,HIV infection in combination with two other antiretroviral drugs,CAPSULE/TABLET Lopinavir + Ritonavir 200 mg + 50 mg.,"Adult and child with body surface area1.4 m2, body weight 40 kg and over- 2 tabletstwice daily.Child over 2 years with body weight 40 kg and body surface area 0.5 to 0.9 m2 - 2 tablets (Lopinavir 100 mg + Ritonavir 25 mg), twice daily. Body surface area 0.9 to1.4 m2 - 3 tablets twice daily.",Hypersensitivity, avoid concomitant use withergot derivatives.,Hepatic impairment-avoid if severe, renalimpairment, haemophilia, pregnancy (seenotes above and (Appendix 7c), lactation(see notes above and Appendix 7b), diabetesmellitus.Signs and symptoms suggestive of pancreatitis (including raised serum amylase and lipase) should be evaluated-discontinue if pancreatitis diagnosed.,"Diarrhoea, nausea, vomiting, colitis, abdomi-nal discomfort, asthenia, headache, insom-nia; rash; less frequently, dry mouth, hepaticdysfunction, pancreatitis (see also Precau-tions), dyspepsia, dysphagia, oesophagitis,influenza-like syndrome, appetite changes;hypertension, palpitations, thrombophlebi-tis, vasculitis, chest pain, dyspnoea, agita-tion, anxiety, ataxia, hypertonia, confusion,depression, dizziness, dyskinesia, paraes-thesia, peripheral neuritis, somnolence;Cushing syndrome, hypothyroidism, sexualdysfunction, anaemia, leukopenia, dehy-dration, oedema, lactic acidosis; arthralgia,myalgia, abnormal vision, otitis media, tastedisturbances, tinnitus; acne, alopecia, dryskin, pruritus, skin discolouration, nail disor-ders, sweating; lipodystrophy and metaboliceffects (see notes above); raised bilirubinand lowered sodium, low platelet and lowneutrophil counts also reported in children;myocardial infarction, loss of taste.",Store protected from moisture at a temperature not exceeding 30⁰C for tablets and store protected from moisture in refrigerator (2 to 8⁰C) for capsules.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Nelfinavir,Pregnancy Category-B,Schedule H ,HIV infection in combination with two other antiretroviral drugs.,TABLET 250 mg.,Adult- 750 mg thrice daily.Child- 3 to 13 years: initially 25 to 30 mg/kg body weight three times a day (max. 1.25 g) or 50 to 55 mg/kg body weight twice daily. Not recommended under 3 years.,Moderate to severe liver disease, concurrentuse of alprazolam, midazolam, lactation,hypersensitivity.,"Hepatic and renal impairment; diabetesmellitus; haemophilia; pregnancy (Appendix7c) and lactation (Appendix 7b) (see notesabove); interactions (Appendix 6b, 6c, 6d);HIV cross resistance, immune reconstitutionsyndrome.","Diarrhoea, nausea, vomiting, flatulence,abdominal pain; rash; reports of elevatedcreatine kinase; hepatitis; pancreatitis;neutropenia; hypersensitivity reactionsincluding bronchospasm, fever, pruritus andfacial oedema, lipodystrophy and metaboliceffects, see notes above; backpain, myopathy,anxiety, sleep disorder, kidney calculus, QTprolongation.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Oseltamivir,Pregnancy Category-C,Schedule X,"Influenze A, B and its subtypes like swine flu","CAPSULES 30, 45 and 75 mg.","OralAdult and adolescent- Prevention of influenza, over 13 years: 75 mg once daily for 10 days for post exposure prophylaxis, for up to 6 weeks in epidemics. Treatment of influenza, over 13 years: 75 mg every 12 hfor 5 days. Child- Prevention of influenza: body weight under 15 kg: 30 mg once daily; 15 to 23 kg:45 mg once daily; 23 to 40 kg: 60 mg once daily: above 40 kg: adult dose.Treatment of influenza: body weight under 15 kg: 39 mg every 12 h for 5 days; 15 to 23kg: 45 mg every 12 h for 5 days; 23 to 40 kg:60 mg every 12 h for 5 days; above 40 kg:adult dose.",Hypersensitivity.,Hepatic impairment, pregnancy (Appendix7c), lactation, renal impairment,"Nausea, vomiting, abdominal pain,dyspepsia, diarrhoea; headache, fatigue,insomnia, dizziness; conjunctivitis, epistaxis;rash; very rarely, hepatitis, Stevens-Johnsonsyndrome and toxic epidermal necrolysis;neuropsychiatric disorders also reported(in children); cough, bronchitis, eczema,seizures, aggravation of diabetes.",Store protected from moisture and light at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ritonavir,Pregnancy Category-C,Schedule H,"HIV infection, as a booster to increase effectof indinavir, lopinavir or saquinavir and incombination with two other antiretroviraldrugs.",TABLET 100 and 250 mg, CAPSULE 100 mg,SyRUP 400 mg/5 ml.,"Adult- Initially 300 mg every 12 h for three days increased in steps of 100 mg every 12 h over not longer than 14 days to 600 mg every 12 h.Child- Over 2 years: initially 250 mg/m2 of body surface area every 12 h, increase by 50 mg/m2 at intervals of 2 to 3 days to 350 mg/m2 body surface area every 12 h (max. 600 mg/12 h).",Severe hepatic impairment.,"Hepatic impairment, diabetes mellitus;haemophilia; pregnancy (Appendix 7c) andlactation (Appendix 7b) (see notes above);interactions (Appendix 6b, 6c, 6d); PR intervalprolongation, lipid disorder.Signs and symptoms suggestive of pancreatitis (including raised serum amylase and lipase) should be evaluated-discontinue if pancreatitis diagnosed.","Nausea, vomiting, diarrhoea (may impairabsorption-close monitoring required),abdominal pain, taste disturbances,dyspepsia, anorexia, throat irritation;vasodilatation; headache, circumoral andperipheral paraesthesia, hyperaesthesia,dizziness, sleep disturbances, asthenia,rash, hypersensitivity reactions, leukopenia;raised liver enzymes, bilirubin and uricacid; occasionally flatulence, eructation,dry mouth and ulceration, cough, anxiety,fever, pain, myalgia, weight loss, decreasedthyroxine, sweating, pruritus, electrolytedisturbances, anaemia, neutropenia,increased prothrombin time; pancreatitis (seealso Pancreatitis, above); lipodystrophy andmetabolic effects, see notes above; posturalhypotension, abnormal stool, albuminuria.",Store protected from light at temperature (2 to 8⁰C) for capsules.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Saquinavir,Pregnancy Category-B,Schedule H,HIV infection in combination with two otherantiretroviral drugs and usually with low-dose ritonavir booster.,TABLETS 500 mg, CAPSULES 200 mg.,"Adult and adolescent over 16 years with low dose ritonavir, 1g saquinavir every 12 h",Hypersensitivity.,"Hepatic impairment (Appendix 7a); renalimpairment; diabetes mellitus; haemophilia;pregnancy (Appendix 7c) and lactation(Appendix 7b) (see notes above); interactions(Appendix 6d); hyperlipidemia, lactoseintolerance, fat redistribution, immunereconstitution syndrome.","Diarrhoea, buccal and mucosal ulceration,abdominal discomfort, nausea, vomiting;headache, peripheral neuropathy,paraesthesia, dizziness, insomnia, moodchanges, ataxia, musculoskeletal pain,asthenia; fever, pruritus, rash and otherskin eruptions, rarely, Stevens-Johnsonsyndrome; other rare adverse effects includethrombocytopenia and other blood disorders;liver damage; pancreatitis and nephrolithiasis;reports of elevated creatine kinase, raisedliver enzymes and neutropenia when usedin combination therapy; lipodystrophy andmetabolic effects (see notes above); cyanosis,heart murmur; decrease appetite; amnesia.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Zanamivir,Pregnancy Category-B,Schedule X,Most effective for the treatment of influenzaif started within a few hour of the onset ofsymptoms, they are to be used within 48 h(36 h for children) of the first symptoms.,"CAPSULE 5 mg, powder for inhalation.",Oral- powder for inhalation.Adult- minimum 10 mg (2 inhalations)inhaled, orally twice a day for 5 days. Max.20 mg.,,"Anaphylaxis; encephalitis; pediatric, geriatric,lactation, pregnancy (Appendix 7c).","Nausea, vomiting, abdominal pain,dyspepsia, diarrhoea; headache, fatigue,insomnia, dizziness; conjunctivitis, epistaxis;rash; very rarely, hepatitis, Stevens-Johnsonsyndrome and toxic epidermal necrolysis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Praziquantel,Pregnancy Category-B,Schedule H,"Taenia saginata, T. solium, Hymenolepisnana and Diphyllobothrium latum infections;trematode infections, schistosomiasis.",TABLETS 600 mg.,Schistosomiasis: 40 mg/kg body weight is given in two divided doses 4 to 6 h apart in one day. S. japonicum infection: 60 mg/kg body weight in three divided doses in one day.,Ocular cysticercosis, hypersensitivity.,"Pregnancy (Appendix 7c); lactation (Appendix7b); areas endemic for cysticercosis-possibleoedematous reaction; impaired renalfunction, cardiac irregularities.May impair ability to perform skilled tasks, for example operating machinery, driving.","Abdominal discomfort, anorexia, nausea,vomiting, malaise, headache, dizziness,drowsiness, rectal bleeding; rarely,hypersensitivity reactions, including fever,pruritus, eosinophilia (may be due to dead anddying parasites); ectopic rhythms, urticaria,erythema, convulsions.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Acyclovir,Pregnancy Category-B,Schedule H,Treatment of primary genital herpes, dissemi-nated Varicella-zoster in immunocompro-mised patients, Herpes simplex encephalitis,chicken pox.,"TABLETS Plain/DT 200, 400 and 800 mg;SUSPENSION 400 mg/5 ml; INFUSION 100 ml(after reconstitution) (250 mg); OINTMENT5g (3%w/w); DROPS 5 ml (3% w/w); CREAM5g (5% w/w).","Oral Adult- Non-genital herpes simplex treatment, 200 mg five times daily usually for 5 days, longer if new lesions appear during treatment or if healing is incomplete. 400 mg for immunocompromised patients or if absorption is impaired.Genital herpes simplex treatment; 200 mg 5 times daily for 5 days or 400 mg three times daily for three days. Longer if new lesions appear or healing is incomplete.Immunocompromised or HIV positive patients; 400 mg is given five times daily for 7 to 10 days during first episode or 400 mg three times a day for 5 to 10 days during recurrent injection.Herpes simplex prevention of recurrence; 200 mg 4 times daily or 400 mg twice daily reduced to 200 mg two or three times daily interrupted every 6 to 12 months.Varicella and herpes zoster; 800 mg five times daily for 7 days.Chicken pox; 800 mg five times daily for 7 to 10 days.Intravenous infusionSevere initial genital herpes, Varicella zoster, Herpes simplex infection; 5 mg/kg body weight every 8 h for five days.Child- Under 2 years; half dose. Above 2 years; adult dose.Varicella and herpes zoster; 20 mg/kg body weight (max. 800 mg) four times daily for 5 days, under 2 years 200 mg four times daily, for 2 to 5 years; 400 mg four times daily. Over 6 years; 800 mg four times daily.Chicken pox; 20 mg/kg body weight (max 800 mg) four times daily for 5 days.",Hypersensitivity, glaucoma, psychiatricdisease, depression.,Maintainadequatehydration,renalimpairment(Appendix 7d), lactation (Appendix 7b),pregnancy (Appendix 7c), paediatrics.,"Nausea, vomiting, abdominal pain, diarrhoea,headache, fatigue, rash, urticaria, pruritus,photosensitivity; rarely, hepatitis, jaundice,dyspnoea, angioedema, anaphylaxis;neurological reactions (including dizziness,confusion, hallucinations, drowsiness), acuterenal failure; decrease in haematologicalindices; on intravenous infusion, severelocal inflammation (sometimes resultingin ulceration), fever, agitation, tremor,psychosis and convulsions somnolence, visualabnormalities.",Store tablets protected from light. For infusion: Store protected from moisture in a sterile tamper evident container sealed so as to exclude micro-organisms at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Flunarizine,Pregnancy Category-C,Schedule H,Prophylaxis of migraine,TABLETS/CAPSULES 5 and 10 mg.,OralAdults- 10 mg at night.Child < 40 kg- 5 mg at night.,Pregnancy (Appendix 7c), lactation.,"Patient may have drowsiness, should notoperate hazardous machines.","Drowsiness; weight gain; depression; gastricpain, dry mouth; insomnia; extrapyramidalside effects.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Propranolol,Pregnancy Category-C,Schedule H,Prophylaxis of migraine,,Oral Initially 40 mg 2 to 3 times a day. Maintenance dose 80 to 160 mg daily. Child- 2-4 mg/kg/day,"Asthma or history of obstructive airwaydisease; uncontrolled heart failure; Prinzmetalangina, marked bradycardia, hypotension;sick sinus syndrome, second- or third-degreeatrioventricular block, cardiogenic shock,metabolic acidosis, severe peripheral arterialdisease; pheochromocytoma.","First-degree atrioventricular block; renalimpairment; liver disease; pregnancy(Appendix 7c); lactation (Appendix 7b); portalhypertension; diabetes mellitus; myastheniagravis; history of hypersensitivity (increasedreaction to allergens, also reduced responseto epinephrine (adrenaline); interactions(Appendix 6a, 6b, 6d).","Bradycardia, heart failure, hypotension,conduction disorders, bronchospasm,peripheral vasoconstriction, exacerbationof intermittent claudication and Raynaudphenomenon; gastrointestinal disturbances,fatigue, sleep disturbances includingnightmares; rarely; rash, dry eyes (reversible);exacerbation of psoriasis.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Dihydroergotamine,Pregnancy Category-X,Schedule H,Acute treatment of migraine headaches withor without aura and acute treatment of clusterheadache episodes.,TABLET 1 mg, INJECTION 1 ml Ampoule (1mg/ml).,"Usually in combination with other analgesicse.g. caffeine.Adult and child over 12 years- 1 to 2 tablets at onset (max. 4 tablets in 24 h), not to be repeated at intervals of less than 4 days.Intravenous infusionTermination of an acute attack of cluster headache, migraine:Adult- 0.5 to 1 mg, 1 dose (Max: 3 mg/day or6 mg/week).","Peripheral vascular disease, coronary heartdisease, obliterative vascular disease andRaynaud’s syndrome, temporal arteritis;hepatic impairment, renal impairment,sepsis; severe or inadequately controlledhypertension, hyperthyroidism, pregnancy(Appendix 7c); lactation; porphyria, ischaemicheart disease; angina pectoris.","Risk of peripheral vasospasm; elderly; itshould not be used for migraine prophylaxis;interactions (Appendix 6c). Warn patient tostop treatment immediately if numbnessor tingling of extremities develops and tocontact doctor, compromised circulation;hypertension.","Nausea, vomiting, vertigo, abdominal pain,diarrhoea, muscle cramps and occasionallyheadache provoked (usually because ofprolonged excessive dosage or abruptwithdrawal); precardial pain, myocardialand intestinal ischaemia, rarely, myocardialinfarction; repeated high dosage may causeergotism with gangrene and confusion;pleural, peritoneal and heart-valve fibrosismay occur with excessive use; coronary arteryvasospasm; ventricular tachycardia; alteredsense of taste; rhinitis.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Paracetamol Sumatriptan,Pregnancy Category-C,Schedule H,Acute treatment of migraine.,"TABLET 25, 50 and 100 mg; INJECTION 0.5 mlampoule (6 mg/ml).","OralThe recommended oral dose is 25-100 mg, repeatable after 2 hours upto a total dose of 200 mg over a 24 hour period.Parenteral6 mg at onset subcutaneously, may be repeated once after 1 h for maximum of 2 doses in 24 hours.","Ischaemic heart disease, hypertension;pregnancy (Appendix 7c); renal impairment.",Ischaemic heart disease, hepatic impairment,"Tightness in head and chest, paraesthesiain limbs, dizziness; rise in BP, bradycardia,sudden death, seizures.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Actinomycin,Pregnancy Category-C,Schedule H,"Trophoblastic tumours, Wilm’s tumour,Ewing’s sarcoma, rhabdomyosarcoma",INJECTION Vial 500 mg.,Intravenous injectionAdult and child above 6 months- 15 µg/kg/ day.Principally used to treat paediatric cancers.,See notes above and consult literature,hypersensitivity, lactation, infection withchildren, herpes zoster, pregnancy (Appendix7c) and lactation.,See notes above and consult literature.,See notes above and consult literature.Hair loss, nausea, vomiting, mouth sores,diarrhoea.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Alpha Interferon,Pregnancy Category-C,Schedule H,"Hairy cell leukaemia, AIDS related Kaposi’ssarcoma in patients above 18 years.Malignant melanoma.","VIALS 3, 5 & 6 million IU; 44 µg (Interferon B)."," Adult- Hairy cell leukaemia induction: 3 million IU daily for 16 to 24 weeks. Maintenance 3 million IU three times a week. Treatment for 6 months approx. Kaposi’s Sarcoma: 36 million IU for 10 to 12 weeks, maintenance 36 million IU three times a week.Child- Not recommended for children.",Consult product literature, avoid injectionscontaining benzyl alcohol in neonates,pregnancy (Appendix 7c), lactation.,Consult product literature, hairy cellleukaemia, renal impairment.,"Anorexia, nausea, influenza-like symptomsand lethargy. Ocular side-effects anddepression (including suicidal behaviour)have also been reported. Myelosuppressionmay occur, particularly affecting granulocytecounts. Cardiovascular problems(hypotension,hypertensionandarrhythmias),nephrotoxicity and hepatotoxicity havebeen reported. Hypertriglyceridaemia,monitoring of lipid concentration isrecommended. Hypersensitivity reactions,thyroid abnormalities, hyperglycaemia,alopecia, psoriasiform rash, confusion, comaand seizures (usually with high doses in theelderly), leucopenia; thrombocytopenia;mucosities; pancreatitis.",Store protected from light at or below -20⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Bleomycin,Pregnancy Category-D,"Schedule H, G","Adjunct to surgery and radiotherapy inpalliative treatment of Hodgkin’s andnon-Hodgkin’s lymphomas; reticulum cellsarcoma and lymphoma; carcinomas of thehead, neck, larynx, cervix, penis, skin, vulva,testicles including embryonal cell carcinoma,choriocarcinoma and teratoma; malignanteffusions",INJECTION 15 and 30 mg/vial.,"Intramuscular and subcutaneous injection30 mg twice a week, dose can also vary from 15 mg daily to 15 mg weekly; total 300 to 400 mg. Small cell cancer; 0.25 to 0.5 mg/kg body weight once or twice a week.",See notes above and literature, preexistinglung disease, pregnancy (Appendix 7c) andlactation (Appendix 7b),See notes above and consult literature, renalimpairment, interactions (Appendix 6c).,See notes above and consult literature.Dermatitis, nephrotoxicity, hepatotoxicity.,Store protected from light in a sealed container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Busulphan,Pregnancy Category-D,Schedule G,"Chronic granulocytic leukaemia, chronicmyelogenous leukaemia, polycythaemiavera, myelofibrosis, thrombocythaemia.",TABLET 2 mg,"OralChronic myeloid leukaemia, induction of remission: 60 µg/kg body weight daily (max 4 mg) maintenance dose 0.5 to 2 mg daily.",Pregnancy (Appendix 7c), bone marrowsuppression, chronic lymphocytic leukaemia,lactation.,"Monitor cardiac function; pregnancy;lactation previous radiation therapy; avoid inporphyria, hepatic impairment; interactions(Appendix 6c).","Hepatotoxicity (including hepatic veno-occlusive disease, hyperbilirubinaemia,jaundice and fibrosis); cardiac tamponadeat high doses in thalassaemic patients;pneumonia; skin hyperpigmentation;hyperuraecemia; pulmonary fibrosis.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Chlorambucil,Pregnancy Category-D,Schedule G,"Chronic lymphocytic leukaemia; some non-Hodgkin’s lymphomas; Hodgkin’s disease,ovarian cancer and Waldenstrom (primary)macroglobulinaemia.",TABLETS 2 and 5 mg.,"Oral Adult- Chronic lymphocytic leukaemia: initially 150 µg/kg body weight daily until leucocyte count sufficiently reduced. Maintenance (started 4 weeks after first course) 100 µg/kg body weight.Waldarstrom’s macroglobulinaemia: 6 to 12 mg daily until leucopenia occurs, then reduce to 2 to 8 mg daily.Child- Not recommended.",See notes above and consult literature,hypersensitivity, porphyria, pregnancy(Appendix 7c) and lactation (Appendix 7b).,See notes above and consult literature,renal impairment, hepatic impairment(Appendix 7a).,See notes above and consult literature.Hepatotoxicity, peripheral neuropathy,cystitis, seizures, pulmonary fibrosis.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cisplatin,Pregnancy Category-D,Schedule H,"Metastatic testicular tumours, metastaticovarian tumours, advanced bladdercarcinoma and other solid tumours.",INJECTION 10 ml (10 mg) and 50 ml (50 mg)vials.,Intravenous injection (use syringes devoid of aluminium component)Ovarian tumor: 50 mg/m2 of body surface area once every three weeks. Bladder cancer: 50 to 70 mg/m2 once every 3 to 4 weeks. Testicular tumor: 20 mg/m2 for 5 days every 3 weeks for 3 courses.,See notes above and consult literature,hypersensitivity, renal impairment(Appendix 7d), pregnancy (Appendix 7c)and lactation (Appendix 7b).,See notes above and consult literature,hyperuraemia, hypomagnesaemia,hypocalcaemia, interactions (Appendix 6c).,See notes above and consult literature.Tinnitus, neuropathy.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cyclophosphamide,Pregnancy Category-D,Schedule G,"Malignant lymphomas including Non-Hodgkin’s lymphomas, lymphocyticlymphoma, Burkitt’s lymphoma; multiplemyeloma; leukaemias, mycosis fungoides;neuroblastoma; adenocarcinoma of theovary; retinoblastoma; breast cancer.","TABLET 50 mg; INJECTION 15 ml (200 mg), 30ml (500 mg) and 50 ml (1g) vials; dry powderto be reconstituted before administration.",Intravenous injectionMalignancy: 40 to 50 mg/kg body weight in divided doses over 2 to 5 days. Alternatively 10 to 15 mg/kg body weight every 7 to 10 days or 3 to 5 mg/kg body weight twice a week.Oral1 to 5 mg/kg body weight. Minimal change nephrotic syndrome: 2.5 to 3 mg/kg body weight.,See notes above and consult literature,bladder haemorrhage, thrombocytopenia,severe bone marrow depression, pregnancy(Appendix 7c) and lactation (Appendix 7b).,See notes above and consult literature,renal impairment (Appendix 7d) and hepaticimpairment (Appendix 7a), interactions(Appendix 6c).,See notes above and consult literature.Haemorrhagic cystitis, colitis, cardiac toxicity,anorexia, thrombocytopenia, dermatitis.,Injection: Store in refrigerator (2 to 8⁰C). Avoid long exposure to temperature above 30⁰C. The solution should be used immediately after preparation as it deteriorates on storage. Tablet: Store at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cytosine Arabinoside (Cytarabine),Pregnancy Category-D,Schedule H,Acute lymphoblastic leukaemia, chronic mye-loid leukaemia, meningeal leukaemia, eryth-roleukaemia, Non-Hodgkin’s lymphomas,lymphosarcoma.,"INJECTION vials 1 ml (100 mg), 5 ml (500 mg)and 10 ml (1g).",Intravenous injectionAdult- 100 mg/m2 body surface area every 12 h for seven days.Child- 100 mg/m2 body surface area twice daily by rapid injection or 100 mg/m2 body surface area daily by contiuous infusion given by 5 to 10 days,See notes above and consult literature,hypersensitivity, pregnancy (Appendix 7c)and lactation (Appendix 7b).,See notes above and consult literature,uric acid level monitoring recommended,hepatic impairment (Appendix 7a).,See notes above and consult literature, g.i.t.disturbances.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Doxorubicin,Pregnancy Category-D,"Schedule H, G","Soft tissue and bone sarcomas, acute leuke-mia, malignant lymphoma, Hodgkin'sdisease, non-Hodgkin's disease, breast car-cinoma, small-cell carcinoma of lungs, AIDS-related Kaposi’s sarcoma, multiple myeloma,gastro-intestinal tract carcinoma, bladdercancer, ovarian carcinoma, acute myelob-lastic leukemia, thyroid carcinoma, neurob-lastoma.","INJECTION 10 & 50 mg lyophilized powder/vial,2 mg/ml solutionLIPOSOMAL injection 10 ml vial (2 mg/ml).",Intravenous 50-75 mg/m2 body surface area by slow i.v injection every 3 weeks.AIDS-related Kaposi's sarcoma:Adult: As pegylated liposome: 20 mg/m2body surface area infused over 1 hr onceevery 3 weeks.Ovarian carcinoma:Adult: As pegylated liposome: 50 mg/m2 BSAinfused over 1 hr once every 4 weeks.,"Known hypersensitivity, cardiac disease,pregnancy (Appendix 7c), lactation, neonates.","Avoid extravasation, monitor ECG changes,arrhythmias, blood counts, hypotensionor congestive heart failure, hepaticimpairment, interactions (Appendix 6c).Liposomal and non-liposomalpreparations are not interchangeable.","Infusion reactions, cardiotoxicity, bonemarrow suppression, liver impairment,nausea and vomiting, reversible alopecia,stomatitis, conjunctivitis, keratitis, mucositis,discolouration of body fluids, local skinreactions and tissue damage, secondaryleukemias.","Store protected from light, in well closed containers at temperature between (15- 30⁰C); Store intact vials of solution under refrigeration at 2-8⁰C.Use the solution prepared using the liquid stated on the label immediately after preparation but, in any case, within the period recommended by the manufacturer when prepared and stored strictly in accordance with the instructions of the manufacturer. Liposomal formulations: Refrigerate at 2-8⁰C. Do not freeze.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Etoposide,Pregnancy Category-D,Schedule H,Refractory testicular tumours, acuteleukaemia, malignant lymphoma, lungcancer.,"CAPSULES 25, 50 and 100 mg; INJECTION vial100 mg/5 ml.","Intramuscular injectionAdult- Initially 50 to 100 mg/m2 body surface area daily by infusing over 30 to 60 min. Thereafter, no injection for 3 to 4 weeks is given. Small cell lung cancer: 350 mg/m2 daily.OralAdult- 100 to 200 mg/m2 body surface area from day 1 to 5 taken on empty stomach, thereafter no treatment for 3 to 4 weeks.",See notes above and consult literature,hypersensitivity, severe liver dysfunction,pregnancy (Appendix 7c) and lactation(Appendix 7b),See notes above and consult literature,hepatic impairment (Appendix 7a),interactions (Appendix 6c), renal impairment(Appendix 7d).,See notes above and consult literature.Alopecia, gastrointestinal disturbances,thrombophlebitis, neuritis.,Store protected from moisture at a temperature not exceeding 30⁰C. Capsules should not be stored in refrigerator.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5-Fluorouracil,Pregnancy Category-D,Schedule H,"Carcinomas of the colorectum, breast,stomach, pancreas, cervix, prostate, ovaryand endometrium; liver tumours; head andneck tumours; actinic keratosis.",INJECTION 5 and 10 ml ampoule (50 mg/ml).TABLETS 50 mg.,"Intravenous injectionInitially 12 mg/kg body weight once a day for 4 days, max. daily dose 800 mg. If tolerated well without toxicity 6 mg/kg body weight can be given on 6th, 8th, 10th and 12th day. Discontinue on 12th day.Maintenance dose 10 to 15 mg/kg body weight every week (max dose 1g/week).",See notes above and consult literature, bonemarrow depression, pregnancy (Appendix7c) and lactation (Appendix 7b).,See notes above and consult literature,lactation, pelvic irradiation, renalimpairment, hepatic impairment (Appendix7a), interactions (Appendix 6c).,See notes above and consult literature.Cardiac toxicity, tachycardia, dermatitis,diarrhoea.,Store protected from light in single dose container at a temperature not exceeding 30⁰C. The injection should not be allowed to freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Folinic Acid,Pregnancy Category-A,,High-dose methotrexate therapy (‘folaterescue’), inadvertent overdose of methotrex-ate, with 5-fluorouracil in the palliative treat-ment of advanced colorectal cancer.,INJECTION 3 mg/ml.,Prevention of methotrexate induced adverse reactions, started 24 h after treatment with methotrexate by intravenous infusion or by intravenous injection. 15 mg repeat every 6 h for 48 to 72 h.,Intrathecal injection.,Avoid simultaneous administration ofmethotrexate, not indicated for perniciousanaemia or other megaloblastic anaemiasdue to vitamin B12 deficiency, pregnancy (Appendix 7c) and lactation, interactions (Appendix 6c).,"Hypersensitivity reactions; rarely, pyrexiaafter parenteral use; wheezing; swelling offacial features.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Gemcitabine,Pregnancy Category-D,Schedule H,Adenocarcinoma of pancreas,INJECTION Vial 200 mg and 1g (dry powderto be reconstituted before administration).,"1g/m2 body surface area for over 30 min once a week for up to 7 weeks, if not tolerated reduce or withhold. After one week rest administer by infusion once weekly for three weeks, withhold for 4th week before repeating.",Pregnancy (Appendix 7c), concurrent radialradiotherapy, hypersensitivity, lactation.,"Gemcitabine is not recommended forpatients who can have potentially curativesurgery. There is insufficient evidence aboutits use for second-line treatment of pancreaticadenocarcinoma, hepatic impairment; renalimpairment, interactions (Appendix 6c).","Nausea, vomiting, oral mucositis,hyperuricaemia, bone marrow suppression,alopecia, thromboembolism, flu likesyndrome; edema; thrombocyathemia;somnolence; hematuria; dyspnoea; loss ofappetite.","Store in a sterile, airtight, tamperproof container.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Imatinib,Pregnancy Category-D,,"Chronic myeloid leukaemia, Philadelphiachromosome positive acute lymphoblasticleukaemia, Gastrointestinal stromal tumor.",CAPSULES 100 and 400 mg.,400-600 mg/day.,Hypersensitivity.,Interactions (Appendix 6c), pregnancy(Appendix 7c).,"Acute-nausea and vomiting; chronic fluidretention with ankle and periorbital edema,diarrhoea, myalgias, congestive heartfailure.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
L- Asparaginase,Pregnancy Category-C,Schedule G,Acute lymphoblastic leukaemia.,"INJECTION 5,000, 6,000 and 10,000 IU (forreconstitution before administration)","Intramuscular, intravenous or subcutaneous injectionExclusively in acute lymphoblastic leukaemia. Careful monitoring is required. Urine is tested for glucose because of risk of hyperglycaemia",See notes above and consult literature,pregnancy (Appendix 7c) and lactation(Appendix 7b).,See notes above and consult literature.,See notes above and consult literature.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Melphalan,Pregnancy Category-D,Schedule H,"Breast carcinoma, multiple myeloma,advanced ovarian carcinoma, malignantmelanoma, polycythaemia vera",TABLETS 2 and 5 mg, INJECTION 50 mg/vial.,"Oral Adult- Multiple myeloma: usual dose 6 mg/ day. Maintenance dose 2 mg/day.Alternatively 10 mg daily for 7 days (total dose 70 mg), repeat if required after blood counts particularly neutrophils and platelets.Ovarian carcinoma: 0.2 mg/kg body weight daily for 5 days, repeat after 4 to 5 weeks.Child- 0.15 mg/kg body weight daily for 7 days. Maintenance dose is 0.05 mg/kg body weight daily when platelet count is rising.Intravenous injectionFor Injection: 16 mg/m2.",Pregnancy (Appendix 7c), hypersensitivity,myelosuppression, lactation.,Hepatic impairment, renal impairment,interactions (Appendix 6d),"Nausea, vomiting, oral mucositis,hyperuricaemia, bone marrow suppression,alopecia, thromboembolism, leucopenia;menstrual irregularities; haemolyticanaemia.",Store protected from light and moisture at a cool place.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6-Mercaptopurine,6-Mercaptopurine,Schedule G,Acute leukaemias, Chronic granulocyticleukaemia, choreocarcinoma,INJECTION 2 ml ampoule (200 mg/2 ml)TABLET 50 mg.,OralLeukaemia in children (maintenance): 2.5 mg/ kg body weight in continuation with other drugs daily.,See notes above and consult literature,hypersensitivity, pregnancy (Appendix 7c)and lactation (Appendix 7b).,See notes above and consult literature,monitor blood count, uric acid levels,renal impairment and hepatic impairment(Appendix 7a), interactions (Appendix 6c).,See notes above and consult literature.Hepatotoxicity, anorexia, nausea,hyperuricaemia, ulcers.,Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Methotrexate,Pregnancy Category-X,Schedule H,"Carcinoma of the breast, head and neckand lung; trophoblastic tumours; acutelymphoblastic leukaemia, meningealleukaemia; non-Hodgkin’s lymphomas;advanced cases of mycosis fungoides;non-metastatic osteosarcoma; severerheumatoid arthritis.","TABLETS 2.5, 5, 7.5, 10 and 15 mg; INJECTION2, 5, 15 and 50 ml/vial; ampoule (5 mg/ml and25 mg/ml); VIALS 5, 25, 100 mg/ml; GEL 1%w/w.","OralChoriocarcinoma: 15 to 30 mg daily for 5 days repeat 3 to5 full courses after 1 week.Intramuscular route15 to 30 mg daily for 5 days, repeat 3 to5 courses after 1 week.Leukaemia, maintenance after remission: 30 mg/m2 body surface area (max upto 15 mg twice a week).",See notes above and consult literature,severe renal and hepatic impairment,alcohol liver disease, severe leucopenia,thrombocytopenia, pregnancy (Appendix 7c)and lactation (Appendix 7b).,"See notes above and consult literature;bone marrow depression; renal and hepaticimpairment (Appendix 7a); interactions(Appendix 6a, 6c, 6d).",See notes above and consult literature. CNStoxicity, stomatitis, hepatobiliary disorder,fatigue.,Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Mitomycin,Pregnancy Category-D,,"Adrenocarcinoma, lymphosarcoma andseminoma, superficial bladder cancer(adjuvant therapy).",INJECTIONS vial 2 and 10 mg (dry powder tobe reconstituted before administration).,"Intravenous injectionAdult- 6 to 10 mg twice a week, alternatively0.5 mg/kg body weight daily for 5 days,repeat after 2 weeks.",Pregnancy (Appendix 7c), bone marrowdepression, severe anaemia, thrombocyto-penia, lactation.,"It causes delayed bone-marrow toxicity andtherefore it is usually administered at 6-weeklyintervals. Caution in handling because itis irritant to tissues, thrombocytopenia;necrosis; leucopenia.",Prolonged use may result in permanentbone-marrow damage. It may also causelung fibrosis and renal damage, dyspnea.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Paclitaxel,Pregnancy Category-D,Schedule H,Metastatic ovarian and breast cancer.,"INJECTION vial 30, 100, 200, 260 and 300mg (dry powder to be reconstituted beforeadministration).","Intravenous infusionAdult- 175 mg/m2 body surface area over 3 h, repeat every 3 weeks.Antihistamines, corticosteroids or H2 antago- nist may be required during treatment.Child- Not recommended.",Hypersensitivity, severe hepatic impairment,lactation, pregnancy (Appendix 7c).,,"Myelosuppression, peripheral neuropathyand cardiac conduction defects witharrhythmias (which are nearly alwaysasymptomatic); alopecia, muscle pain;nausea and vomiting is mild to moderate,hypersensitivity reactions; myalgia;arthralgia.",Store protected from light at a temperature not exceeding 25⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Procarbazine,Pregnancy Category-D,Schedule H,Part of MOPP regimen in Hodgkin’s and Non- Hodgkin’s lymphomas.,TABLETS 50 mg.,"Oral50 mg daily to start with initially, increased to 250 to 300 mg individual doses.Maintenance (on remission): 50 to 100 mg daily to cumulative total of at least 6g.",See notes above and consult literature,hypersensitivity, pregnancy (Appendix 7c)and lactation (Appendix 7b),See notes above and consult literature,ulceration, haemorrhage, leucopenia: renaland hepatic impairment (Appendix 7a),interactions (Appendix 6a).,See notes above and consult literature,leucopenia, anaemia, thrombocytopenia,hypotension, retinal haemorrhage.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tamoxifen Thalidomide,Pregnancy Category-X,Schedule H,"Multiple myeloma, erythema nodosum lep-rosum",CAPSULES 50 and 100 mg.,"OralMultiple myelomaAdult: The dose is 200 mg administered orally once daily with water, preferably at bedtime and at least 1-hour after the evening meal. Thalidomide is adminis- tered in combination with dexametha- sone in 28-day treatment cycles.Dexamethasone is 40 mg daily adminis- tered orally on days 1-4, 9-12, and 17-20every 28 days.Erythema nodosum leprosum (ENL)Adult: For cutaneous ENL, thalidomide dosing should be initiated at 100 to 300 mg/day, administered once daily with water, preferably at bedtime and at least 1 hour after the evening meal. Not for monotherapy if moderate or severe neuritis present. Max: 400 mg/day. Patients < 50 kg: Initially, 100 mg daily.Dosing with thalidomide should continue until signs and symptoms of active reaction have subsided, usually a period of at least 2 weeks. Patients may then be tapered off medication in 50 mg decrements every 2 to 4 weeks.Patients who have a history of requiring prolonged maintenance treatment to prevent the recurrence of cutaneous ENL or who flare during tapering, should be maintained on the minimum dose necessary to control the reac- tion. Tapering off medication should be attempted every 3 to 6 months, in decre- ments of 50 mg every 2 to 4 weeks","Hypersensitivity, pregnancy (Appendix7C) and lactation, interactions (Appendix6c)","During the period of treatment both malesand females should take adequate meansof contraception before, during and after(atleast 4 weeks) the therapy, therapy to bestopped immediately if pregnancy occurs,no blood or sperm donation during therapy,signs and symptoms of hypersensitivityinclude the occurrence of erythematousmacular rash, possibly associated with fever,tachycardia, and hypotension, and if severe,may necessitate interruption of therapy,Serious dermatologic reactions includingStevens-Johnson syndrome and toxicepidermal necrolysis, seizures, impairment ofmental and/or physical abilities required forthe performance of hazardous tasks such asdriving a car or operating complex machinery,potentiation of somnolence caused by alcohol,peripheral neuropathy, thromboembolismreported.","Teratogenicity, Drowsiness/somnolence,peripheral neuropathy, constipation,dizziness, bradycardia, orthostatic hypoten-sion, hypersensitivity, and neutropenia.","Store protected from moisture, at a temperature not exceeding 30⁰C.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Vinblastine,Pregnancy Category-D,Schedule H,"Disseminated Hodgkin’s and Non-Hodgkin’slymphomas; advanced testicular carcinoma,breast carcinoma; palliative treatment ofKaposi’s sarcoma; trophoblastic tumours;Letterer-Siwe disease; Histolytic lymphoma.",VIAL 10 ml (1 mg/ml).,Intravenous injection only3.7 mg/m2 body surface surface area in single dose. Increase on weekly intervals depending on WBC count (max 18.5 mg/m2 body area).,See notes above and consult literature,hypersensitivity, severe granulocytopenia,lactation (Appendix 7b).Intrathecal injection is contraindicated.,See notes above and consult literature,neurotoxicity, ischaemic heart disease,hepatic impairment (Appendix 7a),interactions (Appendix 6c), pregnancy(Appendix 7c).,See notes above and consult literature.Stomatitis, lucopenia, constipation, bonepain.,Store in sealed container in a deep freezer (below -18⁰C).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Vincristine,Pregnancy Category-D,Schedule H,"Acute lymphoblastic leukaemia; neuroblas-toma, Wilm’s tumour, Hodgkin’s and Non-Hodgkin’s lymphomas; rhabdomyosarcoma,Ewing’s sarcoma; mycosis fungoides.",INJECTION 1 mg/ml.,Intravenous routeAdult- 1.4 mg/m2 body surface area per week.,See notes above and consult literature, lactation (Appendix 7b).Intrathecal injection is contraindicated.,See notes above and consult literature, uricacid neuropathy, branchospasm, hepaticimpairment (Appendix 7a), pregnancy(Appendix 7c).,See notes above and consult literature,Store in sealed container in a deep freezer (below-18⁰C).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Azathioprine,Pregnancy Category-D,Schedule H,To prevent rejection in transplant recipi-ents, rheumatoid arthritis, inflammatorybowel disease, Multiple sclerosis, autoim-mune hepatitis, atopic dermatitis (AD).,TABLETS 25 and 50 mg.,OralAdult and child over 3 months-Renal transplantation: initially 5 mg/kg body weight daily. Maintenance 2 to 2.5 mg/kg daily. Atopic dermatitis (AD): 1 to 3 mg/ kg/day once daily.,Hypersensitivity to azathioprine andmercaptopurine, lactation (Appendix 7b).,"Monitor for toxicity throughout treatment;full blood counts necessary every week(or more frequently with higher dosesand in renal or hepatic impairment) forfirst 4 weeks of treatment and at leastevery 3 months thereafter; reduce dosein elderly; renal impairment; liver disease(Appendix 7a); interactions (Appendix 6c,6d); lactation (Appendix 7b); pregnancy(Appendix 7c).Patients should be warned to report im- mediately any signs or symptoms of bone marrow suppression, for example unex- plained bruising or bleeding, infection.","Hypersensitivity reactions including malaise,dizziness, vomiting, fever, muscular pains,arthralgia; rash; hypotension or interstitialnephritis call for immediate withdrawal;haematological toxicity includes leukopeniaand thrombocytopenia (reversible uponwithdrawal); liver impairment, cholestaticjaundice; hair loss; increased susceptibilityto infections and colitis in patients alsoreceiving corticosteroids; nausea; rarely,pancreatitis, pneumonitis, hepatic veno-occlusive disease; microcystosis.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cyclosporine,Pregnancy Category-C,Schedule H,"Rejection in kidney, liver, heart or bone-marrow transplantation; graft-versus-host disease; in severe recalcitrant atopicdermatitis","CAPSULES 10, 25, 50 and 100 mg; INFUSION50 and 100 ml (100 mg/ml); INJECTION 1 and5 ml ampoule (250 mg/ml).","Oral and intravenous infusionAdult and child over 3 months- Initially 5 mg/ kg b.i.d. for 2 weeks; can be reduced to 1.5 to 3 mg/kg/day according to patients response. If no response after 2 weeks, increase dose 7 mg/kg/day.Organ transplant: 10 to 15 mg/kg body weight 2 to 4 h before transplantation, fol- lowed by 10 to 15 mg/kg body weight for 1 to 2 weeks post operatively. Decrease there- after gradually to 2 to 6 mg/kg body weight for maintenance (adjust according to blood cyclosporine concentration and renal func- tion), if required 1/3rd corresponding oral dose can be administered by intravenous infusion over 2 to 6 h.Intravenous infusionBone marrow transplantation; 3 to 5 mg/kg body weight by intravenous infusion over 2 to 4 h from day before transplantation.",Patients affected by psoriasis.,"Monitor kidney function (dose dependentincrease in serum creatinine and ureaduring first few weeks may necessitatedose reduction, exclude rejection if kidneytransplant), monitor liver function (adjustdosage according to bilirubin and liverenzymes, also refer Appendix 7a); monitorblood pressure (discontinue if hypertensioncannot be controlled by antihypertensives);monitor serum potassium, particularlyif marked renal impairment (risk ofhyperkalaemia); monitor serum magnesium;hyperuricaemia; measure blood lipids beforeand during treatment; avoid in porphyria;vaccination ineffective; monitor serumcreatinine levels; patients affected withpsoriasis; lactation (Appendix 7b); interactions(Appendix 6b, 6c); pregnancy (Appendix 7c).","Dose-related and reversible increases inserum creatinine and urea unrelated to tissuerejection; burning sensation in hands and feetduringinitialtherapy;electrolytedisturbancesincluding hyperkalaemia, hypomagnesaemia;hepatic dysfunction; hyperuricaemia;hypercholesterolaemia; hyperglycaemia,hypertension (especially in heart transplantpatients); increased incidence of malignanciesand lymphoproliferative disorders;increased susceptibility to infections dueto immunosuppression; gastrointestinaldisturbances; gingival hyperplasia; hirsutism;fatigue; allergic reactions; thrombocytopenia(sometimes with haemolytic uraemicsyndrome), also mild anaemia; tremors;convulsions, neuropathy; dysmenorrhoeaor amenorrhoea; pancreatitis, myopathy ormuscle weakness; cramps, gout, oedema;headache; gingival hypertrophy; renaldysfunction; hypertrichosis; paresthesia;renal toxicity; gastrointestinal symptoms.",Store in a well closed container below 25⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tacrolimus,Pregnancy Category-C,,"Prophylaxis of organ rejection in patientsreceiving allogeneic liver, kidney, or hearttransplants. Tacrolimus ointment is indicatedfor atopic dermatitis and psoriasis.","TABLETS 0.5, 1, 2 and 5 mg CAPSULES 0.5, 1,2 and 5 mg OINTMENTS 0.03%, 0.1 %, 0.3%w/w INJECTIONS 5 mg/ml.","Starting dose for injection- 0.03 to 0.05 mg/ kg/day as a continuous infusion.OralAdult- Initial-0.15 to 0.2 mg/kg/day for kidney transplants, 0.1 to 0.15 mg/kg/day for liver transplants.Child- 0.15 to 0.2 mg/kg/day for liver transplant patients in two divided doses 12 hours apart.",Hypersensitivity to tacrolimus.,"Monitoring of blood trough serumconcentrations for preventation of organrejection and to reduce drug related toxicity,pregnancy (Appendix 7c); interactions(Appendix 6c, 6d).","Nephrotoxicity; neurotoxicity; hyperglyc-emia, hypertension, hyperkalemia, and gas-trointestinal disturbances.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cetrimide,,,Antiseptic, disinfectant for surgicalinstruments,SOLUTION 100 ml and 1 litre pack (2%w/v),CREAM 1g (0.5% w/w).,To be applied to the affected area.,Hypersensitivity.,Avoid contact with eyes, avoid use in bodycavities, meninges and middle ear.,"Skin irritation and occasionally sensitisation;rarely, burns.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Chlorhexidine,Pregnancy Category-B,,Antiseptic, disinfection of clean instruments,gingivitis.,"SOLUTION 100 ml (2% and 4% w/v); MOUTHWASH 100 ml (0.2%, w/v).","Antiseptic (pre-operative skin disinfection and hand washing): use solution in alcohol (70%). Antiseptic (wounds, burns and other skin damage): apply 0.05% aqueous solution.Disinfection of clean instruments: immerse for at least 30 min in 0.05% solution containing Sodium nitrite 0.1% (to inhibit metal corrosion). Emergency disinfection of clean instruments: immerse for 2 min in 0.5% solution in alcohol (70%).",Meningitis, middle ear surgery, sensitivetissues.,Aqueous solutions-susceptible to microbialcontamination-use sterilized preparationor freshly prepared solution and avoidcontamination during storage or dilution,instruments with cemented glass components(avoid preparations containing surface activeagents), irritant-avoid contact with middleear, eyes, brain and meninges, not for usein body cavities, alcoholic solutions notsuitable before diathermy, syringes andneedles treated with chlorhexidine (rinsethoroughly with sterile water or saline beforeuse), inactivated by cork (use glass, plastic orrubber closures), alcohol based solutions areflammable, pregnancy (Appendix 7c).,Occasional skin sensitivity and irritation,Upper respiratory tract infection.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ethyl Alcohol,,,"Disinfection of skin prior to injection,venepuncture or surgical procedures.","Regulated by state excise, license is required.",Apply undiluted solution.,,Flammable, avoid broken skin, patients havesuffered severe burns when diathermy hasbeen preceded by application of alcoholicskin disinfectants, lactation (Appendix 7b).,Skin dryness and irritation with frequentapplication.,"Store in a tightly closed container at a temperature not exceeding 30⁰C, away from fire and protected from moisture.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Gentian Violet, Povidone Iodine",Pregnancy Category-D,,Antiseptic, skin disinfection, Mouth wash.,"SOLUTIONS 100 and 500 ml (5% w/v),500 ml (7.5% w/v and 10% w/v);OINTMENT 15g (5% w/w).",Adult and Child- Pre- and post-operative skin disinfection: apply undiluted.Antiseptic (minor wounds and burns): apply twice daily.,Avoid regular or prolonged use in patientswith thyroid disorders or those taking lithium,avoid regular use in neonates, avoid in verylow birthweight infants, burn covering largesurface area, hypersensitivity to iodine.,Pregnancy (Appendix 7c), lactation (Appendix7b), broken skin (see below), renal impairment,avoid contact with eyes, neonates.The application of povidone iodine to large wounds or severe burns may produce systemic adverse effects such as metabolic acidosis, hypernatraemia, and impairment of renal function.,Irritation of skin and mucous membranes,may interfere with thyroid function tests,systemic effects (see under Precautions).,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Bleaching Powder,,,"Disinfection of surfaces, equipments, water.",POWDER FOR SOLUTION 1g chlorine/litre(1000 parts per million, 0.1%).,Surface disinfection (minor contamination): apply solutions containing 1000 parts per million.Instrument disinfection: soak in solution containing 1000 parts per million for a minimum of 15 min, to avoid corrosion do not soak for more than 30 min, rinse with sterile water.,,,,Store protected from moisture in a tightly closed container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Chloroxylenol,Pregnancy Category-C,,Antiseptic, disinfection of instruments andsurfaces.,"SOLUTIONS 50, 100, 200, 500 ml, 1 and 5 litres.",Antiseptic (wounds and other skin damage): apply a 1 in 20 dilution of 5% concentrate in water. Disinfection of instruments: use a 1 in 20 dilution of 5% concentrate in alcohol (70%).,Meningitis, ear infection,Aqueous solutions should be freshly prepared,appropriate measures required to preventcontamination during storage or dilution,pregnancy (Appendix 7c), lactation.,"Skin sensitivity, reported dryness.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Formaldehyde,,,Warts particularly planter warts.,Prepared as 0.75% v/v water miscible gel.,0.75% gel, apply twice a day. ,Hepatic dysfunction, pregnancy.,Significant peripheral neuropathy, patientswith diabetes at risk of neuropathic ulcers,protect surrounding skin and avoid brokenskin, not suitable for application to face,anogenital region, or large areas, increasedlevels of serum aminotransferase.,"Skin irritation; angioedema, myopathy;anaphylaxis, blurred vision; headache.",Store protected from light at a temperature of 15 to 25⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Glutaraldehyde,,,Disinfection and sterilization of instrumentsand surfaces, conditions like warts andhyperhidrosis of palms and soles.,"SOLUTIONS 1, 2 and 5 Litre. (2% aqueous alkaline (pH 8) solution).",Disinfection of clean instruments - immerse in undiluted solution for 10 to 20 min, up to 2 h may be required for certain instruments (for example bronchoscopes with possible mycobacterial contamination), rinse with sterile water or alcohol after disinfection.Sterilization of clean instruments - Immerse in undiluted solution for up to 10 h, rinse with sterile water or alcohol after disinfection.,Damaged skin,"Minimize occupational exposure by adequateskin protection and measures to avoidinhalation of vapour; lung damage; oral andnasal lesions, if swallowed do not inducevomiting.",Nausea (occupational exposure), headache,airway obstruction, asthma, rhinitis,eye irritation and dermatitis and skindiscolouration.,Store at a temperature not exceeding 15⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Acetylsalicylic Acid,Pregnancy Category-D,,"As an antiplatelet agent for prophylaxis ofmyocardial infarction, stable angina; stableangina pectoris; stroke prohphylaxis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Atenolol,Pregnancy Category-D,Schedule H,Angina and myocardial infarction,arrhythmias, hypertension, migraineprophylaxis.,"TABLETS 12.5, 25, 50, and 100 mg; INJECTIONampoule 5 mg/ml (10 ml).","OralAdult- 50 mg once daily, increased if neces- sary to 50 mg twice daily or 100 mg once dai- ly. Angina: 50 mg daily administered alone or with a diuretic, dose can be increased to 100 mg (over 100 mg has no added advantage). May also be administered in combination with a mlodipine besylate 2.5 or 5 mg.Child- 1 to 1.3 mg/kg body weight once daily or divided every 12 h.Intravenous injection2.5 mg at a rate of 1 mg/min, repeat at 5 min interval to a max. 10 mg.","Asthma or history of obstructive airwaysdisease (unless no alternative, then withextreme caution and under specialistsupervision); uncontrolled heart failure,Prinzmetal angina, marked bradycardia,hypotension, sick sinus syndrome, second-and third-degree atrioventricular block,cardiogenic shock; metabolic acidosis;severe peripheral arterial disease;pheochromocytoma (unless used with alpha-blocker).","Avoid abrupt withdrawal especially inangina; may precipitate or worsen heartfailure; acute myocardial infarction,pregnancy (Appendix 7c), thyrotoxicosis,pheochromocytoma; lactation (Appendix7b); first-degree atrioventricular block; liverfunction deteriorates in portal hypertension;reduce dose in renal impairment; diabetesmellitus (small decrease in glucose tolerance,masking of symptoms of hypoglycaemia);history of hypersensitivity (increasedreaction to allergens, also reduced responseto epinephrine (adrenaline); myastheniagravis; interactions (Appendix 6a, 6b, 6c).","Gastrointestinal disturbances (nausea,vomiting, diarrhoea, constipation, abdominalcramp); fatigue; cold hands and feet;exacerbation of intermittent claudicationand Raynaud phenomenon; bronchospasm;bradycardia, heart failure, conductiondisorders, hypotension; sleep disturbances,including nightmares; depression, confusion;hypoglycaemia or hyperglycaemia;exacerbation of psoriasis; rare reports ofrashes and dry eyes (oculomucocutaneoussyndrome-reversible on withdrawal).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Diltiazem,Pregnancy Category-C,Schedule H,Angina pectoris due to coronary artery spasm,chronic stable angina, cardiac arrhythmia.,"TABLETS/TABLETS (SR) 30, 60, 90, 120, 180and 240 mg; CAPSULE 60, 90, 120, 180 and240 mg; INJECTION 5 ml (25 mg/5 ml).","OralAdult-30 mg 2 to 5 times a day before food and at night (bed time), increase gradually to 240 mg in 3 to 4 divided doses daily.Child- Not recommended.Cardiac arrhythmiaAdult-Initially 250 µg/kg by i.v. bolus over 2 min.",Severe bradycardia, left ventricular failurewith pulmonary congestion, second- orthird-degree AV block (unless pacemakerfitted), sick sinus syndrome, lactation.,Reduce dose in hepatic and renal impairment,heart failure or significantly impaired leftventricular function, bradycardia (avoid ifsevere), first degree AV block, or prolongedPR interval, interactions (Appendix 6c),sinoatrial nodal dysfunction, pregnancy(Appendix 7c).,"Bradycardia, sino-atrial block, AV block;palpitation; dizziness; hypotension, malaise;asthenia; headache; hot flushes; gastro-intestinal disturbances; oedema (notably ofankles); rarely, rashes (including erythemamultiforme and exfoliative dermatitis),photosensitivity; hepatitis; gynaecomastia;gum hyperplasia; extrapyramidal symptoms;depression reported; gastrointestinalhaemorrhage; sinus arrest.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Esmolol, Glyceryl Trinitrate",Pregnancy Category-C,Schedule H,"Prophylaxis and treatment of angina,myocardial infarction; post operativehypertension; cardio-pulmonary edema.","TABLETS 0.5, 2.6 and 6.4 mg; CAPSULES 2.5and 6.4 mg; INJECTION 5 and 10 ml (5 mg/ml); SUBLINGUAL TAB 500 µg. SPRAy 0.4mg/puff (200 mdi)","SublingualAdult- 0.5 to 1 mg, repeated as required.Intravenous infusion10 to 200 µg/min.","Hypersensitivity to nitrates; hypotension;hypovolaemia; raised intracranial pressure;hypertrophic obstructive cardiomyopathy,aortic stenosis, cardiac tamponade,constrictive pericarditis, mitral stenosis;marked anaemia; head trauma; cerebralhaemorrhage; angle-closure glaucoma.","Severe hepatic or renal impairment;hypothyroidism; malnutrition; gastrointesti-nal hypermotility; malabsorption syndrome;hypothermia; recent history of myocardialinfarction; interactions (Appendix 6b, 6c).","Throbbing headache; flushing; dizziness,postural hypotension; tachycardia(paradoxical bradycardia also reported);abdominal pain; collapse; neurologicaldeficit.","Store protected from light and moisture in glass container of not more than 100 tablets at a temperature not exceeding 30⁰C. The container should be closed by means of screw cap lined with aluminium or tin foil. Cotton, wool wadding or other additional packing that absorbs glyceryl trinitrate should be avoided.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Isosorbide-5-Mononitrate,Pregnancy Category-C,Schedule H,"Prophylaxis and treatment of angina, congestive heart failure","TABLETS 10, 20, 40, 50 and 60 mg; TABLETS(SR) 50 mg and 60 mg; CAPSULE 30, 40 and60 mg.","Oral20 mg 2 to 3 times a day initially, or 40 mg twice daily (max 120 mg daily individual dose).",Hypersensitivity to nitrates, hypotensiveconditions and hypovolaemia, hypertrophiccardiomyopathy, aortic stenosis, cardiactamponade, constrictive pericarditis, mitralstenosis, marked anaemia, glaucoma,obstructive cardiomyopathy, raisedintracranial pressure.,Hypothyroidism, malnutrition, hypothermia,head trauma, cerebral haemorrhage,gastrointestinal disease, recent history ofmyocardial infarction, hypoxaemia or otherventilation and perfusion abnormalities,susceptibility to angle-closure glaucoma,metal-containing transdermal systemsshould be removed before cardioversionor diathermy, avoid abrupt withdrawal,tolerance, severe hepatic impairment, severerenal impairment, pregnancy (Appendix 7c),lactation, interactions (Appendix 6a).,"Postural hypotension, tachycardia (but para-doxical bradycardia also reported); throbbingheadache; dizziness; less commonly nausea;vomiting; heartburn; flushing; temporaryhypoxaemia; rash; application site reactionswith transdermal patches; very rarely, angle-closure glaucoma; decreased cardiac output;urinary and faecal incontinence.Specific side-effects following injection (particularlyifgiventoorapidly)includesevere hypotension, diaphoresis, apprehension, restlessness, muscle twitching, retrosternal discomfort, palpitation, abdominal pain, syncope; prolonged administration has been associated with methaemoglobinaemia.",Store at a temperature not exceeding 30⁰C,,,,,,,,,,,,,,,,,,,,,,,
Isosorbide Dinitrate,Pregnancy Category-C,Schedule H,Prophylaxis and treatment of angina, heartfailure.,TABLETS (sublingual) 5 and 10 mg, CAPSULES(timed release) 20 and 40 mg.,"SublingualAdult- Angina acute attack: 5 to 10 mg, repeated as required.Angina prophylaxis: 120 mg daily in divided doses.Angina prophylaxis: 20 to 120 mg.","Hypersensitivity to nitrates; hypotension;hypovolaemia; myocardial infarction;hypertrophic obstructive cardiomyopathy,aortic stenosis, cardiac tamponade,constrictive pericarditis, mitral stenosis;marked anaemia; head trauma; cerebralhaemorrhage; angle-closure glaucoma.","Severe hepatic or renal impairment;hypothyroidism; malnutrition; hypothermia;recent history of myocardial infarction;interactions (Appendix 6a, 6b, 6c, 6d);pregnancy (Appendix 7c).Patients taking isosorbide dinitrate for the long-term management of angina may often develop tolerance to the antianginal effect; this can be avoided by giving the second of 2 daily doses of longer-acting oral presentations after an 8-h rather than a 12-h interval, thus ensuring a nitrate-free interval each day.","Throbbing headache; flushing; dizziness,postural hypotension, tachycardia(paradoxical bradycardia also reported);palpitation, decreased cardiac output;confusion; increased intracranial pressure.",Store at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Metoprolol,Pregnancy Category-C,Schedule H,"Supraventricular arrhythmia, anginapectoris, hypertension, myocardial infarction;migraine prophylaxis; hyperthyroidism, heartfailure.","TABLETS 10, 25, 50 and 100 mg; CAPSULE12.5, 25, 50 and 100 mg; INJECTION 100mg/2 ml, 250 mg/2 ml, 500 mg/2 ml.","OralHeart failure: Initiating dose 12.5 - 25 mg once a day, Maximum dose: 200 mg once a day; Hypertension: initially 100 mg daily, increase if required to 200 mg in two divided doses (max 400 mg daily). Angina: 50 mg daily, up to 300 mg daily in 2 to 3 divided doses if necessary.Intravenous injectionArrhythmia: up to 5 mg at a rate of 1 to2 mg per min, repeated after 5 min ifnecessary (max dose 10 to 15 mg). Arrythmiadeveloping during anaesthesia: 2 to 4 mgduring induction.","Asthma (important: see Bronchospasmbelow), uncontrolled heart failure,Prinzmetal's angina, marked bradycardia,hypotension, sick sinus syndrome, second-or third- degree AV block, cardiogenic shock,metabolic acidosis, severe peripheral arterialdisease; pheochromocytoma (apart fromspecific use with alpha-blockers).Beta-blockers, including those considered to be cardioselective, should not be given to patients with a history of asthma or bronchospasm. However, in rare situations where there is no alternative a cardioselective beta-blocker is given to these patients with extreme caution and under specialist supervision.","Avoid abrupt withdrawal especially in is-chaemic heart disease, first-degree AV block,portal hypertension (risk of deterioration inliver function); diabetes; history of obstruc-tive airways disease (introduce cautiouslyand monitor lung function); myastheniagravis; symptoms of hypoglycaemia andthyrotoxicosis may be masked; history ofhypersensitivity-may increase sensitivity toallergens and result in more serioushypersensitivity response; also mayreduce response to adrenaline (epinephrine);reduce dose of oral propranolol in hepaticimpairment; renal impairment; lactation;pregnancy (Appendix 7c).","Gastro-intestinal disturbances; bradycardia,heart failure, hypotension, conductiondisorders; peripheral vasoconstriction(including exacerbation of intermittentclaudication and Raynaud’s phenomenon);bronchospasm; dyspnoea; headache; fatigue;sleep disturbances; paraesthesia; dizziness;vertigo; psychosis; sexual dysfunction;purpura; thrombocytopenia; visualdisturbances; exacerbation of psoriasis;alopecia; rarely, rashes and dry eyes (reversibleon withdrawal); on infusion venous irritationand thrombophlebitis; agranulocytosis;hyperglycemia; myocardial depression.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Propranolol,Pregnancy Category-C,Schedule H,Cardiac arrhythmias, tachycardia, hyper-trophic obstructive cardiac myopathy, pheo-chromocytoma, thrombosis, managementof angina, essential and renal hypertension,prophylaxis of migraine,"TABLETS 10, 20, 40, 60 and 80 mg plain; 40,60 and 80 mg (SR); CAPSULE 40, 60 and 80mg (SR); INJECTION 1 ml ampoule (1 mg/ml).","OralAdult- Hypertension: initially 40 mg twice a day or 80 mg once a day; increased at weekly intervals as required, maintenance 160 to 320 mg in three divided doses. Prophylaxis of variceal bleeding in portal hypertension: 40 mg twice daily, increased to 80 mg twice daily according to heart rate (max. 160g twice daily). Angina: Initially 40 mg 3 times a day, maintenance 120 to 240 mg daily. Prophylaxis after myocardial infarction: 40 mg 4 times daily for 2 to 3 days, then 80 mg twice daily beginning 5 to 21 days after infarction.","Asthma (important: see Bronchospasmbelow); uncontrolled heart failure,Prinzmetal's angina, marked bradycardia,hypotension; sick sinus syndrome, second-or third- degree AV block, cardiogenicshock, metabolic acidosis, severe peripheralarterial disease, pheochromocytoma (apartfrom specific use with alpha-blockers);haemorrhage.Beta-blockers, including those considered to be cardioselective, should not be given to patients with a history of asthma or bronchospasm. However, in rare situations where there is no alternative a cardioselective beta-blocker is given to these patients with extreme caution and under specialist supervision.","Avoid abrupt withdrawal especially inischaemic heart disease, first-degreeAV block, portal hypertension (risk ofdeterioration in liver function), diabetes;history of obstructive airways disease(introduce cautiously and monitor lungfunction); myasthenia gravis; symptomsof hypoglycaemia and thyrotoxicosis maybe masked; history of hypersensitivity-may increase sensitivity to allergens andresult in more serious hypersensitivityresponse; also may reduce response toadrenaline (epinephrine); reduce dose oforal propranolol in hepatic impairment;renal impairment; lactation (Appendix 7b);interactions (Appendix 6a, 6b, 6d); pregnancy(Appendix 7c).","Gastro-intestinal disturbances; bradycardia;heart failure, hypotension, conduction disor-ders; peripheral vasoconstriction (includingexacerbation of intermittent claudication andRaynaud’s phenomenon); bronchospasm;dyspnoea; headache; fatigue; sleep distur-bances; paraesthesia; dizziness; vertigo;psychosis; sexual dysfunction; purpura;thrombocytopenia; visual disturbances;exacerbation of psoriasis; alopecia; rarely,rashes and dry eyes (reversible on withdraw-al); on infusion venous irritation and throm-bophlebtis; eosinophilia; hyperglycemia;cardiogenic shock; visual hallucinations.",Store protected from light and moisture.Injection: Store protected from light andmoisture in a single dose container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Verapamil,Pregnancy Category-C,Schedule H,"Angina, including stable, unstable andPrinzmetal angina; arrhythmias; ischaemicheart disease; migraine.","TABLETS 40, 80, 120 and 240 mg (SR);INJECTION 2 ml (5 mg/2 ml).","OralAdult- 80 to 120 mg 3 times daily (120 mg 3 times daily usually required in Prinzmetal angina).Supraventricular arrhythmias: 40 to 120 mg3 times daily.Intravenous injectionAdult- Supraventricular arrhythmias: 5 to10 mg over 2 min (preferably with ECGmonitoring).Elderly- Paroxysmal tachyarrhythmias: 5 to 10 mg over 3 min, further 5 mg may be given after 5 to 10 min if required.","Hypotension, bradycardia, second- andthird-degree atrioventricular block, sinoatrialblock, sick sinus syndrome; cardiogenicshock; history of heart failure or significantlyimpaired left ventricular function (evenif controlled by therapy); atrial flutter orfibrillation complicating Wolff-Parkinson-White syndrome; porphyria; plateletdysfunction.","First-degree atrioventricular block; kidneyimpairment; cirrhosis patients; acute phaseof myocardial infarction (avoid if bradycardia,hypotension, left ventricular failure); hepaticimpairment (Appendix 7a); children (special-ist advice only); lactation; pregnancy (Appen-dix 7c); interactions (Appendix 6b, 6c).","Constipation; less commonly nausea,vomiting, flushing, headache, dizziness,fatigue, ankle oedema; rarely, allergicreactions (erythema, pruritus, urticaria,angioedema, Stevens-Johnson syndrome);myalgia; arthralgia, paraesthesia, increasedprolactin concentration; gynaecomastiaand gingival hyperplasia on long-termtreatment; with high doses, hypotension,heart failure, bradycardia, heart blockand asystole (due to negative inotropiceffect), impotence; hepatotoxicity;hyperprolactinemia; myoclonic dystonia.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Adenosine,Pregnancy Category-C,Schedule H,Coronary vasodilator, paroxysmal supraven-tricular tachycardia, cardiac imaging forcoronary artery disease, angina pectoris.,"TABLETS 40, 80 and 120 mg (DT); INJECTION2 ml ampoule (3 mg/ml).","Oral40 to 80 mg, 3 to 4 times daily (Max. 480 mg/ day).Rapid intravenous injection (into central or large peripheral vein)3 mg every 2 seconds with regular cardiac monitoring, if necessary, followed by 6 mg every 1 to 2 min. Increment should not be given if higher level AV block occurs at any particular dose","Second- or third-degree AV block and sicksinus syndrome (unless pacemaker fitted),acute myocardial infarction, cardiovascularshock; asthma.",Atrial fibrillation or flutter with accessorypathway (conduction down anomalouspathway may increase), heart transplant,pregnancy (Appendix 7c).,"Transient facial flush, chest pain, dyspnoea,bronchospasm, choking sensation, nausea,light-headedness; severe bradycardiareported (requiring temporary pacing); ECGmay show transient rhythm disturbances;edema; constipation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Amiodarone,Pregnancy Category-D,Schedule H,"Severe rhythmic disorder where othertherapies cannot be used includingtachyarrhythmia associated with Wolff-Parkinson-White syndrome, atrial flutterand fibrillation; all types of paroxysmaltachycardia",TABLETS 100 and 200 mg, INJECTION 3 mlampoule (50 mg/ml).,"Oral200 mg three times a day for one week, reduced to 200 mg twice daily for further one week. Maintenance 200 mg daily or reduced to minimum required to control arrhythmia.Intravenous infusion(with central venous catheter).Initially 5 mg/kg body weight over 20 to 120 min with ECG monitoring, subsequent infusion given if necessary according to response (up to max 1.2g in 24 h).","Sinus bradycardia, sino-atrial heart block;unless pacemaker fitted avoid in severeconduction disturbances or sinus nodedisease; thyroid dysfunction; iodinesensitivity; goitre; avoid intravenous usein severe respiratory failure, circulatorycollapse, severe arterial hypotension, avoidbolus injection in congestive heart failureor cardiomyopathy; lactation; pregnancy(Appendix 7c).",Liver-function and thyroid-function testsrequired before treatment and then every6 months, hypokalaemia (measure serum-potassium concentration before treatment),chest x-ray required before treatment, heartfailure, elderly, severe bradycardia andconduction disturbances in excessive dosage,intravenous use may cause moderate andtransient fall in blood pressure (circulatorycollapse precipitated by rapid administrationor overdosage) or severe hepatocellulartoxicity (monitor transaminases closely),ECG monitoring and resuscitation facilitiesmust be available during intravenous use,porphyria, interactions (Appendix 6d).,"Nausea, vomiting, taste disturbances, raisedserum transaminases (may require dosereduction or withdrawal if accompanied byacute liver disorders), jaundice; bradycardia;pulmonary toxicity (including pneumonitisand fibrosis); tremor, sleep disorders;hypothyroidism, hyperthyroidism; reversiblecorneal microdeposits (sometimes with nightglare); phototoxicity, persistent slate-greyskin discolouration; less commonly onsetor worsening of arrhythmia, conductiondisturbances, peripheral neuropathy andmyopathy (usually reversible on withdrawal);very rarely, chronic liver disease includingcirrhosis, sinus arrest, bronchospasm (inpatients with severe respiratory failure),ataxia, benign intracranial hypertension,headache, vertigo, epididymo-orchitis,impotence, haemolytic or aplastic anaemia,thrombocytopenia, rash (including exfoliativedermatitis), hypersensitivity includingvasculitis, alopecia, impaired vision due tooptic neuritis or optic neuropathy (includingblindness), anaphylaxis on rapid injection,also hypotension, respiratory distresssyndrome, sweating and hot flushes.",Store protected from light at temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Digoxin,Pregnancy Category-C,Schedule H,"Supraventricular arrhythmias, particularlyatrial fibrillation; heart failure",TABLET 0.25 mg, INJECTION 2 ml (0.5 mg/2ml), ELIXIR 0.05 mg/ml (paediatric use),SyRUP 1.5 mg/30 ml.,"OralAdult- Atrial fibrillation and heart failure: 1 to 1.5 mg in divided doses over 24 h for rapid digitalization or 250 µg 1 to 2 times daily if digitalization less urgent; maintenance 62.5 to 500 µg daily (higher dose may be divided), according to renal function and heart rate response; usual range 125 to 250 µg daily.Elderly- Lower dose more appropriate.Intravenous infusionEmergency control of atrial fibrillation, over at least 2 h: 0.75 to 1 mg.Emergency loading dose for heart failure, over at least 2 h: 0.75 to 1 mg.","Hypertrophic obstructive cardiomyopathy(unless also atrial fibrillation andheart failure); ventricular tachycardia;hypokalaemia; digitalis toxicity; arrhythmias;Wolff-Parkinson-White syndrome orother accessory pathway, particularlyif accompanied by atrial fibrillation;intermittent complete heart block; second-degree atrioventricular block.","Recent myocardial infarction; sick sinussyndrome; severe pulmonary disease;thyroid disease; congestive cardiacmyopathy; hypercalcaemia; aortic valvedisease, heart block, cardiac dysrrythmias;elderly (reduce dose); renal impairment(Appendix 7d); avoid hypokalaemia; avoidrapid intravenous administration (nausea andrisk of arrhythmias); lactation; interactions(Appendix 6c, 6d); pregnancy (Appendix 7c).","Usually associated with excessive dosageand include anorexia, nausea, vomiting,diarrhoea, abdominal pain; visualdisturbances, headache, fatigue, drowsiness,confusion, delirium, hallucinations,depression; arrhythmias, heart block; rarely,rash, intestinal ischaemia; gynaecomastia onlong-term use; thrombocytopenia reported;sinus bradycardia; apathy; psychosis;malaise.",Tablet: Store protected from light. Injection: Store protected from light in a single dose container. Solution: store protected from light at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Diltiazem , Esmolol",Pregnancy Category-C,,Supraventricular arrhythmias (short termtreatment), atrial fibrillation, flutter,tachycardia and hypertension in pre-operative period.,INJECTION 10 ml (100 and 250 mg).,Intravenous infusionUsually with a range of 50 to 200 µg/kg body weight/min under strict professional supervision of cardiologist.,"Asthma (important: see Bronchospasmbelow), uncontrolled heart failure,Prinzmetal's angina, marked bradycardia,hypotension, sick sinus syndrome, second-or third- degree AV block, cardiogenic shock,metabolic acidosis, severe peripheral arterialdisease; pheochromocytoma (apart fromspecific use with alpha-blockers).The Cardiovascular Society of Medicine has advised that beta-blockers, including those considered to be cardioselective, should not be given to patients with a history of asthma or bronchospasm. However, in rare situations where there is no alternative a cardioselective beta-blocker is given to these patients with extreme caution and under specialist supervision.","Avoid abrupt withdrawal especially inischaemic heart disease, first-degreeAV block, portal hypertension (risk ofdeterioration in liver function); diabetes;history of obstructive airways disease(introduce cautiously and monitor lungfunction); myasthenia gravis; symptomsof hypoglycaemia and thyrotoxicosis maybe masked; history of hypersensitivity-may increase sensitivity to allergens andresult in more serious hypersensitivityresponse, also may reduce response toadrenaline (epinephrine); reduce dose oforal propranolol in hepatic impairment; renalimpairment; lactation; pregnancy (Appendix7c); interactions (Appendix 6c).","Gastro-intestinal disturbances; bradycardia,heart failure, hypotension, conductiondisorders, peripheral vasoconstriction(including exacerbation of intermittentclaudication and Raynaud’s phenomenon);bronchospasm, dyspnoea; headache,fatigue, sleep disturbances, paraesthesia,dizziness, vertigo, psychoses; sexualdysfunction; purpura, thrombocytopenia;visual disturbances; exacerbation ofpsoriasis, alopecia; rarely, rashes and dryeyes (reversible on withdrawal); on infusionvenous irritation and thrombophlebitis;asthenia.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Isoprenaline,Pregnancy Category-C,Schedule H,"Severe bradycardia, unresponsive to atropine;short-term emergency treatment of heartblock; ventricular arrhythmias secondary toatrio-ventricular nodal block.",TABLETS 20 mg, INJECTION 1 ml ampoule (2mg/ml).,Slow intravenous injection2 mg/ml injection under strict professional supervision of cardiologist,Angina pectoris, tachycardia.,"Ischaemic heart disease, diabetes mellitus orhyperthyroidism; pregnancy (Appendix 7c).","Arrhythmias, hypotension, sweating,tremor, headache, palpitations, tachycardia,nervousness, excitability, insomnia.",Store protected from light at temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Lidocaine (Lignocaine),Pregnancy Category-B,,Ventricular arrhythmias (especially aftermyocardial infarction), local anaesthesia.,"INJECTION vial 30 ml (1, 2%w/v), 50 ml (21.3mg/ml); 2%/50 ml; ampoule 5%/2 ml. JELLy2% w/v OINTMENT 5% w/v","Adult- Ventricular arrhythmias: loading dose of 50 to 100 mg (or 1 to 1.5 mg/kg) at a rate of 25 to 50 mg/min by intravenous injection, followed immediately by intravenous infusion of 1 to 4 mg/min, with ECG monitoring of all patients (reduce infusion dose if required for longer than 24 h).","Sino-atrial disorder; any grade ofatrioventricular block or any other type ofconduction disturbances, severe myocardialdepression, acute porphyria or hypovolaemia,bradycardia, cardiac decompensation.","Lower dosage in congestive heart failure,bradycardia, ECG monitoring must duringtherapy, pediatrics; hypotension; renalimpairment; porphyria; debilitated patients;hepatic impairment (Appendix 7a); markedhypoxia; severe respiratory depression;following cardiac surgery and in elderly;lactation; interactions (Appendix 6c);pregnancy (Appendix 7c).","Dizziness; paraesthesia; drowsiness,confusion; apnoea, respiratory depression;coma; seizures and convulsions; hypotension,arrhythmias, heart block; cardiovascularcollapse and bradycardia (may lead tocardiac arrest); nystagmus often an earlysign of lidocaine overdosage; blurred vision,disorientation.",Store protcted from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Mexiletine,Pregnancy Category-C,Schedule H,Ventricular arrhythmias especially after myocardial infarction.,"CAPSULES 50, 100 and 150 mg;INJECTION 250 mg/10 ml","OralInitial dose; 400 to 600 mg, followed by 200to 250 mg after 2 h, 3 to 4 times a day.Intravenous infusionSlow i.v. infusion of 200 to 250 mg at the rate of 25 mg/min followed by i.v. infusion of 1 mg/min over 1 h.","Sinus node dysfunction; hepatic dysfunction;cardiogenic shock, myocardial infarction.","Hepatic; cardiac or renal failure; hypotension,bradycardia; interactions (Appendix 6d);pregnancy (Appendix 7c).","Dizziness; confusion; ataxia; bradycardia,hypotension, nausea; vomiting; constipation;palpitations; jaundice; hepatitis; dysarthria.",Store protected from light. Store injection in single dose containers,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Procainamide,Pregnancy Category-C,Schedule H,"Severe ventricular arrhythmias, especiallythose resistant to lidocaine or thoseappearing after myocardial infarction; atrialtachycardia, atrial fibrillation; maintenanceof sinus rhythm after cardioversion of atrialfibrillation.",TABLET 250 mg, INJECTION 10 ml ampoule/vial (100 mg/ml).,"OralAdult- Ventricular arrhythmias: up to 50 mg/kg daily in divided doses every 3 to 6 h, preferably controlled by monitoring plasma- procainamide concentration (therapeutic concentration usually within range of 3 to 10µg/ml).Atrial arrhythmias: higher doses may be required.Slow intravenous injection Ventricular arrhythmias: 100 mg at a rate not exceeding 50 mg/min, with ECG monitoring; may be repeated at 5 min intervals until arrhythmias controlled (max 1g).Intravenous infusion0.2 to 1g i.v.; 0.5 to 1g i.m. until oral therapy is possible.Ventricular arrhythmias: 500 to 600 mg over 25 to 30 min with ECG monitoring, reduced to maintenance dose of 2 to 6 mg/min; if further treatment by mouth required, allow interval of 3 to 4 h after infusion.","Asymptomatic ventricular prematurecontractions; torsades de pointes; systemiclupus erythematosus; heart block, heartfailure, hypotension; lactation; children;myasthenia gravis.","Elderly, renal and hepatic impairment(Appendix 7a), asthma, myasthenia gravis;blood dyscrasias; heart failure, cardiomy-opathy; cytopenia; digitalis intoxication;electrolyte imbalance; monitor blood countand ECG; pregnancy (Appendix 7c); lactation(Appendix 7b); use only under specialistsupervision; interactions (Appendix 6d).","Nausea, vomiting, diarrhoea, anorexia,rashes, pruritus, urticaria, flushing, fever,myocardial depression, heart failure,angioedema, depression, dizziness,psychosis; blood disorders includeleukopenia, haemolytic anaemia andagranulocytosis after prolonged treatment;lupus erythematosus-like syndrome; highplasma procainamide concentration mayimpair cardiac conduction; hypotension,heart block; hallucinations.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Quinidine,Pregnancy Category-C,Schedule H,Suppression of supraventricular arrhythmiasand ventricular arrhythmias, maintenanceof sinus rhythm after cardioversion of atrialfibrillation.,TABELTS 100 and 200 mg,OralInitial test dose of 200 mg to detect hypersensitivity to quinidine. Adult- Arrhythmias: 200 to 400 mg 3 to4 times daily, increased if necessary insupraventricular tachycardia to 600 mg every2 to 4 h (max. 3 to 4g daily), frequent ECGmonitoring required.,Complete heart block, myasthenia gravis, history of embolism.,"Partial heart block, extreme care inuncompensated heart failure, myocarditis,severe myocardial damage; myastheniagravis; acute infections or fever (symptomsmay mask hypersensitivity reaction toquinidine); lactation (Appendix 7b);pregnancy (Appendix 7c).","Hypersensitivity reactions, nausea, vomiting,diarrhoea, rashes, anaphylaxis, purpura,pruritus, urticaria, fever, thrombocytopenia,agranulocytosis after prolonged treatment,psychosis, angioedema, hepatotoxicity,respiratory difficulties; cardiac effectsinclude myocardial depression, heartfailure, ventricular arrhythmias andhypotension; cinchonism including tinnitus,impaired hearing, vertigo, headache, visualdisturbances, abdominal pain and confusion;lupus erythematosus-like syndrome.",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Amlodipine,Pregnancy Category-C,Schedule H,"Angina, hypertension, coronary arterydisease.","TABLETS 1.25, 2.5, 5, 7.5, 10 and 20 mg.","OralAngina:Adult- Initially 5 mg once daily, increased ifnecessary; max. 10 mg once daily.Hypertension:Adult- Initially 5 mg once daily, increased ifnecessary; max. 10 mg once daily.Elderly- Initial dose- 2.5 mg once daily","Significant aortic stenosis, sinoatrial nodedisease,hypersensitivitytodihydropyridines,cardiogenic shock, unstable angina;interactions (Appendix 6d).","Hypotension, myocardial infarction,impaired renal function sick-sinus syndrome,severe ventricular dysfunction, hypertrophiccardiomyopathy, severe aortic stenosis, eld-erly, children, pregnancy (Appendix 7c); lac-tation; hepatic impairment (Appendix 7a).","Arrhythmias, postural hypotension; dizziness,ankle edema, hypoesthesia, flatulence,dizziness, blurred vision, facial flushing,dyspnoea, asthenia, muscle cramps,conduction system delay, abdominal pain,headache; sleep disturbances, fatigue.",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Atenolol, Clonidine",Pregnancy Category-C,Schedule H,"Hypertension of all grades except pheochro-mocytoma, glaucoma and migraine.",TABLETS 100 and 150 µg.,"OralAdult- 75 to 225 µg/day in two divided doses, increase gradually every two weeks.Child- Not recommended.","Hypersensitivity; sinoarterial node disease,atrioventricular node disease","Depressive illness; concurrentantihypertensive therapy, cerebrovasculardisease; porphyria; interactions (Appendix6a, 6c); pregnancy (Appendix 7c).",Dry mouth, sedation, dizziness, nausea,nocturnal restlessness, occasionallyrashes, cardiac arrhythmias, systemiclupus erythmatosus, anxiety, constipation,abdominal pain, hallucination, impotenceand depression,Store injection in a single dose container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Enalapril,Pregnancy Category-D,Schedule H,Heart failure (with a diuretic), prevention ofsymptomatic heart failure and prevention ofcoronary ischaemic events in patients withleft ventricular dysfunction, hypertension,renal hypertension.,"TABLETS 2.5, 5 and 10 mg; INJECTION 1 mlampoule (1.25 mg/ml).","OralAdult- Hypertension: initially 5 mg once daily; if used in addition to diuretic.Heart failure, asymptomatic left ventricular dysfunction: initially 2.5 mg daily under close medical supervision; usual maintenance dose 20 mg daily in 1 to 2 divided doses.Elderly- Renal impairment: initially 2.5 mg daily. Usual maintenance dose 10 to 20 mg once daily; In severe hypertension may be increased to max. 40 mg once daily.","Hypersensitivity to ACE inhibitors (includingangioedema), renovascular disease, aorticstenosis; pregnancy (Appendix 7c).","Use with diuretics; hypotension with firstdoses; especially in patients on diuretics; ona low-Sodium diet; on dialysis; if dehydrated;or with heart failure; peripheral vasculardisease or generalized atherosclerosis(risk of clinically silent renovasculardisease); use with great care in severe orsymptomatic aortic stenosis; monitor renalfunction before and during treatment; renalimpairment (reduce dose; see also Appendix7d); liver impairment (Appendix 7a); possiblyincreased risk of agranulocytosis in collagenvascular disease; history of idiopathic orhereditary angioedema (use with care oravoid); lactation; interactions (Appendix6a, 6b, 6c); hypervolemia; patients withimmunosuppression; hyperkalemia.Risk of very rapid fall in blood pressure in volume-depleted patients; treatment should therefore be initiated with very low doses. High-dose diuretic therapy (furosemide dose greater than 80 mg) should be discontinued, or dose significantly reduced, at least 24 h before starting enalapril (may not be possible in heart failure-risk of pulmonary oedema). If high-dose diuretic cannot be stopped, medical supervision advised for at least 2 h after administration or until blood pressure stable.Avoid enalapril during dialysis with high-flux polyacrilonitrile membranes and during low- density lipoprotein apheresis with dextran sulphate ; also withhold before desensitization with wasp or bee venom.","Dizziness; headache; less commonlynausea; diarrhoea; hypotension (severe inrare cases); dry cough; fatigue; asthenia;muscle cramps; rash and renal impairment;rarely, vomiting; dyspepsia; abdominal pain;constipation; glossitis; stomatitis; ileus;anorexia; pancreatitis; liver damage; chestpain; palpitations; arrhythmias; angioedema;bronchospasm; rhinorrhoea; sore throat;pulmonary infiltrates; paraesthesia; vertigo;nervousness; depression; confusion;drowsiness or insomnia; pruritus; urticaria;alopecia; sweating; flushing; impotence;Stevens-Johnson syndrome; toxic epidermalnecrolysis; exfoliative dermatitis; pemphigus;taste disturbance; tinnitus; blurred vision;electrolyte disturbances and hypersensitivity-like reactions (including fever; myalgia;arthralgia; eosinophilia and photosensitivity)reported; azotemia; acute renal failure; tastedisturbances.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hydralazine,Pregnancy Category-C,,"In combination therapy in moderate tosevere hypertension, hypertensive crisis;hypertension associated with pregnancy(including pre-eclampsia or eclampsia);heart failure",TABLET 25 mg, INJECTION 20 mg/ml.,"OralAdult- Hypertension: 25 mg twice daily, increased if necessary to max. 50 mg twice daily.Slow intravenous injectionAdult- Hypertensive crisis (including during pregnancy): 5 to 10 mg diluted with 10 ml Sodium Chloride 0.9%; if necessary may be repeated after 20 to 30 min.Intravenous infusionAdult- Hypertensive crisis (including during pregnancy: initially 200 to 300 µg/min;maintenance usually 50 to 150 µg/min.","Idiopathic systemic lupus erythematosus;severe tachycardia, high output heart failure,myocardial insufficiency due to mechanicalobstruction; cor pulmonale; dissectingaortic aneurysm; porphyria; angina; mitralvalvular heart disease; rheumatic disease.","Hepatic impairment (Appendix 7a); renalimpairment; coronary artery disease (mayprovoke angina, avoid after myocardialinfarction until stabilized); cerebrovasculardisease; check acetylator status beforeincreasing dose above 100 mg daily; test forantinuclear factor and for proteinuria every6 months; coronary artery disease; alcoholintake; lactation (Appendix 7b); occasionallyover-rapid blood pressure reduction evenwith low parenteral doses; interactions(Appendix 6b, 6c); pregnancy (Appendix 7c).","Tachycardia, palpitations, posturalhypotension; fluid retention; gastrointestinaldisturbances including anorexia; nausea;vomiting; diarrhoea; rarely, constipation;dizziness; flushing; headache; abnormalliver function; jaundice; systemic lupuserythematosus-like syndrome; particularlyin women and slow acetylators; nasalcongestion; agitation; anxiety; polyneuritis;peripheral neuritis; rash; fever; paraesthesia;arthralgia; myalgia; increased lacrimation;dyspnoea; raised plasma creatinine;proteinuria; haematuria; blood disordersincluding haemolytic anaemia; leukopenia;thrombocytopenia; peripheral neuritis.",Store protected from light at temperature not exceeding 30⁰C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hydrochlorothiazide,Pregnancy Category-B,,Alone in mild hypertension and in combinationwith other drugs in moderate to severehypertension, heart failure, oedema, diabetesinsipidus.,"TABLETS 12.5, 25 and 50 mg.","OralAdult- Hypertension: 12.5 to 25 mg daily. Heart failure: initially 25 mg daily on waking up, increasing to 50 mg daily if necessary.Elderly- Initially 12.5 mg daily for hypertension as well as heart failure.",Severe renal or severe hepatic impairment,hyponatraemia, hypercalcaemia, refractoryhypokalaemia, symptomatic hyperuricaemia,Addison’s disease, gout, diabetes mellitus,persisting hypercalcaemia, anuria,sulphonamide allergy.,"Renal and hepatic impairment (Appendix7a); lactation (Appendix 7b); elderly (reducedose); may cause hypokalaemia; mayaggravate diabetes mellitus and gout; mayexacerbate systemic lupus erythematosus;porphyria; severe heart failure; edema;hyperlipidemia; interactions (Appendix 6a,6b, 6c); pregnancy (Appendix 7c).","Fluid and electrolyte imbalance leading to drymouth; thirst; gastrointestinal disturbances(including nausea; vomiting); weakness;lethargy; drowsiness; seizures; headache;muscle pains or cramps; hypotension(including postural hypotension); arrhythmias;hypokalaemia; oliguria; hypomagnesaemia;hyponatraemia; hypochloraemic alkalosis;hypercalcaemia; hyperglycaemia;hyperuricaemia; gout; rash; photosensitivity;altered plasma lipid concentration; rarely,impotence (reversible); blood disorders(including neutropenia; thrombocytopenia);pancreatitis; intrahepatic cholestasis; acuterenal failure; hypersensitivity reactions(pneumonitis; pulmonary oedema; severeskin reactions); increased heart rate andventricular ectopic activity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Losartan,Pregnancy Category-D,Schedule H,"Congestive heart failure, hypertension(myocardial infarction along with strokeincluding reduction of stroke risk inhypertension) with left ventricular hypertrophy,diabetic nephropathy in type II diabetes.","TABLETS 25, 50 and 100 mg","Hypertension and diabetic nephropathy: Adult- 50 mg once daily, increased to 100 mg daily as single dose or in two divided doses, if needed.Child- ≥ 6 years, initially 700 µg/kg, increased to a max. of 50 mg once daily, if needed. Elderly over 75 years initially 25 mg daily. Maintenance dose 25 to 100 mg orally in 1 to 2 divided doses.","Hyperaldosteronism, hypersensitivity,pregnancy (Appendix 7c), lactation, Notrecommended in children <6yrs of age orGFR <30 ml/min/1.73msq.","Pre-existing heart, liver or kidney diseases,diabetes, lactation, volume depletedpatients, renal artery stenosis, monitorserum potassium concentration, elderly,interactions (Appendix 6a).","Abdominal pain, edema, palpitation, backpain, dizziness, sinusitis, upper respiratorytract infection, rash, gastrointestinaldisturbances, transient elevation of liverenzymes, impaired renal function, tastedisturbances, hyperkalaemia, arthralgia,thrombocytopenia, vasculitis.",Store protected from light and moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Methyldopa,Pregnancy Category-B,Schedule H,Hypertension in pregnancy.,TABLET 250 mg,"OralAdult- Hypertension in pregnancy: initially250 mg 2 to 3 times daily; if necessary,gradually increased at intervals of 2 or moredays (max 3g daily).",Depression, active liver disease,hypersensitivity, therapy with MAOinhibitors, pheochromocytoma, porphyria.,"History of hepatic impairment (Appendix 7a);renal impairment; blood counts and liver-function tests advised; history of depression;positive direct Coomb test in up to 20% ofpatients (affects blood cross-matching);interference with laboratory tests; lactation;pregnancy (Appendix 7c); interactions(Appendix 6b, 6c).May impair ability to perform skilled tasks; for example operating machinery; driving.","Tend to be transient and reversible includingsedation; dizziness; lightheadedness;postural hypotension; weakness; fatigue;headache; fluid retention and oedema;sexual dysfunction; impaired concentrationand memory; depression; mild psychosis;disturbed sleep and nightmares; drugfever; influenza-like syndrome; nausea;vomiting; constipation; diarrhoea; drymouth; stomatitis; sialadenitis; liverfunction impairment; hepatitis; jaundice;rarely, fatal hepatic necrosis; bone-marrow depression; haemolytic anaemia;leukopenia; thrombocytopenia; eosinophilia;parkinsonism; rash (including toxic epidermalnecrolysis); nasal congestion; black orsore tongue; bradycardia; exacerbation ofangina; myalgia; arthralgia; paraesthesia;Bell palsy; pancreatitis; hypersensitivityreactions including lupus erythematosus-like syndrome; myocarditis; pericarditis;gynaecomastia; hyperprolactinaemia;amenorrhoea; urine darkens on standing.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Nifedipine,Pregnancy Category-C,Schedule H,Hypertension, angina prophylaxis, heartfailure, Raynaud’s phenomenon.,"TABLETS 5, 10, 20 and 30 mg plain and SR;CAPSULES 5, 10, 20 and 30 mg",OralAdult- Hypertension (as sustained-release tablets): usual range 20 to 100 mg daily in 1 to 2 divided doses.,"Cardiogenic shock, advanced aortic stenosis,within 1 month of myocardial infarction,unstable or acute attacks of angina,porphyria; hypersensitivity.","Stop if ischaemic pain occurs or existing painworsens shortly after starting treatment;poor cardiac reserve; heart failure or sig-nificantly impaired left ventricular function;monitor drug response in cirrhosis patients;blood pressure monitoring; calcium channelblockers; reduce dose in hepatic impairment;diabetes mellitus; may inhibit labour; lacta-tion (Appendix 7b); pregnancy (Appendix7c); interactions (Appendix 6b, 6c).",Headache, flushing, dizziness, lethargy,tachycardia, palpitations, gravitationaloedema (only partly responsive to diuretics),rash (erythema multiforme reported),pruritus, urticaria, nausea, constipationor diarrhoea, increased frequency ofmicturition, eye pain, visual disturbances,gum hyperplasia, paraesthesia, myalgia,tremor, impotence, gynaecomastia,depression, telangiectasis, cholestasis,jaundice, exacerbated angina, cardiovascularcollapse, ankle swelling, gastrointestinalupset, reversible gingival hyperplasia.,Store protected from light and moisture.,,,,,,,,,,,,,,,,,
"Propranolol, Ramipril",Pregnancy Category-D,Schedule H,"Reduction in risk of myocardial infarction,stroke and death from cardiovascular causes;hypertension; heart failure post myocardialinfarction.","TABLETS AND CAPSULES 1.25, 2.5, 5 and 10mg.","Reduction in risk of myocardial infarction, stroke, and death from cardiovascular causes: Initial dose of 2.5 mg, once a day for 1 week, 5 mg, once a day for the next 3 weeks, and then increased as tolerated, to a maintenance dose of 10 mg once a day.Hypertension: The recommended initial dose for patients not receiving a diuretic is 2.5 mg once a day. The usual maintenance dosage range is 2.5 to 20 mg per day administered as a single dose or in two equally divided doses.Heart failure post myocardial infarction: Initial dose is 2.5 mg twice daily, after one week at the starting dose titrate to ( if tolerated) toward a target dose of 5 mg twice daily, with dosage increases being about 3 weeks apart.","Hypersensitivity to ramipril or any other ACEinhibitor, bilateral renal artery stenosis ora single kidney with unilateral renal arterystenosis.","Impaired renal function, impaired liverfunction, diabetes mellitus (increased risk ofhyperkalemia), patients undergoing surgery,history of angioedema; symptomatichypotension is most likely to occur in patientswho have been volume- and/or salt-depletedas a result of prolonged diuretic therapy,dietary salt restriction, dialysis, diarrhoea,or vomiting. Volume and/or salt depletionshould be corrected before initiating therapy;monitoring of white blood cell counts shouldbe considered in patients with collagen-vascular disease, especially if the diseaseis associated with impaired renal function;administration during pregnancy (Appendix7c) can cause fetal/neonatal morbidity anddeath; when pregnancy is detected ACEinhibitors should be discontinued as soon aspossible, interactions (Appendix 6a and 6c).","Hypotension, cough, asthenia, dizziness,headache, angioneurotic edema,hypersensitivity reactions, erythemamultiforme, toxic epidermal necrolysis,Stevens Johnson syndrome, hepaticnecrosis, pancreatitis, pancytopenia,thrombocytopenia.",Store protected from moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sodium Nitroprusside,Pregnancy Category-C,Schedule H,"Hypertensive crisis (when treatment by mouthnot possible), congestive heart failure.",INJECTION ampoule/vial 5 ml (50 mg/ml).,Intravenous infusionAdult- Hypertensive crisis: initially 0.3 µg/kg/ min, usual maintenance dose 0.5 to 6 µg/kg/ min, max. dose 8 µg/kg/min, stop infusion if response is unsatisfactory after 10 min at max. dose, lower doses in patients already being treated with antihypertensives.,Compensatory hypertension, severe vitaminB12 deficiency, Leber optic atrophy, arterial venous shunting, patients with acute CHF associated with reduced peripheral vascular resistance.,Impaired pulmonary function,hypothyroidism, renal impairment, ischaemicheart disease, impaired cerebral circulation,hyponatraemia, raised intracranial pressure,elderly, hypothermia, monitor blood pressureand blood-cyanide concentration, alsoblood-thiocyanate concentration if given formore than 3 days, avoid sudden withdrawal(reduce infusion over 15-30 min to avoidrebound effects), pregnancy (Appendix 7c),lactation, interactions (Appendix 6b), hepaticimpairment (Appendix 7a).,"Severe hypotension; effects associatedwith over-rapid reduction in blood pressureinclude headache; dizziness; retching;abdominal pain; perspiration; palpitations;apprehension; retrosternal discomfort;rarely, reduced platelet count; acute transientphlebitis; muscle twitching; hypothyroidism;increased anaerobic metabolism.Adverse effects associated with excessive concentration of cyanide metabolite include tachycardia; sweating; hyperventilation; arrhythmias; marked metabolic acidosis (discontinue infusion and give antidote).",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,
Telmisartan,Pregnancy Category-C,Schedule H,Hypertension.,"TABLETS 20, 40 and 80 mg.",Adult- 40-80 mg once daily.,"Renal artery stenosis, pregnancy (Appendix7c), hyperkalemia.",Interactions (Appendix 6c). ,"Cough, angioedema. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Terazosin,Pregnancy Category-C,Schedule H,"Mild to moderate hypertension, benignprostatic hyperplasia.","TABLETS 1, 2 and 5 mg.","Hypertension:Adult-Initially 1 mg at bedtime (compliancewith bedtime dose is important, seeprecautions), gradually increase at 7 dayintervals. Maintainance dose- 2-10 mg oncedaily.Max. 20 mg daily in 1 or 2 divided doses.Benign prostatic hyperplasia:Adult- 1 mg at bedtime, gradually increase at7-day interval. Maintainance dose- 5-10 mgonce daily.Max. 20 mg daily.",Hypersensitivity.,"First dose syncope (should be taken justbefore retiring to bed), kidney disease, liverdisease, elderly, pregnancy (Appendix 7c),lactation, interactions (Appendix 6a).","Dizziness, drowsiness, fatigue, dyspnoea,blurred vision, postural hypotension,asthenia, nasal congestion, miosis, chestpain, urinary frequency, weight gain,thrombocytopenia, decreased libido, backpain and pain in extremities",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Abciximab,Pregnancy Category-C,Schedule H,Patients undergoing percutaneous coronaryinterventions.,INJECTION 5 ml vial (2 mg/ml).,0.25 mg/kg bolus followed by infusion of0.125 µg/kg per min (maximum 10 µg/min)for 12 to 24 h.,"Surgery within 10 days, including organbiopsy, puncture of noncompressiblevessels, serious trauma, cardiopulmonaryresuscitation, active bleeding, seriousgastrointestinal bleeding within 3 months,previous cerebrovascular accident or activeintracranial process, thrombocytopenia,severe uncontrolled hypertension, aorticdissection, acute pericarditis",Monitor platelet count forthrombocytopenia, interactions (Appendix6c), pregnancy (Appendix 7c).,"Bleeding, thrombocytopenia.","Store between 2-8⁰C, do not freeze.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Acetylsalicylic Acid,Pregnancy Category-D,,"Prophylaxis of cerebrovascular diseaseor myocardial infarction; pyrexia, pain,inflammation; arterial thromboembolismprophylaxis.",,OralAdult- Prophylaxis of cerebrovascular disease or myocardial infarction: 75 to 100 mg daily.,Hypersensitivity (including asthma,angioedema, urticaria or rhinitis) toacetylsalicylic acid or any other NSAID,children and adolescents under 16 years(Reye’s syndrome), active peptic ulceration,haemophilia and other bleeding disorders,hypoprothrombinemia,"Asthma; uncontrolled hypertension; historyof blood coagulation defects; lactation(Appendix 7b); interactions (Appendix 6a,6c, 6d), pregnancy (Appendix 7c), hepaticimpairment and renal impairment (Appendix7a and 7d).","Bronchospasm;gastrointestinalhaemorrhage(rarely, major); also other haemorrhage(for example subconjunctival); urticaria;hepatomegaly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Alteplase,Pregnancy Category-C,Schedule H,"Acute myocardial infarction, acute massivepulmonary embolism, acute ischaemicstroke.",INJECTION 20 and 50 mg/vial.,"IntravenousAcute myocardial infarctionAdult: The recommended total dose is 100mg. Administer as soon as possible after theonset of symptoms.Accelerated infusion (1.5 h): Max 100 mg;as a 15 mg intravenous bolus, followed by50 mg infused over the next 30 minutes, andthen 35 mg infused over the next 60 minutes.Patients <67 kg: total dose should be ≤1.5mg/kg; 15 mg as i.v bolus, then 0.75 mg/kg(up to a max of 50 mg) to be infused over 30minutes, and then 0.50 mg/kg over the next60 minutes not to exceed 35 mg.3-Hour Infusion: Max 100 mg; 60 mg in thefirst hour (of which 6 to 10 mg is administeredas a bolus) then 20 mg/h for 2 h. For patients< 65 kg, 0.75 mg/kg in 1st hour (including0.045-0.075 mg/kg bolus in first 1-2 minutes),then 0.25 mg/kg/h x 2 hours.Acute massive pulmonary embolismAdult: 100 mg (not >1.5 mg/kg for patientsweighing < 65 kg).First 10 mg as bolus followed by infusion ofthe remainder dose over 2 hours.Heparin therapy to be instituted orreinstituted near the end of or immediatelyfollowing the alteplase infusion when thepartial thromboplastin time returns to twicenormal or less.Acute ischemic strokeAdult: Use recommended within first 3 h ofonset of the symptoms. Infuse 0.9 mg/kg (upto a max. of 90 mg) over 60 minutes with 10%of the dose as bolus over the first minute.","Uncontrolled hypertension with possiblecerebrovascular haemorrhage, recentsurgery or trauma, susceptibility to internalbleeding, uncontrolled hypertension,esophageal varices, heavy vaginal bleeding,bleeding diathesis, active peptic ulceration.","Monitor for bleeding and BP in acutestroke.Caution in recent surgery or invasiveprocedures, diabetic hemorrhagicretinopathy, severe hepatic and renalimpairment, pregnancy (Appendix 7c),lactation, children, elderly, interactions(Appendix 6c).","Hemorrhage including intracranial,gastrointestinal or genitourinary bleeding,transient hypotension, reperfusiondysrythmias, cerebral edema, seizures,allergic-type reactions, nausea, vomiting.","Store protected from heat, light and moisture at room temperature (<30°C) or under refrigeration. Use reconstituted solution within 8 hours.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Clopidogrel,Pregnancy Category-B,Schedule H,"Prophylaxis in thromboembolic disordersincluding myocardial infarction, peripheralarterial disease and stroke, acute coronarysyndrome.",TABLETS 75 and 150 mg,Adult- 75 mg once daily.Non-ST segment elevation myocardial infarction: loading dose 300 mg followed by 75 mg once daily.,"Hypersensitivity, active pathological bleed-ing such as peptic ulcer or intracranial hem-orrhage, coagulation disorders, lactation.","Patient with increased risk of bleedingfrom trauma, surgery or other pathologicalconditions, ulcers, renal impairment,hepatic impairment, history of bleeding orhaemostatic disorder, pregnancy (Appendix7c); interactions (Appendix 6c).","Bleeding, neutropenia, thrombocytopenia,other bone marrow toxicity, diarrhoea, epi-gastric pain, rashes, paraesthesia, vertigo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Heparin, Streptokinase",Pregnancy Category-C,Schedule H,"Life-threatening deep-vein thrombosis,pulmonary embolism, acute arterial throm-boembolism; thrombosed arteriovenousshunts; acute myocardial infarction.","INJECTION (Powder for solution for injection)7,50,000 and 15,00,000 units vial.","Intravenous infusion.Adult- Thrombosis: 2,50,000 units over 30 min, followed by 1,00,000 units every h for 12 to 72 h according to condition with monitoring of clotting parameters.Myocardial infarction: 15,00,000 units over 60 min.",Recent haemorrhage, surgery (includingdental), parturition, trauma, heavy vaginalbleeding, haemorrhagic stroke, historyof cerebrovascular disease (especiallyrecent or if residual disability), coma,severe hypertension, coagulation defects,bleeding diatheses, aortic dissection, riskof gastrointestinal bleeding such as recenthistory of peptic ulcer, oesophageal varices,ulcerative colitis, acute pancreatitis, severeliver disease, acute pulmonary diseasewith cavitation, previous allergic reactions,pregnancy (Appendix 7c),Risk of bleeding from any invasive procedure,including injection, external chest compres-sion, abdominal aneurysm or where throm-bolysis may give rise to embolic complica-tions such as enlarged left atrium with atrialfibrillation (risk of dissolution of clot and sub-sequent embolization), diabetic retinopathy(small risk of retinal haemorrhage), recent orconcurrent anticoagulant treatment, plateletcount, fibrinogen level, thrombin and pro-thrombin time.,Nausea and vomiting, bleeding, usuallylimited to site of injection but internalbleeding including intracranial haemorrhagemay occur (if serious bleeding occurs,discontinue infusion-coagulation factorsmay be required), hypotension, arrhythmias(particularly in myocardial infarction),allergic reactions including rash, flushing,uveitis, anaphylaxis, fever, chills, back orabdominal pain, Guillain-Barré syndromereported rarely.,Store in a sealed container protected from light in refrigerator (2 to 8⁰C). The container should be sterile and sealed so as to exclude micro-organisms. Under these conditions the contents may be expected to retain potency for 2 years.,,,,,,,,,
Urokinase,Pregnancy Category-C,Schedule H,Acute myocardial infarction, pulmonaryembolism, deep vein thrombosis, peripheralvascular thrombosis, peripheral arterialthromboembolism, arterial thrombosis.,"INJECTION 20,000, 50,000, 2,50,000,5,00,000, 7,50,000 and 10,00,000 IU/vial.","Intravenous infusionDeep vein thrombosis: 4,400 units/kg body weight in 15 ml Sodium Chloride (0.9%w/v) over 10 min followed by 4,400 units/kg body weight for 12 to 24 h.Pulmonary embolism: 4,400 units/kg body weight in 15 ml Sodium Chloride (0.9%w/v) over 10 min followed by 4,400 units/kg body weight for 12 to 24 h, alternatively 15,000 units/kg body weight directly into the pulmonary artery initially, subsequent doses adjusted according to response, max. 3 doses in 24 h.",In recent haemorrhage, trauma, or surgery(including dental extraction), coagulationdefects, bleeding diatheses, aortic dissection,coma, history of cerebrovascular diseaseespecially recent events or with any residualdisability, recent symptoms of possible pepticulceration, heavy vaginal bleeding, severehypertension, active pulmonary disease withcavitation, acute pancreatitis, pericarditis,bacterial endocarditis, severe liver diseaseand oesophageal varices.,Should be used with caution if there is a riskof bleeding including that from venepunctureor invasive procedures. They should alsobe used with caution in external chestcompression, pregnancy (Appendix 7c),elderly, hypertension, abdominal aneurysmor other conditions in which thrombolysismight give rise to embolic complications suchas enlarged left atrium with atrial fibrillation(risk of dissolution of clot and subsequentembolisation), diabetic retinopathy (verysmall risk of retinal bleeding) and recent orconcurrent use of drugs that increase therisk of bleeding, hematocrit platelet count,thrombin and prothrombin time.,"Nausea; vomiting and bleeding. Whenused in myocardial infarction, reperfusionarrhythmias may occur. Hypotension canalso occur and can usually be controlled byelevating the patient's legs or by reducing therate of infusion or stopping it temporarily.Back pain; fever and convulsions havebeen reported. Bleeding is usually limitedto the site of injection; but intracerebralhaemorrhage or bleeding from othersites can occur. Serious bleeding calls fordiscontinuation of the thrombolytic and mayrequire administration of coagulation factorsand antifibrinolytic drugs (aprotinin ortranexamic acid). Rarely, further embolismmay occur (either due to clots that breakaway from the original thrombus or tocholesterol crystal emboli). It causes allergicreactions (including rash; flushing and uveitis)and anaphylaxis has also been reported.","Store in a sealed container protected from light in refrigerator (2 to 8⁰C). The container should be sterile, tamper evident and sealed so as to exclude micro-organisms.",,,,,,,,,,,,,,,,,,,,,,
Albumin,Pregnancy Category-C,,"Burns,hypoproteinaemia,shock,hypovolemia, acute liver failure, dialysis.","SOLUTION 5%, 10%, 20%.","Intravenous infusionFor hypovolemia: Adult- 25g,Child- 1g/kg.Max.- 2g of 20%/kg body weight.For hypoproteinaemia: Adult- 2g/kg daily. Usual rates of infusion: up to 5 ml/min (5%) or1 to 2 ml/min (20%)","Congestive heart failure, severe anaemia,history of allergic reactions to human albumin;pregnancy (Appendix 7c).","If dehydration is present additional fluidmust follow the administration of albumin.Administration of albumin should besupplemented or replaced by packed red bloodcells, history of cardiac or circulatory disease,increased capillary permeability.","Allergic (or) pyrogenic reactions, tachycardia,rash, anaphylactic shock, increasedsalivation.",Store protected from light at a tempreture between 2-25⁰C. Human albumin stored at 2-8⁰C may be expected to continue to meet the requirements of the monograph for five years from the date on which it was heated at at 60⁰C for 10 hours. Human albumin stored at a temperature not exceeding 25⁰C may be expected to meet the requirements of the monograph for three years from the date on which it was heated at 60⁰C for 10 hours.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Dextran 40,Pregnancy Category-C,Schedule H,"Plasma volume expansion during hypovolemicshock when blood not available, Prophylaxisof thromboembolic disorders to improve localcirculation in peripheral vascular occlusion.",INFUSION 10% dextran 40 + 5% dextrose or0.9% sodium chloride.,"IntravenousTo improve local circulation in peripheralvascular occlusion: Adult- 500-1000 ml (10-20 ml/kg) in first 24 hours; thereafter 500 mlevery 1-2 days for up to 2 weeks.Thromboembolism prophylaxis: Adult- 500-1000 ml (10-20 ml/kg) on day of surgery, then500 ml daily for 2-3 days, then 500 ml everysecond or third day, for up to 2 weeks.Shock: Adult- initially 500-1000 ml (10-20 ml/kg) infused as rapidly as needed; may followwith 500 ml (10 ml/kg) during the same 24hour period; thereafter 500 ml (10 ml/kg)may be repeated daily for up to 5 days.","Hypersensitivity, cardiac decompensation,oliguria or anuria, hemostatic defects,thrombocytopenia, blood coagulationdisorder, pulmonary oedema, neonates.","Renal and hepatic impairment, pregnancy(Appendix 7c), lactaion, diabetes, cardiacpatients, elderly, monitor urine output,monitor for signs of circulatory overload,interactions (Appendix 6c).","Nausea, vomiting, local injection sitereaction, hypersensitivity and anaphylactoidreactions, increased serum SGOT and SGPTconcentrations, osmotic nephrosis.",Store protected from light at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hydroxy Ethyl Starch,Pregnancy Category-C,,"Therapy for hypovolaemia, shock in surgery,trauma and infection to improve haemody-namics, macrocirculation, microcirculationand oxygen supply; improve organ function inblood loss.",INFUSION 300 and 500 ml.,Intravenous infusion500 to 1000 ml (daily max. 1500 ml),Renal failure, haemorrhage, coagulationdisorders, anuria, oligouria.,Should be used with caution in patientswith cardiac disease, liver disease, orrenal impairment, urine output should bemonitored. Care should be taken to avoidhaematocrit concentration from fallingbelow 25-30% and the patient should bemonitored for hypersensitivity reactions,bleeding disorder, sufficient fluid should beadministered to avoid dehydration, pregnancy(Appendix 7c).,"Hypersensitivity reactions may occurincluding; rarely,; severe anaphylactoidreactions; transient increase in bleeding timemay occur; headache; tachycardia; itching;fall in blood pressure.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Factor IX Complex (Coagulation Factors II, VII, IX, X) Concentrate",Pregnancy Category-C,,"Replacement therapy for factor IX deficiencyin haemophilia; bleeding due to deficienciesof factors II, VII or X.","INFUSION (Powder for solution for infusion),factor II, VII, IX and X 500 to1500 units.","Slow intravenous infusionAdult and child- Haemophilia B: according to patient’s needs. Treatment of bleeding due to deficiencies in factor II, VII or X as well as IX: according to patient’s need",Disseminated intravascular coagulation,hypersensitivity to any component of theproduct,Risk of thrombosis (probably less risk withhighly purified preparations), pregnancy(Appendix 7c), preexisting disease, checkheart rate, interactions (Appendix 6c).,Allergic reactions including chills, fever,hepatitis,pulmonaryembolism,disseminatedintravascular coagulation.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Factor VIII Concentrate,Pregnancy Category-C,,Control of haemorrhage in haemophilia A.,"INFUSION (Powder for solution for infusion),factor VIII 250 to 1500 units.",Slow intravenous infusionAdult and child- Haemophilia A, according to patient’s needs.,Hypersensitivity to any component of theproduct.,Intravascular haemolysis after large orfrequently repeated doses in patients withblood groups A, B, or AB (less likely withhigh potency, highly purified concentrates),pregnancy (Appendix 7c), check heart rate.,Allergic reactions including chills, fever,hepatitis, anaphylaxis, fulminating hepatitis.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tranexamic Acid,Pregnancy Category-C,Schedule H,"Prevention of hemorrhage due to dentalprocedures in hemophilics, cyclic heavymenstrual bleeding, hereditary angioedema,cone biopsy, epistaxis, traumatic hyphema","TABLETS- 250 mg, 500 mg and 1g.INJECTION- 100 mg/ml, 500 mg/5 ml.","Dental extraction in Hemophilics: Immediately before tooth extraction, 10 mg/ kg intravenously.Following tooth extraction, intravenous therapy, at a dose of 10 mg/kg body weight three to four times daily, may be used for 2 to 8 days.Menorrhagia: 1300 mg orally 3 times daily up to 5 days during menstruation.Cone biopsy: 1000-1500 mg 2-3 times daily for 12 days postop eratively.Epistaxis: 1000 mg 3 times daily for 7 days. Hyphema: 1000-1500 mg 2-3 times daily for 7 days.Hereditary angioedema: 1000-1500 mg 2-3 times daily.","Hypersensitivity, acquired defective colourvision, subarachnoid hemorrhage, activeintravascular clotting, pregnancy (Appendix7c), interactions (Appendix 6c).","Renal impairment, disseminatedintravascular coagulation, thromboembolichistory, coadministration with hormonalcontraceptives may increase risk ofthrombosis, stroke, or myocardial infarction;women using hormonal contraception shouldtake tranexamic acid only if there is a strongmedical need, and if the benefit of treatmentoutweighs risks. Ligneous conjunctivitis hasbeen reported. Retinal venous and arterialocclusion has been reported in patientsusing tranexamic acid. Patients shouldbe instructed to report visual and ocularsymptoms promptly.","Nausea, vomiting, diarhoea, disturbances incolour vision (discontinue), thromboembolicevents, allergic skin reactions; giddiness andhypotension on rapid intravenous injection,headache, backache, musculoskeletal pain.",Store protected from light and moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Heparin,Pregnancy Category-C,Schedule H,Treatment and prophylaxis of deep-veinthrombosis and pulmonary embolism, atrialfibrillation with embolism, treatment andprophylaxis of peripheral arterial embolism,prophylaxis of deep vein thrombosis in majorsurgery, lipemia clearing.,"INJECTION vials 1000, 5000 and 25,000 IU/ml.","Intravenous injectionAdult-Treatment of deep-vein thrombosis and pulmonary embolism: loading dose of 5000 units (10,000 units in severe pulmonary embolism) followed by continuous intravenous infusion of 15 to 25 units/kg/h. Child- 50 to 100U/kg every 4 to 6 h.Subcutaneous injection15,000 units every 12 h; laboratory monitoring is essential, preferably on a daily basis and dose adjusted accordingly.Prophylaxis in general surgery: 5,000 units 2 h before surgery, then every 8 to 12 h for 7 days or until patient is ambulant (monitoring not needed); during pregnancy (with monitoring) 5,000-10,000 units every 12 h.Child- 250 units/kg every 12 h.Intravenous injection and continuous intravenous infusion.Child- By intravenous injection: lower loading dose, then by continuous intravenous infusion; 15 to 25 units/kg/h.",Hypersensitivity to heparin, haemophiliaand other haemorrhagic disorders,thrombocytopenia, peptic ulcer, recentcerebral haemorrhage, severe hypertension,severe liver or renal disease, after majortrauma or recent surgery (especially to eye ornervous system), threatened abortion, piles,bacterial endocarditis, large malignancies,tuberculosis, lumbar puncture, chronicalcoholics, acetylsalicylic acid and otherantiplatelet drugs.,Hepatic impairment (Appendix 7a) and renalfailure, hypersensitivity to low molecularweight heparins, spinal or epiduralanaesthesia-risk of spinal haematoma,diabetes mellitus, acidosis, concomitantpotassium-sparing drugs-increased riskof hyperkalaemia, lactation, paediatrics,elderly, interactions (Appendix 6c),pregnancy (Appendix 7c).,"Immune-mediatedthrombocytopeniausuallydeveloping 6 to 10 days after commencementof therapy (requires immediate withdrawalof heparin); haemorrhage; skin necrosis;hypersensitivity reactions including urticaria;angioedema and anaphylaxis; osteoporosisafter prolonged use and rarely, alopecia;bleeding due to overdose.",Store at a temperature not exceeding 30⁰C,,,,,,,,,,,,,,,,,,,,
Phytomenadione,Pregnancy Category-C,Schedule H,"Antagonist to warfarin; prophylaxis againsthaemorrhagic disease of the newborn; vit Kdeficiency, hematuria, menorrhagia.",TABLETS 5 and 10 mg, INJECTION 10 mg/ml.,"Slow intravenous injectionAdult- Warfarin-induced hypoprothrom- binaemia, no bleeding or minor bleeding: 500 µg.OralFor vitamin K deficiency: 10 to 40 mg daily. Warfarin-induced hypoprothrombinaemia, no bleeding or minor bleeding: 5 mg.Oral or intramuscular injectionLess severe haemorrhage: 10 to 20 mg.Slow intravenous injectionSevere haemorrhage: 2.5 to 5 mg; very rarely, up to 50 mg (but risk of over correction with high dosage).Intravenous or intramuscular injectionChild- Neonates: Haemorrhagic disease of the newborn (treatment): 1 mg with further doses if necessary at 8 h intervals (prophylaxis).Intramuscular injectionChild- 0.5 to 1 mg as single dose.OralChild- 2 mg followed by a second dose after 4 to 7 days and for breastfed babies a third dose after 1 month.",Hypersensitivity.,Reduce dose in elderly, hepatic impairment,not an antidote to heparin, can causehaemolysis in patients with G-6-PD,increased risk of severe haemolytic anaemiain neonates after large doses, prematureneonates weighing < 2.5 kg, pregnancy(Appendix 7c).,Hypersensitivity reactions includingflushing, dyspnoea, bronchospasm,dizziness, hypotension and respiratory orcirculatory collapse which may be due topolyethoxylated castor oil surfactant in someinjection formulations rather than due tophytomenadione.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Protamine,Pregnancy Category-C,,Antidote to overdosage with heparin,antidote for heparin in controlled bleeding,SOLUTION 5 ml (1%), INJECTION 5 ml ampoule (10 mg/ml).,"Intravenous injectionHeparin overdose, over approximately 10 min; 1 mg neutralizes 80 to 100 units heparin when given within 15 min, if longer time, less protamine needed as heparin is rapidly excreted. 1 ml neutralises the effect of 1000 ml i.u. of circulating heparin; max. single dose 50 mg (5 ml).",,If used in excess protamine has ananticoagulant effect, allergic reactionsincreased in persons at risk including previoustreatment with protamine or protamineinsulin, fish allergies, men who are infertileor who have had a vasectomy, pregnancy(Appendix 7c), lactation, children.,Nausea, vomiting, lassitude, flushing,hypotension, bradycardia, dyspnoea,allergic reactions (including angioedema,anaphylaxis), allergy specially if previousexposure to protamine insulin, fish allergy,infertile or vasectomised men.,Store protected from light in a single dose container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Warfarin,Pregnancy Category-X,Schedule H,Prophylaxis of embolisation in rheumaticheart disease and atrial fibrillation,prophylaxis after insertion of prosthetic heartvalve, prophylaxis and treatment of venousthrombosis and pulmonary embolism,transient ischaemic attacks, myocardialinfarction, vulvular heart disease.,"TABLETS 1, 2 and 5 mg.","OralAdult- Prophylaxis and treatment of thromboembolic disorders; usual induction dose is 10 mg daily for 2 days, according to the individual patient; the subsequent dose depends upon the prothrombin time; the usual daily maintenance dose is 3 to 9 mg administered at the same time each day. Given as slow injection over 1 to 2 minutes into peripheral vein, initially 5 mg daily.For rapid anticoagulation: initially 10 mg daily for 2 days, maintenance dose 2 to 10 mg daily.",Pregnancy (Appendix 7c), peptic ulcer,severe hypertension, bacterial endocarditis,hypersensitivity, blood dyscrasias, recentsurgery, psychosis, pericardial effusion,cerebrovascular disorder, alcoholism,senility, aneurysm.,"Heparin induced thrombocytopenia; surgeryor trauma; Vit C, K; lactation; alcoholics;purple toes syndrome; discontinue if necrosisdevelops; elderly; hepatic impairment(Appendix 7a) or renal failure; recentsurgery; lactation (Appendix 7b); interactions(Appendix 6a, 6b, 6c, 6d).",Haemorrhage, hypersensitivity, rash,alopecia, diarrhoea, unexplained drop inhaematocrit, ‘purple toes’, skin necrosis,jaundice, hepatic dysfunction, nausea,vomiting and pancreatitis.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,
"Digoxin ,Dobutamine",Pregnancy Category-B,Schedule H,Acute heart failure, acute myocardialinfarction, cardiogenic shock followingcardiac surgery, specific shock, acutedecompensation of chronic CHF.,"INJECTION 250 mg/20 ml, 40 mg/ml, 12.5mg/ml, 5 ml ampoule (50 mg/ml), vial 250mg/20 ml, 50 mg/4 ml; 250 mg dry sterilelyophilised powder.",2.5 to 10 µg/kg/min which can be titrated to 40 µg/kg/min as per the individual requirement.,Hypersensitivity, idiopathic hypertrophicsubaortic stenosis.,Interactions (Appendix 6c), pregnancy(Appendix 7c), monitor heart rate andrhythm, arterial BP and infusion rate closely,correct hypovolemia prior to treatment,elderly, neonates, risk of rapid ventricularresponse in patients with atrial fibrillation,children.,"Tachycardia and marked increase in systolicblood pressure indicate overdosage;phlebitis; rarely, thrombocytopenia.",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Dopamine,Pregnancy Category-C,Schedule H,Cardiogenic shock in myocardial infarction orcardiac surgery, acute heart failure,"INJECTIONS 5 ml vial (40 mg/ml), 5 and 10ml ampoule (200 mg/5 ml).","Intravenous infusionAdult- Cardiogenic shock: into large vein, initially 2 to 5 µg/kg/min; gradually increased by 5 to 10 µg/kg/min according to blood pressure, cardiac output and urine output; seriously ill patients up to 20 to 50 µg/kg/ min. By intravenous route initially 1 to 5 µg/ kg/min can be increased gradually to 5 to 10 µg/kg/min. max 20 to 50 µg/kg/min in serious patients.","Hypersensitivity; tachyarrhythmias, ven-tricular fibrillation, ischaemic heart disease;pheochromocytoma; hyperthyroidism.",Correct hypovolaemia before and maintainblood volume during treatment, correcthypoxia, hypercapnia and metabolic acidosisbefore or at same time as starting treatment,lowdoseinshockduetomyocardialinfarction,history of peripheral vascular disease(increased risk of ischaemia of extremities),elderly, interactions (Appendix 6c), history ofatherosclerosis, Raynaud’s disease, diabeticendocarditis, dispropotionate increase indiastolic pressure, pregnancy (Appendix 7c),lactation, paediatrics. Dopamine must bediluted before i.v. administration.,Nausea and vomiting, peripheralvasoconstriction, hypotension with dizziness,fainting, flushing, tachycardia, ectopicbeats, palpitations, anginal pain, headache,dyspnoea, hypertension particularly inoverdosage.,Store in an airtight container protected from light.,,,,,,,,,,,,,,,,,,,,,,,,
Furosemide,Pregnancy Category-C,,Oedema, mild to moderate hypertension.,"TABLETS 40, 100 and 500 mg; INJECTIONampoule 20 mg/ml, 10 mg/2 ml, 250 mg/25ml, 20 mg/2 ml.","OralAdult- Oedema: initially 40 mg daily on waking up. Maintenance. 20 to 40 mg daily; may be increased to 80 mg daily or more in resistant oedema: max 600 mg daily in severe cases.Child- 1 to 3 mg/kg daily (max. 40 mg daily).Slow intravenous injectionAdult- Acute pulmonary oedema: 20 to 50 mg, if necessary increase by 20 mg step-by- step every 2 h; if effective single dose is more than 50 mg, at a rate not exceeding 4 mg/ min.Child- 0.5 to 1.5 mg/kg daily (max. 20 mg daily).Slow intravenous infusionAdult- Oliguria (glomerular filtration rate less than 20 ml/min): at a rate not exceeding 4 mg/min, initially 250 mg over 1 h.If urine output not satisfactory during the h after first dose, infuse 500 mg over 2 h then; if no satisfactory response is there in an h after second dose, infuse 1g over 4 h.If no response is there after third dose, dialysis is probably necessary.",Renal failure with anuria, precomatosestates associated with liver cirrhosis, severesodium and water depletion, hypersensitivityto sulphonamides and furosemide,hypokalaemia, addison’s disease, lactation.,"Monitor electrolytes particularly potassiumand Sodium; hypotension; elderly (reducedose); pregnancy (Appendix 7c); lactation;correct hypovolaemia before using in oliguria;renal impairment; hepatic impairment(Appendix 7a); prostatic enlargement;porphyria; interactions (Appendix 6b, 6c);gout; impaired micturition; infusion rateshould not exceed 4 mg/min to reduce therisk of ototoxicity; monitor serum levels forcalcium or magnesium (may be lowered).","Hypokalaemia; hypomagnesaemia; hyponat-raemia; hypochloraemic alkalosis (for symp-toms of fluid and electrolyte imbalance;see introductory notes); increased calciumexcretion; hypovolaemia; hyperglycaemia(but less often than with thiazide diuret-ics); temporary increase in plasma cho-lesterol and triglyceride concentration;less commonly hyperuricaemia and gout;rarely, rash; photosensitivity; bone marrowdepression (withdraw treatment); pancreati-tis (with large parenteral doses); tinnitus anddeafness (with rapid administration of largeparenteral doses and in renal impairment;deafness may be permanent if other ototoxicdrugs taken); gastrointestinal upset; malaise;blood dyscrasias; vertigo; orthostatic hypo-tension; jaundice; tinnitus; renal calcificationin premature infants.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Atorvastatin,Pregnancy Category-X,Schedule H,"Primaryand secondaryhypercholesterolemia,prevention of cerebrovascular accidents,primary prevention of coronary heartdisease.","TABLETS 5, 10, 20, 40 and 80 mg","OralAdult- 10 mg daily, increased at 4 weeks interval. Max dose 80 mg.","Hypersensitivity; active liver diseases orunexplained persistent elevation of serumtransaminase; pregnancy (Appendix 7c),lactation.","Patients who consume substantial quantitiesof alcohol and have a history of liver diseases,Children below 10 years, premenarchealfemales; interactions (Appendix 6a, 6c)","Myopathy is the serious adverse effect;headache; infrequent elevation of creatininephosphokinase; rhabdomyolysis; insomnia;dizziness; abdominal pain, constipation,diarrhoea, dyspepsia, flatulence and nausea.",Store protected from moisture at a tempreture not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ezetimibe,Pregnancy Category-C,,"Hypercholesterolemia, hyperlipidaemias,homozygous familial sitosterolaemia.",TABLETS 10 mg.,Adult- 10 mg once daily.10-18 years: 10 mg once daily.,"Hypersensitivity, children below 10 years,pregnancy (Appendix 7c), interactions(Appendix 6c, 6d), lactation, moderate tosevere liver disease or unexplained serumtransaminase elevation, acute pancreatitis.","Renal or mild hepatic impairment,immediately discontinue ezetimibe and anyH mg-CoA reductase inhibitor or fibrates ifmyopathy is diagnosed.","Diarrhoea, sinusitis, pharyngitis, cough,arthralgia, myalgia, respiratory infectionand fatigue, hepatitis/increased serumtransaminases, increased creatininephosphokinase, myopathy/rhabdomyolysis,headache, nausea, rash, dizziness, chestpain, abdominal pain with cramps, back pain,biliary calculus, thrombocytopenia.",Store protected from light and moisture at a temperature not exceeding 30⁰C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Fenofibrate,Pregnancy Category-C,Schedule H,"Hypercholesterolemia, hypertriglyceridemia.","CAPSULES 67 and 200 mg, TABLETS 145 and160 mg INJECTIONS 20, 40 and 60 mg/vial.",Hyperlipidemia:Adult- Initial dose 67 mg 2-4 times a day(micronized) or 200 mg/day in divided doses(non-micronized).Child- 5 mg/kg daily.,"Hypersensitivity, severe renal and hepaticimpairment, preexisting gall bladderdisease, primary biliary cirrhosis, pregnancy(Appendix 7c), lactation.",Pancreatitis, skeletal muscle effects, renaland hepatic impairement, monitor for LFTand blood counts regularly, interactions(Appendix 6c).,"Myalgia; hepatitis; rashes; cholelithiasis,rhabdomyolysis; increased SGPT and SGOT,abdominal pain, photosensitivity; rhinitis;sinusitis.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Nicotinic acid,Pregnancy Category-C,Schedule H,"High risk hyperlipidaemia, nicotinic aciddeficiency, peripheral vascular disease",Tablets 375 and 500 mg Plain and 375 mg SR.,"Oral Treatment and prophylaxis of nicotinic acid deficiency: Adult- 500 mg daily. Hyperlipidaemia: Adult- 1-2 g, two to three times daily, maximum dose- 6 g per day; (As extended release tablets max. dose is 2 g). Niacin should be started at low doses and increased slowly over several weeks. Peripheral vascular disease: Adult- 100- 150 mg, three to five times daily; (Extended release preparation-) 300-400 mg 12 hourly","Hypersensitivity, liver disease, severehypotension, diabetes, arterial bleeding.","Gout, hepatic dysfunction, children,pregnancy (Appendix 7c), lactation,myasthenia gravis, interactions (Appendix 6aand 6c).","Headache, diarrhoea, vomiting, fainting,peptic ulcer, hyperuricaemia, gout, toxicamblyopia, flushing, hyperpigmentation,dry skin, muscle pain, jaundice, pruritus,atrial fibrillation. Flushing can be blocked byadministering 300 mg of aspirin half an hourbefore taking niacin, or by taking one tabletof ibuprofen per day",Store protected from heat and moisture at room temperature,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Gentian Violet,Pregnancy Category-C,,Superficial fungal and bacterial infections.,SOLUTION 0.5%, TINCTURE 0.5%,Skin infections: apply 2 or 3 times daily for 2 to 3 days.,Sensitivity to gentian violet.,External use only, avoid contact with eyes, itcan dye skin, pregnancy (Appendix 7c).,"Redness, swelling; irritation; allergicreaction.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Neomycin + Bacitracin,Pregnancy Category-C,Schedule H,Superficial bacterial infections of the skin dueto staphylococci and streptococci,"CREAM 5, 10 and 15g (Aluminium tubes)",Adult and child- Bacterial skin infections over 2 years: apply as a thin layer 3 times daily.,Neonates,Avoid application to substantial areas of skinor to broken skin (risk of significant systemicabsorption), overgrowth of resistantorganisms on prolonged use, pregnancy(Appendix 7c),Sensitization, especially to neomycin,causing reddening and scaling, systemicabsorption leading to irreversible ototoxicity,particularly in children, elderly, and in renalimpairment, pregnancy (Appendix 7c).,Store protected from light at temperature not exceeding 30⁰C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Potassium Permanganate,,,"Wet dressings to assist healing of suppuratingsuperficial wounds, tropical ulcers, tineapedis infection, pemphigus, impetigo.","SOLUTION 1:10,000 (0.01% solution).","Suppurating superficial wounds and tropical ulcers: wet dressings of 1:10,000 (0.01%) solution, changed 2 or 3 times daily; tropical ulcers also require treatment for 2 to 4 weeks with procaine benzylpenicillin.Tinea pedis: soak severe weeping lesions in 1:10,000 (0.01%) solution every 8 h.Pemphigus: soak compresses in 1:10,000 (0.01%) solution and apply every 4 h.Impetigo: superficial crusts should be gently separated with a 1:10,000 (0.01%) solution.",Avoid occlusive dressings, interactions(Appendix 6d).,Irritant to mucous membranes, redness ofskin.,Local irritation, skin and fabrics stainedbrown,Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Silver Sulfadiazine,Pregnancy Category-B,Schedule H,Prophylaxis and treatment of infection inburns.,CREAM 1%w/w.,"Infection in burns: apply using aseptic technique daily (more frequently if volume of exudate is large) whilst there is a possibility of infection, or until healing is complete.",Hypersensitivity to sulfonamides, neonates,premature infants.,Renal or hepatic impairment, G-6-PDdeficiency, lactation (Appendix 7b), monitorserum sulphadiazine concentration andcheck urine for sulpha crystals, pregnancy(Appendix 7c),Allergic reactions include rashes, burningand itching, argyria and sulfonamide-induced systemic toxicity, including blooddisorders following application to large areasor prolonged use, transient leukopenia, skinnecrosis, skin discolouration.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Benzoic Acid + Salicylic Acid,Salicylic Acid Pregnancy Category-C,,"Mild dermatophyte infections, particularlycaused by Tinea pedis and Tinea corporis","CREAM 25 and 50g (Aluminium tubes, jars).",Fungal skin infections: apply twice daily until the infected skin is shed (usually at least 4 weeks).,,"Avoid contact with eye, nose and mouth,pregnancy (Appendix 7c)","Occasionally localized; mild inflammatoryreaction; swelling of face, lips and tongue;difficulty in breathing",Store at a temperature not exceeding 30⁰C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Miconazole,Pregnancy Category-C,Schedule H,"Superficial fungal infections due todermatophytes and yeasts, and secondaryinfections caused by Gram-positive cocci,including ringworm, intertrigo, candidanapkin rash, paronychia, and pityriasisversicolor.",CREAM 10 and 15g (2%), GEL 2% w/w.,"Skin infections: apply twice daily to clean dry lesions, continuing for at least 10 days after the condition has cleared.Nail infections: apply 1 to 2 times daily.",,Contact with eyes and mucous membranesshould be avoided, pregnancy (Appendix 7c).,Occasional local irritation and burning, alsocontact dermatitis, discontinue if sensitizationoccurs.,Store protected from light and moisture at a temperature not exceeding 30⁰C. If it is packed in aluminates, the inner surface of tubes should be coated with suitable lacquer.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sodium Thiosulphate,Pregnancy Category-C,,Pityriasis versicolor, cyanide poisoning.,SOLUTION 15%,Pityriasis versicolor: apply twice daily for 4 weeks.,,Pregnancy (Appendix 7c).,Mild temporary burning or stingning at siteof application.,Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Betamethasone,Pregnancy Category-C,Schedule H,"Severe inflammatory skin conditions inludingcontact dermatitis, atopic dermatitis(eczema), seborrhoeic dermatitis, lichenplanus, psoriasis of the scalp, hands andfeet, intractable pruritus; Addison’s disease,Simmond’s disease, bursitis",TABLETS 0.5 mg, INJECTION 1 ml ampoule(4 mg/ml), CREAM 0.1%, OINTMENT 0.1%,"Adult and child- Inflammatory skin conditions, over 2 years of age: apply small quantity to the affected area 1 to 2 times daily until improvement occurs, then less frequently.",Untreated skin infections or broken skin,rosacea, acne, perioral dermatitis, systemicinfections unless specific anti-infectivetherapy is employed.,Children (avoid prolonged use), adrenalsuppression if used on a large area of thebody or for a long time, particularly withan occlusive dressing or on broken skin,avoid use on the face for more than 7 days,secondary infection requires treatment withan appropriate antimicrobial, may impair theability to resist and counteract infections,diabetes mellitus, pregnancy (Appendix 7c),elderly, lactation (Appendix 7b),Exacerbation of local infection, localatrophic changes particularly on the faceand in skinfolds, characterized by thinningof the dermis, depigmentation, dilatationof superficial blood vessels and formationof striae, perioral dermatitis, acne atsite of application, suppression of thehypothalamic-pituitary-adrenal axis withprolonged or widespread use (particularlyunder occlusion), subcapsular cataract,osteoporosis, glaucoma, intracranialhypertension, psychic instability.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,
Calamine,,,Calamine,LOTION 50 and 100 ml (8%), CREAM 1g.,Mild pruritus: apply liberally 3 to 4 times daily.,,,,For lotion and Cream: Store at a temperature not exceeding 30⁰C. Do not freeze,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hydrocortisone,Pregnancy Category-C,Schedule H,"Contact dermatitis, atopic dermatitis(eczema), lichen planus; intractablepruritus and phototoxic reactions, includingpolymorphic light eruptions and actinicprurigo; short-term treatment of psoriasis ofthe face and flexures; ulcerative colitis",CREAM 10 and 15g (1%).,"Inflammatory skin conditions: apply a small quantity to the affected area 1 to 2 times daily until improvement occurs, then less frequently.",Untreated skin infections or broken skin,rosacea, acne, perioral dermatitis.,Children (avoid prolonged use), occlusivedressings increase penetration intokeratinized lesions (use occlusive dressingsonly at night and for no longer than 2 days,avoid use on weeping lesions), secondaryinfection requires treatment with anappropriate antimicrobial, latent pepticulcer, hypertension, hypothyroidism,psychic derangement, lactation (Appendix7b), interactions (Appendix 6d), pregnancy(Appendix 7c).,Exacerbation of local infection, atrophicchanges (see under Betamethasone)less likely with mild corticosteroids,but infants and children particularlysusceptible, fluid retention, hypokalaemia,osteoporosis, impaired wound healing,increased intracranial and intraoccularpressure,negative nirogen balance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Coaltar,Pregnancy Category-C,,"Chronic psoriasis, either alone or incombination with exposure to ultravioletlight; eczema.",CREAM 20g (1 - 6% w/w), LOTION 50 ml(1 - 6 %w/v).,"Psoriasis: apply 1 to 4 times daily, preferably starting with lower strength preparation.Coal tar bath; use 100 ml in bath of tepid water and soak for 10 to 20 min; use once daily to once every 3 days for at least 10 baths; often alternated with ultraviolet (UV) rays, allowing at least 24 h between exposure and treatment with coal tar.","Inflamed, broken or infected skin.",Skin protection possibly required to reducephotosensitivity reactions, avoid contactwith eyes, pregnancy (Appendix 7c).,"Irritation; photosensitivity reactions; rarely,hypersensitivity, skin; hair and fabricsdiscoloured; stinging.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Dithranol,Pregnancy Category-C,,Moderately severe psoriasis,"OINTMENT 30g (0.25, 0.5 and 1% w/w).","Psoriasis: initiate under medical supervision starting with 0.1%, carefully apply to lesions only, leave in contact for 30 min, then wash off thoroughly; repeat application daily, gradually increasing strength to 2% and contact time to 60 min at weekly intervals; wash hands thoroughly after use.",Hypersensitivity, avoid use on face, acuteeruptions, excessively inflamed areas,Irritant-avoid contact with eyes and healthyskin, not to be used in acute psoriasis,pregnancy (Appendix 7c).,Local irritation, discontinue use if excessiveerythema or spread of lesions, conjunctivitisfollowing contact with eyes, staining of skin,hair, and fabrics, stains skin.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5-Fluorouracil,Pregnancy Category-D,Schedule H,Actinic keratosis, genital warts unresponsiveto podophyllum resin, malignant disease.,CREAM 5%w/w,"Actinic keratosis, genital warts: apply thinly 1 to 2 times daily until marked inflammatory response occurs (usually 3 to 4 weeks); healing may require further 2 months after completion of treatment.",Haemorrhagic ulcerated tissue, patientswith dihydropyrimidine dehydrogenaseenzyme deficiency, pregnancy (Appendix7c), hypersnesitivity.,Avoid mucous membranes and eyes, since UVlight intensifies the inflammatory reaction,avoid prolonged exposure to sunlight,inflamed ulcerated skin, hepatic impairment(Appendix 7a), lactation (Appendix 7b),interactions (Appendix 6c).,"Local inflammatory and allergic reactions;rarely, erythema multiforme; photosensitivityreactions during and for up to 2 months aftertreatment; eye irritation.",Store protected from light. For injection: store protected from light in a single dose container at a temperature not exceeding 30⁰C. Injection should not be allowed to freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Isotretinoin,Pregnancy Category-X,,"Resistant and severe nodulocystic acne,dry scaly surface, mottling, wrinkles, roughand leathery texture, acute promyelocyticleukemia, actinic keratoses","TABLET 20 mg; CAPSULES 5, 10, 20, 30 and 40mg; CREAM 15 and 20 g (0.025 & 0.05%w/w);GEL 10 and 20 mg (0.05 & 0.025% w/w);OINTMENT 20 g (0.05% w/w)",OralAcneAdult: 0.5-1 mg/kg daily in 2 divided doses.Duration of treatment: 15-20 week, may bediscontinued if number of cysts is reducedby >70% (whichever is sooner). Patientsintolerant to initial dose: Treatment continuedat a lower dose. Patients with very severe acneor acne evident on the body instead of face:max dose of 2 mg/kg daily. There should bea 2-month drug-free interval if a 2nd courseis necessary.Topical/Cutaneous AcneAdult: As 0.05% gel: Apply sparingly once or twice daily. Effect may not be evident for 6-8 week.,"Female patients who are or may becomepregnant (Appendix 7c), lactation,hypersensitivity, acute eczematous, sunburntor abraded skin, hypervitaminosis of VitaminA, hyperlipidemia, pancreatitis.","Contraceptive measures must be followedfor any subsequent course of therapy,concomitant application with keratolyticagents, avoid exposure to sunlight and UVlight, renal and hepatic impairment, patientsand their relatives should be informed ofthe depressive symptoms and the samemay be actively assessed during each visitand appropriate action taken, interactions(Appendix 6c).","Dryness of skin and mucous membranes,pruritus, epistaxis, cheilitis, erythema,sometimes Stevens-Johnson syndrome,paresthesias, anxiety, conjunctivitis,paronychia, rise in serum lipids, pancreatitis,hypervitaminosis (however it is less thanthat of tretinoin), edema, hair thinning andintracranial tension leading to nausea andvomiting,hearingimpairment,hepatotoxicity,visual impairment. Psychiatric side effectssuch as depression, suicidal tendencies andpsychotic symptoms can occur frequently inadolescents and young adults.","Store protected from moisture, light and at a temperature 15-30⁰C.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Salicylic Acid,Pregnancy Category-C,,Hyperkeratotic conditions.,"TOPICAL SOLUTION 2%w/w, OINTMENT 6%,12%w/w.","Hyperkeratotic skin disorders: apply once daily, starting with lower strength preparations; gradually increase strength until satisfactory response obtained.",Broken or inflamed skin, children under 2years.,Diabetes mellitus or if peripheral bloodcirculation impaired, avoid contact witheyes, mouth, and mucous membranes, avoidapplication to large areas, iritated, loose/infected skin, pregnancy (Appendix 7c).,Local irritation, dermatitis, salicylism onexcessive application or treatment of largeareas, particularly in children, salicylic acidpoisoning, confusion, dizziness, headache,rapid breathing, ringing/buzzing in ears.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Urea,Pregnancy Category-D,,"Hydrating agent and keratolytic for dry,scaling and itching skin conditions","CREAM 10% in combination with other drugs(Aluminium tubes/jars) 20, 30 and 50g","Dry, scaling skin disorders: apply twice daily, preferably to damp skin",,Avoid application to face or broken skin, avoidcontact with eyes, pregnancy (Appendix 7c).,Transient stinging and local irritation,irritation to eyes, skin and respiratory tract.,Store protected from moisture. Store cream in accordance with the instructions of the manufacturer.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Benzyl Benzoate,,,"Scabies; head, body and pubic lice;pediculosis.",LOTION 100 ml (25% w/v), OINTMENT 25%w/w (25g).,Adult- Scabies: apply from neck down at night for 2 nights, on each occasion wash off after at least 24 h.Pediculosis: apply to affected area and wash off 24 h later, further applications possibly needed after 7 and 14 days.,Irritated skin, neonates, pregnancy.,Do not use on inflamed or broken skin, avoidcontact with eyes and mucous membranes,not recommended for children, lactation(withhold during treatment), apply belowneck only, elderly.,Local irritation, particularly in children,Store protected from light and air in well filled containers.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Gamma Benzene Hexachloride,Pregnancy Category-B,,"Pediculosis (but use for head lice is restricted by resistance), scabies.",LOTION 1%w/v, OINTMENT 1%w/w,CREAM 1%w/w, SHAMPOO 1%w/v.,"For pediculosis: As 1% preparation, apply to scalp and hair (taking care not to enter eyes), it should be massaged for 4 minutes and rinsed thoroughly.For scabies: Take a proper bath and dry your skin then apply lotion in a thin layer below the neck upto the sole of feet. Leave it for 8-12 hour and then take bath.",Seizure, hypersensitivity, skin inflammation,broken skin, premature infants, lactation,pregnancy (Appendix 7c).,"Seizure disorder; open wound or sores;neonates, infants below 2 years; avoidcontact with face, eyes; mucus membranesurethral meatus, psoriasis, elderly","Insomnia; paresthesia; giddiness,agranulocytosis, aplastic anaemia, skinirritation, contact dermatitis; ataxia; alopecia;severe neurologic toxicities; symptoms ofacute poisoning include nausea, vomiting,tremors, coma, convulsions and respiratoryfailure. Liver, kidney and myocardial toxicityhave been reported.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tuberculin Purified Protein Derivative,,,Used for test of hypersensitivity totuberculoprotein,Available at special clinics or by specialists,Intradermal injectionAdult and Child- 5 to 10 units (1 unit may be used in hypersensitive patients or if tuberculosis is suspected).,Should not be used within 3 weeks of receivinga live viral vaccine.,"Elderly; malnutrition; viral or bacterialinfections (including HIV and severetuberculosis),malignantdisease,corticosteroidor immunosuppressant therapy-diminishedsensitivity to tuberculin; avoid contact withopen cuts, abraded or diseased skin, eyes ormouth","Occasionally nausea, headache, malaise, rash;immediate local reactions (more common inatopic patients); rarely, vesicular or ulceratinglocal reactions, regional adenopathy andfever; necrosis, pruritis, pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Fluorescein,Pregnancy Category-B,,Detection of lesions and foreign bodies in theeye.,EyE DROPS 5 and 10 ml (2% w/v).,Ocular instillationAdult and Child- Detection of lesions and foreign bodies in eye: instill sufficient solution dropwise to stain damaged area.,Hypersensitivity, avoid use with soft contactlenses.,History of allergy or bronchial asthma,lactation, pregnancy (Appendix 7c),Gastrointestinal distress, hypotension,syncope, cardiac arrest, thrombophlebitis.,Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Lidocaine, Tropicamide",Pregnancy Category-C,,Dilatation of the pupil to examine the fundus,cycloplegia.,EyE DROPS 5 and 10 ml vial (0.08 & 1.0 %w/v).,"Ocular instillationAdult and Child- Dilatation of pupil to examine the fundus: 1 drop, 15 to 20 min before examination of eye.",,,,Store protected from light and moisture. For eye drops: store in a refrigerator (8 to 15⁰C). It should not be allowed to freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Barium Sulphate,,,Radiographic examination of the gastrointestinal tract,"DRY POWDER (to be administered with waterbefore procedure); SUSPENSIONS 100%w/v,250%w/v.",Adult and Child- Radiographic examination of gastrointestinal tract: route and dosage depend on procedure and preparation used (consult literature).,Intestinal obstruction, conditions such aspyloric stenosis or lesions which predisposeto obstruction, intestinal perforation orconditions with risk of perforation, suchas acute ulcerative colitis, diverticulitis, orafter rectal or colonic biopsy, sigmoidoscopyor radiotherapy, hypersensitivity,gastrointestinal haemorrhage, inflammation.,Adequate hydration after procedure toprevent severe constipation.,Constipation or diarrhoea, abdominal crampsand bleeding, perforation of bowel resultingin peritonitis, adhesions, granulomas andhigh mortality rate, electrocardiographicalchanges-may occur with rectaladministration, pneumonitis or granulomaformation-following accidental aspirationinto lungs, bloating, constipation, stomachpain, ringing in ears, nausea, vomiting, paleskin, weakness.,,,,,,,,,,,,,,,,,,,,,,,,,,,
Iopanoic Acid,,,Examination of gall bladder and biliary tract.,TABLET 500 mg.,"Oral Adult- 3g with plenty of water 10 to 14 h before examination; if examination needs to be repeated, a further 3g on the same day. Alternatively, repeat examination carried out after 5 to 7 days with single 6g dose. Avoid dose over 3g in case of renal impairment.",Severe renal disease and hepatic disease,jaundice caused by biliary-tract obstruction,impaired absorption due to acutegastrointestinal disorders.,Hypersensitivity to iodine-containingcompounds or other contrast media,severe hyperthyroidism, hyperuricaemiaor cholangitis, may interfere with thyroid-function tests, adequate resuscitationfacilities must be immediately availablewhen radiographic procedures are carriedout, interactions (Appendix 6c),Nausea and vomiting, abdominal pain anddiarrhoea, mild stinging on micturition,rashes and flushing, acute renal failure,thrombocytopenia and hypersensitivityreactions reported, also uricosuric andanticholinesterase effects.,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Meglumine Iotroxate,Pregnancy Category-D,,Examination of the gallbladder and biliarytract.,INJECTION 30 and 50 ml, SOLUTION 5-8g iodine in 100-250 ml.,Intravenous injectionAdult- Examination of gallbladder and biliary tract: 100 ml of meglumine iotroxate 10.5% solution over at least 15 min (consult literature).,Hypersensitivity to iodine-containingcompounds.,History of allergy, atopy or asthma, severehepatic impairment, renal impairment,dehydration-correct fluid and electrolytebalance before administration, multiplemyeloma (risk if dehydrated, may precipitatefatal renal failure), cardiac disease,hypertension,pheochromocytoma,sickle-celldisease, hyperthyroidism, elderly, debilitatedor children-increased risk of adverse effects,pregnancy, lactation, may interfere withthyroid-function tests, biguanides (withdraw48 h before administration, restart whenrenal function stabilized), because of riskof hypersensitivity reactions, adequateresuscitation facilities must be immediatelyavailable during radiographic procedures,pregnancy (Appendix 7c),"Nausea, vomiting, metallic taste; flushing;sensations of heat; weakness; dizziness;headache; cough; rhinitis; sweating; sneezing;lacrimation; visual disturbances; pruritus;salivary gland enlargement; pallor; cardiacdisorders, haemodynamic disturbances andhypotension or hypertension; convulsions;paralysis; coma; rigors; arrhythmias;pulmonary oedema; circulatory failure andcardiac arrest; occasionally anaphylactoid orhypersensitivity reactions; hyperthyroidism;pain on injection; extravasation mayresult in tissue damage; thrombophlebitis;thrombosis; venospasm and embolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,
Propyliodone,,,Examination of the bronchial tract.,SUSPENSION 20 ml ampoule (600 mg/ml).,Instillation into the lungsAdult- Examination of bronchial tract: consult literature.,Hypersensitivity to iodine-containingcompounds, severe heart disease.,Asthma, bronchiectasis, pulmonaryemphysema or reduced pulmonary function,use of excessive volume or too rapidadministration may result in lobar collapse,may interfere with thyroid-function tests,important: because of risk of hypersensitivityreactions, adequate resuscitation facilitiesmust be immediately available whenradiographic procedures are carried out.,"Pyrexia; malaise; arthralgia; cough;occasionally; dyspnoea; atelectasis; pneu-monia; rarely,; hypersensitivity reactions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Intraperitoneal Dialysis Solution,,,"Haemodialysis and peritoneal dialysis inrenal failure; acute pulmonary oedema withrenal insufficiency, cardiac dropsy.Peritoneal dialysisIt is preferred in children, diabetic patients, and patients with unstable cardiovascular disease; also used in patients who can manage their condition, or those who live far from a dialysis centre. Unsuitable for patients who have had significant abdominal surgery.The two forms of peritoneal dialysisa) Continuous Ambulatory Peritoneal Dialysis (CAPD), in which dialysis is performed manually by the patient several times each day.b) Automated Peritoneal Dialysis (APD), in which dialysis is performed by machine overnight.","lntraperitoneal dialysis solution withDextrose - 1.5% w/v, 2.5% w/v and 4.25%w/v.",,"Abdominal sepsis; previous abdominalsurgery; severe inflammatory bowel disease;pregnancy, excessive obesity; behaviouraldisturbances",Care required with technique to reduce riskof infection, warm dialysis solution to bodytemperature before use, some drugs may beremoved by dialysis, generalised peritonitis,traumatic abdominal lesions,"Infection including peritonitis; hernia;haemoperitoneum; hyperglycaemia,protein malnutrition; blocked catheter; fluidand electrolyte imbalance, disequilibriumsyndrome, muscle cramp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Azathioprine,Pregnancy Category-D,Schedule H,Rheumatoid arthritis in cases that have failedto respond to chloroquine or penicillamine,psoriatic arthritis, transplant rejection,inflammatory bowel disease,TABLET 50 mg.,"OralAdult- Rheumatoid arthritis and ankylosing spondylitis: 1.2g daily in 2 to 4 divided doses. Acute gout: 1.8g daily in divided doses until acute symptoms are resolved.Elderly over 60 years- Rheumatoid arthritis and ankylosing spondylitis: 300 mg twice daily. Acute gout: 1.8g daily in divided doses for the first 24 h, reduce to 600 mg daily in divided doses as soon as possible.Child- Not recommended.",Hypersensitivity to azathioprine ormercaptopurine,"Monitor throughout treatment includingblood counts; hepatic impairment (Appendix7a); renal impairment; elderly (reducedose); lactation (Appendix 7b); interactions(Appendix 6c, 6d); pregnancy (Appendix 7c).Patients should be warned to report immediately any signs or symptoms of bone marrow suppression; for example unexplained bruising or bleeding; purpura; infection; sore throat.","Hypersensitivity reactions requiringimmediate and permanent withdrawal includemalaise; dizziness; vomiting; diarrhoea; fever;rigors; myalgia; arthralgia; rash; hypotensionand interstitial nephritis; dose-related bonemarrow suppression; liver impairment;cholestatic jaundice; hair loss and increasedsuceptibility to infections and colitis in patientsalso receiving corticosteroids; nausea; rarely,pancreatitis and pneumonitis. hepatic veno-occlusive disease; herpes zoster infection.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Chloroquine,Pregnancy Category-D,Schedule H,Rheumatoid arthritis (including juvenilearthritis), malaria.,"TABLETS 150, 250 and 500 mg; SyRUP 100mg/5 ml; INJECTION 5 ml ampoule and 30 mlvial (40 mg/ml).",OralAcute rheumatoid arthritis including juvenile idiopathic arthritis: 150 mg/day (max. 2.5 mg/ kg/day).,Psoriatic arthritis.,"Monitor visual acuity throughout treatment;warn patient to report immediately anyunexplained visual disturbances; hepaticimpairment; renal impairment (Appendix 7d);lactation (Appendix 7b); neurological disordersincluding epilepsy; severe gastrointestinaldisorders; G-6-PD deficiency; elderly;may exacerbate psoriasis and aggravatemyasthenia gravis; porphyria; interactions(Appendix 6c, 6d)","Gastrointestinal disturbances; headache;skin reactions (rash; pruritus); less frequentlyECG changes; convulsions; visual changes;retinal damage; keratopathy; ototoxicity; hairdepigmentation; alopecia; discolouration ofskin; nails and mucous membranes; rarely,blood disorders (including thrombocytopenia;agranulocytosis; aplastic anaemia);mental changes (including emotionaldisturbances; psychosis); myopathy (includingcardiomyopathy and neuromyopathy); acutegeneralized exanthematous pustulosis;exfoliative dermatitis; erythema multiforme(Stevens-Johnson syndrome) and hepaticdamage; arrhythmias and convulsions inoverdosage",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Leflunomide,Pregnancy Category-X,Schedule H,"Active rheumatoid arthritis, psoriaticarthritis.",Tablet- 10 and 20 mg.,OralActive rheumatoid arthritis: Adults- 100mg once daily as loading dose for 3 days.Maintainance dose- 10-20 mg daily.,"Pregnancy (Appendix 7c), interactions (Appendix 6a and 6c).","Liver disease, kidney disease, heart disease,women of child bearing age, monitor bloodcounts and blood pressure regularly.May impair the ability to drive or operatemachinery.","Diarrhoea occurs in approximately 25% ofpatients, other adverse effect associated aremild alopecia, weight gain, increased bloodpressure. Leukopenia and thrombocytopeniaoccur rarely.","Store protected from heat, light and moisture at room temperature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Methotrexate,Pregnancy Category-X,Schedule H,Rheumatoid arthritis which has failed torespond to penicillamine or chloroquine,malignant disease.,"TABLETS 2.5, 5.0 and 7.5 mg; INJECTIONvial/ampoule 25 mg/ml and 100 mg/ml.","OralSevere active rheumatoid arthritis: 7.5 mg once weekly, adjusted according to response (max. weekly dose 20 mg).Intramuscular, subcutaneous or intravenous route in severe attack under expert medical supervision at a dose of 7.5 mg once weekly.",Lactation (Appendix 7b), pregnancy (Appendix7c), immunodeficiency syndromes, significantpleural effusion or ascites,"Monitor throughout treatment includingblood counts and hepatic and renal functiontests; renal and hepatic impairment (avoidif severe; see also Appendices 7a); reducedose or withdraw if acute infection develops;for woman or man; during contraceptionand for at least 6 months after treatment;peptic ulceration; ulcerative colitis; diarrhoea;ulcerative stomatitis; advise patient to avoidself-medication with salicylates or otherNSAIDs; warn patient with rheumatoid arthritisto report cough or dyspnoea; interactions(Appendix 6a, 6c, 6d).Patients should be warned to report immedi- ately any signs or symptoms of bone marrow suppression; for example unexplained bruising or bleeding; purpura; infection; sore throat.",Blood disorders (bone marrow suppression),liver damage, pulmonary toxicity,gastrointestinal disturbances-if stomatitisand diarrhoea occur, stop treatment, renalfailure, skin reactions, alopecia, osteoporosis,arthralgia, myalgia, ocular irritation,precipitation of diabetes.,Tablet: Store protected from light and moisture.Injection: store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
D-Penicillamine,Pregnancy Category-D,Schedule H,Severe rheumatoid arthritis, copper and leadpoisoning,CAPSULE/TABLET 250 mg.,"OralAdult- Severe active rheumatoid arthritis: initially 125 to 250 mg daily for one month, increased by increments of similar amount at intervals of not less than 4 weeks to usual maintenance dose of 500 to 750 mg daily in divided doses (max 1.5g daily). If remission sustained for 6 months, reduce daily dose (125 to 150 mg every 12week may be attempted).Elderly- Severe active rheumatoid arthritis: initially usual 125 mg daily for 1 month. Increase by increments of similar amount at intervals of not less than 4 weeks (max. 1g daily).Child- Severe active rheumatoid arthritis: maintenance dose of 15 to 20 mg/kg daily, initial amount at intervals of 4 weeks over a period of 3 to 6 months.",Hypersensitivity, lupus erythematosus, pregnancy (Appendix 7c).,Monitorthroughouttreatmentincludingbloodcounts and urine tests, renal impairment,avoid concurrent gold, chloroquine orimmunosuppressive treatment, avoid oraliron within 2 h of a dose.Patients should be warned to report immediately any signs or symptoms of bone marrow suppression, for example unexplained bruising or bleeding, purpura, infection, sore throat.,"Initially nausea (less of a problem if takenbefore food or on retiring; and if initial dose isonlygraduallyincreased);anorexia;fever;tasteloss (mineral supplements not recommended);blood disorders including thrombocytopenia;neutropenia; agranulocytosis and aplasticanaemia; proteinuria; rarely, haematuria(withdraw immediately); haemolytic anaemia;nephrotic syndrome; lupus erythematosus-like syndrome; myasthenia-like syndrome;polymyositis (rarely, with cardiacinvolvement); dermatomyositis; mouthulcers; stomatitis; alopecia; bronchiolitis andpneumonitis; pemphigus; glomerulonephritis(Goodpasture syndrome) and erythemamultiforme (Stevens-Johnson syndrome);male and female breast enlargement; rash(early rash disappears on withdrawingtreatment-reintroduce at lower dose andincrease gradually; late rash is more resistant-either reduce dose or withdraw treatment).",Store protected from moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sulfasalazine,Pregnancy Category-B,Schedule H,Severe rheumatoid arthritis, ulcerative colitis,Crohn’s disease.,TABLETS 500 and 1000 mg Enteric coated.,OralAcute rheumatoid arthritis: Adult- initially 500 mg daily increase by 500 mg at interval of one week (max. 2 to 3g in divided doses). Child- 40-50 mg/kg/day.,Hypersensitivity to salicylates andsulfonamides, severe renal impairment, childunder 2 years, porphyria,"Monitor during first 3 months of treatmentincluding blood counts and hepatic and renalfunction tests; lactation (Appendix 7b); historyof allergy; G-6-PD deficiency; slow acetylatorstatus; interactions (Appendix 6c, 6d);pregnancy (Appendix 7c).Patients should be warned to report immediately any signs or symptoms of bone marrow suppression; for example unexplained bruising or bleeding; purpura; infection; sore throat.","Nausea; diarrhoea; headache; loss of appe-tite; fever; blood disorders (including Heinzbody anaemia; megaloblastic anaemia; leu-kopenia; neutropenia; thrombocytopenia);hypersensitivity reactions (including rash; urti-caria; erythema multiforme (Stevens-Johnsonsyndrome); exfoliative dermatitis; epidermalnecrolysis; pruritus; photosensitization; ana-phylaxis; serum sickness; interstitial nephritis;lupus erythematosus-like syndrome); lungcomplications (including eosinophilia; fibros-ing alveolitis); ocular complications (includ-ing periorbital oedema); stomatitis; parotitis;ataxia; aseptic meningitis; vertigo; tinnitus;alopecia; peripheral neuropathy; insomnia;depression; hallucinations; kidney reactions(including proteinuria; crystalluria; haematu-ria); oligospermia; rarely, acute pancreatitis;hepatitis; urine may be coloured orange.",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Allopurinol,Pregnancy Category-C,Schedule H,Prophylaxis of gout, prophylaxis ofhyperuricaemia associated with cancerchemotherapy.,TABLET 100 mg.,"OralAdult- Initially 100 mg daily after food, thereafter adjust according to uric acid concentration. (Usual maintenance dose in mild conditions: 100 to 200 mg daily, in moderately severe condition: 300 mg daily given in divided doses).Child- Neoplastic conditions and enzyme disorders: 10 to 20 mg/kg daily (max. 400 mg).",Acute gout, if an acute attack occurs whilereceiving allopurinol, continue prophylaxisand treat attack separately.,"Ensure adequate fluid intake of 2-3 litresdaily; lactation (Appendix 7b); renal andhepatic impairment (Appendices 7d and7a); withdraw treatment if rash occurs;reintroduce if rash is mild but discontinueimmediately if it recurs; interactions(Appendix 6c, 6d); pregnancy (Appendix 7c).","Rash(seeprecautionsabove);hypersensitivityreactions occur rarely, and include fever;lymphadenopathy; arthralgia; eosinophilia;erythema multiforme (Stevens-Johnsonsyndrome) or toxic epidermal necrolysis;vasculitis; hepatitis; renal impairment.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Colchicine,Pregnancy Category-C,Schedule H,Acute gout, short-term prophylaxis duringinitial therapy with allopurinol.,TABLET 0.5 mg.,OralAcute gout: 1-2 tablets (0.5 mg each) can be given every 6-8 hours over several days with subsequent tapering. The drug must be stopped promptly at the first sign of loose stools and symptomatic treatment must be given for diarrhoea.Prophylaxis: 0.5 mg once or twice daily.,Pregnancy (Appendix 7c).,Elderly, gastrointestinal disease, cardiacimpairment, hepatic impairment, renalimpairment, lactation (Appendix 7b),"Nausea; vomiting; abdominal pain; excessivedoses may cause severe diarrhoea;gastrointestinal haemorrhage; rash; renaland hepatic damage; rarely, peripheralneuritis; myopathy; alopecia; inhibition ofspermatogenesis with prolonged treatment;blood disorders.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Amiloride,Pregnancy Category-B,Schedule H,"Oedema associated with heart failure orhepatic cirrhosis (with ascites), usually withthiazide or loop diuretic; hypertension.","TABLETS 5 mg (Amiloride) + 50 mg(Hydrochlorothiazide), 5 mg (Amiloride) + 40mg (furosemide).","OralOedema: used alone initially 10 mg daily in 1 or 2 divided doses, adjusted according to response (max. 20 mg daily).Combined with a thiazide or a loop diuretic: initially 5 mg daily, increasing to 10 mg if necessary (max. 20 mg daily).",Hyperkalaemia, renal failure, potassiumsupplementation,"Monitor electrolytes; particularly potassium;hypocholeremia, hepatic cirrhosis, renalimpairment (Appendix 7d); diabetes mellitus;elderly (reduce dose); lactation; interactions(Appendix 6b, 6c); pregnancy (Appendix 7c).","Hyperkalaemia;hyponatreamia(forsymptomsof fluid and electrolyte imbalance seeintroductory notes); diarrhoea; constipation;anorexia; paraesthesia; dizziness; minorpsychiatric or visual disturbances; rash;pruritus; rise in blood urea nitrogen;headache; abdominal pain, flatulence.",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Furosemide,Pregnancy Category-C,,Oedema, oliguria due to renal failure,pulmonary oedema, hypertension.,"TABLETS 40, 100, 200 and 500 mg; INJECTION2 ml (20 mg/ml).",OralAdult- Oedema: initially 40 mg daily on waking up, maintenance dose 20 to 40 mg daily, may be increased to 80 mg daily or more in resistant oedema.Child- 1 to 3 mg/kg daily (max. 40 mg daily).,Renal failure with anuria, precomatosestates associated with liver cirrhosis,hypersensitivity.,"Monitor electrolytes particularlypotassium and Sodium; hypotension;asymptomatic hyperuricaemia, systemiclupus erythmatosus, elderly (reduce dose);pregnancy (Appendix 7c); lactation; correcthypovolaemia before using in oliguria; renalimpairment; hepatic impairment (Appendix7a); prostatic enlargement; porphyria;interactions (Appendix 6b, 6c).","Hypokalaemia; hypomagnesaemia;hyponatraemia; hypochloraemic alkalosis(for symptoms of fluid and electrolyte im-balance; see introductory notes); increasedcalcium excretion; hypovolaemia; hyperg-lycaemia (but less often than with thiazidediuretics); temporary increase in plasmacholesterol and triglyceride concentration;less commonly hyperuricaemia and gout;rarely, rash; photosensitivity; bone marrowdepression (withdraw treatment); pancrea-titis (with large parenteral doses); tinnitusand deafness (with rapid administration oflarge parenteral doses and in renal impair-ment; deafness may be permanent if otherototoxic drugs taken); hepatic encephalopa-thy, anorexia, orthostatic hypotension.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hydrochlorothiazide,Pregnancy Category-B,,Oedema, diabetes insipidus, hypertension,heart failure,,"Oral Adult- Hypertension: 12.5 to 25 mg daily. Oedema: initially 25 mg daily on waking up, increased to 50 mg daily if necessary. Severe oedema in patients unable to tolerate loop diuretics: up to 100 mg either daily or on alternate days (max. 100 mg daily). Nephrogenic diabetes insipidus: initially up to 100 mg daily.Elderly- Hypertension: initially 12.5 mg daily. Oedema: initially 12.5 mg daily.",Same as in chapter 13.4.,Same as in chapter 13.4.,"Hypokalaemia; hypomagnesaemia; hyponat-raemia; hypochloraemic alkalosis (for symp-toms of fluid and electrolyte imbalance seeintroductory notes); hypercalcaemia; hyperg-lycaemia; hyperuricaemia; gout; rash; photo-sensitivity; altered plasma lipid concentration;rarely, impotence (reversible); blood disorders(including neutropenia; thrombocytopenia);pancreatitis; intrahepatic cholestasis and hy-persensitivity reactions (including pneumoni-tis; pulmonary oedema; severe skin reactions)also reported; acute renal failure.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Mannitol,Pregnancy Category-C,,"Cerebral edema, impending acute renal failure,acute poisonings, raised intraocular pressure(emergency treatment or before surgery).","INFUSION 5, 10 and 20%","Test dose (if patient is oliguric or if renal function is inadequate), By intravenous infusion as a 20% solution infused over 3–5 minutes, Adult and Child- 200 mg/kg; repeat test dose if urine output is less than 30–50 ml/h; if response is inadequate after a second test dose, re-evaluate the patient.Raised intracranial or intraocular pressure: By i.v infusion as a 20% solution infused over 30–60 minutes, Adult- 0.25–2g/kg; Child- 0.5–1.5g/kg.Cerebral oedema: By i.v infusion as a 20% solution infused rapidly,Adult and Child- 1g/kg.","Acidosis, congestive heart failure, pulmonaryoedema (particularly in diminished cardiacreserve), dehydration, inadequate urineflow, acute tubular necrosis, anuria, acuteleft ventricular failure, intracranial bleeding.",Patients with cardiovascular disease,hypervolemia, urinary tract obstruction,should not be given with whole blood,pregnancy (Appendix 7c).,"Headache, nausea, vomiting, dehydration,edema, hypernatraemia, inflammation,skin necrosis, urticaria, chills, convulsions,fluid and electrolyte imbalance, acidosis,circulatory overload, visual disturbance","Store at temperatures between 20⁰ and 30⁰C. Exposure to lower temperatures may cause the deposition of crystals, which should be dissolved by warming before use.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Spironolactone,Pregnancy Category-D,Schedule H,Refractory oedema in congestive heart failure,adjunct to ACE inhibitor and loop or thiazidediuretic in severe congestive heart failure,nephrotic syndrome, hepatic cirrhosis withascites and oedema, ascites associated withmalignancy, primary hyperaldosteronism.,TABLETS 25 and 100 mg,"OralAdult- Oedema: 100 to 200 mg daily, increased if necessary to 400 mg daily in resistant oedema; usual maintenance dose 75-200 mg daily.Primary hyperaldosteronism (diagnosis): 400 mg daily for 3 to 4 weeks. Preoperative management: 100 to 400 mg daily. If not suitable for surgery; lowest effective dose for long-term maintenance.Adjunct in severe heart failure: usually 25 mg daily.Child- Initially 3 mg/kg daily in divided doses.",Pregnancy (Appendix 7c), lactation,hyperkalaemia, hyponatraemia, severe renalimpairment, Addison’s disease, anuria.,"Monitor blood urea nitrogen and plasmaelectrolytes (discontinue if hyperkalaemia);concomitant administration of potassiumsparing diuretics and its inhibitors and NSAIDs,elderly (reduce dose); diabetes mellitus;renal impairment; hepatic impairment;porphyria; high doses carcinogenic inrodents; interactions (Appendix 6b, 6d).","Hyperkalaemia; hyponatraemia;hyperchloraemic acidosis; dehydration(for symptoms of fluid and electrolyteimbalance see introductory notes); transientincrease in blood urea nitrogen; diarrhoea;gynaecomastia; menstrual irregularities;impotence; hirsutism; deepening of voice;rash; ataxia; fever; hepatotoxicity; gastricbleeding, ulceration; agranulocytosis.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Alendronate,Pregnancy Category-C,Schedule H,"Treatment and prevention of postmeno-pausal osteoporosis, glucocorticoid-inducedosteoporosis, Paget’s disease","Tablet- 5, 10, 35, and 70 mg.","OralAdultTreatment of postmenopausal osteoporosis:5-10 mg daily or 35-70 mg weekly.Paget's disease: 40 mg once daily for sixmonths.Glucocorticoid-induced osteoporosis: 5mg once daily, except for postmenopausalwomen not receiving estrogen, for whomthe recommended dose is 10 mg once daily.","Esophageal dysmotility, esophagealobstruction, esophageal ulcer, hypocalcae-mia, hypersensitivity, lactation, pregnancy(Appendix 7c), interactions (Appendix 6c, 6d)","History of ulcers, hypocalcaemia, severerenal insufficiency, should be taken on anempty stomach and remain upright for notless than 30 minutes.","Oesophagitis, abdominal pain with cramps,abdominal swelling, constipation, diarrhoea,dysphagia, headache, myalgia, nausea,vomiting, peptic ulcer, flatulence, retrosternalpain, bodyache.","Store protected from heat, light and moisture at room temperature not exceeding 30⁰C.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Raloxifene,,Schedule H,Prevention and treatment of postmenopausalosteoporosis,TABLET 60 mg.,Prevention of post menopausal osteoporosis:Adult- 60 mg daily.,"Active or past history of venous thromboem-bolism including deep vein thrombosis;pulmonary embolism; retinal vein thrombo-sis; pregnancy (Appendix 7c), lactation.","Not to be used for primary or secondary pre-vention of cardiovascular disease; prolongedimmobilisation; CHF, active malignancy; priorstroke or transient ischemic attack, premen-opausal women, moderate/severe renal im-pairement, liver disease; history of estrogen-induced hypertriglyceridaemia; interactions(Appendix 6c).","Hot flushes; leg cramps; peripheral oedema,influenza-like symptoms; less commonlyvenous thromboembolism, thrombophle-bitis; rarely, rashes, gastro-intestinal distur-bances, hypertension, arterial thromboem-bolism, headache (including migraine); breastdiscomfort; thrombocytopenia; weight gain;endometrial carcinoma.",Store protected from light and moisture between 20-25⁰C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Strontium Ranelate,,,To reduce risk of fractures in postmenopausalosteoporosis.,Granules- 2g sachet,OralAdult- 2g once daily at bedtime preferably 2 hours after meals. Mix the granules in a glass of water and administer the suspension immediately after preparation.,"Hypersensitivity, phenylketonuria, severerenal impairment (creatinine clearance <30ml/min), patients at increased risk of venousthromboembolism","Pregnancy, lactation, children and elderly,interactions (Appendix 6c)","Nausea and diarrhoea are common;headache, eczema, transient reversibleincrease in creatine kinase activity,memory loss on long term use, venousthromboembolism, dermatitis are alsoreported.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Halothane,Pregnancy Category-C,Schedule H,Induction and maintenance of anaesthesia,"VOLATILE LIQUID 30, 50, 200, and 250 ml",Induction of anaesthesia using specially calibrated vaporiser, in oxygen or oxygen– nitrous oxide.Introductory dose: 0.5 to 3%.Maintenance dose: 0.5 to 1.5%.Adult- Increase gradually 2 to 4%.Child- 1.5 to 2%.Maintenance of anaesthesia using specially calibrated vaporiser, oxygen, oxygen–nitrous oxide 0.5 to 2%.,"History of unexplained jaundice or pyrexiafollowing previous exposure to halothane;family history of malignant hyperthermia;raised cerebrospinal fluid pressure;porphyria; not recommended for obstetricalanaesthesia, interactions (Appendix 6c)",Anaesthetic history should be carefully takento determine previous exposure and previousreactions to halothane (at least 3 monthsshould be allowed to elapse between eachre-exposure), avoid for dental proceduresin patients under 18 years unless treated inhospital (high risk of arrhythmias), pregnancy(Appendix 7c), lactation (Appendix 7b), renalfailure, hyperkalaemia.,Arrhythmias, bradycardia, respiratorydepression, hepatic damage, malignanthyperthermia, cyanosis, post operativenausea and vomiting.,Store protected from light at a temperature not exceeding 25⁰C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ketamine,Pregnancy Category-B,Schedule H,Induction and maintenance of anaesthesia,analgesia for painful procedures of shortduration especially for patients at the risk ofhypotension and branchospasm,INJECTIONS 2 ml ampoule (50 mg/ml),10 ml vial (10 and 50 mg/ml).,Intravenous injectionShort Procedures: Initially 6.5 to 13 mg/kg adjusted according to response (10 mg/kg usually produces 12 to 25 min. of surgical anesthesia).Procedures not involving intense pain: initially 4 mg/kg, (usual dose is 1 to 4.5 mg/ kg).Short procedure over at least 60 min: initially 4 mg/kg (2 mg/kg usually produces 5 to 10 min. of surgical anesthesia).Longer Procedure: induction by intravenous injection using solution containing 1 mg/ml.Longer procedure: induction dose 0.5 to 2 mg/kg, maintenance 10 to 45 mg/kg/min. rate adjusted according to response.,Thyrotoxicosis, hypertension (includingpre-eclampsia), history of cerebrovascularaccident, cerebral trauma, intracerebral massor haemorrhage or other cause of raisedintracranial pressure, open eye injury andincreased intraocular pressure, psychiatricdisorders, particularly hallucinations,hypersensitivity to the drug.,Supplementary analgesia often requiredin surgical procedures involving visceralpain pathways (morphine may be usedbut addition of nitrous oxide will oftensuffice), during recovery, patient mustremain undisturbed but under observation,lactation, children, alcohol intoxicatedpatients, increased CSF pressure, cardiacdecompensation, pregnancy (Appendix 7c).Warn patient not to perform skilled tasks, for example operating machinery or driving, for 24 h and also to avoid alcohol for 24 h.,"Hallucinations and other emergence reactionsduring recovery possibly accompanied byirrational behaviour (effects rarely, persist formore than few hour but can recur at any timewithin 24 h); transient elevation of pulse rateand blood pressure common; arrhythmiashave occurred; hypotension and bradycardiaoccasionally reported; confusion; delirium;mobilliformrash;transienterythema;diplopia;increased intraocular pressure; anorexia;nausea; vomiting; local pain and exanthemaat injection site; apnoea; laryngospasm.",Store protected from light at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,
Nitrous Oxide,Pregnancy Category-C,,Maintenance of anaesthesia in combinationwith other anaesthetic agents (halothane,ether, or ketamine) and muscle relaxants,analgesia for obstetric practice, foremergency management of injuries, duringpostoperative physiotherapy and forrefractory pain in terminal illness,INHALATIONAL GAS,Maintenance of anesthesia using suitable equipment up to 66% in oxygen.Analgesic use: 50% in oxygen or according to patient’s need.,Demonstrable collection of air in pleural,pericardial or peritoneal space, intestinalobstruction, occlusion of middle ear,arterial air embolism, decompressionsickness, chronic obstructive airway disease,emphysema.,Minimize exposure of staff, interactions(Appendix 6c), pregnancy (Appendix 7c).,Nausea and vomiting, after prolongedadministration megaloblastic anaemia,depressed white cell formation, peripheralneuropathy.,Store under pressure in metal cylinders of the type conforming to the appropriate safety regulations and at temperature not exceeding 37⁰C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Oxygen,,,To maintain an adequate oxygen tensio ininhalational anaesthesia.,INHALATIONAL GAS,(Oxygen is treated as drug since it is prescribed for hypoxemic patient to support alveolar oxygen in emergencies).40 to 60% oxygen using special oxygen therapy equipment.,,,Concentrations greater than 80% have a toxiceffect on the lungs leading to pulmonarycongestion, exudation and atelectasis.,Store under pressure in metal cylinder of the type conforming to appropriate safety regulations. Valves and taps should not be lubricated with oil or grease.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Propofol,Pregnancy Category-B,Schedule H,"Induction and maintenance of general anaesthesia, sedation.","INJECTIONS 10, 20 and 50 ml vials (10 mg/ml), 10 and 20 ml vials (20 mg/ml); Ampoule12, 20 and 50 ml (1%)","IntravenousInduction and maintenance of generalanaesthesia:Adult: Induction: 40 mg by injection orinfusion every 10 seconds. Usual dose: 2-2.5mg/kg. Maintenance: Infusion- 6-12 mg/kg/h, intermittent bolus injection - 20-50 mgas needed.Child: >3 years: Induction dose of 2.5-3.5mg/kg. Maintenance dose: 7.5-18 mg/kg/hby i.v infusionElderly: Including debilitated patients:Infuse at a rate of 20 mg every 10 seconds.Maintenance: 3-6 mg/kg/h.Sedation:Adult: In diagnostic and surgical procedures:Initially, 6-9 mg/kg/h by infusion given for3-5 minutes or an alternative dose of 0.5mg/kg by slow injection over 3-5 minutes.Maintenance: 1.5-4.5 mg/kg/h infusion.Reduce maintenance dose by 20% for high-risk patients needing sedation. For ventilatedpatients: 0.3 mg/kg/h by infusion, subsequentmaintenance dose: 0.3 – 3 mg/kg/h.","Sedationinchildrenandadolescents≤16years,Known hypersensitivity to propofol.","Cardiac impairment; respiratory impairment;elderly; hypovolaemia; epilepsy; hypotension;patients with high intracranial pressure; moni-tor blood-lipid concentration if risk of fat over-load or if sedation longer than 3 days; hepaticimpairment; renal impairment, pregnancy(Appendix 7c), interactions (Appendix 6c).","Apnoea, bradycardia, arrhythmias, hypoten-sion, anaphylaxis, rash, pruritus, involuntarymuscle movements, headache, pain, burningor stinging at injection site.",Store at a temperature not exceeding 30oC. It should not be allowed to freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Thiopental,Pregnancy Category-C,Schedule H,Induction of anaesthesia prior toadministration of inhalational anaesthetic,anaesthesia of short duration. Preferred ifcerebral ischemia is expected.,STERILE POWDER 500 mg and 1g/vial.,Slow intravenous injection3 to 5 mg/kg as 2.5% solution.Adult- over 18 year fit and premeditated: 10 to 150 mg.Child- 4 to 7 mg/kg.,Inability to maintain airway, hypersensitivityto barbiturates, cardiovascular disease,dyspnoea or obstructive respiratory disease,porphyria, hypotension or shock, Addison’sdisease, hepatic or renal dysfunction,increased blood urea, severe anaemia,asthma, myasthenia gravis.,Local extravasation can result in extensivetissue necrosis and sloughing, intra-arterialinjection causes intense pain and mayresult in arteriospasm, hepatic impairment(Appendix 7a), interactions (Appendix6a), pregnancy (Appendix 7c), patientswith advanced cardiac disease, increasedintracranial pressure, asthma, myastheniagravis, endocrine insufficiency.,Respiratory depression, myocardial depres-sion, cardiac arrhythmias, somnolence,bronchospasm, urticaria, vasodilation,apnoea, emergence delirium, headache,nausea, oedema.,Store in single dose container,,,,,,,,,,,,,,,,,
Bupivacaine,Pregnancy Category-C,Schedule H,Infiltration anaesthesia, peripheral andsympathetic nerve block, spinal anaesthesia,postoperative pain relief.,INJECTION 20 ml vial (0.25%, 0.5% and 1%).,Adult-Local: Infiltration using 2.5 mg/ml solution (max. 60 ml).Peripheral nerve block: 2.5 mg/ml solution (max. 20 ml) or 5.0 mg/ml solution (max. 30 ml).Epidural block: Lubricant surgery 5 mg/ml solution (max. 20 ml).Sympathetic nerve block: 2.5 mg/ml solution (max. 50 ml).,Adjacent skin infection, inflamed skin,concomitant anticoagulant therapy, severeanaemia or heart disease, spinal or epiduralanaesthesia in dehydrated or hypovolaemicpatient,Respiratory impairment, hepatic impairment(Appendix7a),epilepsy,porphyria,myastheniagravis, lactation, interactions (Appendix 6c),pregnancy (Appendix 7c).,With excessive dosage or followingintravascular injection, light-headedness,dizziness, blurred vision, restlessness,tremors and occasionally convulsions rapidlyfollowed by drowsiness, unconsciousnessand respiratory failure, cardiovascular toxicityincludes hypotension, heart block and cardiacarrest, hypersensitivity and allergic reactionsalso occur, epidural anaesthesia occasionallycomplicated by urinary retention, faecalincontinence, headache, backache or lossof perineal sensation, transient paraesthesiaand paraplegia very rare.,Store in single dose or multi-dose containers preferably of Type-I glass,,,,,,,,,,,,,,,,,,,,
Lignocaine,Pregnancy Category-B,,Surface anaesthesia of mucous membranes,infiltration anaesthesia, peripheral andsympathetic nerve block, dental anaesthesia,spinal anaesthesia, intravenous regionalanaesthesia, arrhythmias.,INJECTIONS 30 ml vial (1%) and 10 ml (5%/2ml) ampoule and 30 ml vial (2%), TOPICAL30 ml vial (4%), 30 ml vial (lignocaine 20 mgand adrenaline 5 mg/ml), GEL 2% and 4%,OINTMENT 5% w/w, SPRAy 15% w/w.INJECTIONS 2 ml ampoule (Lignocaine HCl53.3 mg and Dextrose 75 mg/ml) for spinalanaesthesia.,Induction of anaesthesia: By injection according to patient weight and nature of procedure. (max. 200 mg lignocaine or 500 mg with adrenaline).Local application: Rub gently on the affected area.,Adjacent skin infection, inflamed skin,concomitant anticoagulant therapy, severeanaemia or heart disease, spinal or epiduralanaesthesia in dehydrated or hypovolaemicpatient, hypersensitivity.,Respiratory impairment, hepatic impairment(Appendix 7a), epilepsy, porphyria,myasthenia gravis, avoid (or use with greatcare) solutions containing epinephrine(adrenaline) for ring block of digits orappendages (risk of ischaemic necrosis),lactation, pregnancy (Appendix 7c),interactions (Appendix 6c).,Same as Bupivacaine (above).,Store in a cool place.,,,,,,,,,,,,,,,,,,,,,,,,,
Atropine,Pregnancy Category-C,Schedule H,To inhibit salivary secretions, to inhibitarrhythmias resulting from excessive vagalstimulation,toblocktheparasympathomimeticeffects of anticholinesterases such asneostigmine, organophosphate poisoning,antispasmodic, mydriasis and cycloplegia.,INJECTION 10 ml (0.6 mg/ml).,Intravenous injectionAdult- 0.3 to 0.6 mg immediately before induc- tion of anaesthesia. Intra-operative bradycar- dia, 300 to 600 µg (longer dose in emergency). Inhibition of bradycardia, 0.4 to 1 mg. Reversal of neuromuscular block, 0.6 to 1.2 mg.Child- Premedication: 20 µg/kg, Inhibition of bradycardia: 10 to 30 µg/kg. Reversal of neuromuscular block: 20 µg/kg.Intramuscular route or subcutaneousPremedication (30 to 60 min before induction of anaesthesia): 300 to 600 µg.Child- 20 µg/kg (max. 60 µg). Intra operative bradycardia: (1 to 12 years) 10 to 20 µg/kg.,Angle-closure glaucoma, myasthenia gravis,paralytic ileus, pyloric stenosis, prostaticenlargement.,Down syndrome, children, elderly, ulcerativecolitis, diarrhoea, hyperthyroidism, heartfailure, hypertension, patients with atrialfibrillation or flutter, lactation (Appendix7b), interactions (Appendix 6a), pregnancy(Appendix 7c).Since atropine has a shorter duration of action than neostigmine, late unopposed bradycardia may result, close monitoring of the patient is necessary.,Dry mouth, blurred vision, photophobia,flushing and dryness of skin, rash, difficultyin micturition, less commonly arrhythmias,tachycardia, palpitations, confusion(particularly in elderly), heat prostrationand convulsions, ventricular fibrillation,hallucinations, dilated pupils, psychosis.,Store protected from light,,,,,,,,,
Diazepam,Pregnancy Category-D,Schedule H,Premedication before major or minorsurgeries, sedation with amnesia forendoscopic procedures and surgeries underlocal anaesthesia, emergency reduction offractures (in combination with pethidine whenanaesthetics are not available), epilepsy,anxiety disorders.,"TABLETS 2, 5 and 10 mg; CAPSULE 10 mg;INJECTION 2 ml ampoule (5 mg/ml).",OralAdult- 5 mg on night before surgery or minor procedure, thereafter 5 mg for 2h before procedures.Elderly- Half of adult dose.Intravenous injection10 to 20 mg over 2 to 4 min immediatelybefore procedure. Premedication: 100 to 200µg/kg.Child- 2.5 to 10 mg over 2 to 4 min.0.1 to 0.3 mg/kg in divided doses over 24 h, every 4 to 8 h (adjust according to response).,Central nervous system depression orcoma, shock, respiratory depression, acutepulmonary insufficiency, acute narrow angleglaucoma, sleep apnoea, acute alcoholintoxication, severe hepatic impairment,myasthenia gravis, pregnancy (Appendix 7c).,"Respiratory disease; muscle weakness;history of alcohol or drug abuse; markedpersonality disorder; elderly or debilitatedpatients (adverse effects more common inthese groups); hepatic impairment (Appendix7a) or renal failure; lactation (monitoringfor adverse effcts required Appendix 7b);porphyria; interactions (Appendix 6a, 6c);organic cerebral changes; epileptic patients.Warn patient not to perform skilled tasks; for example operating machinery; driving for 24 h.",Central nervous system effects common andinclude drowsiness, sedation, confusion,amnesia, vertigo and ataxia, hypotension,bradycardia, or cardiac arrest, particularly inelderly or severely ill patients, also paradoxicalreactions, including irritability, excitability,hallucinations, sleep disturbances, pain andthromboembolism on intravenous injection.,Store protected from light.,,,,,,,,,,,,,,,,,,,,
"Metoclopramide, Midazolam",Pregnancy Category-D,Schedule H,Intravenous sedative administered before orduring minor surgical procedures, sedativeadministered by intravenous route in intensivecare induction of anaesthesia.,INJECTION 1 ml ampoule (5 mg/ml), 5 and 10ml vial (1 mg/ml).,Slow intravenous injectionAdult- Conscious sedation: approximately 2 mg/min, 5 to 10 min before procedure,initially 2 to 2.5 mg. Usual total dose 3.5 to 5 mg (Max. 7.5 mg).Elderly- 0.5 to 1.0 mg. Increase if necessary in steps of 1 mg.Intravenous injection (Over 2 to 3 min) Child- 6 months to 7 years: initially 50 to 100µg/kg, increase if necessary in steps (max. totaldose 6.0 mg). 6 to 12 years: initially 25 to 50µg/kg increase in steps if necessary (max. totaldose 10 mg).Intramuscular injectionAdult- Sedation in combined anaesthesia:30 to 100 µg/kg repeated as required bycontinuous intravenous infusion 30 to 100 µg/kg/h (lower doses in elderly). Premedication:70 to 100 µg/kg.1 to 15 years: 50 to 150 µg/kg (max.1 mg).Elderly and debilitated- 25 to 50 µg/kg. (20 to60 min induction).,Acute narrow angle glaucoma, comatosepatients, shock, acute alcohol intoxication, forintrathecal and epidural use, acute pulmonaryinsufficiency, myasthenia gravis,"Chronic renal failure; cardiac disease; openangle glaucoma; respiratory disorders;neonates; prolonged use and abruptwithdrawal should be avoided; hepaticimpairment; pregnancy (Appendix 7c) andlactation; interactions (Appendix 6a, 6c).",Hypersensitivity,cardiacarrest,laryngospasm,apnoea, headache, hiccups, nausea, vomiting,cough, kernicterus, nystagmus, skin rash,CNS symptoms like euphoria, hallucination,ataxia,,,,,,,,,,,,,,,,,,,,,,,,,
Morphine,Pregnancy Category-C,"Schedule H, X",In severe pain (acute and chronic), myocardialinfarction, acute pulmonary oedema, adjunctduring major surgery and postoperativeanalgesia,"INJECTION 10 ml ampoule (1 mg/ml, 10 mg/mland 15 mg/ml); TABLETS 10, 20, 30 and 60 mg.",Subcutaneous or intramuscular injectionAdult- Preoperative medication before procedure: up to 10 mg, 60 to 90 min before procedure, 20 to 30 mg per 12 h depending on patient weight. Postoperative analgesia: 150 to 300 µg/kg every 4 h.Child- (By intramuscular injection) Preopera- tive medication before procedure: 150 µg/kg. Postoperative analgesia: 100 to 200 µg/kg.Intravenous injection Adult- Intra-operative analgesia: 100 µg/ kg, repeated every 40 to 60 min as required. Postoperative analgesia: 8 to10 mg over 30 min (slow intravenous infusion), then 2 to 2.5 mg/h.Child- Intra-operative analgesia: 100 µg/kg, repeated every 40 to 60 min as required.,"Patients with acute respiratory depressionand when there is risk of paralytic ileus;conditions associated with raised intracranialpressure and in head injury (they interferewith pupilary responses vital for neurologicalassessment); comatose patients; acuteasthma; acute liver disease; acute alcoholism;pulmonary oedema; interactions (Appendix6a, 6c, 6d); lactation (Appendix 7b); hepaticimpairment (Appendix 7a)",Patients with impaired respiratory function(avoid in chronic obstructive pulmonarydisease) and asthma (avoid during an acuteattack), hypotension, myasthenia gravis,prostatic hypertrophy and hyperplasia,obstructive or inflammatory bowel disorders,disease of the biliary tract and convulsivedisorders, pancreatitis, cardiac arrhythmias,hypothyroidism, head injury, circulatoryshock, lactation, pregnancy (Appendix 7c).,Nausea and vomiting (particularly in initialstages), constipation, dry mouth and biliaryspasm, larger doses produce muscle rigidity,hypotension and respiratory depression,bradycardia, paralytic ileus, abdominalpain, anorexia, dyspepsia, exacerbation ofpancreatitis, taste disturbance, hypertension,hypothermia, syncope, bronchospasm,inhibition of cough reflex, restlessness,seizures, paraesthesis, asthenia, malaise,disorientation, excitation, agitation, delirium,raised intracranial pressure, amenorrhoea,myoclonus, muscle fasciculation andrhabdomyolysis.,Store protected from light.
"Omeprazole, Promethazine",Pregnancy Category-C,Schedule G,Premedication prior to surgery, antiemetic,TABLETS 10 and 25 mg, SyRUP 60 ml (5 mg/5ml), INJECTION 2 ml ampoule (25 mg/ml).,"Oral Adult- Premedication: 25 mg at night and increase to 25 mg twice daily; if necessary; alternately 10 to 20 mg 2 to 3 times daily.Child- 2 to 5 years: not recommended. 5 to 10 years: 20 to 25 mg.Deep intramuscular routeAdult- 50 mg (max. 100 mg). Premedication: 25 to 60 mg 1 h before operation.Child- 5 to 10 years: 6.25 to 12.5 mg.Premedication, 5 to 10 years: 6.5 to 12.5 mg.Slow intravenous injectionIn emergencies: 25 to 50 mg as solution containing 2.5 mg/ml in water for injection (max. 100 mg).",Child under 1 year, impaired consciousnessdue to cerebral depressants or of other origin,porphyria.,"Prostatic hypertrophy; urinary retention;glaucoma; epilepsy; hepatic impairment(Appendix 7a); lactation (Appendix 7b);interactions (Appendix 6a); pregnancy(Appendix 7c).Warn patient not to perform skilled tasks; for example operating machinery, driving for 24 h.","Drowsiness (rarely, paradoxical stimulation inchildren); headache; anticholinergic effectssuch as dry mouth; blurred vision; urinaryretention.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Dicyclomine,Pregnancy Category-B,Schedule H,"Infantile colic, gastrointestinal tract spasm.",TABLETS 10 and 20 mg. DROPS 10 mg/ml,INJECTION 10 mg/ml.,OralAdult- 10-20 mg three times a day.ParenteralIM injection: 80 mg daily in 4 divided doses,"Glaucoma, reflux oesophagitis, myastheniagravis, lactation, intestinal obstruction.","Patients with mental depression and mentaldisturbances, hepatic or kidney disease, angleclosure glaucoma, hyperthyroidism, CHF,elderly, pregnancy, may impair the abilityto drive or operate machinery; interactions(Appendix 6c); pregnancy (Appendix 7c)","Dry mouth; nausea; vomiting; constipation;taste loss; anorexia; dizziness; dyskinesia;lethargy, respiratory arrest; drowsiness;photophobia, blurred vision; increased ocularpressure; tachycardia; urinary retention.","Injection: Store protected from light, in single dose or multiple dose containers. Tablets: Store protected from light",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hydrocortisone,Pregnancy Category-C,Schedule H,"Ulcerative colitis, proctitis, proctosigmoidi-tis; anaphylaxis; skin; adrenocortical insuf-ficiency",INJECTION 100 mg/vial, SUPPOSITORIES25 mg, RETENTION ENEMA 60 ml (Rectalsolution 100 mg/60 ml), CREAM 0.1% w/w.,"Rectal (suppositories)Adult- Ulcerative colitis, proctitis: 25 mg twice daily for 2 weeks; may be increased to 25 mg 3 times daily or 50 mg twice daily in severe cases; in factitial proctitis treatment may be required for 6 to 8 weeks.Rectal (retention enema) Adult- Ulcerative colitis, ulcerative proctitis, ulcerative proctosigmoiditis: 100 mg at night for 21 days or until clinical and proctological remission; if no clinical and proctological improvement after 21 days, discontinue; treatment for 2 to 3 months may be required for proctological remission; when used for more than 21 days, discontinue gradually using 100 mg every other night for 2 to 3 weeks.","Use of enemas in bowel obstruction, bowelperforation, or extensive fistulas; untreatedinfections.",Proctological examination required beforetreatment, systemic absorption may occur,prolonged use should be avoided, lactation(Appendix 7b), interactions (Appendix 6d),pregnancy (Appendix 7c).,Local pain or burning sensation, rectalbleeding (reported with use of enema),exacerbation of untreated infections,suppositories may stain fabrics, systemicadverse effects.,Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sulfasalazine,Pregnancy Category-B,Schedule H,Ulcerative colitis, Crohn’s disease, severerheumatoid arthritis, inflammatory boweldisease.,TABLETS 500 and 1000 mg.,"OralAdult- Ulcerative colitis: 1 to 2g 4 times daily in acute attack until remission, reducing to maintenance dose of 500 mg 4 times daily. Active Crohn's disease: 1 to 2g four times daily in acute attack until remission occurs.Child- Ulcerative colitis: over 2 years; 40 to 60 mg/kg daily in acute attack, reducing to maintenance dose of 20–30 mg/kg daily. Active Crohn disease: over 2 years, 40–60 mg/kg daily in acute attack",Hypersensitivity to salicylates orsulfonamides, child under 2 years, porphyria,intestinal or urinary obstruction, severerenal impairment, G-6-PD deficiency, blooddyscracias.,"Renal impairment; hepatic impairment;G-6-PD deficiency; slow acetylator status;monitor blood counts and liver functioninitially and at monthly intervals for first 3months; monitor kidney function initiallyand at intervals during treatment; history ofallergy; lactation (Appendix 7b); interactions(Appendix 6c, 6d).Patients should be advised to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise occurring during treatment; blood count should be performed and sulfasalazine stopped immediately if there is suspicion or evidence of blood disorder; pregnancy (Appendix 7c).","Nausea, exacerbation of colitis; diarrhoea,loss of appetite, fever; blood disorders(including Heinz body anaemia, megaloblast-ic anaemia, leukopenia, neutropenia, throm-bocytopenia); hypersensitivity reactions (in-cluding rash, urticaria, Stevens-Johnson syn-drome (erythema multiforme), exfoliativedermatitis, epidermal necrolysis, pruritus,photosensitization, anaphylaxis, serum sick-ness, interstitial nephritis, lupus erythema-tosus-like syndrome); lung complications(including eosinophilia, fibrosing alveolitis);ocular complications (including periorbitaloedema); stomatitis, parotitis; ataxia, asep-tic meningitis, vertigo, tinnitus, alopecia, pe-ripheral neuropathy, insomnia, depression,headache, hallucinations; kidney reactions(including proteinuria, crystalluria, haema-turia); oligospermia; rarely, acute pancreati-tis, hepatitis; urine may be coloured orange;some soft contact lenses may be stained.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Azathioprine,Pregnancy Category-D,Schedule H,Long term immunosuppression in Myastheniagravis,TABLET 50 mg.,"Adult- 1 to 3 mg/kg per day, discontinue if no improvement after 12 weeks.Child- 1 to 2 mg/kg/day.","Hypersensitivity, pregnancy (Appendix 7c); lactation (Appendix 7b).","Monitor liver function; hepatic impairment(Appendix 7a); WBC and platelets;interactions (Appendix 6c, 6d).","Nausea, fatigue; hair loss; rash; liverdysfunction; flu-like reaction.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cyclosporine,Pregnancy Category-C,Schedule H,"Long term immunosuppression, treatmentof Myasthenia gravis when prednisolone isineffective","CAPSULES 25, 50 and 100 mg; INJECTION50 ml ampoule (100 mg/5 ml) (50 mg/5 ml).",Adults- 2.5 mg/kg twice daily.,Hypersensitivity,"Monitor renal function and blood pressure;liver or kidney disease; blood disorders;diabetes; pregnancy (Appendix 7c), lactation(Appendix 7b); hepatic impairment (Appendix7a), interactions (Appendix 6b, 6c)","Nephrotoxicity; stomach upset, nausea,diarrhoea; hypertension; swollen gums;blurred vision; fever, chest pain; unusualbleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Mycophenolate Mofetil,Pregnancy Category-C,Schedule H,"Long term immunosuppression, treatmentof cases resistant to prednisolone or whereprednisolone is contraindicated.",TABLETS/CAPSULES 250 and 500 mg.,1g twice daily.,Hypersensitivity, allergy to polysorbate 80.,"Renal impairment; active disorders ofgastrointestinal tract; neutropenia;interactions (Appendix 6c, 6d); pregnancy(Appendix 7c)",Anaemia, electrolyte disturbances, dizziness,disturbances of blood lipids, gastrointestinaldisturbances,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Neostigmine,Pregnancy Category-C,Schedule H,Treatment of Myasthenia gravis,TABLET 15 mg, INJECTION 0.5 mg/ml.,OralAdult- 15 mg every 3 to 4 hrs. Total daily dose 75 to 300 mg in divided doses.Child- 2 mg/kg daily in divided doses every 3 to 4 hrs. Total daily dose 15 to 90 mg.Neonate- 1 to 5 mg every 4 hour.IntramuscularAdult- 0.02 mg/kg as a single dose.Child- 0.04 mg/kg as a single dose.IntravenousAdult- 0.5 to 2.5 mg to a total daily dose of 5-20 mg.Child- 200 to 500 µg as single daily dose.Neonate- 50 to 250 µg every 4 hour,Mechanical gastrointestinal or urinary tract obstruction, peritonitis,"Renal impairment; peptic ulcer; lactation(Appendix 7b); heart blockage, slow heart-beat; bradycardia, hypotension; urinary tractinfection; epilepsy; asthma; interactions (Ap-pendix 6c); pregnancy (Appendix 7c).","Abdominal cramps, diarrhoea; pupildilatation; excess saliva; headache; jointpain; severe allergic reactions; fainting;interrupted breathing; irregular heart beat;seizures; vision changes; anxiety",Tablets: Store protected from light and moisture. Injection: Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Prednisolone,Pregnancy Category-C,Schedule H,"Effective long term immunosuppression inpyridostigmine resistant patient, refractoryocular Myasthenia gravis.","TABLETS 4, 8, 5, 10, 16, 20 and 40 mg;SyRUP 30, 40 and 60 ml; INJECTION vial 40mg/ml; EyE DROPS 1% w/v.",Initially 20 mg four times daily.Maximum dose 50 mg four times daily.,Hypersensitivity, systemic infections including tuberculosis.,"Monitor weight; blood pressure, bloodglucose and electrolytes, antibioticcoverage may be required, doses shouldbe tapered and not withdrawn suddenly;hepatic impairment (Appendix 7a); lactation(Appendix 7b); pregnancy (Appendix 7c);interactions (Appendix 6c, 6d)","Initial transient exacerbation; elevation ofintraocular pressure; optic nerve damage;posterior subcapsular cataract formation;delayed wound heeling; weight gain; moonface; avascular necrosis; osteoporosis;psychosis and mood change, increasedchance of opportunistic infections","Tablets: Store protected from light.Injection: Store protected from light, in asingle dose or in multi dose containers.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pyridostigmine,Pregnancy Category-C,Schedule H,"Treatment of Myasthenia gravis, neonatalMyasthenia gravis.",TABLETS 30 and 60 mg Plain, 180 mg SR,INJECTIONS 10 mg/2 ml.,OralAdult- 0.3 to 1.2g daily in divided doses. Children under 6 yrs- Initially 30 mg. Children 6-12 yrs- Initially 60 mg. Increase by15 to 30 mg daily until control. Neonate- 5 to 10 mg given every 4 to 6 hours.IntramuscularChild- 50 to 150 µg/kg every 4 to 6 hours,Recent intestinal or bladder surgery,gastrointestinal or urinary tract obstruction,after suxamethonium, pneumonia,peritonitis,Asthma,urinarytractinfection,cardiovasculardisease including arrhythmias (especiallybradycardia or atrioventricular block),hyperthyroidism, hypotension, peptic ulcer,epilepsy, parkinsonism, avoid intravenousinjection, renal impairment, pregnancy(Appendix 7c), lactation.,"Muscarinic effects generally weaker thanwith neostigmine: increased salivation,nausea, salivation, vomiting, abdominalcramps, diarrhoea; signs of overdosageinclude bronchoconstriction, increasedbronchial secretions; lacrimation, excessivesweating, involuntary defecation andmicturition, miosis, nystagmus; bradycardia,heart block, arrhythmias, hypotension;agitation, excessive dreaming, weaknesseventually leading to fasciculation andparalysis, thrombophlebitis; rash associatedwith bromide salt; diaphoresis, increasedperistalsis",Store protected from light and moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Aminophylline,Pregnancy Category-C,,"Status asthmaticus, chronic obstructivepulmonary disease (COPD), reversible airwayobstruction, chronic bronchitis, pulmonaryedema, adjunct in treating CHF, apnoea inpremature infants","TABLETS 100, 200, 225, and 350 mg;INJECTION 10 ml (250 mg/2 ml, 25 mg/ml);ORAL LIQUID 105 mg/5 ml; SUPPOSITORy250 mg, 500 mg.",Parenteral/OralAdult- 250-500 mg orally or by slow i.v injection. Loading dose- 5 mg/kg.Maintainance dose- 0.5 mg/kg/h.Child- (6 months – 9 years) 1 mg/kg/h.(10 – 16 years) 800 µg/kg/h,Hypersensitivity to theophyllines,"Alcohol dependence; hyperthyroidism;peptic ulcer; febrile illness; patients withsevere heart, liver or kidney disease; lactation(Appendix 7b); renal impairment (Appendix7d); interactions (Appendix 6c); congestiveheart failure; neonates and elderly patients;epilepsy; high blood pressure; glaucoma;diabetes; allergies, pregnancy (Appendix 7c).","Convulsions; hypokalemia; dizziness,headache; palpitation, tachycardia,diarrhoea; anxiety; urinary retention;restlessness; tremors; abdominal pain;exfoliative dermatitis; erythema.","Store protected from light and from atmospheric carbon dioxide. Injection: Store in single dose containers, from which carbon dioxide has been excluded. Do not allow contact with metals. Tablets: Store protected from light.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Beclomethasone,Pregnancy Category-C,Schedule H,Chronic asthma not controlled by short-acting β2-adrenoceptor agonists.,"INHALER 100 and 200 µg per actuation;CREAM 5, 10, 15 (0.025%) and 20g (0.0125%);OINTMENT 20g.","Aerosol inhalationAdult- Metered dose inhaler: 200 µg twice daily or 100 µg 3 to 4 times daily (in more severe cases, initially 600 to 800 µg daily).High dose inhaler: 500 µg twice daily or 250 µg 4 times daily; if necessary may be increased to 500 µg 4 times daily.Child- Metered dose inhaler: 50 to 100 µg 2 to 4 times daily or 100 to 200 µg twice daily.High dose inhaler: not recommended.",Acne, respiratory tract infection, pulmonarytuberculosis, ulcer, perioral dermatitis.,"See notes above; active or quiescenttuberculosis; systemic therapy may berequired during periods of stress or whenairway obstruction or mucus prevent drugaccess to smaller airways; not for relief ofacute symptoms; monitor height of childrenreceiving prolonged treatment-if growthslowed; review therapy; untreated fungal,bacterial and systemic viral infection, lactation(Appendix 7b); pregnancy (Appendix 7c).","Oropharyngeal candidosis; cough anddysphonia (usually only with high doses);adrenal suppression; growth retardationin children and adolescents; impairedbone metabolism; glaucoma and cataract(with high doses; but less frequent thanwith systemic corticosteroids); paradoxicalbronchospasm-requires discontinuationand alternative therapy (if mild; may beprevented by inhalation of β2 -adrenoceptor agonist or by transfer from aerosol to powder inhalation); rarely,; urticaria; rash; angioedema; telangiectasia; increased intraocular pressure; dermal thinning. Candidosis can be reduced by use of a spacing device (see notes above); rinsing the mouth with water after inhalation may help to prevent candidosis.",Store protected from moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Budesonide,Preganacy Category-B,Schedule H,"Nasal allergy, prophylaxis and treatment ofseasonal and perennial allergic or vasomotorrhinitis, nasal polyposis, asthma","INHALER 100 and 200 µg, ROTACAP 100, 200and 400 µg, NASAL SPRAy 0.02% w/v.","AsthmaAdult- 200-400 µg Meter Dose Inhaler twice daily by inhalation, as dry powder inhaler 200-800 µg in single or two divided doses, as nebulised solution 0.5-1 mg twice daily.Child- 50-400 µg Meter Dose Inhaler twice daily, as nebulised solution 0.25-0.5 mg twice daily.Nasal polyps and allergic rhinitis: 200-400 µg/day by intranasal spray.",Hypersensitivity, presence of infections ornasal ulcers.,"Paradoxical bronchospasm; children, elderly,pregnancy (Appendix 7c), lactation; activeor quiescent tuberculosis, interactions(Appendix 6c).","Inhalation leads to hoarseness of voice,opportunistic fungal infection in oropharynx,respiratory infection, headache.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Epinephrine, Formoterol + Fluticasone propionate",Preganacy Category-B,Schedule H,"Asthma, severe chronic obstructivepulmonary disease (COPD)",Inhalation Aerosol-Formoterol + Fluticasone Propionate6 µg + 125 µg6 µg + 250 µg,InhalationAsthma: Adults- 1-2 inhalations twice daily.Child- 1 rotacap twice daily.(Rotacaps to be used with a rotahaler deviceonly. Do not swallow the capsules).COPD: Adults- 2 inhalations twice daily.Not recommended for children below 4years of age.,"Hypersensitivity, acute asthma symptoms","Severe cardiovascular disorders, cardiacrhythm abnormalities, seizure disorder, dia-betes, thyrotoxicosis, hypokalemia, pulmo-nary tuberculosis, pregnancy (Appendix 7c),lactation, interactions (Appendix 6c).","Headache, pharyngitis, throat irritation,upper respiratory tract infections,pneumonia, bronchitis, oral candidiasis,nausea, vomiting, diarrhea, chest pain,musculoskeletal pain, back pain, allergicreactions, wheezing, cough, skin rash,tremors, paradoxical bronchospasm,insomnia, adrenal suppression.",Store protected from light and moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Hydrocortisone, Ipratropium",Pregnancy Category-B,Schedule H,"Chronic asthma; chronic obstructivepulmonary disease; bronchospasm; rhinor-rhoea, rapid reversal of sinus rhythm.",METERED DOSE INHALER 200 doses (200 µgper actuation), CAPSULE 40 mg,"Aerosol inhalationAdult- Metered dose inhaler; 20 to 40 µg, in early treatment up to 80 µg at a time, 3 to 4 times daily.Child- Metered dose inhaler; up to 6 years; 20 µg 3 times daily. 6 to 12 years; 20 to 40 µg3 times daily.",Glaucoma, hypersensitivity, bladderobstruction, urinary retention.,Prostatic hypertrophy, pregnancy (Appendix7c), glaucoma (standard doses unlikely tobe harmful, reported with nebulized drug,particularly in association with nebulizedsalbutamol), lactation, allergy to atropine orAtropa belladona leaves,Occasionally dry mouth, constipation, angina,tremors, palpitation, nasal congestion.,Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Mometasone,Pregnancy Category-C,Schedule H,"Dermatoses, prophylaxis and treatment ofallergic rhinitis, nasal polyps, prophylaxis ofasthma",CREAMS 0.1% w/w, LOTIONS 0.1 % w/v,OINTMENTS 0.1% w/v, NASAL SPRAy 0.05%w/v.,Dermatoses: Adult 0.1% cream or ointment or lotion.Allergic rhinitis: 100 µg in each nostril once daily. Usual maintenance dose 50 µg in each nostril daily.Asthma: Adult- 200-400 µg daily in 1-2 divided doses.Child- 100 µg once daily.,Hypersensitivity.,"Hepatic and renal disease; myasthenia gravis,cardiovascular disease; ocular diseases;osteoporosis, glucocorticosteroid insufficiency;discontinue if irritation or sensitizationoccurs; interactions (Appendix 6c); pregnancy(Appendix 7c).",Adrenal suppression, immunosuppression,anaphylaxis, musculoskeletal pain,depression,fatigue,sinusitis,oropharyngealinfections, upper respiratory tractinfection, gastrointestinal disturbances,conjuctivitis, otitis media, local irritationand sensitization, bacterial skin infection,skin depigmentation, cataract, growthsuppression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Montelukast,Pregnancy Category-B,Schedule H,Prophylaxis of mild to moderate asthma.,TABLETS 5 and 10 mg,OralAdult- 10 mg once a day.Child- 2-5yrs: 4 mg once daily, 6-14 yrs: 5 mg once daily, ≥ 15 yrs: 10 mg once daily.,Hypersensitivity.,"History of liver disease, pregnancy (Appendix7c).",Headache, rashes, eosinophilia, neuropathy, Churg-strauss syndrome,Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Salbutamol,Pregnancy Category-C,Schedule H,Prophylaxis and treatment of asthma,premature labour, reversible airwayobstruction.,"TABLETS 2 and 4 mg; SyRUP 2 mg/5 ml (100ml); CAPSULES 4 mg; INHALER 100, 200doses (100 µg per actuation).","OralAdult- Chronic asthma (when inhalation is ineffective): 2 to 4 mg, 3 or 4 times daily; in some patients up to max. of 8 mg, 3 or 4 times daily.Child- Chronic asthma (when inhalation is ineffective): under 2 years; 100 µg/kg, 4times daily. 2 to 6 years; 1 to 2 mg, 3 to 4 times daily.Slow intravenous injectionAdult- Severe acute bronchospasm: 250 µg, repeated if necessary.Aerosol inhalation and intramuscular or subcutaneous injection Adult- Relief of acute bronchospasm: 100 to 200 µg (1 to 2 puffs) by aerosol inhalation and 500 µg by intramuscular or subcutaneous injection; repeated every 4 h if necessary.Child- Relief of acute bronchospasm: 100µg (1 puff) increased to 200 µg (2 puffs); ifnecessary.Aerosol inhalationAdult- Prophylaxis of exercise-induced bronchospasm: 200 µg (2 puffs).Chronic asthma (as adjunct in stepped treatment): 100 to 200 µg (1 to 2 puffs), up to3 to 4 times daily.Child- Prophylaxis of exercise-induced bronchospasm: 100 µg (1 puff) increased to 200 µg (2 puffs); if required.Chronic asthma (as adjunct in stepped treatment): 100 µg (1 puff) 3 to 4 times daily,increased to 200 µg (2 puffs) 3 to 4 times daily; if necessary.Inhalation of nebulized solutionAdult- Severe acute asthma or chronic bronchospasm unresponsive to conventional treatment: 2.5 mg repeated up to 4 times daily; may be increased to 5 mg, if necessary- medical assessment should be considered since alternative therapy may be indicated.Child- Severe acute asthma or chronic bronchospasm unresponsive to conventional treatment, over 18 months: 2.5 mg repeated up to 4 times daily; may be increased to 5 mg, if necessary- medical assessment should be considered since alternative therapy may be indicated. Under 18 months: clinical efficacy uncertain (transient hypoxaemia may occur- consider oxygen supplementation).",β2agonists are contraindicated in cardiacdisease, antepartum haemorrhage,intrauterine infection, intrauterine fetaldeath, placenta praevia, abruptio placenta,threatened miscarriage, cord compression,eclampsia or severe pre-eclampsia, diabetesmellitus, thyrotoxicosis.,Hyperthyroidism, myocardial insufficiency,arrhythmias, susceptibility to QT-intervalprolongation, hypertension, pregnancy(Appendix 7c) (but appropriate to use, seealso notes above), lactation (Appendix 7b),diabetes mellitus-especially intravenousadministration (monitor blood glucose,ketoacidosis reported), interactions(Appendix 6c),Hypokalaemia after high doses, arrhythmias,tachycardia, palpitations, peripheral vasodi-lation, fine tremor (usually hands), musclecramps, headache, insomnia, behaviouraldisturbances in children, hypersensitivityreactions including paradoxical bronchos-pasm, urticaria and angioedema, slight painon intramuscular injection.,Store protected from light and moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,
"Terbutaline, Theophylline",Pregnancy Category-C,,Chronic asthma including nocturnalasthma, acute severe asthma, apnoea ofprematurity.,"TABLETS 100, 150, 200, 250, 300, 400 and600 mg; CAPSULES 125, 200, 250 and 400 mg;SyRUP 5 mg/5 ml (100 ml) Aminophylline,100 ml (50 mg/5ml), 200 ml (80 mg/5ml),(125 mg/5ml); INJECTION 10 ml ampoule(25 mg/ml).(Theophyllinetabletsavailableincombination with aminophylline).","OralAdult- Chronic asthma (as tablets): 100 to 200 mg, 3 to 4 times daily after food.Chronic asthma (as modified-release tablets): 300 to 450 mg every 12 h.Nocturnal asthma (as modified-release tablets): total daily requirement as single evening dose.Child- Chronic asthma (as tablets); over 12 years: 100 to 200 mg, 3 to 4 times daily after food.Slow intravenous injection and infusion Adult- Acute severe asthma; by slow intravenous injection (over at least 20 min): 5 mg/kg. Maintenance by intravenous infusion: 500 µg/kg/hr.Child- Acute severe asthma; by slow intravenous injection (over at least 20 min):5 mg/kg. Maintenance by intravenous infusion; 6 months to 9 years: 1 mg/kg/h.10 to 16 years: 800 µg/kg/h, adjusted according to plasma concentration.",Porphyria, known hypersensitivity toethylenediamine (for aminophylline).,"Cardiac disease; hypertension; hyperthy-roidism; peptic ulcer; epilepsy; hepaticimpairment; pregnancy (Appendix 7c); lacta-tion (Appendix 7b); elderly; fever; smokersmay require larger or more frequent doses;interactions (6b, 6c)",Nausea vomiting and other gastrointestinaldisturbances, restlessness, anxiety, tremor,palpitations, headache, insomnia, dizziness,convulsions, arrhythmias and hypotension-especially if given by rapid injection, urticaria,erythema and exfoliative dermatitis-resultingfrom hypersensitivity to ethylenediaminecomponent of aminophylline, neurotoxicity,hypokalemia, metabolic acidosis,gastrointestinal haemorrhage.,Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Codeine, Dextromethorphan",Pregnancy Category-C,,Dry cough,TABLET 10 mg, SyRUP 15 mg/5 ml and 30mg/5 ml.,OralAdult- 10 – 20 mg every 4 hour or 30 mgevery 6 – 8 hours.Child- 6 – 12 years: 5 – 10 mg every 4 hoursor 15 mg every 6 – 8 hours.2 – 6 years: 2.5 – 5 mg every 4 hours or 7.5mg every 6 – 8 hours.,Patients at risk of developing respiratoryfailure, persistent or chronic cough, patientsreceiving monoamine oxidase inhibitors(with or within 2 weeks).,"Moderate/severe renal impairment; liverdisease, atopic children; patients confinedto supine position; debilitated patients;third trimester of pregnancy (Appendix 7c);asthma; interactions (Appendix 6a, 6c).",Dependency, dizziness, restlessness, mentalconfusion, excitation, gastrointestinaldisturbance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Centchroman,Pregnancy Category-X,Schedule H,Contraception.,TABLET 30 mg.,Oral 30 mg tablets. A single tablet should be taken twice a week (on a sunday and a wednesday) for the first three months and then weekly (every sunday) thereafter.,"Medical history of liver disease, jaundice;ovarian disease (polycystic ovaries); cervicalhyperplasia; cervicitis; chronic renaldisorders","Prolongation of menstrual cycles may beexperienced by some individuals. Delayedmenstruation is inconsequential if dosageshave not been missed. In case of delayexceeding 15 days, pregnancy shouldbe ruled out with routine investigations.Administration should be discontinuedimmediately if pregnancy is confirmed(Appendix 7c).",Water retention, tender breasts, acne, heavymenstruation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ethinylestradiol+Levonorgestrel and Ethinylestradiol+Norethisterone,Pregnancy Category-X,Schedule H,Contraception, menstrual symptoms,endometriosis.,TABLETSLevonorgestrel + Ethinylestradiol0.15 mg + 0.03 mg0.25 mg + 0.05 mgLevonorgestrel 0.15 mg + Ethinylestradiol0.03 mg + Ferrous fumarate 60 mg.Norethisterone + Ethinylestradiol0.5 mg + 0.03 mg1.0 mg + 0.03 mg,OralAdult- Contraception: 1 tablet (pill) daily for 21 days, subsequent courses repeated after 7-day pill-free interval (during which withdrawal bleeding occurs). Each tablet (pill) should be taken at approximately the same time each day, if delayed by longer than 24 h contraceptive protection may be lost. It is important to bear in mind that the critical time for loss of protection is when a pill is omitted at the beginning or end of a cycle (which lengthens the pill-free interval).,"Use within 3 weeks of birth; lactation untilweaning or for first 6 months after birth(Appendix 7b); personal history of 2 or morerisk factors for venous or arterial thrombosis(see notes above); heart disease associatedwith pulmonary hypertension or risk ofembolism; migraine (see below); history ofsub-acute bacterial endocarditis; ischaemiccerebrovascular disease; liver disease(Appendix 7a), including disorders of hepaticsecretion such as Dubin-Johnson or Rotorsyndromes, infectious hepatitis (until liverfunction normal); porphyria; systemic lupuserythematosus; liver adenoma; history ofcholestasiswithoralcontraceptives;gallstones;estrogen-dependent neoplasms; neoplasmsof breast or genital tract; undiagnosed vaginalbleeding; history of pruritus during pregnancy,chorea, herpes, deteriorating otosclerosis,cholestatic jaundice; diabetes mellitus (ifeither retinopathy, neuropathy or if morethan 20 years duration); after evacuation ofhydatidiform mole (until return to normal ofurine and plasma gonadotrophin values).Migraine with typical focal aura; migraine without aura regularly lasting over 72 h duration despite treatment; migraine treated with ergot derivatives; migraine without focal aura or controlled with 5-HT1 agonist.","Risk factors for venous thromboembolismand arterial disease (see notes above);migraine (see below); hyperprolactinaemia(seek specialist advice); some types of hyper-lipidaemia; gallbladder disease; severe de-pression; long-term immobilization (see alsoTravel below); sickle-cell disease; inflamma-tory bowel disease including Crohn'sdisease,interactions (Appendix 6c, 6d).Patients should report any increase in head- ache frequency or onset of focal symptoms (discontinue immediately and refer urgently to neurology expert if focal neurological symptoms not typical of aura persist for more than one hour). Women taking oral contraceptives may be at increased risk of deep-vein thrombosis during travel involving long periods of immobility (over 5 h). The risk may be reduced by appropriate exercise during the journey and possibly by wearing elastic hosiery; pregnancy (Appendix 7c).","Nausea, vomiting, headache; breasttenderness; increase in body weight;thrombosis; changes in libido; depression;chorea; skin reactions; chloasma;hypertension; impairment of liver function;‘spotting’ in early cycles; absence ofwithdrawal bleeding; breast cancer (smallincrease in risk of breast cancer during usewhich reduces during the 10 years afterstopping; risk factor seems related to age atwhich contraceptive is stopped rather thantotal duration of use; small increase in riskof breast cancer should be weighed againstthe protective effect against cancers of theovary and endometrium which persists afterstopping); dizziness, stomach upset, bloating,mental and mood changes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Levonorgestrel,Pregnancy Category-X,Schedule H,Emergency hormonal contraception,TABLETS 0.75 and 1.5 mg.,"OralAdult- Contraception: 1 tablet (‘pill’) (30 µg) daily, starting on the first day of the cycle and then continuously.",Progestogen-only oral contraceptives,undiagnosed vaginal bleeding, severearterial disease, liver tumours, breastcancer, thromboembolic disorders, sickle-cell anaemia, porphyria, after evacuation ofhydatidiform mole (until return to normalurine and plasma gonadotrophin values),progestogen-only emergency hormonalcontraceptives, severe liver disease.,"Possible small increase in risk of breastcancer; cardiac disease; sex-steroiddependent cancer; past ectopic pregnancy;malabsorption syndrome; ovarian cysts;active liver disease, recurrent cholestaticjaundice, history of jaundice in pregnancy(Appendix 7c); increase in frequency orseverity of headache (discontinue pendinginvestigation); lactation (Appendix 7b);pregnancy (Appendix 7c).","Menstrual irregularities (including oligomen-orrhoea and menorrhagia); nausea, vomit-ing, headache, dizziness; breast discomfort,depression; skin disorders; disturbances ofappetite; weight increase; change in libido.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Medroxyprogesterone,Pregnancy Category-X,Schedule H,Parenteral progestogen-only contraception(short- term or long-term), menstrual symp-toms and endometriosis, dysmenorrhoea.,"TABLETS 2.5, 5 and 10 mg; INJECTION 150 mg(1 ml VIAL/PREFILLED SYRINGE).","Deep intramuscular injectionAdult- Contraception (short-term): 150 mg within first 5 days of cycle or within first 5 days after parturition (delay until 6 weeks after parturition if lactating). Contraception (long-term); as for short-term, repeated every 3 months.Mild to moderate endometriosis: 10 mg3 times daily for 90 consecutive days,beginning on day 1 of cycle. Dysfunctionaluterine bleeding; 2.5 to 10 mg daily for 5 to10 days beginning on day 16 to 21 of cyclefor 2 cycles. Secondary amenorrhoea; 5 to 10mg daily for 5 to 10 days beginning on day 16to 21 of cycle for 3 cycles.If interval between injections is greater than 3 months and 14 days, exclude pregnancy before next injection and advise patient to use additional contraceptive measures (for example barrier) for 7 days after the injection.",Pregnancy (Appendix 7c), hormone-dependent breast or genital neoplasms,undiagnosed vaginal bleeding, hepaticimpairment or active liver disease (Appendix7a), severe arterial disease, porphyria, activethromophlebitis, lactation (Appendix 7b).,"Small increase in possible risk of breast cancer;migraine; liver disease; thromboembolic orcoronary vascular disease; diabetes mellitus;trophoblastic disease; hypertension; renaldisease; fluid retention, CNS disorder andconvulsions.","Menstrual irregularities; delayed return tofertility; reduction in bone mineral density;weight gain; depression; rarely, anaphylaxis;abdominal pain, asthenia, breast pain,bloating, insomnia, vaginitis.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Norethisterone,Pregnancy Category-X,Schedule H,Parenteral progestogen-only contraception(short-term).,TABLETS 1 and 5 mg INJECTION 1 ml ampoule(200 mg/ml).,"Deep intramuscular injection (into the gluteal muscle).Adult- Short-term contraception: 200 mg within 5 days of cycle or immediately after parturition; repeated after 2 months.If interval between injections is greater than 2 months and 14 days, exclude pregnancy before next injection and advise patient to use additional contraceptive measures (for example barrier) for 7 days after the injection.","Pregnancy (Appendix 7c); breast orendometrial cancer; severe liver disease(Dubin-Johnson or Rotor’s syndromes)(Appendix 7a); history of jaundice, pruritus,herpes or of deteriorating otosclerosisduring pregnancy; severe diabetes mellituswith vascular changes; hypertension;12 weeks before planned surgery andduring immobilization; thromboembolicdisease; disturbances of lipid metabolism;undiagnosed vaginal bleeding; porphyria;epilepsy, hepatitis, amenorrhoea, herpesgestation","Possible small increase in risk of breastcancer; migraine; liver dysfunction;depression; diabetes mellitus; previousectopic pregnancy; cardiac and renaldisease; interactions (Appendix 6b); vaginalbleeding; blood clots; seizures, lactation(Appendix 7b).","Bloating; breast discomfort; headache;dizziness, depression; nausea; menstrualirregularities; rarely; weight gain; hepatitis;cataract; optic neuritis; mental discomfort.",Tablets: Store protected from light and moisture. Injection: Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hormone Releasing IUD,,,For contraception.,At Family Welfare clinics or specialitycentres,"For contraception, the device can be inserted at any time between day 4 and day 12 after the start of menstrual bleeding; not to be fitted during heavy menstrual bleeding.Emergency contraception, the device may be inserted up to 120 h (5 days) after unprotected intercourse, at any time of menstrual cycle; if intercourse has occurred more than 5 days previously, device can still be inserted up to 5 days after the earliest likely calculated day of ovulation; device can be removed at the beginning of menstruation if no longer required.",Abnormal pap smear or abnormal vaginalbleeding.,,"Heavy bleeding, perforation of uterus;cramps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
IUD Containing Copper,,,Contraception, emergency contraception.,Single IUD in pouch pack.,"For contraception, the device can be inserted at any time between day 4 and day 12 after the start of menstrual bleeding; not to be fitted during heavy menstrual bleeding.Emergency contraception, the device may be inserted up to 120 h (5 days) after unprotected intercourse, at any time of menstrual cycle; if intercourse has occurred more than 5 days previously, device can still be inserted up to 5 days after the earliest likely calculated day of ovulation; device can be removed at the beginning of menstruation if no longer required.",Pregnancy, 48h-4 weeks post partum,puerperal sepsis, postseptic abortion, cervicalor endometrial cancer, pelvic inflammatorydisease, recent sexually transmitted disease(if not fully investigated and treated), pelvictuberculosis, unexplained uterine bleeding,malignant gestational trophoblastic disease,distorted or small uterine cavity, copper allergy,Wilson’s disease, medical diathermy, abnormalpap smear or abnormal vaginal bleeding.,"Anaemia; heavy menstrual bleeding, en-dometriosis, severe primary dysmenorrhoea,history of pelvic inflammatory disease, his-tory of ectopic pregnancy or tubal surgery,fertility problems, nulliparity and young age,severely scarred uterus or severe cervicalstenosis, valvular heart disease (requires an-tibacterial cover)-avoid if prosthetic valve orhistory of endocarditis; HIV infection or im-munosuppressive therapy (risk of infection-avoid if marked immunosuppression); jointand other prostheses; increased risk of ex-pulsion if inserted before uterine involution;gynaecological examination before insertionand 4-6 weeks afterwards-counsel women tosee doctor promptly if significant symptomssuch as pain; anticoagulant therapy; removeif pregnancy occurs (consider possibility ofectopic pregnancy).","Uterine or cervical perforation, displacement,expulsion; pelvic infection exacerbated;heavy menstrual bleeding; dysmenorrhoea;pain and bleeding and occasionally epilepticseizure or vasovagal attack on insertion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ethinylestradiol,Pregnancy Category-X,Schedule H,"Hormone replacement for menopausal symp-toms; osteoporosis prophylaxis; palliation inbreast cancer in men and postmenopausalwomen; contraception in combination with aprogestogen; dysfunctional uterine bleeding,prostatic carcinoma","TABLETS 0.01, 0.05 and 1 mg; INJECTION 1 ml ampoule (10 mg/ml).",OralAdult- Hormone replacement: 10 to 20 µg daily. Palliation in breast cancer in postmen- opausal women: 0.1 to 1 mg 3 times daily.,"Pregnancy (Appendix 7c); estrogen-dependent cancer; active thrombophlebitisor thromboembolic disorders or historyof recent venous thromboembolism(unless already on anticoagulant therapy);undiagnosed vaginal bleeding; lactation(Appendix 7b); liver disease (where liverfunction tests have failed to return to normal),Dubin-Johnson and Rotor syndromes (ormonitor closely); jaundice; cerebrovasculardisease; hepatic carcinoma; CV disease;estrogen dependent cancer.","Progestogen may need to be added toregimen to reduce risk of endometrialcancer due to unopposed estrogen (seenotes above); migraine (or migraine-likeheadache); history of breast nodules of fibro-cystic disease-closely monitor breast status(risk of breast cancer, see notes above); uter-ine fibroids may increase in size; symptomsof endometriosis may be exacerbated; pre-disposition to thromboembolism (see notesabove); presence of antiphospholipid anti-bodies; increased risk of gallbladder disease;hypophyseal tumours; porphyria; interac-tions (Appendix 6c, 6d); hepatic impairment(Appendix 7a)","Nausea and vomiting, abdominal crampsand bloating, weight increase; breastenlargement and tenderness; premenstrual-like syndrome; Sodium and fluid retention;thromboembolism (see notes above); alteredblood lipids; cholestatic jaundice; rashes andchloasma; changes in libido; depression,headache, migraine, dizziness, leg cramps(rule out venous thrombosis); contact lensesmay irritate; impotence; hypertension.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tamoxifen,Pregnancy Category-D,Schedule G,"Adjuvant treatment for estrogen receptorpositive breast cancer, metastatic breastcancer, male infertility, anovulatory infertility","TABLETS 10, 20, 25, 40 and 100 mg.",Breast cancer:Adult- 20 mg daily as a single dose or in 2divided doses. max. 40 mg/day.Anovulatory infertility:Adult- 20 mg daily on second- fifth day of themenstrual cycle. max.- 80 mg/day.,"Hypersensitivity, deep vein thrombosis,pulmonary embolism, pregnancy (Appendix7c) (exclude before treatment and advisenon-hormonal contraception if appropriate),lactation (Appendix 7b).","If patient experiences swelling around anklesor legs, decrease salt intake, cystic ovarianswellings in premenopausal woman.","Hypersensitivity reactions such asangioedema, Steven’s Johnson syndromeand bullous pemphigoid. Hot flushes, nausea,vomiting; vaginal discharge and bleeding,menstrual irregularities, increased risk ofvenous thromboembolism; distaste of food;depression; hair thinning; hypercalcaemia;peripheral oedema; decreased platelet count;increased pain and hypercalcaemia withbony maetastasis; tumor flare; liver enzymechanges (rarely, cholestasis); hepatitis;hepatic necrosis; hypertriglyceridaemia(sometimes with pancreatitis).",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Dexamethasone,Pregnancy Category-C,Schedule H,Suppression of inflammatory and allergicdisorders, shock, diagnosis of Cushingsyndrome, congenital adrenal hyperplasia,cerebral oedema, respiratory distresssyndrome.,"TABLETS 0.5, 2 and 4 mg; INJECTION 2 ml vial(4 mg/ml). CREAM 5 and 15 gm (0.1% w/w).","OralAdult- 0.5 to 10 mg daily.Intramuscular injection or slow intravenous injection or intravenous infusionAdult- Initially 0.5 to 20 mg daily.Child- 200 to 500 µg/kg daily. Adult- Cerebral oedema: 10 mg initially by intravenous injection, then 4 mg by intramuscular injection every 6 h, as required for 2-10 days.","See notes above; systemic infection (unlesslife-threatening or specific antimicrobialtherapy given); avoid live virus vaccines inthose receiving immunosuppressive doses(serum antibody response diminished);diabetes, hypertension, psychosis,osteoporosis, gastric ulceration.","Adrenal suppression during prolongedtreatment which persists for years afterstopping treatment (see notes above);ensure patients understand importance ofcompliance with dosage and have guidance onprecautions to reduce risks; monitor weight,blood pressure, fluid and electrolyte balanceandbloodglucoselevelsthroughoutprolongedtreatment; infections (greater susceptibility,symptoms may be masked until advancedstage); clinical presentation may be atypical;risk of chickenpox and measles increased(see notes above); quiescent tuberculosis-chemoprophylactic therapy during prolongedcorticosteroid treatment; elderly; childrenand adolescents (growth retardation possiblyirreversible); hypertension, recent myocardialinfarction (rupture reported), congestiveheart failure, liver failure, renal impairment,diabetes mellitus including family history,osteoporosis (may be manifested as backpain, postmenopausal women at special risk),glaucoma including family history, epilepsy,psoriasis, peptic ulcer, hypothyroidism, historyof steroid myopathy; lactation (Appendix7b); interactions (Appendix 6c); pregnancy(Appendix 7c).",Refer adverse effects of corticosteroids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hydrocortisone,Pregnancy Category-C,Schedule H,Adrenocortical insufficiency, hypersensitivityreactions including anaphylactic shock,inflammatory bowel disease, asthma,perineal trauma, joint inflammation,seborrheic dermatitis.,"TABLETS 5, 10 and 20 mg, CREAM 10g (1%w/w), OINTMENT 1%, 2.5% w/w INJECTION100, 200 and 400 mg vial (25 mg/5 ml).","OralAdult-20 to 30 mg daily in divided doses (usually 20 mg in the morning and 10 mg in early evening). Child-400-800 µg/kg/day in 2-3 divided doses.Slow intravenous injection or intravenous infusionAdult- Acute adrenocortical insufficiency: 100 to 500 mg, 3 to 4 times in 24 h or as required.Child- Up to 1 year: 25 mg; 1 to 5 years: 50mg; 6 to 12 years: 100 mg.",See notes above, systemic infection (unlesslife-threatening or specific antimicrobialtherapy given), avoid live virus vaccines inthose receiving immunosuppressive doses(serum antibody response diminished),ulcers.,"Refer corticosteroids; lactation (Appendix7b); interactions (Appendix 6b, 6c, 6d);pregnancy (Appendix 7c).",Refer adverse effects of corticosteroids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Methyl Prednisolone,Pregnancy Category-C,Schedule H,"Corticosteroid responsive conditions such assevere allergic rhinitis, asthma, rheumatoidarthritis, osteoarthritis, collagen disease,dermatoses","TABLETS 4, 8, 16 and 24 mg; INJECTION vials40, 125, 500 and 1000 mg, 2 ml ampoule (80mg/2 ml).","OralAdult- Asthma, allergies and dermatological conditions: 40 and 120 mg.Dose should be regulated in accordance with severity of condition; large joints- 20 to 80 mg; medium joints- 10 to 40 mg; small joints- 4 to 10 mg directly in bursae.",Systemic fungal infection (unless specificantimicrobial therapy given), avoidlive virus vaccines in those receivingimmunosuppressive doses (serum antibodyresponse diminished), hypersensitivity.,"Refer notes above; interactions (Appendix6c, 6d); pregnancy (Appendix 7c)",Refer adverse effects of corticosteroids.,Store protected from light at a temperature not exceeding 30⁰C. The injection should not be allowed to freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Prednisolone,Pregnancy Category-C,Schedule H,Suppression of inflammatory and allergicreactions, with antineoplastic drugs foracute leukaemias and lymphomas, asthma,rheumatic disorder, hematologic disorder.,"TABLETS 5, 10, 20 and 40 mg; INJECTION 1ml vial (40 mg/ml); SyRUP 60 ml (5 mg/5 mland 15 mg/5 ml).","OralAdult- Suppression of inflammatory and allergic disorders: initially up to 10 to 20 mg daily (severe disease, up to 60 mg daily), preferably taken in the morning after breakfast; dose can often be reduced within a few days, but may need to be continued for several weeks or months. Maintenance dose 2.5 to 15 mg daily or higher; cushingoid features are increasingly likely with doses above 7.5 mg daily.Myasthenia gravis: initially 10 mg on alternate days, increased in steps of 10 mg on alternate days to 1-1.5 mg/kg (max. 100 mg) on alternate days or initially 5 mg daily increased in steps of 5 mg daily to usual dose of 60-80 mg daily (0.75-1 mg/kg daily).Child- Fractions of adult dose may be used (At 1 year: 25% of adult dose; at 7 years: 50%; and at 12 years: 75%) but clinical factors must be given due weight.",See notes above, systemic infection (unlesslife-threatening or specific antimicrobialtherapy given), avoid live virus vaccines inthose receiving immunosuppressive doses(serum antibody response diminished).,"Refer notes above; hepatic impairment(Appendix 7a); lactation (Appendix 7b);interactions (Appendix 6c, 6d); pregnancy(Appendix 7c).",Refer Adverse effects of Corticosteroids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Danazol,Pregnancy Category-X,Schedule H,"Endometriosis, fibrocystic mastitis, hereditaryangioedema, menorrhagia, gynaecomastia,precocious puberty.","TABLETS/CAPSULES 50, 100 and 200 mg.","Endometriosis: Adult- 200 to 600 mg daily in 2 divided doses.Fibrocystic mastitis: Adult- 100 to 400 mg daily in 2 divided doses.Hereditary angioedema: Adult- 200 mg twice or thrice daily.Gynaecomastia: Adult- Initially 400 mg daily in 4 divided doses for 6 months.Child- Initially 200 mg daily, may increase to 400 mg after 2 months. Menorrhagia: Adult- 200 mg once daily.","Hepatic dysfunction; undiagnosed vaginalbleeding; porphyria; thromboemboliccomplication; hypersensitivity; pregnancy(Appendix 7c), lactation.","Use with caution in patients with migraine,headache, heart, liver or kidney disease.History of seizures; abnormal bleeding;previous strokes; severe hypertension;diabetes mellitus, polycythaemia;interactions (Appendix 6c).","Androgen like effects including weight gain,acne, deepening of voice; seborrhoea;edema; hair loss; amenorrhoea; hirsutism;benign intracranial hypertension; dizziness.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Testosterone,Pregnancy Category-X,Schedule H,Hypogonadism, palliative treatment ofadvanced breast cancer in women,"INJECTION 10 ml ampoule (25 mg/ml, 50 mg/ml, 100 mg/ml).","Slow intramuscular injectionAdult- Hypogonadism: initially 200 to 250 mg every 2 to 3 weeks; maintenance dose 200 to 250 mg every 3 to 6 weeks. Breast cancer: 250 mg, every 2 to 3 weeks.","Breast cancer in men; prostate cancer;hypercalcaemia; pregnancy (Appendix 7c),lactation (Appendix 7b); nephrosis; historyof primary liver tumours.","Cardiac, renal or hepatic impairment(Appendix 7a), elderly; ischaemic heartdisease; hypertension, epilepsy; migraine;diabetes mellitus; skeletal metastases (riskof hypercalcaemia); regular examination ofprostate during treatment; prepubertal boys;breathing disturbance.","Prostate abnormalities and prostate cancer;headache, depression, gastrointestinalbleeding, nausea; polycythaemia; cholestaticjaundice; changes in libido; gynaecomastia,anxiety, asthenia; generalized paraesthesia;electrolyte disturbances including sodiumretention with oedema and hypercalcaemia;increased bone growth; androgenic effectssuch as hirsutism, male-pattern baldness,seborrhoea, acne, priapism, precocioussexual development and premature closureof epiphyses in pre-pubertal males, virilism infemales, and suppression of spermatogenesisin men.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sildenafil,,Schedule H,Erectile dysfunction,"TABLETS 25, 50 and 100 mg.","50 mg about 1 hour before sexual intercourse, maximum 100 mg per dose and not more than once in 24 hours.Elderly (greater than 65 yrs)- lower initial dose at 25 mg",Hypersensitivity, coronary heart disease, patients on nitrates.,"Liver or kidney disease; peptic ulcer; bleedingdisorder; leukemia, sickle cell anaemia,myloma predisposing priapism; recent historyof stroke, myocardial infarction, arrthymias,unstable angina; anatomical deformation ofpenis; interactions (Appendix 6c); pregnancy(Appendix 7c)","Headache, nasal congestion, dizziness,flushing; fall in blood pressure; diarrhoea;impairment of colour vision; AV-block,angina pectoris, cardiac arrest, myocardialinfarction, cerebral thrombosis, abnormalLFT, hypoglycaemia; retinal vascular disease;photosensitivity, paresthesia; tremor;depression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Glibenclamide,Pregnancy Category-C,Schedule G,Type II diabetes mellitus,"TABLETS 1.25, 2.5 and 5 mg","Oral Schedule G Adult- initially 5 mg once daily with or immediately after breakfast; max. 15 mg daily.Elderly- 2.5 mg, but it should preferably be avoided, adjusted according to response (max. 15 mg daily).",Ketoacidosis, porphyria, lactation (Appendix7b).,"Renal impairment; hepatic impairment(Appendix 7a); elderly; substitute insulinduring severe infection, trauma, surgery (seenotes above); interactions (Appendix 6b, 6c);diabetic coma; pregnancy (Appendix 7c).","Mild and infrequent, including gastrointestinaldisturbances and headache; liver disorders;hypersensitivity reactions usually in first6-8 weeks; rarely; erythema multiforme,exfoliative dermatitis, fever and jaundice;hypoglycaemia, particularly in the elderly;rarely, blood disorders including leukopenia,thrombocytopenia, agranulocytosis,pancytopenia, haemolytic anaemia, andaplastic anaemia; cholestatic jaundice.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Gliclazide,Pregnancy Category-C,Schedule H,Type II diabetes mellitus.,"TABLETS 20, 30, 40, 80 and 160 mg;MODIFIED RELEASE TABLETS 30 and 60 mg;CAPSULES 30, 40, 60 and 80 mg.","40- 320 mg daily, doses >160 mg daily may be given in 2 divided doses.Modified release tablets 30-120 mg daily.","Type I diabetes mellitus, severe renal andhepatic impairment, diabetic ketoacidosis,pregnancy (Appendix 7c), lactation.","Monitor blood glucose concentration,increased risk of hypoglycaemia in elderly;debilitated patients; renal and hepaticimpairment, metabolic stressful situations;interactions (Appendix 6c).","Cutaneous reactions; blood dyscrasias,gastrointestinal disturbances; cholestaticjaundice.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Glimepiride,Pregnancy Category-C,Schedule H,Type II diabetes mellitus,"TABLETS 1, 2, 3 and 4 mg",Adult 1-2 mg daily.Max dose 8 mg daily.,Hypersensitivity, pregnancy (Appendix 7c), diabetic ketoacidosis.,"Elderly; hepatic and renal impairment;interactions (Appendix 6b, 6c); monitorblood-glucose concentration; lactation.",Hypoglycaemia, weight gain.,Storeprotectedfrommoistureattemperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Glipizide,Pregnancy Category-C,,Type II diabetes mellitus,"TABLETS 2.5, 5, 7.5 and 10 mg.",2.5-20 mg once or twice daily. Maximum 40 mg daily.,"Hypersensitivity; type I diabetes mellitus,ketoacidosis with or without coma; severehepatic or renal insufficiency; pregnancy(Appendix 7c), lactation.",Stress, fever, trauma, infection or surgery,elderly, thyroid impairment, monitor bloodglucose concentration.,"Hypoglycemia, nausea, diarrhoea, allergicskin reactions, thrombocytopenia,leucopenia, agranulocytosis, jaundice,hemolytic anaemia.",Store protected from moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Glucagon,Pregnancy Category-B,Schedule H,Severe hypoglycaemia and radiologicalexamination of gastrointestinal tract.,INJECTION (powder for reconstitution)- 1mg vial with pre-filled syringe containingwater for injection.,"ParenteralSevere hypoglycaemia:Adult and child over 8 years (or body weightover 25 kg)- 1 mg by s.c, i.m or i.v route.Child under 8 years (or body weight under 25 kg)- 500 µg, if no response within 10 minutes i.v glucose must be given.As diagnostic aid in gastrointestinal examination: Adult- 1-2 mg by i.m or 0.2-2 mg by i.v. injection.Diagnosis of pheochromocytoma: 1 mg i.v. ",Pheochromocytoma, hypersensitivity,"Patients with insulinoma, glucagonoma,monitor prothrombin time, starvationand adrenal insufficiency, ineffective inchronic hypoglycaemia, alcohol-inducedhypoglycaemia, pregnancy (Appendix 7c),lactation, interactions (Appendix 6b, 6c).","Hypokalemia; nausea, vomiting, abdominalpain; rarely, hypersensitivity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Insulin,Pregnancy Category-B,"Schedule H, G",Diabetes mellitus, diabetic emergencies andat surgery, diabetic ketoacidosis or coma.,INJECTION (multi-dose vials/prefilledsyringes/cartridges) - 40 and 100 IU/ml.,"Subcutaneous, intramuscular, intravenous injection or intravenous infusion.Adult and Child- Diabetes mellitus: according to individuals requirement.",,"See notes above; reduce dose in renalimpairment, lactations; interactions (Appen-dix 6a, 6b, 6c); pregnancy (Appendix 7c).","Hypoglycaemia in overdose; localized,and rarely, generalized allergic reactions;lipodystrophy at injection site.",Store in multi dose container in a refrigerator (2 to 8⁰C). It should not be allowed to freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Intermediate Acting Insulin, Insulin Zinc",,Schedule G,Diabetes mellitus.,INJECTION 40 and 80 IU/ml.,Subcutaneous injection Schedule G Adult and Child- Diabetes mellitus: according to individuals requirement.,,See notes above, reduce dose in renal impairment, lactation.,"Hypoglycaemia in overdose; localized,and rarely, generalized allergic reactions;lipodystrophy at injection site.",Store in multi dose containers in a refrigerator (2 to 8⁰C). It should not be allowed to freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Isophane Insulin,,Schedule G,Diabetes mellitus,INJECTION 40 and 80 IU/ml.,Subcutaneous injection Adult and Child- Diabetes mellitus: according to individual’s requirement.,,See notes above, reduce dose in renal impairment, lactation.,"Hypoglycaemia in overdose; localizedand rarely, generalized allergic reactions;lipodystrophy at injection site.",Store in multi dose containers in a refrigerator (2 to 8⁰C). It should not be allowed to freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Metformin,Pregnancy Category-B,Schedule H,Diabetes mellitus.,"TABLETS 250, 500, 850 mg, and 1g.","OralAdult- Diabetes mellitus: initially 500 mg with breakfast for at least 1 week, then 500 mg with breakfast and evening meal for at least 1 week, then 500 mg with breakfast, lunch and evening meal or 850 mg every 12 h with or after food (max. 2g daily in divided doses).","Renal impairment (withdraw if renalimpairment suspected; Appendix 7d);withdraw if tissue hypoxia likely (for examplesepsis, respiratory failure, recent myocardialinfarction, hepatic impairment), use ofiodine-containing X-ray contrast media (donot restart metformin until renal functionreturns to normal) and use of generalanaesthesia (suspend metformin 2 daysbeforehand and restart when renal functionreturns to normal); alcohol dependence;pregnancy (Appendix 7c); anaemia; ketosis","Measure serum creatinine before treatmentand once or twice annually during treatment;substitute insulin during severe infection;trauma, surgery (see notes above andcontraindications); lactation (Appendix 7b);interactions (Appendix 6a, 6b, 6c); hepatic orrenal disease (Appendix 7a); heart disease.","Anorexia, nausea and vomiting, diarrhoea(usually transient), abdominal pain, metallictaste; lactic acidosis most likely in patientswith renal impairment (discontinue);decreased vitamin B12 absorption.",Store protected from light and moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pioglitazone,Pregnancy Category-C,Schedule H,Type 2 diabetes mellitus,TABLETS 15 and 30 mg,Oral Type 2 diabetes mellitus: Adult- 15-30 mg once daily.Max. dose- 45 mg per day.,"Hypersensitivity, type 1 diabetes, diabeticketoacidosis, symptomatic or history of heartfailure, children, lactation.","Oedema, congestive heart failure, hepaticdysfunction, anaemia, concomitant oralcontraceptives and hormone replacementtherapy, pregnancy (Appendix 7c),interactions (Appendix 6c).","Oedema, headache, upper respiratory tractinfection, GI disturbances, nausea, shortnessof breath, weight gain, blurred vision,dizziness, arthralgia, impotence.","Store protected from heat, light and moisture at a temperature not exceeding 30⁰C.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Clomifene,Pregnancy Category-X,Schedule H,Anovulatory infertility.,"TABLETS 25, 50 and 100 mg.","Oral Adult- Anovulatory infertility: 50 mg daily for 5 days, starting within 5 days of onset of menstruation, preferably on the second day, or at any time if cycles have ceased; a second course of 100 mg daily for 5 days may be given in the absence of ovulation.","Hepatic impairment (Appendix 7a); ovariancysts;hormonedependenttumoursoruterinebleeding of undetermined cause; pregnancy(exclude before treatment, Appendix 7c);hyperprolactinaemia; depression.","Visual disturbances (discontinue and initiateeye examination) and ovarian hyperstimu-lation syndrome (discontinue treatmentimmediately); polycystic ovary syndrome(cysts may enlarge during treatment); uter-ine fibroids, ectopic pregnancy, incidenceof multiple births increased (consider ultra-sound monitoring); lactation (Appendix 7b).",Visualdisturbances,ovarianhyperstimulation,hot flushes, abdominal discomfort, occasionalnausea and vomiting, depression, insomnia,breast tenderness, headache, intermenstrualspotting, menorrhagia, endometriosis,convulsions, weight gain, rashes, dizzinessand hair loss.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Medroxyprogesterone, Norethisterone",Pregnancy Category-X,Schedule H,Endometriosis, menorrhagia, severedysmenorrhoea,contraception,premenstrualtension,TABLET 5 mg, INJECTION 1 ml ampoule (200mg/ml).,"OralAdult- Endometriosis: 10 mg daily starting on fifth day of cycle (increased if spotting occurs to 20 to 25 mg daily, reduce once bleeding has stopped). Menorrhagia: 5 mg three times daily for 10 days to stop bleeding; to prevent bleeding 5 mg twice daily from day 19 to 26 of cycle. Dysmenorrhoea: 5 mg, 2 to 3 timesdaily from day 5 to 24 for 3 to 4 cycles.","Pregnancy (Appendix 7c); undiagnosedvaginal bleeding; hepatic impairment oractive liver disease (Appendix 7a); severearterial disease; breast or genital tractcancer; porphyria; history in pregnancy ofidiopathic jaundice, severe pruritus.",Epilepsy, migraine, diabetes mellitus,hypertension, cardiac or renal disease andthose susceptible to thromboembolism,depression, lactation (Appendix 7b).,"Acne, urticaria; fluid retention; weight increase,gastrointestinal disturbances; changes inlibido, breast discomfort, premenstrualsymptoms, irregular menstrual cycles;depression; insomnia, somnolence; headache;dizziness; alopecia; hirsutism; anaphylactoid-like reactions; exacerbation of epilepsy andmigraine; rarely, jaundice.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ergometrine,Pregnancy Category-C,Schedule H,Prevention and treatment of postpartum andpost-abortion haemorrhage in emergencysituations and where oxytocin not available,"TABLETS 0.125, 0.25 and 0.5 mg; INJECTION5 ml ampoule (0.2 mg/ml).","OralAdult and adolescent- Secondary postpartum haemorrhage: 400 µg 3 times daily for 3 days.Intramuscular injection Adult and adolescent- Prevention and treatment of postpartum haemorrhage: when oxytocin is not available, 200 µg when the anterior shoulder is delivered or immediately after birth.Slow intravenous injectionAdult and adolescent- Excessive uterine bleeding: 250 to 500 µg when the anterior shoulder is delivered or immediately after birth.","Induction of labour, first and second stagesof labour; vascular disease, severe cardiacdisease especially angina pectoris; severehypertension; hepatic impairment (Appendix7a) and renal impairment; sepsis; eclampsia.","Cardiac disease, hypertension; multiplepregnancy (Appendix 7c); porphyria.","Nausea, vomiting; headache; dizziness;tinnitus, abdominal pain; chest pain;palpitations; dyspnoea; bradycardia,transient hypertension, vasoconstriction;stroke, myocardial infarction and pulmonaryoedema also reported.",Tablets: Store protected from light at a temperature not exceeding 30⁰C. Injection: Store protected from light in a single dose container at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Oxytocin,Pregnancy Category-C,Schedule H,Routine prevention and treatment ofpostpartum and post-abortion haemorrhage,induction of labour.,INJECTION 2 IU/2 ml and 5 IU/ml.,"Intravenous infusionAdult and adolescent- Induction of labour: initially 0.001 to 0.002 units/min increasedin 0.001 to 0.002 units/min increments at intervals of 30 min until a max. of 3 to4 contractions occur every 10 min; max. recommended rate 0.02 units/min.Slow intravenous injectionAdult and adolescent- Prevention of postpartum haemorrhage: 5 units when the anterior shoulder is delivered or immediately after birth. Treatment of postpartum haemorrhage: 5-10 units. Intramuscular injectionAdult and adolescent- Prevention of postpartum haemorrhage: 10 units when the anterior shoulder is delivered or immediately after birth.10 units, followed in severe cases by slow intravenous infusion, a total of 40 units should be infused at a rate of 0.02-0.04 units/min; this should be started after the placenta is delivered.","Hypertonic uterine contractions, mechanicalobstruction to delivery, fetal distress; anycondition where spontaneous labour orvaginal delivery inadvisable; avoid prolongedadministration in oxytocin-resistant uterineinertia, in severe pre-eclamptic toxaemiaor in severe cardiovascular disease;uterine hyperactivity; major cephalopelvicdisproportion, placental previa.",Induction or enhancement of labour inpresence of borderline cephalopelvicdisproportion (avoid if significant), mild tomoderate pregnancy (Appendix 7c)-associatedhypertension or cardiac disease, age over35 years, history of low-uterine segmentcaesarean section, avoid tumultuous labourif fetal death or meconium-stained amnioticfluid (risk of amniotic fluid embolism), waterintoxication and hyponatraemia (avoid largevolume infusions and restrict fluid intake),caudal block anaesthesia (risk of severehypertension due to enhanced vasopressoreffect of sympathomimetics), interactions(Appendix 6a).,"Uterine spasm, uterine hyperstimulation(usually with excessive doses-may cause fetaldistress, asphyxia and death, or may leadto hypertonicity, tetanic contractions, soft-tissue damage or uterine rupture); waterintoxication and hyponatraemia associatedwith high doses and large-volume infusions;nausea, vomiting, arrhythmias, rashes andanaphylactoid reactions also reported;hypotension; sinus bradycardia; hematoma;fetal asphyxia.",Store at a temperature not exceeding 30⁰C. Do not freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Mifepristone + Misoprostol,Pregnancy Category-X,Schedule H,"Medical termination of pregnancy ofupto 49 days, cervical dilatation prior tosurgical termination of pregnancy in thefirst trimester, therapeutic termination ofpregnancy for medical reasons beyond thefirst trimester, labor induction in case of fetaldeath in utero.","TABLET KIT mifopristone 200 mg, misoprostol 200 µg.",Mifepristone 200 mg orally followed 1 to 3 days latter by misoprostol 800 µg vaginally. Patients should return for followup visit after approximately 14 days after administration of mifepristone.,"Hypersensitivity to Mifepristone, Misoprostolor other prostaglandin; confirmed orsuspected ectopic pregnancy (Appendix7c); chronic adrenal failure; haemorrhagicdisorders or concurrent anticoagulanttherapy; inherited porphyria.","IUD in place; asthma, chronic obstructivepulmonary disease; alcoholism; prostheticheart valve; infective endocarditis;interactions (Appendix 6c), pregnancy(Appendix 7c).","Abdominal pain, diarrhoea, nausea, vomiting;fever, chills, uterine cramping; vaginalbleeding or spotting; Pelvic inflammatorydisease.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Isoxsuprine,Pregnancy Category-C,Schedule H,Cerebral and peripheral vascular disorder,threatened abortion and premature labour,night cramps, habitual abortion,TABLETS 10 and 20 mg, INJECTION 2 mlampoule (5 mg/ml).,"Oral Premature labour and threatened abortion: initially 20 mg 6 hly after food, maintenance dose after improvement 10 mg thrice a day.Intravenous injection/infusionPremature labour and threatened abortion:0.2 to 0.5 mg/min, adjust according toresponse, monitor BP and heart rate.","Anaemia; heart disease, arterial hemorrhage;postpartum; premature detachment ofplacenta; hypersensitivity.","Blood disorders, bleeding episodes orallergies, pregnancy (Appendix 7c), lactation.","Dizziness,nausea and vomiting; tachycardia,Irregular heart beat, hypotension, chestpain; flushed skin, rashes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Terbutaline,Pregnancy Category-B,Schedule H,Bronchial spasm in bronchial asthma andchronic bronchitis, emphysema, prematurelabour, lymphoma.,"TABLETS 2.5 and 5 mg; INJECTION 1ml ampoule (0.5 mg/ml), NEBULISINGSOLUTION 10 mg/ml, METERED DOSEINHALER (MDI) 250 µg/puff","OralPremature abortion: 2.5 to 5 mg thrice daily. Acute bronchospasm: Adult- 2.5 to 5 mgthrice daily.Subcutaneous, intramuscular or intravenous injectionUncomplicated premature labour: Adult- 5µg/min for 20min, increased every 20min insteps of 2.5 µg/min until contractions haveceased continue for 1 h then decreasedevery 20 min in steps of 205 µg/min to low-est dose that maintain suppression, max.dose 20 µg/min.Severe bronchospasm: Adult- 250-500 µg, 4 times daily. Child: >2 years-10 µg/kg, max. dose- 300 µg.Inhalation Acute bronchospasm: Adult/Child- MDI- 250 or 500 µg every 4-6 h, max. dose- 2000 µg/24 h; As nebuliser- 5-10 mg inhaled 2-4times. Child- As nebuliser- 2-5 mg inhaled 2-4 times.",Cardiac disease, antepartum haemorrhage,intrauterine infection, intrauterine fetaldeath, placenta praevia, abruptio placenta,threatened miscarriage, cord compression,and eclampsia or severe pre-eclampsia,thyrotoxicosis, toxaemia.,"Suspected cardiovascular disease (suchpatients should be assessed by a cardiologistbefore initiating therapy), hypertension, mildto moderate pre-eclampsia, hyperthyroidism,and hypokalaemia (particular risk withpotassium-depleting diuretics). It isimportant to monitor pulse rate (should notexceed 140 beats per min) and the patient’sfluid and electrolyte status (avoid over-hydration-discontinue drug immediatelyand initiate diuretic therapy if pulmonaryoedema occurs). It should also be used withcaution in diabetes-monitor blood glucose(risk of hyperglycaemia and ketoacidosis,especially with intravenous β2 agonist); pregnancy (Appendix 7c).","Nausea, vomiting; pulmonary oedema;palpitation; tachycardia, arrhythmias,peripheral vasodilation; headache, tremor,hyperglycaemia, hypokalaemia, musclecramps and tension and hypersensitivityreactions (including angioedema, urticaria,rash, bronchospasm, hypotension, andcollapse).",Tablet: Store protected from light and moisture. Injection: Store protected from light in a single dose container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Carbimazole,Pregnancy Category-D,Schedule H,Thyrotoxicosis, Grave’s disease,TABLETS 5 and 10 mg.,OralInitially 15 to 45 mg daily in 4 divided doses depending upon severity. Maintenance dose 25 to 50 mg for 1 year.,"Nodular goitre; subacute thyroiditis,postpartum painless thyroiditis.","Liver disorders; pregnancy (Appendix 7c), lactation; neutropenia.","Nausea, mild gastro-intestinal disturbances;headache; rashes and pruritus, arthralgia;rarely, myopathy, alopecia, bone marrowsuppression (including pancytopenia andagranulocytosis); vasculitis; cholestaticjaundice, hepatic necrosis.",Store protected from light and moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Iodine,Pregnancy Category-D,,Hypothyroidism, sporotrichosis,COLLOIDAL IODINE 8 mg/5 ml,5 to 10 ml diluted in water 3 times a day.,"Lactation (Appendix 7b), tuberculosis, bron-chitis, asthma, hyperkalaemia, acne vulgaris.","Pregnancy (Appendix 7c), children; notfor long-term treatment; cardiac disease,interactions (Appendix 6c).","Hypersensitivity reactions including coryza-like symptoms; headache; lacrimation;conjunctivitis, pain in salivary glands;laryngitis, bronchitis, rashes; on prolongedtreatment depression, insomnia, impotence;goitre in infants of mothers taking iodides;eosinophilia, hypothyroidism, abdominalpain, arrhythmia.",Store in ground glass stoppered container or earthenware container with waxed bungs,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Levothyroxine,Pregnancy Category-A,Schedule H,Hypothyroidism,TABLETS 50 and 100 µg.,"OralAdult- Hypothyroidism: Initially 50 to 100 µg daily (25 to 50 µg for those over 50 years) before breakfast, increased by 25 to 50 µg every 3 to 4 weeks until normal metabolism maintained (usual maintenance dose, 100 to 200 µg daily); where there is cardiac disease, initially 25 µg daily or 50 µg on alternate days, adjusted in steps of 25 µg every 4 weeks.Child- Congenital hypothyroidism and juvenile myxoedema; Up to 1 month: initially 5 to 10 µg/kg daily. Over 1 month: initially 5µg/kg daily, adjusted in steps of 25 µg every 2 to 4 weeks, until mild toxic symptoms appear, then reduce dose slightly.",Thyrotoxicosis,"Cardiovascular disorders (myocardialinsufficiency or ECG evidence ofmyocardial infarction); hypopituitarismor predisposition to adrenal insufficiency(must be corrected by corticosteroidprior to initial levothyroxine); elderly;long-standing hypothyroidism, diabetesinsipidus, diabetes mellitus (may need toincrease dose of insulin or oral antidiabeticdrug); pregnancy (Appendix 7c), lactation;interactions (Appendix 6c, 6d).","Anginal pain, arrhythmias, palpitations,tachycardia, skeletal muscle cramps;diarrhoea, vomiting; tremors; restlessnessexcitability, insomnia, headache, flushing,sweating; excessive loss of weight andmuscular weakness; heat intolerance.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Anti-D Immunoglobulin (Human),,,Prevention of formation of antibodies torhesus-positive blood cells in rhesus-negativepatients,INJECTIONS 150 µg/vial and 300 µg/vial.,"Intramuscular injectionAdult and Child- Following birth of a rhesus- positive infant in rhesus-negative mother: 250 µg immediately or within 72 h.Following any potentially sensitizing episode like amniocentesis, still birth, up to 20 weeks gestation: 250 µg per episode, after 20 weeks: 500 µg immediately or within 72 h.Following Rho (D) incompatible blood transfusion: 10 to 20 µg/ml transfused rhesus-positive blood.",See introductory notes, knownhypersensitivity.,See introductory notes, caution in rhesus-positive patients for treatment of blooddisorders, caution in rhesus-negativepatients with anti-D antibodies in theirserum, patients should be observed for 20min after injection.,"Rubella vaccine may be administered inthe postpartum period at the same timeas anti-D immunoglobulin injection, butonly using separate syringes and separatecontralateral sites. If blood is transfused,the antibody response to the vaccine maybe inhibited and a test for antibodies shouldbe performed after 8 weeks and the subjectrevaccinated if necessary.See introductory notes; local pain andtenderness, fever, headache; cutaneousreaction; tachycardia, hypotension.",For liquid preparations: Store protected from light at temperature stated on the label. For freeze dried preparation: Store protected from light in a colourless glass cotainer at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Antitetanus Immunoglobulin (Human),Pregnancy Category-C,,Passive immunisation against tetanus aspart of the management of tetanus-pronewounds.,"INJECTIONS 250, 500 and 1000 I.U/vial.","Intramuscular injectionAdult and Child-250 units, increased to 500 units if wound older than 12 h or there is risk of heavy contamination or if patient weighs more than 90 kg. Second dose of 250 µg given after 3 to 4 weeks if patient is immunosuppressed or if active immunisation with tetanus vaccine contraindicated.",See introductory notes.,See introductory notes, must not beadministered i.v and patient must beobserved for 20 min after administration,pregnancy (Appendix 7c).,See introductory notes, chest pain, dyspnoea,facial oedema.,Store as stated In the label.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Diphtheria Antitoxin,,,Passive immunisation in suspected cases ofdiphtheria.,INJECTION 10000 IU/10 ml.,"Intramuscular injectionAdult and Child- 10,000 to 30,000 units in mild to moderate cases; 40,000 to 1,00,000 units in severe cases.Both intramuscular and intravenous injectionFor doses more than 40,000 units, a portion should be given by intramuscular injection followed by the bulk of the dose intravenously after an interval of 0.5 to 2 h.",Hypersensitivity.,Initial test dose to exclude hypersensitivity,observation required after full dose[epinephrine (adrenaline) and resuscitationfacilities should be available], history ofasthma.,"Anaphylaxis with urticaria, hypotension,dyspnoea and shock; serum sickness up to12 days after injection; fever, respiratorydistress.",Refer antivenom serum.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Rabies Immunoglobulin,Pregnancy Category-C,,Passive immunisation either post-exposureor in suspected exposure to rabies in high-risk countries in unimmunised individuals (inconjunction with rabies vaccine),INJECTION 150 IU/2 ml, 300 IU/ml, 200-400IU/5 ml, 1000 IU/ml, 1000 IU/5 ml, 1500 IU/5ml.,Intramuscular injection and wound infiltrationAdult and Child- 20 units/kg (half by intramuscular injection and half by wound infiltration).,See introductory notes, avoid repeat dosesafter vaccine treatment initiated, intravenousadministration.,"Epinephrine should be available formanagement of anaphylactic reaction.If schedule requires rabies vaccine and rabies immunoglobulin to be administered at the same time, they should be administered using separate syringes and separate sites.; pregnancy (Appendix 7c).",See introductory notes, soreness at injectionsite, fever, chest pain, tremor, dyspnoea.,Refer antivenom serum,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Antivenom Sera,,,Treatment of snake bites.,INJECTION 10 ml ampoule,"60-100 ml in 5% dextrose or normal saline intravenously over one hour; start at 1 ml of diluted solution per minute initially, watch- ing for reaction. Skin sensitivity test is not recommended; In hemotoxic snake bites, may repeat a second dose at 6 h. if bleeding/ clotting abnormalities continue, or whole blood clotting time is still prolonged at 6 h; In neurotoxic snake bites, may repeat at 1-2 h.",,Resuscitation facilities should be immediatelyavailable, antihistamine and treatment foranaphylactic shock should be kept ready,"Serum sickness; anaphylaxis withhypotension, dyspnoea, urticaria and shock",Store liquid vaccines at a temperature below 2 to 8⁰C. Should not be allowed to freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCG Vaccine,Pregnancy Category-C,,Active immunisation against tuberculosis,Between 1x106 and 33x106 CFU/ml INJECTION(1 million units of BCG Strain/dose).,"Intradermal injectionAdult- 0.1 ml.Child- Over 3 months: 0.1 ml; Infant, up to 3 months: 0.05 ml.","See introductory notes; generalizedoedema; antimycobacterial treatment;HIV infection, febrile illness, burn patients;hypersensitivity.","Eczema, scabies-vaccine site must be lesion-free; severly immunocompromised patients;pregnancy (Appendix 7c).","See introductory notes; lymphadenitis andkeloid formation; osteitis and localizednecrotic ulceration; rarely, disseminated BCGinfection in immunodeficient patients; rarely,anaphylaxis; bladder irritation, anorexia,weight loss.",Store as stated in the label.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Diphtheria, Pertussis and Tetanus (DPT) Vaccine",,,"Active immunisation against diphtheria,tetanus and pertussis",INJECTIONS 0.5 ml/ampoule and 5 ml/vial.,"Intramuscular injectionChild- Infant; 0.5 ml at 6, 10 and 14 weeks.","Seeintroductorynotesandnotesabove;hypersensitivity, do not administer i.v., seizures,hypotension, hyporeactivity syndrome","See introductory notes and notes above;in cases of severe reaction, the pertussiscomponent should be omitted and theprimary course of immunization completedwith diphtheria and tetanus vaccine; post-pone vaccination if fever, acute disease.","See introductory notes; tetanus componentrarely, associated with peripheral neuropathy;pertussis component rarely, associated withconvulsions and encephalopathy; induction,oedema.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Haemophilus Influenza Type B Vaccine,Pregnancy Category-C,,Active immunisation against influenza inindividuals at risk,INJECTION 10 µg/vial.,Intramuscular or deep subcutaneous injectionAdult- 0.5 ml as a single dose.Child- Over 13 years: 0.5 ml as a single dose. 3 to 12 years: 0.5 ml with a second dose after at least 4 weeks if child was not previously infected or vaccinated. 6 to 35 months, 0.25 ml repeated after at least 4 weeks if child was not previously infected or vaccinated.,,Allergy to ranitidine, pregnancy (Appendix7c).,Soreness or redness at injection site,breathing problem, numbness in hand.,Store as stated in the label,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hepatitis A Vaccine,Pregnancy Category-C,,Active immunization against hepatitis A,"INJECTIONS vials 0.5 ml (80, 160, 360 and720 units), 1 ml (1440 units).","Intramuscular injectionAdult- 1440 Elisa units.Child- 360 or 720 Elisa units in accordance with age. 6 months to 1 year: 360 Elisa units, up to 18 years: 720 Elisa units.",Thrombocytopenia, hypersensitivity.,"Haemodialysis, febrile illness; pregnancy(Appendix 7c).","Usually mild, include transient soreness,erythema, and induration at the injection site,fever, malaise, fatigue, headache, nausea,diarrhoea, and loss of appetite; arthralgia,myalgia and convulsions; anorexia.",Store as stated in the label.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hepatitis B Vaccine,Pregnancy Category-C,Schedule H,Active immunisation against hepatitis B.,"INJECTIONS 2 ml/vial (10 µg/0.5 ml) 10 µg/ml, 10 µg/2 ml, 10 µg/5 ml, 10 µg/10 ml, 100µg/10 ml, and multidose vial 10 ml/vial (20µg/ml).","Intramuscular injectionAdult- Immunisation of unimmunised and high risk persons: 3 doses of 1 ml with an interval of 1 month between the first and second dose and 5 months between the second and third doses.Child- Immunisation of children, Infant: 0.5 ml either (Scheme A) at birth and at 6 and 14 weeks of age or (Scheme B) at 6, 10 and 14 weeks of age.Immunisation of unimmunised and high risk children, over 15 years: 3 doses of 1 ml with an interval of 1 month between the first and second dose and 5 months between the second and third doses. Under 15 years; 0.5 ml.",See introductory notes, acute febrile illness.,See introductory notes, severelycompromised cardiopulmonary status,pregnancy (Appendix 7c).,"See introductory notes; abdominalpain and gastrointestinal disturbances;muscle and joint pain, dizziness and sleepdisturbance; occasionally cardiovasculareffects; convulsions, neuropathy, meningitis,paralysis, syncope.",Store as stated in the label.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Influenza Vaccine,Pregnancy Category-C,,Active immunisation against influenza inindividuals at risk.,INJECTION 0.5 ml Pre filled syringesampoule.,Intramuscular or deep subcutaneous injectionAdult- 0.5 ml as a single dose.Child- Over 13 years: 0.5 ml as a single dose. 3 to 12 years: 0.5 ml with a second dose after at least 4 weeks if child was not previously infected or vaccinated. 6 to 35 months: 0.25 ml repeated after at least 4 weeks if child was not previously infected or vaccinated.,"See introductory notes; whole virionvaccine not recommended in children;hypersensitivity to any antibiotic present invaccine (consult literature); hypersensitivityto egg; thrombocytopenia, febrile illness.","See introductory notes; pregnancy (Appendix7c), lactation","See introductory notes; occasionally, severefebrile reactions-particularly after wholevirion vaccine in children; convulsions;thrombocytopenia, angioedema, neuritis;encephalomyelitis; urticaria.",Store as stated in the label.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Measles Vaccine,Pregnancy Category-X,,Active immunization against measles.,INJECTION 0.5 ml ampoule containing at least 1000 CCID - 50.,"Intramuscular or deep subcutaneous injectionChild- For immunisation of children against measles; Infant, at 9 months: 0.5 ml.Prophylaxis in susceptible children after exposure to measles; over 9 months: 0.5 ml within 72 h of contact","See introductory notes; hypersensitivity toany antibiotic present in vaccine (consultliterature); hypersensitivity to egg or gelatin;respiratory tract infection, tuberculosis,AIDS.","See introductory notes; febrile seizures,cerebral injury, pregnancy (Appendix 7c),.","See introductory notes; rashes some-times accompanied by convulsions; rarely,encephalitis and thrombocytopenia; head-ache, pruritus, purpurea.",Store as stated in the label.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Polio Vaccine,,,Active immunisation against poliomyelitis,INJECTION 0.5 ml/vial.,"OralPrimary immunisation of unimmunised adult: 3 doses each of 3 drops with an interval of at least 4 weeks between each dose.Reinforcing immunisation of unimmunised adult: 3 doses after 10 years of completion of primary course.Intramuscular injection2 booster doses of injection first before school entry and second at leaving school. Further booster doses may be required to adults at special risk of polio endemic areas.Child- Primary immunisation: 3 drops at birth and at 6, 10 and 14 weeks of age.Reinforcing immunisation of children: 3 drops at least 3 years after completion of primary course and a further 3 drops at 15 to 19 years of age.",See introductory notes, primaryimmunodeficiency or immunosuppression,not to be taken with food which contains apreservative, hypersensitivity to any antibioticpresent in vaccine (consult literature).,See introductory notes,"Rarely, vaccine-associated poliomyelitisin recipients of vaccine and contacts ofrecipients; paralytic poliomyelitis.",Store as stated in the label,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Rabies Vaccine,Pregnancy Category-C,,"Active immunisation against rabies;pre-exposure prophylaxis, post-exposuretreatment.",INJECTIONS 1 ml/vial and 1 ml/ampoulecontaining 2.5 IU inactivated rabies antigenfor reconstitution before use,"Intramuscular or deep subcutaneous injectionAdult- Immunisation against rabies; pre- exposure prophylaxis: 1 ml on days 0, 7 and 28 with reinforcing doses 2 to 3years for those at continued risk. Immunisation against rabies; post-exposure treatment (in unimmunised individuals): 5 doses of 1 ml each on days 0, 3, 7, 14 and 28 (plus rabies immunoglobulin given on day 0).Immunisation against rabies; post-exposure treatment (in fully immunised individuals): 2 doses of 1 ml separated by 3 to 7 days.Child- Immunisation against rabies; pre- exposure prophylaxis: 1 ml on days 0, 7 and 28 with reinforcing doses 2 to 3years for those at continued risk.Immunisation against rabies; post-exposure treatment (in unimmunised individuals): 5 doses of 1 ml on days 0, 3, 7, 14 and 28 (plus rabies immunoglobulin given on day 0).Immunisation against rabies; post-exposure treatment (in fully immunised individuals): 2 doses of 1 ml separated by 3 to 7 days.",See introductory notes, febrile illness.,"See introductory notes; acute illness;pregnancy (Appendix 7c).If schedule requires rabies vaccine and rabies immunoglobulin to be administered at the same time, they should be administered using separate syringes and separate sites.","See introductory notes; pain, erythema andinduration at injection site; nausea, myalgia;hypersensitivity-less likely with vaccines fromhuman sources; headache, fever.","Store in single dose, light-resistant containers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Rubella Vaccine,Pregnancy Category-X,,Active immunisation against rubella inwomen of child-bearing age,INJECTION 0.5 ml vial containing 1000 CCID- 50 of live virus particles,Intramuscular or deep subcutaneous injectionAdult- 0.5 ml as a single dose.,See introductory notes, pregnancy (Appendix7c) (see notes above), hypersensitivity to anyantibiotic present in vaccine-consult manu-facturer’s literature, hypersensitivity to egg.,"See introductory notes; illness, infection,blood disorder.","See introductory notes; rash, lymphad-enopathy; arthralgia and arthritis; rarely,thrombocytopenia, neurological symptoms;pharyngitis.","Store in single dose, light-resistant containers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tetanus Vaccine,Pregnancy Category-C,,Active immunisation against tetanus andneonatal tetanus, wound management(tetanus-prone wounds and clean wounds).,INJECTION 0.5 ml ampoule,"Intramuscular injectionAdult- Primary immunisation: 3 doses each of 0.5 ml with an interval of 4 weeks between each dose.Reinforcing immunisation: 2 doses each of0.5 ml, the first dose; 10 years aftercompletion of primary course and the seconddose; after 10 years.Immunisation of women of child-bearing age against tetanus: 3 primary doses each of 0.5 ml with an interval of not less than 4 weeks between the first and second doses and 6 months between the second and third dose. 2 reinforcing doses each of 0.5 ml, the first dose; 1 year after completion of the primary course and the second dose; 1 year later.Unimmunised pregnant women: 2 doses each of 0.5 ml with an interval of 4 weeks between each dose (second dose at least 2 weeks before delivery) and 1 dose during each of subsequent 3 pregnancies (max. 5 doses).Intramuscular or deep subcutaneous injectionAdult- Management of tetanus-prone wounds and clean wounds: 0.5 ml, the dose schedule being dependent upon the immune status of the patient and the level of contamination of the wound","See introductory notes and notes above;anaphylactic reaction, hypersensitivity","See introductory notes and notes above;mild cold.If schedule requires tetanus vaccine and antitetanus immunoglobulin to be administered at the same time, they should be administered using separate syringes and separate sites, pregnancy (Appendix 7c).","See introductory notes; tetanus componentrarely, associated with peripheral neuropathy;seizures, neurological disturbance, fever, lossof appetite.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Typhoid Vaccine,Pregnancy Category-B,,Active immunization against typhoid.,INJECTIONS 30 µg/vial and 150 µg/vial.,"OralAdult- Each dose given on days 0, 2 and 4 (total of 3 doses), with reinforcing doses every year for travellers to disease-endemic countries and every 3 years for those living in disease-endemic areas.Child- Over 6 years: each dose given on days 0, 2 and 4 (total of 3 doses), with reinforcing doses every year for travellers to disease- endemic countries and every 3 years for those living in disease-endemic areas.Intramuscular or deep subcutaneous injectionAdult- 0.5 ml, with reinforcing doses every 3 years for those at continued risk.Child- 0.5 ml, with reinforcing doses every 3 years for those at continued risk.",See introductory notes, hypersensitivity.,"See introductory notes and notes above;illness, infection, allergy, radiation therapy,interactions (Appendix 6d); pregnancy(Appendix 7c).",See introductory notes, anaphylactoidreaction, nausea, vomiting, fever, redness,itching, abdominal pain,Store at a temperature 2 to 8⁰C. When stored under these conditions may retain potency for 1 year.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Varicella Vaccine,Pregnancy Category-B,,Active immunization against varicella inhealthy subjects and their susceptible healthyclose contacts from the age of 12 onwards,INJECTION 0.5 mg/vial.,Subcutaneous injection Adult- 2 doses of 0.5 ml at dose intervals of 6 to 10 weeks.Child- Below 1 year: not recommended, 1 to 12 years: 1 dose of 0.5 ml, Above 12 years:2 doses of 0.5 ml at dose intervals of 6 to 10 weeks,"Contraindicated in pregnancy (avoidpregnancy for 3 months after vaccination,Appendix 7c). It must not be given toindividuals with primary or acquiredimmunodeficiency or to individuals receivingimmunosuppressive therapy; leukaemia,tuberculosis, febrile illness, neoplasticdiseases, respiratory depression","Blood or plasma transfused patients,leukaemia, blood dyscrasias, interactions(Appendix 6c).",Skin rashes, breathing difficulty, face and eyeswelling.,Store as stated in the label,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
yellow Fever Vaccine,,,Active immunization against yellow fever,INJECTION 1000 IU/vial.,"Subcutaneous injectionAdult- Immunisation of travellers and others at risk against yellow fever; 0.5 ml.Child- Immunisation of travellers and others at risk against yellow fever; over 9 months:0.5 ml; Infant, 6 to 9 months: 0.5 ml only if risk of yellow fever is unavoidable. At 9 months of age: 0.5 ml.","See introductory notes; not recommendedfor infants under 6 months of age;hypersensitivity to any antibiotic present invaccine-consult manufacturer’s literature;hypersensitivity to egg; febrile illness,impaired immune response.",See introductory notes, acute illness.,"See introductory notes; rarely, encephalitis,generally in infants under 9 months;lymphangitis, myalgia; inflammation.",Store as stated in the label.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Atracurium Besylate,Pregnancy Category-B,Schedule H,Used adjunctively in anaesthesia to facilitateendotracheal intubation and to provideskeletal muscle relaxation during surgery ormechanical ventilation,INJECTION 2.5 and 5 ml ampoule (10 mg/ml).,"Intravenous injectionAdult and child over 1month- Surgery or intubation: 300 to 600 µg/kg body weight, maintenance by 100 to 200 µg as required. Intensive care: 300 to 600 µg/kg body weight.Intravenous infusionAdult and child- 5 to 10 µg/kg body weight/ min (300 to 600 µg/kg/h).",Hypersensitivity.,"Allergic cross-reactivity between neuromus-cular blocking agents has been reported;caution is advised in cases of hypersensitiv-ity. Their activity is prolonged in patientswith myasthenia gravis and in hypothermia,therefore lower doses are required. Non-depolarising muscle relaxants should beused with great care in those with other neu-romuscular disorders and those with fluidand electrolyte disturbances, as responseis unpredictable. Resistance may develop inpatientswithburnswhomayrequireincreaseddoses; low plasma cholinesterase activityin these patients requires dose titration formivacurium, renal or hepatic dysfunction,sever electrolyte disturbance, smoking,pregnancy (Appendix 7c), lactation, periph-eral neuropathy, demyelinating lesions, den-ervations. Neonates, severe CVS disorder,severe electrolyte imbalance, respiratoryinsufficiency or pulmonary disease","Skin flushing; hypotension, tachycardia;bronchospasm and very rarely; anaphylactoidreactions, acute myopathy have also beenreported after prolonged use in intensivecare; prolonged musculoskeletal block,wheezing or bronchial secretion, erythema,dyspnoea",Store protected from light in single dose containers.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Baclofen,Pregnancy Category-C,Schedule H,Severe chronic spasticity.,TABLETS 10 and 25 mg,INJECTIONS 20 ml ampoule (50 µg/ml).,"OralAdult- 5-10 mg thrice daily to 25 mg thrice daily Max. 100 mg daily.Child- 0.75-2.0 mg/kg daily.IntrathecalAdult Screening dose: 50 µg administered into intrathecal space by barbotage over not less than 1 minute, observe for 4-8 hours. Increase dose by 25 µg not more often every 24 hours until appropriate response is obtained or a maximum dose of 100 µg is achieved. Non responders to 100 µg dose are not suitable for intrathecal baclofen therapy. For responders with response lasting >8-12 hours the screening dose can be given as 24 hour infusion, if response lasted ≤ 8-12 hours then a dose equivalent to twice the screening dose is given as 24 hour infusion.Child- Similar to that of adult except that the screening dose to be started initially is 25 µg",Hypersensitivity, active peptic ulcer disease.,"Cerebrovascular disorder; epilepsy; severepsychotic disorder; respiratory depression;hepatic or renal impairment; elderly;pregnancy (Appendix 7c), avoid suddenwithdrawal; interactions (Appendix 6c, 6d).","Drowsiness; mental confusion; weakness;ataxia; rise in serum transaminases, suddenwithdrawal after chronic use may causehallucinations; tachycardia and seizures,respiratory or cardiovascular depression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Neostigmine,Pregnancy Category-C,Schedule H,"Myasthenia gravis; reversal ofnon-depolarizing neuromuscular block,postoperative urinary retention.",TABLETS 15 mg, INJECTION 1 and 5 ml ampoule (0.5 mg/ml).,"Subcutaneous or intramuscular injectionAdult- Myasthenia gravis: as neostigmine metilsulfate: 0.5 to 2.5 mg as required, total daily dose 5 to 20 mg.Child- 200-500 µg as required. Neonate: 50 to 250 µg 30 min before feeds (not usually required beyond 8 weeks of age)",Recent intestinal or bladder surgery,mechanical intestinal or urinary tractobstruction, after suxamethonium,pneumonia, peritonitis.,"Asthma;urinarytractinfections;cardiovasculardisease including arrhythmias (especiallybradycardia, vagotonia, recent myocardialinfarction or atrioventricular block);hyperthyroidism; hypotension; peptic ulcer;epilepsy; parkinsonism; renal impairment;lactation (Appendix 7b); pregnancy (Appendix7c); interactions (Appendix 6c)","Increased salivation, nausea and vomiting,abdominal cramps, diarrhoea; signs ofoverdosage include bronchoconstriction,increased bronchial secretions, lacrimation,excessive sweating, involuntary defecationand micturition, miosis, nystagmus,bradycardia, heart block, arrhythmias,hypotension, agitation, excessive dreaming,weakness eventually leading to fasciculationand paralysis; thrombophlebitis reported;rash associated with bromide salt,anaphylaxis; dizziness; rash; frequenturination.",Tablets: Store protected from light and moisture. Injection: Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pancuronium,Pregnancy Category-C,Schedule H,Adjunct to general anaesthesia to facilitatetracheal intubation and to provide skeletalmuscle relaxation during surgery ormechanical ventilation.,INJECTION 2 ml ampoule (2 mg/ml).,"Intravenous injectionAdult- Initially 50 to 100 µg/kg body weight, 10-20 µg/kg body weight for maintenance dose.Neonates- 30-40 µg/kg body weight","Anuria, reduced airway control, lactation. ","Refer Atracurium; hypermagnesemia, hyper-calcemia, hyperkalemia, hypoproteinemia;pregnancy (Appendix 7c).","Skin flushing, hypotension, tachycardia,bronchospasm, anaphylactoid reactions,acute myopathy have also been reportedafter prolonged use in intensive care.",Store protected from light in single dose container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pyridostigmine,Pregnancy Category-C,Schedule H,Myasthenia gravis,"TABLETS 30, 60 and 180 mg","OralAdult- Myasthenia gravis: initially 30 to 120 mg at suitable intervals throughout the day, gradually increased until desired response obtained, total daily dose within range 0.3 to 1.2g, taken at appropriate intervals when max. strength required.Child- Up to 6 years: initially 30 mg. 6 to 12 years initially 60 mg; dose may be gradually increased by 15-30 mg on daily basis.",Recent intestinal or bladder surgery,gastrointestinal or urinary tract obstruction,after suxamethonium, pneumonia,peritonitis.,Asthma,urinarytractinfection,cardiovasculardisease including arrhythmias (especiallybradycardia or atrioventricular block),hyperthyroidism, hypotension, peptic ulcer,epilepsy, parkinsonism, renal impairment,pregnancy (Appendix 7c), lactation.,"Muscarinic effects generally weaker thanwith neostigmine: increased salivation,nausea, vomiting, abdominal cramps, diar-rhoea; signs of overdosage include bronchoc-onstriction, increased bronchial secretions,lacrimation, excessive sweating, involuntarydefecation and micturition, miosis, nystag-mus, bradycardia, heart block, arrhythmias,hypotension, agitation, excessive dreaming,weakness eventually leading to fascicula-tion and paralysis; thrombophlebitis; rashassociated with bromide salt; diaphoresis,increased peristalsis",Store protected from light and moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Succinyl Choline Chloride,Pregnancy Category-C,Schedule H,"Short-term muscle relaxation needed forsurgical or diagnostic procedures; adjunctto general anesthesia, facilitate trachealintubation","INJECTION 50, 100 and 500 mg Vial (50 mg/ml)","Intravenous injectionInitially 1 mg/kg body weight, maintenance by 0.5 to 1 mg/kg body weight every 5 to 10 min interval (max 500 mg).Intravenous infusion1 to 2 mg/ml (0.1 to 0.2%), reduce infusion rate in child",Low serum levels of serum cholinesterase,myasthenia gravis, hypokalemia, glaucoma,"Severe burns, pregnancy (Appendix 7c),should not be administered until anaestheticis fully effective, hepatic and renal failure,reduced plasma cholinesterase activity.","Cardiac arrest, malignant hyperthermia,arrhythmia, increased intraocular pressure;jaw rigidity; muscle pain.",Store protected from light. Injection should not be allowed to freeze.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Acetazolamide,Pregnancy Category-C,Schedule H,As an adjunct in the treatment of chronicopen-angle glaucoma, secondary glaucoma,as part of pre-operative treatment of acuteangle-closure glaucoma.,TABLET 250 mg, CAPSULE 250 mg,OralAdult- 0.25 to 1g daily in divided doses.,"Hypersensitivity to sulfonamides; chronicangle-closure glaucoma (may mask dete-rioration); hypokalaemia, hyponatraemia,hyperchloraemic acidosis; renal impairment(Appendix 7d), severe hepatic impairment;renal hyperchloremic acidosis, addison’s dis-ease","Elderly; lactation; diabetes mellitus;pulmonary obstruction; monitor bloodcount and electrolytes if used for longperiods; interactions (Appendix 6b, 6c);pregnancy (Appendix 7c); severe respiratoryacidosis.May impair ability to perform skilled tasks, for example operating machinery, driving.","Nausea, vomiting, diarrhoea, tastedisturbance; loss of appetite, paraesthesia,flushing, headache, dizziness, fatigue,irritability, depression; thirst, polyuria;reduced libido; metabolic acidosisand electrolyte disturbances on long-term therapy; occasionally drowsiness,confusion, hearing disturbances, urticaria,melaena, glycosuria, haematuria; abnormalliver function; renal calculi, blooddisorders including agranulocytosis andthrombocytopenia; rashes including Stevens-Johnson syndrome and toxic epidermalnecrolysis; transient myopia reported; blooddyscrasias; crystalluria.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Betaxolol,Pregnancy Category-C,Schedule H,Glaucoma.,EyE DROPS 5 ml (0.5% w/v),"Instillation into the eyeAdult- 1 to 2 drops, twice daily.Child- Not recommended.","Systemic absorption may follow topicalapplication to the eyes, therefore they arecontraindicated in patients with bradycardia,heart block, or uncontrolled heart failure;hypersensitivity.","Avoid in asthma, poor cardiac reserve,hepatic impairment; not for injection;pregnancy (Appendix 7c).","Ocular stinging, burning, pain, itching,erythema, dry eyes and allergicreactions including anaphylaxis andblepharoconjunctivitis; occasionally cornealdisorders have been reported; crusty taste,photophobia, corneal punctuate staining,decreased corneal sensitivity, keratitis,anisocoria; headache; sleep disturbances.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Clonidine,Pregnancy Category-C,Schedule H,Long term treatment of glaucoma and ocularhypertension,"EyE DROPS 0.125%, 0.2%, 0.25% and0.5%w/v.",,,"Patients with coronary insufficiency;interactions (Appendix 6a, 6c), pregnancy(Appendix 7c).",Systemic hypotension, sedation, syncope.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Latanoprost,Pregnancy Category-C,Schedule H,To lower intraocular pressure in open angleglaucoma or ocular hypertension.,EyE DROPS 0.005% w/v.,One drop once daily in the evening.,Hypersensitivity.,"Patients with a history of intraocularinflammation (iritis/uveitis) or activeintraocular inflammation, with torn posteriorlens capsule, brittle or severe asthma,inflammatory, angle closure or congenitalglaucoma, pregnancy (Appendix 7c),lactation, interactions (Appendix 6c)","Conjunctival hyperaemia, iris pigmentation;upper respiratory tract infection; cold, flu;darkening and thickening of eyelashes, eyelidskin darkening; intraocular inflammation,ocular irritation and pain; exacerbation ofasthma; blepharitis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Physostigmine,Pregnancy Category-C,Schedule H,Glaucoma in conjunction with other drugsand not alone (as it is very potent),EyE DROPS 5 ml (0.25%w/v),"Instillation into the eyeAdult-1 to 2 drops, 4 to 5 times daily",,"Care to be taken when administered intoeye, pregnancy (Appendix 7c).","Twitching lids, myopia, ocular and periorbitalpain, cilliary and conjuctival congestion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pilocarpine,Pregnancy Category-C,Schedule H,"Chronic open-angle glaucoma, ocularhypertension; emergency treatment of acuteangle-closure glaucoma; to antagonizeeffects of mydriasis and cycloplegia followingsurgery or ophthalmoscopic examination;Accommodative esotropia.","EyE DROPS 5 ml (2% w/v, 4%w/v).","Instillation into the eyeAdult- Chronic open-angle glaucoma before surgery: 1 drop (2% or 4 %) up to 4 times daily.Acute angle closure glaucoma before surgery: 1 drop (2%) every 10 min for 30 to 60 min, then 1 drop every 1 to 3 h until intra-ocular pressure subsides","Acute iritis, acute uveitis, anterior uveitis,some forms of secondary glaucoma; acuteinflammation of anterior segment; notadvisable after angle-closure surgery (risk ofposterior synechiae).","Retinal disease, conjunctival or cornealdamage; monitor intra-ocular pressurein chronic open-angle glaucoma and inlong-term treatment; cardiac disease,hypertension; asthma; peptic ulceration;urinary-tractobstruction;Parkinson’sdisease;stop treatment if symptoms of systemictoxicity develop; ulcer; hyperthyroidism;seizures.Causes difficulty with dark adaptation; may cause accommodation spasm. Do not carry out skilled tasks, for example operating machinery or driving until vision is clear, pregnancy (Appendix 7c).","Eye pain, blurred vision, ciliary spasm,lacrimation, myopia, browache; conjunctivalvascular congestion, superficial keratitis,vitreous haemorrhage and increasedpupillary block; lens opacities have occurredfollowing prolonged use; rarely, systemiceffects including hypertension, tachycardia;bronchial spasm, pulmonary oedema;salivation; sweating; nausea, vomiting,diarrhoea; flushing, rhinitis, chills, middleear disturbances.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Timolol,Pregnancy Category-C,Schedule H,"Ocular hypertension; chronic open-angleglaucoma, aphakic glaucoma, somesecondary glaucomas","DROPS 5 ml (0.2% w/v, 0.25% and 0.5%w/v);GEL (0.5%/5 ml).",Instillation into the eyeAdult- 1 drop (0.25% or 0.5%) twice daily.,"Uncontrolled heart failure, bradycardia,heart block; asthma, obstructive airwaysdisease; hypersensitivity.","Older people (risk of keratitis); if used inangle-closure glaucoma, use with a miotic,and not alone; interactions (Appendix 6c);pregnancy (Appendix 7c).","Stinging, burning, pain, itching, erythema,transient dryness, allergic blepharitis,transient conjunctivitis, keratitis, decreasedcorneal sensitivity, diplopia, ptosis; systemiceffects; particularly on the pulmonary,cardiovascular and central nervous systems,may follow absorption; blurred vision;headache.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Acyclovir,Pregnancy Category-B,Schedule H,"Treatment of Herpes simplex keratitis; longterm suppression of skin infections in Herpessimplex as well as mucous membrane,prophylaxis in immunocompromised patients;Herpes zoster treatment.",OINTMENT 5g (3% w/w), DROPS 5 ml (3%w/w).,Adult- Herpes simplex keratitis: apply 3% w/w ointment 5 times daily for 3 days.,Hypersensitivity.,Maintain adequate hydration (especially withinfusion or high doses), monitor neutrophilcount at least twice weekly in neonates,renal impairment (Appendix 7d), lactation(Appendix 7b), pregnancy (Appendix 7c), notto be applied on mucous membrane.,"Nausea, vomiting, abdominal pain, diarrhoea,headache, fatigue, rash, urticaria, pruritus,photosensitivity; very rarely, hepatitis,jaundice; dyspnoea; neurological reactions(includingdizziness,confusion,hallucinations,convulsions and drowsiness); acute renalfailure; anaemia, thrombocytopenia andleucopenia; on intravenous infusion; severelocal inflammation (sometimes leadingto ulceration), and very rarely, agitation,tremors; psychosis and fever; increase inblood urea and creatinine, encephalopathy;seizures; anorexia, tremors.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Chloramphenicol,Pregnancy Category-C,Schedule H,"Susceptible bacterial infection; corneal ulcers,intraocular infection, keratoconjuctivits sicca","OINTMENT (1%w/w); DROPS (1%w/v, 0.5%w/v); SUSPENSION 125 mg/5 ml.","Doses instilled into affected eye 3 to 4 times daily. Ointment at night, preferably at bed time","Pregnancy (Appendix 7c), lactation (Appendix7b), porphyria; hypersensitivity",Avoid repeated courses and prolongedtreatment, reduce doses in hepatic impair-ment (Appendix 7a), renal impairment,blood counts required before and peri-odically during treatment, monitor plasma-chloramphenicol concentration in neonates,interactions: (Appendix 6c).,"Blood disorders including reversible andirreversible aplastic anaemia (with reportsof resulting leukaemia); peripheral neuritis,optic neuritis; headache; depression; urticar-ia, erythema multiforme; nausea, vomiting,diarrhoea; stomatitis, glossitis, dry mouth;nocturnal haemoglobinuria; grey syndrome(abdominal distension, pallid cyanosis, circu-latory collapse) may follow excessive doses inneonates with immature hepatic metabolism.",Store protected from moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ciprofloxacin,Pregnancy Category-C,Schedule H,Bacterial infections of eye,"TABLETS 250, 500 and 750 mg; INJECTION100 ml infusion (20 mg/10 ml); OINTMENT 5g(0.3% w/w); DROPS 5 and 10 ml (0.3% w/v).",Adult and child above 12 years- Instill 2 to 3 drops in affected eye 3 to 4 times daily to start with thereafter reduce slowly as infection subsides. Apply about 0.5 cm ribbon of ointment in lower conjuctival sac for 3 to 4 times daily. Reduce as infection subsides.,Epilepsy and hypersensitivity to quinolones,"It should be used with caution in patientswith a history of epilepsy or conditions thatpredispose to seizures; in G-6-PD deficiency;myasthenia gravis (risk of exacerbation); inrenal impairment (Appendix 7d); pregnancy(Appendix 7c), during lactation (Appendix7b), and in children or adolescents. Exposureto excessive sunlight should be avoided(discontinue if photosensitivity occurs).Avoid excessive alkalinity of urine and ensureadequate fluid intake (risk of crystalluria);interactions (Appendix 6c); paediatric use.","Nausea, vomiting, dyspepsia, abdominalpain, diarrhoea (rarely, antibiotic-associatedcolitis); headache; dizziness; sleep disorders;rash (rarely, Stevens-Johnson syndrome andtoxic epidermal necrolysis) and pruritus.Less frequent side-effects include anorexia,increase in blood urea and creatinine;drowsiness,restlessness,asthenia,depression,confusion, hallucinations, convulsions,tremor, paraesthesia, hypoaesthesia;photosensitivity, hypersensitivity reactionsincluding fever, urticaria, angioedema,arthralgia, myalgia, and anaphylaxis; blooddisorders (including eosinophilia, leucopenia,thrombocytopenia); disturbances in vision,taste, hearing and smell. Other side-effectsthat have been reported include haemolyticanaemia, renal failure, interstitial nephritis,and hepatic dysfunction (including hepatitisand cholestatic jaundice). The drug shouldbe discontinued if psychiatric, neurological orhypersensitivity reactions (including severerash)occur.Ophthalmicsolution:localburning,discomfort, corneal ulcers, lid oedema,corneal infiltration. Ointment: discomfort,keratopathy, blurred vision, corneal staining,epitheliopathy, photophobia.",Ointment: Store protected from light at a temperature not exceeding 30⁰C. Drops: Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Gentamicin,Pregnancy Category-C,Schedule H,"Blepharitis; bacterial conjunctivitis; keratitis,corneal ulcers",OINTMENT (1% w/w), DROPS 5 ml (0.3%w/v).,"Instillation into the eyeAdult- Mild to moderate infections: 1 drop every 2 h, reducing frequency as infection is controlled, then continue for 48 h after healing is complete.",Hypersensitivity to aminoglycoside group ofantibiotics.,"Prolonged use may lead to skin sensitizationand emergence of resistant organismsincluding fungi; discontinue if purulentdischarge, inflammation or exacerbationof pain; ophthalmic ointment may retard corneal healing, renal impairment (Appendix 7d), interactions (Appendix 6c), pregnancy (Appendix 7c).",Burning, stinging, itching, dermatitis,conjuctival epithelial defects,conjuctivalhyperemia, thrombocytopenic purpurea,hallucination,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Miconazole,Pregnancy Category-C,Schedule H,Fungal infections of eye,DROPS 5 and 10 ml (1%w/v).,Adult and child- Fungal infection of eye: instill 2 to 3 drops 3 to 4 times a day in infected eye or as required.,Hypersensitivity.,"Contact with eyes and mucous membranesshould be avoided, pregnancy (Appendix 7c).","Occasional local irritation and hypersensitivityreactions include mild burning sensation,erythema; pruritus and itching. Treatmentshould be discontinued if these are severe.",Drops: Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Oxytetracycline,Pregnancy Category-D,Schedule H,"Infections caused by susceptible pathogens,uncomplicated gonorrhoea, externalbacterial infections of the eye, acne vulgaris.",CAPSULES 250 and 500 mg. INJECTION50 mg/ml and 125 mg/ml. OPHTHALMICOINTMENT 1% w/w.,"OralInfections caused by susceptiblepathogens:Adult-250-500 mg 4 times daily. Max. dose-4g daily.Child (above 8 yrs)- 25-50 mg/kg daily in 4divided doses.Therapy should be continued for at least24–48 hours after symptoms and fever havesubsided.Uncomplicated gonorrhoea: Adult- Initially1.5 g, followed by 0.5 g 4 times daily upto atotal of 9 g per treatment course.Acne vulgaris: Adult- 250-500 mg twice daily.IntramuscularInfections caused by susceptible pathogens:Adult- 250 mg once daily.Child (above 8 yrs)- 15-25 mg/kg daily in 2-3divided doses (Max. 250 mg).OphthalmicExternal bacterial infections of the eye:Adult- Apply the ointment 2-3 times daily.","Hypersensitivity to tetracyclines, childrenbelow 8 years, renal impairment, pregnancy(Appendix 7c), lactation.","Hepatic impairment, myasthenia gravis,porphyria, elderly, interactions (Appendix6b, 6c).","GI disturbances, abdominal pain, headache,anorexia, tooth discolouration, allergicreactions, photosensitivity, blurredvision, nephrotoxicity, stinging of the eye,intracranial hypertension, blood dyscrasias.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Povidone, Sulphacetamide",Pregnancy Category-C,Schedule H,"Sulphonamide sensitive infections of eye;blepharitis, conjuctivits, vaginosis.","DROPS 10 ml (10, 20 and 30%w/v)",Instill 2 to 3 drops in infected eye 4 to 5 times a day or as required.,Renal failure, corneal infection,"Pregnancy (Appendix 7c), lactation","Corneal plaques, erythema multiforme,blurred vision, stinging on application",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tetracycline,Pregnancy Category-D,Schedule H,Superficial bacterial infection of the eye,mass treatment of trachoma in endemicareas, prophylaxis of neonatal conjunctivitis(ophthalmia neonatorum) due to Neisseriagonorrhoea or Chlamydia trachomatis,OINTMENT (1% w/w), CAPSULE 250 and500 mg.,"Application to the eyeAdult- Superficial bacterial infection: 1 application of ointment, 3 to 4 times daily.Trachoma, intermittent treatment: 1 application of ointment into each eye either twice daily for 5 days or once daily for 10 days, every month for 6 consecutive months each year, repeated as necessary.Trachoma, continuous intensive treatment: 1 application of ointment into each eye twice daily for at least 6 weeks.Child (over 8 years)- Superficial bacterial infection: 1 application of ointment 3 to 4 times daily. Prophylaxis of neonatal conjunctivitis; newborn at birth after cleansing eyes with sterile gauze: 1 application of ointment into each eye; close eyelids and massage gently to aid spread of ointment.Trachoma, intermittent treatment: 1 application of ointment into each eye either twice daily for 5 days or once daily for 10 days, every month for 6 consecutive months each year, repeated as necessary.Trachoma, continuous intensive treatment: 1 application of ointment into each eye twice daily for at least 6 weeks.",Hypersensitivity to tetracycline group ofantibiotics.,Prolonged use may lead to overgrowth of non-susceptible organisms, lactation (Appendix7b), interactions (Appendix 6d), pregnancy(Appendix 7c).,Rash, stinging, burning,Store protected from moisture at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Prednisolone,Pregnancy Category-C,Schedule H,Short-term local treatment of inflammationof the eye, malignant disease, inflammatoryand allergic reactions.,"TABLETS 5, 10, 20 and 40 mg; DROPS 5 ml(1% w/v).","Doses to be instilled into affected eye 3 to 4 times daily. Ointment at night, preferably at bed time",Undiagnosed ‘red eye’ caused by herpetickeratitis, glaucoma, viral diseases of corneaand conjunctiva,"Cataract, corneal thinning, corneal orconjunctival infection; discontinue treatmentif no improvement within 7 days; risk ofadrenal suppression after prolonged usein infants; hepatic impairment (Appendix7a); lactation (Appendix 7b); interactions(Appendix 6c, 6d); pregnancy (Appendix 7c).","Secondary ocular infection; impaired cornealhealing (due to corneal thinning), optic nervedamage, cataract; glaucoma, mydriasis,ptosis, epithelial punctate keratitis, delayedhypersensitivity reactions including burning,stinging.","Tablets: Store protected from light. Injection: Store protected from light, in a single dose or in multi dose containers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Xylometazoline,Pregnancy Category-C,Schedule H,"Nasal congestion, conjunctival decongestant",DROPS 10 and 15 ml (0.05 to 0.1 %w/v).,Instill 3 to 4 drops every 3 to 4 h or as required.,"Narrow angle glaucoma, atrophic rhinitis, vasomotor rhinitis","Avoid excessive or prolonged use; caution ininfants under 3 months (no good evidenceof value-if irritation occurs, might narrownasal passage); infants and cardiac patients;pregnancy (Appendix 7c)","Local irritation, nausea, headache; afterexcessive use tolerance with diminishedeffect, rebound congestion; cardiovasculareffects also reported; dryness of eye andnose, rhinitis medicamentose.",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tetracaine,Pregnancy Category-C,,Short-acting local anaesthesia of cornea andconjunctiva.,DROPS (0.5 and 1% w/v),Instillation into the eyeInstill 2 to 3 drops every 15 to 20 min till the desired effect is achieved.Adult & Child- 1 drop.,Hypersensitivity to ester-type localanaesthetics, eye inflammation or infection.,"Avoid prolonged use (cause of severekeratitis, permanent corneal opacification,scarring, delayed corneal healing); protecteye from dust and bacterial contaminationuntil sensation fully restored; not to beapplied on highly vascular surface; pregnancy(Appendix 7c).","Burning, stinging, redness; rarely, allergicreactions may occur; twitching; nystagmus;numbness of tongue; convulsions.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Atropine,Pregnancy Category-C,Schedule H,"Iritis, uveitis; cycloplegic refraction procedures; iridocyclitis",DROPS 5 ml (1% w/v),"Instillation into the eyeAdult- Cycloplegic refraction: 1 drop (1%) twice daily for 1 to 2 days before procedure or a single application of 1 drop (1%), 1 h before procedure.Iritis and uveitis: 1 drop (0.5 to 1%) up to 4 times daily.Child- Cycloplegic refraction: 3 months to 1 year: 0.1%; 1 to 5 years: 0.1 to 0.5%; Over 5years: 0.5 to 1.0%. 1 drop twice daily for 1 to 3 days before procedure with a further dose given 1 h before procedure.Iritis and uveitis: 1 drop (0.5 to 1% w/v) up to 3 times daily.",Angle-closure glaucoma, pregnancy(Appendix 7c).,"May precipitate acute attack of angle-closure glaucoma, particularly in the elderlyor far-sighted; risk of systemic effects witheye drops in infants under 3 months-eyeointment preferred. May cause sensitivity to light and blurred vision. Do not carry out skilled tasks, for example operating machinery or driving, until vision is clear, lactation (Appendix 7b); interactions (Appendix 6a).","Transient stinging and raised intra-ocularpressure; on prolonged administration,local irritation, hyperaemia, oedema andconjunctivitis may occur; contact dermatitis;systemic toxicity may occur in the very youngand the elderly; blurred vision, dry mouth,photophobia.",Store at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Epinephrine,Pregnancy Category-C,Schedule H,"Chronic open-angle glaucoma, ocularhypertension.","DROPS 0.25 ml (2%w/v), 5 ml (5%w/v);OINTMENT 3g.","1 to 2 drops in affected eye, every 4 to 6 h","Angle closure glaucoma, unless an iridectomyhas been carried out; occlusive vasculardisease.","Hypertension, heart disease, aneurysm,arrhythmias, tachycardia; hyperthyroidism;cerebral arteriosclerosis; diabetes mellitus;elderly, interactions (Appendix 6c); pregnancy(Appendix 7c); lactation (Appendix 7b).","Stinging, blurred vision, photophobia, eyepain, conjunctival hyperaemia, headacheor browache; occasionally, conjunctivalsensitization and local skin reactions; afterprolonged use conjunctival pigmentationand macular oedema in aphakia; systemicadverse reactions are rare following topicaluse at normal dosage but tachycardia,hypertension, arrhythmia, dizziness,sweating may occur; dyspnoea, weakness.",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Homatropine,Pregnancy Category-C,,To dilate pupil and paralyze ciliary muscle for fundus examination.,DROPS 5 ml (2%w/v).,Adult- 1 to 2 drops in each eye till the desired effect is achieved.Child- 1 to 2 drops in each eye till the desired effect is achieved.,"Narrow angle glaucoma, tendency forglaucoma.","Darkly pigmented iris is more resistant topupillary dilatation and caution should beexercised to avoid overdosage. Mydriasis canprecipitate acute angle-closure glaucoma ina few patients, usually aged over 60 yearsand hypermetropic (long-sighted), who arepredisposed to the condition because of ashallow anterior chamber; glaucoma, checkintraocular pressure before use; pregnancy(Appendix 7c).","Ocular side-effects of mydriatics andcycloplegics include transient stinging andraised intra-ocular pressure; on prolongedadministration, local irritation, hyperaemia,oedema and conjunctivitis can occur. Contactdermatitis can occur with the antimuscarinicmydriatic drugs, especially atropine. Systemicside-effects of atropine and cyclopentolatecan occur in the young and the old; posteriorsynechia, headache, drowsiness, loss oftaste, photophobia, brow ache, lacrimation.",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Phenylephrine,Pregnancy Category-C,Schedule H,"Used in cough syrups, hypotension; mydriaticfor eye conditions; uveitis, wide angleglaucoma, refraction, ophthalmoscopicexaminations.",DROPS 5 ml (5% w/v).,"1 to 2 drops in affected eye, every 4 to 6 h",Hypertension (monitor blood pressure andrate of flow frequently), pregnancy (Appendix7c), narrow angle glaucoma.,"Coronary, mesenteric, or peripheralvascular thrombosis; following myocardialinfarction, Prinzmetal's variant angina;hyperthyroidism, diabetes mellitus; hypoxiaor hypercapnia; uncorrected hypovolaemia;elderly; extravasation at injection site maycause necrosis; infants.","Headache, hypertension, bradycardia,arrhythmias, peripheral ischaemia.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Alprazolam,Pregnancy Category-D,Schedule H,Anxiety disorders, panic attacks,"TABLETS 0.25, 0.5 and 1 mg",OralAdult- 0.25 to 0.5 mg daily 2 to 3 times a day.Child- Not recommended.,"Respiratory depression; markedneuromuscular respiratory weaknessincluding unstable myasthenia gravis; acutepulmonary insufficiency; sleep apnoeasyndrome; severe hepatic impairment;not for chronic psychosis; should not beused alone in depression or in anxiety withdepression; avoid injections containingbenzyl alcohol in neonates; narrow angleglaucoma, hypersensitivity.","Respiratory disease; muscle weaknessand myasthenia gravis; history of drug oralcohol abuse; marked personality disorder;pregnancy (Appendix 7c), lactation; reducedose in elderly and debilitated and inhepatic impairment, renal impairment;avoid prolonged use (and abrupt withdrawalthereafter); interactions (Appendix 6a);periodic blood count; liver function test.Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced","Drowsiness and lightheadedness on the nextday; confusion and ataxia (especially in theelderly); amnesia; dependence; paradoxicalincrease in aggression; muscle weakness;occasionally: headache, vertigo, hypotension,salivation changes, gastro-intestinaldisturbances, visual disturbances, dysarthria,tremor, changes in libido, incontinence,urinary retention; blood disorders andjaundice reported; skin reactions; rarely,apnoea and insomnia.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Diazepam,Pregnancy Category-D,Schedule H,"Short-term treatment of anxiety and insom-nia; status epilepticus, recurrent seizures;febrile convulsions, adjunct in acute alcoholwithdrawal; premedication; agitation","TABLETS 2.5, 5 and 10 mg; INJECTION 10mg/2 ml; CAPSULES 10 and 15 mg.","OralAdult- Anxiety: 2 mg 3 times daily, increased if necessary to 15 to 30 mg daily in divided doses. Insomnia: 5 to 15 mg at bedtime. Child- Oral 1-2.5 mg, 3 or 4 times daily (Not for use under 6 months).Elderly or debilitated- Anxiety: half adult dose.",Respiratory depression, acute pulmonaryinsufficiency, sleep apnoea, severehepatic impairment, myasthenia gravis,hypersensitivity,"Respiratorydisease;muscleweakness;historyof alcohol or drug abuse; marked personalitydisorder; lactation (Appendix 7b); reducedose in elderly or debilitated and in hepaticimpairment (avoid if severe, Appendix 7a);renal impairment; avoid prolonged use andabrupt withdrawal; porphyria; interactions(Appendix 6a, 6c); pregnancy (Appendix 7c);liver function test to be done, least amountof drug should be given in patients in whomdepression accompanies anxiety and suicidaltendencies.May impair ability to perform skilled tasks, for example operating machinery, driving.","Drowsiness and lightheadedness the nextday; confusion and ataxia (especially in theelderly); amnesia; dependence; paradoxicalincrease in aggression; muscle weakness;occasionally headache, vertigo, salivationchanges, gastrointestinal disturbances, visualdisturbances, dysarthria, tremor, changes inlibido, incontinence, urinary retention; blooddisorders and jaundice; skin reactions; raisedliver enzymes; reduces reflexes; jaundice;psychological dependence; physiologicaldependence, respiratory arrest.",Tablet: Store protected from light. Injection: Store in single dose or multi dose container protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Lorazepam,Pregnancy Category-D,Schedule H,Anxiety disorders,"TABLETS 0.5, 1, 2, 2.5 and 3 mgINJECTIONS 2 ml ampoule (2 mg/ml)","2 to 6 mg/day given in divided doses, initial dose of 2 to 3 mg/day given twice or thrice a day.Elderly or debilitated patients: Initial dosage of 1 to 2 mg/day in divided doses.","Severe hepatic impairment; respiratorydepression; acute narrow angle glaucoma;pregnancy (Appendix 7c), lactation.",Hepatic dysfunction, impaired ability todrive or operate machinery, interactions(Appendix 6a).,"Nausea and vomiting, dizziness; weakness; blurred vision; vertigo.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Nitrazepam,Pregnancy Category-D,Schedule H,"Insomnia; epilepsy, vertigo, infantile spasm.","CAPSULES/TABLETS 2.5, 5 and 10 mg","OralInsomnia- 5 to 10 mg at bed time.ChildInfantile spasm- 125 µg/kg twice daily, gradu- ally increase to 250-500 µg/kg twice daily.",Respiratory depression, marked neuromus-cular respiratory weakness including un-stable myasthenia gravis, acute pulmonaryinsufficiency, severe hepatic impairment,sleep apnoea syndrome, not for use alone totreat depression (or anxiety associated withdepression) or chronic psychosis.,"Muscle weakness and myasthenia gravis;history of drug or alcohol abuse; markedpersonality disorder; pregnancy (Appendix7c), lactation; reduce dose in elderly anddebilitated, and in hepatic impairment andrenal impairment; avoid prolonged use (andabrupt withdrawal thereafter); porphyria;interactions (Appendix 6a); blood count,increased salivation.Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.","Drowsiness and lightheadedness the nextday; confusion and ataxia (especially in theelderly); amnesia may occur; dependence;aggression, anaphylaxis, dysarthria, blurredvision, slurred speech.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Zolpidem,Pregnancy Category-C,Schedule H,Short term management of insomnia,"TABLETS 5 and 10 mg, 6.25 and 12.5 mg CR,CAPSULES 5 and 10 mg.","Adult- 10 mg immediately before bed time, maximum 10 mg/day, controlled release tablets 12.5 mg immediately before bed time.Elderly- 5 mg before bed time.",Severe hepatic insufficiency.,"Myasthenia gravis; depressed patients;hazardous occupations requiring completemental alertness or motor coordinationsuch as operating machinery or driving amotor vehicle; obstructive sleep apnoea,compromised respiratory function;pregnancy (Appendix 7c), lactation,interactions (Appendix 6a,6c).","Abnormal thinking, behaviour changes, andcomplex behaviours, withdrawal effects,CNS-depressant effects, ataxia, confusion,diplopia, euphoria; hepatitis; anaphylacticreactions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Amitriptyline,Pregnancy Category-C,Schedule H,"Moderate to severe depression, migraineprophylaxis; tension, headache, enuresis","TABLETS 10, 25, 50 and 75 mg; INJECTION10 ml ampoule (10 mg/ml)",OralAdult- Initially 75 mg (adolescents 30 to 75 mg) daily in divided doses or as a single dose at bed time increased gradually as necessary to 150 to 200 mg daily. Prophylaxis of migraine: 10-75 mg at night.Child- Under 16 years, not recommended.,"Recent myocardial infarction, arrhythmias(especially heart block); manic phase in bipo-lar disorders; severe liver disease; children;porphyria; glaucoma, prostatic hypertrophy.","Cardiacdisease(seeContraindicationsabove);history of epilepsy; lactation (Appendix 7b);elderly; hepatic impairment (Appendix 7a);thyroid disease; pheochromocytoma; historyof mania, psychoses (may aggravate psychoticsymptoms); angle-closure glaucoma;history of urinary retention; concurrentelectroconvulsive therapy; avoid abruptwithdrawal; anaesthesia (increased risk ofarrhythmias and hypotension); interactions(Appendix 6a, 6b, 6c); pregnancy (Appendix7c); pre-existing haematological disorder,abrupt disorientation.May impair ability to perform skilled tasks, for example operating machinery, driving.","Sedation; dry mouth; blurred vision (distur-bance of accommodation, increased intraocu-lar pressure); constipation; nausea; difficultyin micturition; cardiovascular adverse effectsparticularly with high dosage including ECGchanges, arrhythmias, postural hypoten-sion, tachycardia, syncope; sweating, tremor,rash and hypersensitivity reactions (urticaria,photosensitivity); behavioural disturbances;hypomania or mania, confusion (particularlyin elderly), interference with sexual func-tion, blood sugar changes; increased appe-tite and weight gain (occasional weight loss);endocrine adverse effects such as testicularenlargement, gynaecomastia and galactor-rhoea; convulsions, movement disorders anddyskinesias, fever, agranulocytosis, leukope-nia, eosinophilia, purpura, thrombocytopenia,hyponatraemia (may be due to inappropriateantidiuretic hormone secretion); abnormalliver function test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Escitalopram,Pregnancy Category-C,,"Depression, obsessive compulsive disorder,anxiety disorder, panic disorder.","TABLETS 5, 10 and 20 mg.",Initially 10 mg once daily. Maximum- 20 mg daily.,"Concomitant use with MAO Inhibitors,thioridazine","History of panic disorder or seizure disorders,renal impairment, hepatic impairment, workrequiring mental alertness, concomitant useof escitalopram with other SSRIs, serotonin–norepinephrine reuptake inhibitors (SNRIs)or tryptophan, interactions (Appendix 6c),pregnancy (Appendix 7c).","Insomnia, nausea, ejaculation disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Fluoxetine,Pregnancy Category-C,Schedule H,"Major depression (including pediatric de-pression); obsessive-compulsive disorder(in both adult and pediatric populations);bulimia nervosa; anorexia nervosa; panicdisorder and premenstrual dysphoric disor-der; depression illness, Parkinson’s disease","TABLETS 10, 20, 40 and 60 mg; CAPSULES10, 20 and 60 mg",Oral20 mg/day initially (max 60 mg).,"Should not be used if the patient enters amanic phase; renal failure, hypersensitivity.","Should be used with caution in patientswith epilepsy (avoid if poorly controlled,discontinue if convulsions develop), cardiacdisease, diabetes mellitus, susceptibility toangle-closure glaucoma, a history of maniaor bleeding disorders (especially gastro-intestinal bleeding), and if used with otherdrugs that increase the risk of bleeding,hepatic impairment (Appendix 7a), renalimpairment, pregnancy (Appendix 7c),and lactation. They should also be usedwith caution in those receiving concurrentelectroconvulsive therapy (prolongedseizures reported with fluoxetine). The riskof suicidal behaviour is possibly higher inyoung adults, calling for close monitoring ofthose receiving SSRIs. SSRIs may also impairperformance of skilled tasks (e.g. driving),interactions (Appendix 6a, 6c).","Gastro-intestinal effects (dose-related andfairly common-include nausea, vomiting,dyspepsia, abdominal pain, diarrhoea, consti-pation), anorexia with weight loss (increasedappetite and weight gain also reported) andhypersensitivity reactions including rash(consider discontinuation-may be sign ofimpending serious systemic reaction, pos-sibly associated with vasculitis), urticaria,angioedema, anaphylaxis, arthralgia, myal-gia and photosensitivity; other side-effectsinclude dry mouth, nervousness,anxiety,headache, insomnia, tremor, asthenia, hallu-cinations, drowsiness, convulsions, galactor-rhoea, sexual dysfunction, urinary retention,sweating, hypomania or mania, movementdisorders and dyskinesias, visual disturbanc-es, hyponatraemia; serum sickness, eleva-tion of liver enzymes",Store protected from moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Imipramine,Pregnancy Category-D,Schedule H,"Panic attacks; chronic pain; nocturnalenuresis; Kleine-Levin syndrome; depression,hyperactivity, attention deficit disorder","TABLETS 5, 25 and 75 mg; CAPSULES 25 and75 mg","Oral 75 mg/day initially, usual dose 100 to 200 mg daily.Child- <6 years: not recommended, 6-12 years: 25 mg at bed time, >12 years: 50 mg at bed time.","Recent myocardial infarction, arrhythmias(particularly heart block), not indicatedin manic phase, severe liver disease;epilepsy, mania, narrow angle glaucoma,hypersensitivity.","Cardiac disease (particularly witharrhythmias), history of epilepsy, pregnancy(Appendix 7c), lactation, elderly, hepaticimpairment, interactions (Appendix 6a),thyroid disease, pheochromocytoma,history of mania, psychoses (may aggravatepsychotic symptoms), susceptibility toangle-closure glaucoma, history of urinaryretention, concurrent electroconvulsivetherapy; if possible avoid abrupt withdrawal;anaesthesia (increased risk of arrhythmiasand hypotension), see surgery; porphyria;for additional nocturnal enuresis warnings;acetylsalicylic acid hypersensitivity.Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.","Dry mouth, sedation, blurred vision (dis-turbance of accommodation, increasedintraocular pressure), constipation, nausea,difficulty with micturition; cardiovascularsideeffects (such as ECG changes, arrhyth-mias, postural hypotension, tachycardia,syncope, particularly with high doses);sweating, tremor, rashes and hypersensitiv-ity reactions (including urticaria, photosensi-tivity), behavioural disturbances (particularlychildren), hypomania or mania, confusionor delirium (particularly elderly), headache,interference with sexual function, blood sug-ar changes; increased appetite and weightgain (occasionally weight loss); endocrineside-effects such as testicular enlargement,gynaecomastia, galactorrhoea; also convul-sions, movement disorders and dyskinesias,dysarthria, paraesthesia, taste disturbances,tinnitus, fever, agranulocytosis, leucopenia,eosinophilia, purpura, thrombocytopenia,hyponatraemia (see Hyponatraemia andAntidepressant Therapy), abnormal liverfunction tests (jaundice); impairment ofmemory, cutaneous vasculitis.",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Chlorpromazine,Pregnancy Category-C,Schedule H,"Schizophrenia and other psychotic disorders,mania, psychomotor agitation and violentbehaviour; adjunct in severe anxiety;psychosis, mania, hiccups","TABLETS 25, 50 and 100 mg; SyRUP 60 ml(25 mg/5 ml); INJECTION 2 ml ampoule (25mg/ml).","OralAdult- Schizophrenia and other psychoses, mania, psychomotor agitation, violent behaviour and severe anxiety (adjuvant): initially 25 mg 3 times daily (or 75 mg at night) adjusted to response to usual maintenance dose of 100-300 mg daily (but up to 1.2g daily may be required in psychosis).Elderly or debilitated- Schizophrenia and other psychoses, mania, psychomotor agitation, violent behaviour and severe anxiety (adjunct): one-third to one-half adult dose.Child- Schizophrenia and other psychoses, mania, psychomotor agitation, violent behaviour and severe anxiety (adjunct); (for childhood schizophrenia and autism) 1 to 5 years: 500 µg/kg every 4-6 h (max. 40 mg daily). 6 to 12 years: one-third to one-half adult dose (max. 75 mg daily).Deep intramuscular injectionAdult- Relief of acute symptoms: 25 to 50 mg every 6 to 8 h.Child- Relief of acute symptoms: 500 µg/kg every 6 to 8 h (1 to 5 years: max. 40 mg daily.6 to 12 years: max. 75 mg daily).","Impaired consciousness due to CNSdepression; bone-marrow depression;pheochromocytoma; epilepsy, narrow angleglaucoma, Parkinson’s disease; depressedlevel of consciousness.","Cardiovascularandcerebrovasculardisorders,respiratory disease, parkinsonism, epilepsy,acute infections, pregnancy (Appendix 7c),lactation (Appendix 7b), renal and hepaticimpairment (avoid if severe; Appendices7a), history of jaundice, leukopenia (bloodcounts if unexplained fever or infection);hypothyroidism, myasthenia gravis, prostatichypertrophy, angle-closure glaucoma;elderly (particularly in very hot or very coldweather); avoid abrupt withdrawal; patientsshould remain supine and the blood pressuremonitored for 30 min after intramuscularinjection; interactions (Appendix 6a, 6c);extreme heat, alcohol withdrawal, pepticulcer.May impair ability to perform skilled tasks, for example operating machinery, driving.","Extrapyramidal symptoms and on prolongedadministration, occasionally potentiallyirreversible tardive dyskinesias (see notesabove); hypothermia (occasionally pyrexia),drowsiness, apathy, pallor, nightmares,dizziness, excitement, insomnia, headache,confusion, depression; more rarely, agitation;EEG changes; convulsions; nasal congestion;anticholinergic symptoms including drymouth, constipation; blurred vision, difficultyin micturition; hypotension, tachycardiaand arrhythmias; ECG changes; respiratorydepression; menstrual disturbances,galactorrhoea, gynaecomastia, impotence,weight gain; sensitivity reactions such asagranulocytosis, leukopenia, leukocytosis,haemolytic anaemia, photosensitization,contact sensitization and rashes, jaundiceand alterations in liver function; neurolepticmalignant syndrome; lupus erythematosus-like syndrome; with prolonged high dosage,corneal and lens opacities, and purplishpigmentation of the skin, cornea and retina;intramuscular injection may be painful andcause hypotension and tachycardia (seePrecautions) and nodule formation; seizures,temperature disorder, hyperprolactinemia,ocular complication.",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Fluphenazine,Pregnancy Category-C,Schedule H,"Maintenance treatment of schizophreniaand other psychoses; mania, postoperativenausea.",TABLET 1 mg, INJECTION 1 ml ampoule (25mg/ml).,"Deep intramuscular injection into glutealmuscle.Adult- Maintenance in schizophrenia and other psychoses: test dose of 12.5 mg, then after 4 to 7 days, 12.5 to 100 mg repeated at intervals of 2 to 5 weeks, adjusted according to the response.Elderly- Maintenance in schizophrenia and other psychoses: test dose of 6.25 mg, then after 4 to 7 days, 12.5 to 100 mg repeated at intervals of 2 to 5 weeks, adjusted according to the response.Child- Maintenance in schizophrenia and other psychoses: not recommended.","Children; confusional states; impairedconsciousness due to CNS depression;parkinsonism; intolerance to antipsychotics;depression; bone-marrow depression;pheochromocytoma; blood dyscrasias,coma, brain damage.","Treatment requires careful monitoringfor optimum effect; initial small testdose as adverse effects are prolonged;extrapyramidal symptoms occur frequently;when transferring from oral to depottherapy, dosage by mouth should be reducedgradually; cardiovascular and cerebrovasculardisorders; respiratory disease, epilepsy;acute infections; pregnancy (Appendix 7c),lactation (Appendix 7b); renal and hepaticimpairment (avoid if severe; Appendices7a), history of jaundice; leukopenia (bloodcounts if unexplained fever or infection);hypothyroidism, myasthenia gravis, prostatichypertrophy, angle-closure glaucoma;elderly (particularly in very hot or very coldweather); interactions (Appendix 6a, 6c);alcohol withdrawal, extreme heat.May impair ability to perform skilled tasks, for example operating machinery, driving.","As for Chlorpromazine (see above), butless sedating and fewer hypotensive andanticholinergic symptoms; higher incidenceof extrapyramidal symptoms (most likelyto occur a few hours after injection andcontinue for about 2 days but may bedelayed); systemic lupus erythematosus;pain at injection site, occasionally erythema,swelling, nodules; tardive dyskinesia,neurological disturbances, blood dyscrasias",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Haloperidol,Pregnancy Category-C,Schedule H,"Schizophrenia and other psychotic disorders,mania, psychomotor agitation and violentbehaviour; adjunct in severe anxiety;agitation, psychosis, neuroleptanalgesia.","TABLETS 1.5, 5, 10 and 20 mg; LIQUID 30ml (25 mg/ml); INJECTION 5 ml ampoule (5mg/ml)","OralAdult-Schizophrenia and other psychoses, mania, psychomotor agitation and violent behaviour and severe anxiety (adjuvant): initially 1.5 to 3 mg 2 to 3 times daily or 3 to 5 mg 2 to 3 times daily in severely affected or resistant patients (up to 30 mg daily in resistant schizophrenia).Elderly or debilitated-Schizophrenia and other psychoses, mania, psychomotor agitation and violent behaviour and severe anxiety (adjuvant): initially half adult dose.Child-Schizophrenia and other psychoses, mania, psychomotor agitation and violent behaviour and severe anxiety (adjuvant): initially 25 to 50 µg/kg daily in 2 divided doses (max. 10 mg daily).Intramuscular injectionAdult- Acute psychotic conditions: initially 2 to 10 mg, subsequent doses every 4 to 8 h according to response (up to every h if necessary) to max. of 18 mg; severely disturbed patients may require initial dose of up to 18 mg.Elderly or debilitated- Acute psychotic conditions: initially half adult dose.Child- Acute psychotic conditions: not recommended.","Impaired consciousness due to CNSdepression; bone-marrow depression;pheochromocytoma; porphyria; basalganglia disease; parkinsonism, thyrotoxicosis,cardiac arrhythmia, depression, close angleglaucoma.","Cardiovascularandcerebrovasculardisorders;respiratory disease; parkinsonism; epilepsy;acute infections; pregnancy (Appendix 7c),lactation (Appendix 7b); renal and hepaticimpairment (avoid if severe; Appendices 7a),history of jaundice; leukopenia (blood countrequired if unexplained fever or infection);hypothyroidism, myasthenia gravis, prostatichypertrophy, angle-closure glaucoma; alsosubarachnoid haemorrhage and metabolicdisturbances such as hypokalaemia,hypocalcaemia, or hypomagnesaemia;elderly (particularly in very hot or verycold weather); children and adolescents;avoid abrupt withdrawal; patients shouldremain supine and the blood pressuremonitored for 30 min after intramuscularinjection; interactions (Appendix 6a, 6c);photosensitisation, peptic ulcers.May impair ability to perform skilled tasks, for example operating machinery, driving","As for Chlorpromazine (see above), butless sedating and fewer hypotensive andanticholinergic symptoms; pigmentationand photosensitivity reactions rare;extrapyramidal symptoms are common,particularly acute dystonia and akathisia(especially in thyrotoxic patients); rarely,weight loss, hypoglycaemia, inappropriateantidiuretic hormone secretion.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Olanzapine,Pregnancy Category-C,Schedule H,"Schizophrenia, acute mania episodes inbipolar disorder","TABLETS 2.5, 5, 7.5, 10, 15 and 20 mg.","Schizophrenia: initial 5-10 mg, usual dose is 10-20 mg. Acute maniac episodes in bipolarillness: 10-15 mg/day.",,"Impaired renal, hepatic and cardiovascularfunction; prostratic hypertrophy; paralyticileus; parkinsonism; blood dyscrasias;myelosupression; seizures; dementia;pregnancy (Appendix 7c).","Postural hypotension, dizziness, constipation,weight gain, agitation, insomnia, akathesia,tremors, personality disorder, oedema,increases appetite, antimuscarinic effects,hallucination, bradycardia.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Trifluoperazine,Pregnancy Category-C,Schedule H,"Schizophrenia, non-psychotic anxiety, acutepsychosis","TABLETS 1, 2, 5 and 10 mg;INJECTION 10 ml ampoule (10 mg/10 ml), 5ml ampoule (2 mg/ml).","OralSchizophrenia and Psychosis:Adult and child over 12 years- Initially 5 mgtwice daily, increase by 5 mg daily to 15-20mg daily after 1 week and then at intervals of3 days, according to response.Elderly- reduce initial dose by atleast half.Anxiety management:Adult- 1-2 mg twice daily. Max.- 6 mg daily.Child- 3 to 5 years, Max.- 1 mg daily in divided dose.Child- 6 to 12 years, Max.- 4 mg daily.Elderly- reduce initial dose by atleast half.Antiemetic: 2–4 mg daily in divided doses or as a single dose of a modified-release preparation; max. 6 mg daily.Child- 3–5 years up to 1 mg daily, 6–12 years up to 4 mg daily.ParenteralPsychosis:Adult- 1-2 mg by deep i.m injection, repeatevery 4-6 h, if necessary.Child- 1 mg by deep i.m injection, once or twice daily",Hypersensitivity to phenothiazines, bonemarrow depression, blood dyscrasias,pre-existing CNS depression and coma,pheochromocytoma,"Myasthenia gravis; renal and hepaticimpairment; benign prostatic hyperplasia;glaucoma; epilepsy; exposure to extremeheat or phosphorous insecticides; pepticulcer, Parkinson’s disease, interactions(Appendix 6a), pregnancy (Appendix 7c).","Extrapyramidal symptoms particularly inchildren, elderly and debilitated patientsmore frequently at doses exceeding 6 mgdaily; pancytopenia, thrombocytopenia;hyperpyrexia; dizziness, anorexia; insomnia;dry mouth; blurred vision; posturalhypotension.",Injection: Store protected from light. Tablets: Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Carbamazepine,Pregnancy Category-D,Schedule H,"Prophylaxis of bipolar disorder unresponsiveto or intolerant of lithium; epilepsy, trigeminalneuralgia","TABLETS 100, 200 and 400 mg Plain; 100 mg(DT) SyRUP 100 mg/5 ml","OralAdult- Initially 400 mg daily in divided doses increased until symptoms are controlled to a max. of 1.6g daily: usual maintenance range 400 to 600 mg daily.Trigeminal neuralgia: initially 100 mg twice daily, maintenance dose is 400-800 mg/day.",Atrioventricular conduction abnormalities,history of bone-marrow depression,porphyria.,"Hepatic impairment (Appendix 7a); renalimpairment; cardiac disease (see alsoContraindications); skin reactions (seeAdverse effects); history of blood disorders(blood counts before and during treatment);glaucoma; (neural tube screening); lactation(Appendix 7b); avoid sudden withdrawal;interactions (Appendix 6b, 6c, 6d); pregnancy(Appendix 7c); patients on anticoagulants.Patients or their caretakers should be told how to recognize signs of blood, liver or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, sore throat, rash, mouth ulcers, bruising or bleeding develop. Leukopenia which is severe, progressive and associated with clinical symptoms requires withdrawal (if necessary under cover of suitable alternative). May impair ability to perform skilled tasks, for example operating machinery, driving","Dizziness; drowsiness; headache; ataxia;blurred vision; diplopia (may be associatedwith high plasma concentrations);gastrointestinal intolerance including nauseaand vomiting, anorexia, abdominal pain, drymouth, diarrhoea or constipation; commonly,mild transient generalized erythematousrash (withdraw if worsens or is accompaniedby other symptoms); leukopenia and otherblooddisorders(includingthrombocytopenia,agranulocytosis and aplastic anaemia);cholestatic jaundice, hepatitis, acuterenal failure, Stevens-Johnson syndrome(erythema multiforme), toxic epidermalnecrolysis, alopecia, thromboembolism,arthralgia, fever, proteinuria, lymph nodeenlargement, arrhythmias, heart block andheart failure, dyskinesias, paraesthesia,depression, impotence, male infertility,gynaecomastia, galactorrhoea, aggression,activation of psychosis, photosensitivity,pulmonary hypersensitivity, hyponatraemia,oedema, disturbances of bone metabolismwith osteomalacia also reported; confusionand agitation in elderly; exfoliativedermatitis,ankle swelling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Lithium Carbonate,Pregnancy Category-D,Schedule H,"Treatment and prophylaxis of mania,prophylaxis of bipolar disorder and recurrentdepression; ADH secretion syndrome,psychosis.","TABLETS 150, 200, 300 and 400 mg;CAPSULES 150 and 300 mg.","OralAdult-Treatment of mania: initially 0.6 to 1.8g daily.Prophylaxis of mania, bipolar disorder and recurrent depression: initially 0.6 to 1.2g daily.Elderly-Treatment of mania: initially 300 to 900 mg daily.Prophylaxis of mania, bipolar disorder and recurrent depression: initially 300 to 900 mg daily",Renal impairment, cardiac insufficiency,conditions with sodium imbalance such asAddison’s disease, fetal goiter, heart failure,psoriasis, kidney infection, hypothyroidism,"Measure serum-lithium concentrationabout 4 days after starting treatment, thenweekly until stabilized, then at least every3 months; monitor thyroid function every6-12 months on stabilized regimens-riskof hypothyroidism (see below); monitorrenal function; maintain adequate fluid andsodium intake; reduce dose or discontinuein diarrhoea, vomiting and intercurrentinfection (especially if associated withprofuse sweating); lactation (Appendix 7b);pregnancy (Appendix 7c); elderly (reducedose); diuretic treatment, myasthenia gravis;surgery; if possible, avoid abrupt withdrawal(see notes above); interactions (Appendix 6c,6d); kidney, thyroid and heart function test,children and adolescents.Patients should maintain adequate fluid intake and should avoid dietary changes which may reduce or increase sodium intake. Patients should be advised to seek medical attention if symptoms of hypothyroidism (for example, feeling cold, lethargy) develop (women are at greater risk)","Gastrointestinal disturbances; finetremor, renal impairment (particularlyimpaired urinary concentration andpolyuria); polydipsia, weight gain andoedema (may respond to dose reduction);hyperparathyroidism and hypercalcaemiareported; signs of intoxication includeblurred vision; muscle weakness,increasing gastrointestinal disturbances(anorexia, vomiting, diarrhoea); increasedCNS disturbances (mild drowsiness andsluggishness, increasing to giddiness withataxia, coarse tremor, lack of co-ordination,dysarthria) and require withdrawal oftreatment; with severe overdosage (serumconcentrations above 2 mmol/litre),hyperreflexia and hyperextension of thelimbs; convulsions; toxic psychoses; syncope;renal failure; circulatory failure; coma;occasionally death; goitre, raised antidiuretichormone concentration, hypothyroidism,hypokalaemia, ECG changes, exacerbationof psoriasis and kidney changes may occur;sinus bradycardia, leukocytosis, glycosuria,weight gain.",Store protected from moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Clomipramine,Pregnancy Category-C,Schedule H,"Phobic and obsessional states; panic attacks;blocking replacement, cataplexy, chronicdiarrhoea","TABLETS 10, 25, 50 and 75 mg; CAPSULES10 and 25 mg.","OralAdult-Initially 25 mg daily, usually at bedtime increased over 2 weeks to 100 to 150 mg daily.Elderly- Initially 10 mg daily, usually at bedtime increased over 2 weeks to 100 to 150 mg daily.Child- Not usually recommended","Recent myocardial infarction, arrhythmias(especially heart block); manic phase inbipolar disorders; severe liver disease;children; porphyria; narrow angle glaucoma,urinary retention","Cardiac disease (see Contraindicationsabove), history of epilepsy; lactation(Appendix 7b); pregnancy (Appendix 7c);elderly; hepatic impairment (Appendix 7a);thyroid disease; pheochromocytoma; historyof mania, psychoses (may aggravate psychoticsymptoms); angle-closure glaucoma,history of urinary retention; concurrentelectroconvulsive therapy; avoid abruptwithdrawal; anaesthesia (increased risk ofarrhythmias and hypotension); interactions(Appendix 6a, 6b); decreased urine output,breathing problem. May impair ability to perform skilled tasks, for example operating machinery, driving","Sedation; dry mouth; blurred vision(disturbance of accommodation, increasedintra-ocular pressure); constipation; nausea;difficulty in micturition; cardiovascularadverse effects particularly with high dosageincluding ECG changes, arrhythmias, posturalhypotension, tachycardia, syncope; sweating,tremor, rash and hypersensitivity reactions(urticaria, photosensitivity); behaviouraldisturbances; hypomania or mania, confusion(particularly in elderly), interference withsexual function, blood sugar changes;increasedappetiteandweightgain(occasionalweight loss); endocrine adverse effects suchas testicular enlargement, gynaecomastiaand galactorrhoea; convulsions, movementdisorders and dyskinesias, fever,agranulocytosis, leukopenia, eosinophilia,purpura, thrombocytopenia, hyponatraemia(may be due to inappropriate antidiuretichormone secretion); abnormal liver functiontest; extrapyramidal syndrome, bone marrowdepression, hypertension, stroke.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Methadone,Pregnancy Category-C,Schedule H,Adjunct in treatment of opioid dependence,"TABLETS 5, 10, 20 and 40 mg; SyRUP 5 mg/ml.",Oral20-30 mg initially followed by increase of 5 to 10 mg until a dose of 60 to 100 mg/day is achieved.,"Avoid in acute respiratory depression, acutealcoholism and where risk of paralytic ileus;also avoid in raised intracranial pressure orhead injury (affects pupillary responses vitalfor neurological assessment); avoid injectionin pheochromocytoma (risk of pressorresponse to histamine release).","Hypotension, hypothyroidism, asthma (avoidduring attack) and decreased respiratoryreserve, prostatic hypertrophy; pregnancy(Appendix 7c), lactation; may precipitatecoma in hepatic impairment (Appendix7a) (reduce dose or avoid but many suchpatients tolerate morphine well); reducedose or avoid in renal impairment, elderlyand debilitated (reduce dose); convulsivedisorders, dependence (severe withdrawalsymptoms if withdrawn abruptly); useof cough suppressants containing opioidanalgesics not generally recommended inchildren and should be avoided altogetherin those under at least 1 year; interactions(Appendix 6a, 6c, 6d); CNS depression,ulcerative colitis, gastrointestinal surgery,bradyarrhythmia, pulmonary diseases.","Nausea and vomiting (particularly in initialstages), constipation and drowsiness; largerdoses produce respiratory depression;hypotension, and muscle rigidity; other side-effects include difficulty with micturition,ureteric or biliary spasm, dry mouth,sweating, headache, facial flushing, vertigo,bradycardia,tachycardia,palpitation,posturalhypotension, hypothermia, hallucinations,dysphoria, mood changes, dependence,miosis, decreased libido or potency, rashes,urticaria and pruritus; seizures, exacerbationof asthma, itching, pulmonary oedema.",Store protected from light and moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Glucose,,,Fluid replacement without significantelectrolyte deficit, treatment ofhypoglycaemia, varicose veins.,"INJECTION Infusion 250 ml, 500 ml and 1L(5% w/v); i.v.solution 10 and 20 ml (5% w/v).","Intravenous infusionFluid replacement Adult and Child- Determined on the basis of clinical and wherever possible, electrolyte monitoring.Treatment of hypoglycaemiaInfusion of 50% glucose solution into a large vein.Adult-25 ml.",Anuria, thiamine deficiency, trauma,intracranial haemorrhage, haemodilution,acute ischaemic shock, hypophosphatemia,sepsis.,Diabetes mellitus (may require additionalinsulin), mannitol fluid balance.,"Glucose injections, especially if hypertonic,may have a low pH and cause venousirritation and thrombophlebitis; fluid andelectrolyte disturbances; oedema or waterintoxication (on prolonged administrationor rapid infusion of large volumes of isotonicsolutions); hyperglycaemia (on prolongedadministration of hypertonic solutions);anaphylactoid reaction.",Store in a single dose container at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Glucose + Sodium Chloride,,,Fluid and extracellular volume depletion withexcess diuresis, gastroenteritis,"INJECTION 250, 450, 500 ml and 1 L.(Dextrose 5% and sodium chloride 0.9%).","Intravenous infusionAdult and Child- Fluid replacement: determined on the basis of clinical and wherever possible, electrolyte monitoring.",,"Restrict intake in impaired renal function;cardiac failure, hypertension, peripheral andpulmonary oedema; toxaemia of pregnancy.",Administration of large doses may give riseto oedema.,Store in a single dose container at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hypertonic Saline,,,Used in increased intracranial pressure (ICP)with hypovolemia/shock and renal failure,3% w/v solution,Initial dose- 4 ml/kg at a rate of 15 min can be given in case of impending herniation.Continuous infusion of 3% NaCl ranging between 0.1 and 1.0 ml/kg/hour (Administered on a sliding scale if ICP monitoring available to maintain ICP <20).,,"If serum osmalarity >320 -mannitol of little usemay be harmful, given along with mannitol ifno response in 3-6 hours, monitor serumsodium levels.",Hyperchloremic metabolic acidosis, acuterenal failure, subarachnoid hemorrhage,central pontine myelinosis, coagulopathiesdisorder, pulmonary edema, congestiveheart failure due to overload, hypokalemia,hemolysis, phlebitis, rebound cerebraledema.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Potassium Chloride,Pregnancy Category-C,,Electrolyte imbalance, hypokalaemia.,INJECTION 10 ml ampoule (11.2%w/v).,Slow Intravenous infusionAdult and Child- Electrolyte imbalance, depending on the deficit or the daily maintenance requirements,Plasma-potassium concentrations above5mmol/litre, chronic renal failure, systemicacidosis, acute dehydration, adrenalinsufficiency,"For intravenous infusion the concentrationof solution should not usually exceed3.2g (43 mmol)/litre; specialist advice andECG monitoring (see notes above); renalimpairment; interactions (Appendix 6d);pregnancy (Appendix 7c); acute alkalosis,paediatric use.","Cardiac toxicity on rapid infusion; nausea,vomiting, flatulence, diarrhoea.",Store in a single dose container at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sodium Bicarbonate,Pregnancy Category-C,,Metabolic acidosis, cardiopulmonaryresuscitation, hyperkalaemia, muscle spasm,"INJECTION 10 ml ampoule (1.4%w/v),(8.4%w/v).","Slow intravenous infusionAdult and Child-Metabolic acidosis: a strong solution (up to 8.4%), an amount appropriate to the body base deficit.Continuous intravenous infusionAdult and Child- a weaker solution (up to 1.4%), an amount appropriate to the body base deficit.","Metabolic or respiratory alkalosis,hypocalcaemia, hypochlorhydria;hypoventilation; hypoosmolarity.","Restrict intake in impaired renal function,cardiac failure, hypertension, peripheral andpulmonary oedema, toxaemia of pregnancy(Appendix 7c); monitor electrolytes and acid-base status; stomach disorder; allergies.","Excessive administration may causehypokalaemia and metabolic alkalosis,especially in renal impairment; large dosesmay give rise to sodium accumulation andoedema seizures; lactic acidosis; pulmonaryoedema; hyperventilation.",Store in a single dose container at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sodium Chloride,,,Electrolyte and fluid replacement,hyponatremia, diabetic ketoacidosis, legcramps, poisoning.,INJECTION 250 and 500 ml (0.9% Solution),NASAL DROPS 5 ml (0.9% w/v).,"Intravenous infusionAdult and Child- Fluid and electrolyte replacement: determined on the basis of clinical and wherever possible, electrolyte monitoring.",Hypertension, liver cirrhosis, ischaemic heartdisease, nephrotic syndrome, congestiveheart failure.,"Restrict intake in impaired renal function;cardiac failure, hypertension; peripheral andpulmonary oedema; toxaemia of pregnancy;interactions (Appendix 6d).",Administration of large doses may give rise tosodium accumulation and oedema, vomiting,intraocular coagulopathy.,Store in a single dose container at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sodium Lactate,,,Perioperative fluid and electrolytereplacement, hypovolaemic shock, metabolicacidosis, peritoneal dialysis,"INJECTIONS 250, 500 ml and 1L (1.87% w/v)","Intravenous infusionAdult and Child-Fluid and electrolyte replacement or hypovolaemic shock: determined on the basis of clinical and wherever possible, electrolyte monitoring. Common adult dose is 1 to 3 litre/day.",Metabolic or respiratory alkalosis, hypocal-caemia or hypochlorhydria, hypernatremia.,"Restrict intake in impaired renal function;cardiac failure, hypertension; peripheral andpulmonary oedema; toxaemia of pregnancy;corticosteroid therapy; shock; hypoxemia.",Excessive administration may causemetabolic alkalosis, administration of largedoses may give rise to oedema, tissuenecrosis, hypernatremia, hypervolemia,reaction at injection site,Store in a single dose container at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Water for Injection,,,In preparations intended for parenteraladministration and in other sterilepreparations.,"Ampoule 1, 5 and 10 ml.",,,,,Store in a single dose container at a temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Glycerol,,,Used in increased intracranial pressure andhydrocephalus.,10% w/v solution,Oral0.5-1.5 g/kg every 6-8 hourly.ParenteralIntravenous- 0.5 to 1.0 g/kg every 4-6 hours, do not exceed 0.2-1.0 g/kg/hour.Administer as a 10% solution every 4 hours.,Renal failure,"Preparation should not be greater than10%, intravenous preparations should beadministered slowly to prevent haemolysis.","Haemolysis, haemoglobinuria; renal failure;hyperosmolar coma; much frequent andsevere rebound effect; hyperglycemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ascorbic Acid (Vitamin C),"Pregnancy Category-A, C",,Prevention and treatment of scurvy.,TABLETS 100 and 500 mg, DROP 100 mg/ml,INJECTION 5 ml ampoule (100 mg/ml),OralAdult and child- Prophylaxis of scurvy: 25 to 75 mg daily. Treatment of scurvy: 0.5 to 1.5g/day.,Hyperoxaluria,Acetylsalicylic acid hypersensitivity, G-6-PD deficiency, large doses may cause renalcalcium oxalate calculi, pregnancy (Appendix7c),Gastrointestinal disturbances reported withlarge doses, failure of conception, kidneyoxalate stones.,Store protected from light and moisture.Avoid contact with metals,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Calcium Carbonate + Vitamin D3,Pregnancy Category-A,,"Prevention and treatment of osteoporosisand osteomalacia, nutritional supplement.",TABLET Vitamin D3 250 IU + Calcium 500 mgSUSPENSION 200 ml (Calcium 100mg+Vitamin D3 200 IU/5 ml).,Oral AdultCalcium 1000 -1300 mg dailyVitamin D3 200 - 800 IU daily.,"Hypersensitivity to any of the components,hypercalcaemia and/or hypercalciuria,nephrolithiasis, hypervitaminosis.","Renal impairment, impaired calciumabsorption in achlorhydria, risk ofhypercalcaemia and hypercalciuria inhypoparathyroid patients receiving highdoses of vitamin D; interactions (Appendix6c); pregnancy (Appendix 7c).","Constipation, flatulence, nausea, abdominalpain and diarrhoea; pruritus, rash andurticaria.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Calcium Gluconate,,,Hypocalcaemic tetany, cardiopulmonarybypass,TABLETS 250 and 500 mg, INJECTION 10 ml(1g/10 ml).,"Slow intravenous injection and continuous intravenous infusionAdult- Hypocalcaemic tetany: 1g (2.2 mmol) by slow intravenous injection, followed by continuous intravenous infusion of about 4g(8.8 mmol) daily.",Conditions associated with hypercalcaemiaand hypercalciuria (for example some formsof malignant disease).,"Monitor plasma calcium concentration;renal impairment; interactions (Appendix6c); diarrhoea, parathyroid disease; stomachtrouble.","Mild gastrointestinal disturbances;bradycardia, arrhythmias, hypotension;irritation at injection site; soft tissuecalcification; nephrocalcinosis, renal calculi.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ergocalciferol (Vitamin D2),Pregnancy Category-C,,Prevention of vitamin D deficiency, vitamin Ddeficiency caused by malabsorption or chron-ic liver disease, hypocalcaemia of hypopar-athyroidism, osteomalacia, osteoporosis,"CAPSULES 0.25 and 1 mg (50,000 IU)",OralAdult and child- Prevention of vitamin D deficiency: 10 µg (400 units) daily.,Hypercalcaemia, metastatic calcification.,Ensure correct dose in infants, monitorplasma calcium at weekly intervals inpatients receiving high doses or those withrenal impairment, nausea and vomiting-may indicate overdose and hypercalcaemia,lactation (Appendix 7b), interactions(Appendix 6a), pregnancy (Appendix 7c).,"Symptoms of overdosage include anorexia;lassitude; nausea and vomiting, diarrhoea,weight loss; polyuria; sweating; headache;thirst, vertigo and raised concentrationsof calcium and phosphate in plasma andurine; tissue calcification may occur if doseof 1.25 mg continued for several months;cardiac arrhythmia; hypervitaminosis D; overpsychosis; paralytic ileus.",Store protected from light in a hermetically sealed container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Iodine,Pregnancy Category-D,,Prevention and treatment of iodine deficiency,thyrotoxicosis, hyperthyroidism.,CRySTALS BULK.,"OralAdult- Endemic moderate to severe iodine deficiency: during pregnancy and one year postpartum, 300 to 480 mg once a year or 100 to 300 mg every 6 months; women of child-bearing age, 400 to 960 mg once a year or 200 to 480 mg every 6 months. Iodine deficiency; 400 mg, during pregnancy, single dose of 200 mg.Child- Iodine deficiency: infant under 1 year, single dose 100 mg; 1 to 5 years, 200 mg once a year; above 6 years 400 mg once a year.Intramuscular injection Endemicmoderatetosevereiodinedeficiency: women of child-bearing age, including any stage of pregnancy, 480 mg once each year; Iodine deficiency: 380 mg (if aged over 45 or with nodular goiter then 76 mg).Child- Iodine deficiency; 380 mg but for infant up to 1year, 190 mg.",Lactation (Appendix 7b), bronchitis, goitre,hyperkalaemia, asthma, acne vulgaris,tuberculosis.,Over 45 years old or with nodular goitre(especially susceptible to hyperthyroidismwhen given iodine supplements-iodizedoil may not be appropriate), may interferewith thyroid-function tests, pregnancy(see notes above and Appendix 7c), acuteiodide toxicity, cardiac toxicity, interactions(Appendix 6c).,Hypersensitivity reactions, goitre andhypothyroidism, hyperthyroidism, bronchitis,eosinophilia, rashes, headache, salivation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Iron Salts, Methylcobalamin",Pregnancy Category-A,,"To prevent neurological disorder in patientswith neuropathy due to diabetes, alcohol orother drug induced neuropathies","TABLETS 500 µg, INJECTION 500 µg/ml and0.2 mg/vial.","Initially 1000 µg 3 times a day for 2 weeks, thereafter 1000 µg every 3 months by intramuscular injection in case of pernicious anaemia and other macrocytic anaemia. Incase with neurological involvement, initially 1 µg on alternate days. Until no further improvement, thereafter 1000 µg every 2 to 3 months. Prophylaxis: 1000 µgevery 2 to 3 months.",Hypersensitivity.,Allergies, pregnancy (Appendix 7c),"Itching; anaphylactic shock with parenterals,pulmonary oedema; CHF; polycythemiavera.",INJECTION Store in single-dose or multi-dose container protected from light in a refrigerator (2⁰ to 8⁰C). Do not freeze. Tablet: Store protected from light and moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Nicotinamide,Pregnancy Category-A,,Treatment of pellagra, hartnup disease,inflammatory skin disease.,TABLET 50 mg,OralAdult- Treatment of pellagra: up to 500 mg daily in divided doses.,,"Avoid contact with eyes and mucousmembranes (including nose and mouth);reduce frequency of application if excessivedryness, irritation or peeling; history ofheart disease; insulin dependent diabetes;pregnancy (Appendix 7c).","Dryness of skin; also pruritus, erythema,burning and irritation; hepatotoxicity,cholestasis; portal fibrosis; transient liverdysfunction; tautness of face.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Nicotinic acid , Pyridoxine",Pregnancy Category-A,,Treatment of pyridoxine deficiency due tometabolic disorders, isoniazid neuropathy,sideroblastic anaemia.,"TABLETS 10, 25, 40, 50 and 100 mg","OralAdult- Deficiency states: 25 to 50 mg up to 3 times daily. Isoniazid neuropathy, prophylaxis: 10 mg daily. Isoniazid neuropathy, treatment: 50 mg, 3 times daily. Sideroblastic anaemia: 100 to 400 mg daily in divided doses.",,"Interactions (Appendix 6c), pregnancy(Appendix 7c).","Generally well tolerated, but chronicadministration of high doses may causeperipheral neuropathies; paresthesia;neurotoxicity; muscular weakness.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Riboflavin,Pregnancy Category-A,,Vitamin B2 deficiency, arabinoflavinosis,TABLETS 5 mg,OralAdult and child- Treatment of vitamin B2 deficiency: up to 30 mg daily in divided doses. Prophylaxis of vitamin B2 deficiency: 1 to 2 mg daily.,Cataract, hypersensitivity,Largedosesresultindarkyellowdiscolourationof urine, pregnancy (Appendix 7c).,"Swelling of lips, face and tongue and difficultyin breathing",Store protected from light,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Sodium Fluoride,,,Prevention of dental caries.,POWDER IN BULK,As oral rinseChild- Prevention of dental caries: over 6 years of age 10 ml 0.05% solution daily or 10 ml 0.2% solution weekly.,Not for areas where drinking water isfluoridated or where fluorine content isnaturally high, neonates.,Kidney problems,"In recommended doses toxicity unlikely;occasionally white flecks on teeth atrecommended doses; rarely, yellowish-brown discolouration if recommended dosesare exceeded; gum irritation.",Store protected from moisture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Thiamine,Pregnancy Category-A,,"Prevention and treatment of vitamin B1deficiency, acute alcohol intoxication","TABLETS 25, 50 and 100 mg",OralAdult- Mild chronic thiamine deficiency: 10 to 25 mg daily.Acute alcohol intoxication: 50-100 mg daily. Wernicke-Korsakoff syndrome: 50-100 mg daily.,,Parenteral administration (see notesabove), lactation (Appendix 7b), pregnancy(Appendix 7c).,Nausea, urticaria, gastrointestinal bleeding,oedema, pruritus, dizziness, anorexia.,Store protected from light and moisture in a non-metallic container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Vitamin A,Pregnancy Category-X,,Prevention and treatment of vitamin Adeficiency, prevention of complications ofmeasles,"TABLETS 5000 and 10,000 IU; INJECTION50,000 IU/ml.","Oral Adult- Prevention of vitamin A deficiency: 2,00,000 units every 6 months; pregnant woman, max. of 10,000 units daily or max. 25,000 units weekly; mothers, 200,000 units at delivery or within 6 weeks. Treatment of xerophthalmia; (except woman of child- bearing age) 2,00,000 units on diagnosis, repeated next day and then after 2 weeks; (woman of child-bearing age), 5000 to 10,000 units daily for at least 4 weeks or up to 25000 units weekly.Child- Prevention of vitamin A deficiency: infant under 6 months, 50,000 units; 6 to 12months, 100,000 units every 4 to 6 months, preferably at measles vaccination; over 1year, 200,000 units every 4 to 6 months. Treatment of xerophthalmia; infant under 6 months, 50,000 units on diagnosis, repeated next day and then after 2 weeks; 6 to 12 months, 1,00,000 units immediately on diagnosis, repeated next day and then after 2 weeks; over 1 year, same as adults.",Hypervitaminosis,Pregnancy (teratogenic, see notes above and Appendix 7c), lactation,"No serious or irreversible adverse effects inrecommended doses; high intake may causebirth defects; transient increased intracranialpressure in adults or a tense and bulgingfontanelle in infants (with high dosage);massive overdose can cause rough skin,dry hair, enlarged liver, raised erythrocytesedimentation rate, raised serum calciumand raised serum alkaline phosphataseconcentrations; hair loss; redness of skin;anorexia; weight loss.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Cyanocobalamin (Vitamin B12),Pregnancy Category-C,,Cyanocobalamin deficiency, peripheralneuropathy, diabetic neuropathy, medicinerelated or alcoholic neuropathy.,"TABLETS 50, 500 and 1500 µg; CAPSULES 50µg; LIQUID 35 µg/5 ml; INJECTION vial 500µg/30 ml.","OralAdult- Vitamin-B12 deficiency of dietary origin: 50 to 150 µg daily between meals.Child- 50 to 105 µg daily in 1 to 3 divided doses.Intramuscular injectionInitially 1 mg repeated 10 times at intervals of 2 to 3 days, maintenance 1 mg every month.","Hypersensitivity, tobacco amblyopia","Cobalt hypersensitivity, pregnancy (Appendix7c)",Asthenia, dyspepsia, pulmonary edema,shivering, bronchospasm,Store protected from light in a single dose or multi dose container.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Erythropoietin,Pregnancy Category-C,,"Anaemia of chronic renal failure, anaemia inpatients with AIDs, anaemia associated withcancer chemotherapy, reduction of AllogeneicBlood Transfusion in Surgery Patients.","INJECTIONS 1000, 2000, 3000, 4000, 5000,6000, 10000, 20000 and 40000 IU/Vial","Parenteral Anaemia of chronic renal failureAdult: As epoetin alfa: Initially, 50 U/kgsubcutaneous/intravenous 3 times weeklyfor predialysis and haemodialysis patientsand 50 U/kg twice weekly for peritonealdialysis patients, dose may be increasedaccording to response in steps of 25 U/kg 3times weekly at 4 weekly intervals.Child: As epoetin alfa: Initially, 50 U/kg 3times weekly. Dose may be increased at 4weekly intervals in increments of 25 U/kg3 times weekly until a target haemoglobinconcentration of 9.5-11 g/100 ml is reached.Usual maintenance dose: <10 kg: 225-450 U/kg/week; 10-30 kg: 180-450 U/kg/week and>30 kg: 90-300 U/kg/week.Anaemia in zidovudine-treated HIV-infectedpatientsAdult: As epoetin alfa: Initially, 100 U/kgsubcutaneous/intravenous thrice weekly for8 weeks; increase every 4-8 week by 50-100U/kg according to response. Max: 300 U/kgthrice weekly.SubcutaneousAnaemia related to non-myeloid malignantdisease chemotherapyAdult: As epoetin alfa or zeta: Initially, 150U/kg 3 times weekly. Dose may be increasedat 4-8 week intervals to 300 U/kg 3 timesweekly. Stop treatment if response is stillinadequate after 4 week of treatment usingthis higher dose.IntravenousIncrease yield of autologous bloodAdult: As epoetin alfa or zeta: 600 U/kg over2 minutes twice weekly for 3 week beforesurgery; in conjunction with iron, folate andB12 supplementation.","Hypersensitivity to mammalian cellproducts and human albumin, uncontrolledhypertension.","Ischaemic heart diseases, chronic renalfailure, hypertension, seizures, liverdysfunction, pregnancy (Appendix 7c) andlactation, interactions (Appendix 6c)","Nausea, vomiting, increased risk ofhypertension, myalgia, arthralgia, rashes andurticaria, headache, confusion, generalizedseizures, thrombosis specifically duringdialysis, fever, diarrhoea, tissue swelling, flu-like syndrome, paraesthesia, constipation,nasal or chest congestion, immunogenicityleading to Pure Red Cell Aplasia",Store in an air tight container at a temperature below - 20⁰C. Avoid repeated freezing and thawing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Iron Salts,"Ferrous Gluconate, Ferrous Sulphate: Pregnancy Category A Iron Sucrose, Sodium Ferric Gluconate: Pregnancy Category B Iron Dextran: Pregnancy Category C",,Iron-deficiency anaemia.,"TABLETS (sugar coated, film coated) Ferroussulphate 200 mg, Ferrous fumarate 200 mg,Ferrous gluconate 300 mg. (all equivalent to65 mg elemental iron). In women, folic acidmay also be given. SyRUPS also available.CAPSULES Iron sulfate 60-150 mg (20%Iron), Iron fumarate 200-300 mg (33% Iron).INJECTIONS Iron dextran 50 mg/ml, Ironsucrose 20, 50 and 100 mg/ml, Sodium ferricgluconate 12.5 mg/ml.",OralAdult- Iron-deficiency anaemia: elemental iron 100 to 200 mg daily in divided doses. Prevention of iron deficiency anaemia (in those at particular risk): for woman- elemental iron 60 mg daily.Child- under 5 years: elemental iron 2 mg/kg (max. 30 mg) daily. Over 5 years: elemental iron 30 mg daily. Over 5 years: folic acid may also be given.ParenteralTotal dose (ml) = 0.0442 (desired haemoglobin- obseved haemoglobin) x LBW+ (0.26 x LBW)[Note: LBW = Lean Body Weight (Kg)]Total dose may be given in divided doses ina daily or twice weekly basis via IM inj. (intothe upper quadrant of the buttock), mayalso be given intravenously by total-doseinfusion or as divided inj. A-Z track technique(displacement of the skin laterally prior toinjection) is recommended to avoid injectionor leakage into subcutaneous tissue,"Haemosiderosis, haemochromatosis; anyform of anaemia not caused by iron deficiency;evidence of iron overload; patients receivingrepeated blood transfusions; parenteral irontherapy.","A test dose of 0.5 ml should be given &observe patien for at least 1 hour for signsof hypersensitivity, respiratory distress,tachycardia or back/chest pain; should notbe administered for longer than 6 months;pregnancy (Appendix 7c); peptic ulcer;hypotension; regional enteritis, ulcerativecolitis, intestinal strictures, diverticula;interactions (Appendix 6c, 6d).","Nausea, vomiting, metallic taste;constipation, diarrhoea, dark stools,epigastric pain, gastrointestinal irritation;long-term or excessive administration maycause haemosiderosis; allergic reaction; backpain; staining of teeth.Parenteral: Pain at injection site, sterileabscess.",Store protected from light at temperature not exceeding 30⁰C.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Folic Acid,Pregnancy Category-A,,Treatment of folate-deficiency megaloblasticanaemia, prevention of neural tube defect inpregnancy,"TABLETS 1, 5 and 10 mg.","OralAdult- Treatment of folate-deficiency, megaloblastic anaemia: 5 mg daily for 4 months (up to 15 mg daily may be necessary in malabsorption states).Prevention of first occurrence of neural tube defect: 400 to 500 µg daily before conception and during the first twelve weeks of pregnancy.Prevention of recurrence of neural tube defect: 5 mg daily (reduced to 4 mg daily, if suitable preparation available) from at least4 weeks before conception until twelfth week of pregnancy.",Should never be given without vitamin B12in undiagnosed megaloblastic anaemia orother vitamin B12 deficiency states because risk of precipitating subacute combined degeneration of the spinal cord, folate- dependent malignant disease.,Women receiving antiepileptic therapyneed counselling before starting folic acid,pernicious anaemia, folate dependenttumor, interactions (Appendix 6c), pregnancy(Appendix 7c).,Neuropathy, bronchospasm, skin eruption,anorexia, skin rash, status epilepticus,Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hydroxocobalamin,Pregnancy Category-C,,"Megaloblastic anaemia due to vitaminB12 deficiency, congenital intrinsic factordisease",INJECTION 1 ml (1 mg/ml).,"Intramuscular injectionAdult and Child- Megaloblastic anaemia without neurological involvement: initially 1 mg 3 times a week for 2 weeks, then 1 mg every 3 months.Megaloblastic anaemia with neurological involvement: initially 1 mg on alternate days until no further improvement occurs, then 1 mg every 2 months.Prophylaxis of macrocytic anaemias: 1 mg every 2 to 3 months.Tobacco amblyopia and Leber optic atrophy: 1 mg daily for 2 weeks, then 1 mg twice weekly until no further improvement, then 1 mg every 1 to 3 months.",Anaphylactic reaction.,"Except in emergencies, should not be givenbefore diagnosis confirmed; monitor serumpotassium levels-arrhythmias secondary tohypokalaemia in early therapy; pregnancy(Appendix 7c)","Itching, exanthema, fever, chills, hotflushes, nausea, dizziness; rarely, acneiformand bullous eruptions, anaphylaxis;hypersensitivity; headache; diarrhoea.",Store protected from light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Iron Dextran,Pregnancy Category-C,Schedule H,"Iron deficiency anaemia, prevention of irondeficiency before, during or after pregnancy,to make up iron deficiency after pregnancyand during lactation.",INJECTION (iron as iron dextran) 1.5 ml ampoule (50 mg/ml).,"Deep intramuscular injection into the gluteal muscle or slow intravenous injection or intravenous infusion.Adult- Calculated according to body-weight and iron deficit. While deciding on parenteral therapy, oral therapy should be stopped at least 24 h before. Urine may darken on starting.Child- Under 14 years: not recommended.",History of allergic disorders including asthmaand eczema, infection, active rheumatoidarthritis, liver disease,Oral iron not to be given until 5 days afterlast injection, hepatic impairment, renalimpairment, pregnancy (Appendix 7c),interactions (Appendix 6d).Anaphylactic reactions can occur with parenteral iron and a test dose is recommended before each dose, the patient should be carefully observed for 60 min after the first test dose and for 15 min after subsequent test doses (subsequent test doses not necessary for intramuscular administration). Facilities for cardiopulmonary resuscitation must be at hand, risk of allergic reactions increased in immune or inflammatory conditions,"Less commonly nausea, vomiting, abdominalpain, flushing, dyspnoea, anaphylacticreactions (see Anaphylaxis above), numbness,cramps, blurred vision, pruritus and rash;rarely, diarrhoea, chest pain, hypotension,angioedema, arrhythmias, tachycardia;dizziness, restlessness, fatigue; seizures,tremor, impaired consciousness, myalgia,arthralgia and sweating; injection-site reactions also reported, thrombophlebitis;peripheral vascular flushing; tastedisturbances; syncope.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Pyridoxine,Pregnancy Category-A,,"Isoniazid, hydralazine and cycloserineinduced-neurological disturbances; pyridox-ine responsive anaemia and haemocysteinu-rea; morning sickness and hyperemesisgravidarum; convulsions in infants and chil-dren; mental symptoms in women on oralcontraceptives.","TABLETS 10, 25, 40 and 50 mg and 100 mg(sustained release); INJECTION 1 ml (50mg/ml).",OralAdult-Deficiency states: 25 to 50 mg up to 3 times daily.Isoniazid neuropathy (prophylaxis: 10 mg daily.Isoniazid neuropathy (treatment): 50 mg 3 times daily.Sideroblastic anaemia: 100 to 400 mg daily in divided doses.,,Interactions (Appendix 6c), pregnancy(Appendix 7c), long term administrationof high dose may cause severe peripheralneuropathies.,"Sensory neuropathy reported with highdoses given for extended periods, numbness;neurotoxicity; hyperesthesia; muscleweakness.",Store protected from light and moisture.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
